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ABSTRACT
A significant 'phenotype gap' exists between the currently available murine models of
non-alcoholic fatty liver disease (NAFLD) and the human disease process. In the
present study, the pathogenesis of progressive liver disease has been investigated using
mouse models. In particular, new models of NAFLD have been generated using both
genetic and environmental manipulation. Phenotype driven random mutagenesis
screens of Fl animals following paternal N-ethyl-N-nitrosourea exposure have
generated models of simple steatosis (GENA/263) and steatohepatitis (IGT/6). Both
models exhibit many of the features associated with the metabolic syndrome. Similarly,
dietary manipulation using a chronic high saturated and mono-unsaturated fat intake
has allowed identification of mouse models of sensitivity (129S6/Sv and C3H) and
resistance (BALB/c) to dietary induced steatohepatitis. Using microarray technology,
transcriptome level analysis ofIGT/6 mice has been performed to characterise changes
in hepatic gene expression in the presence of insulin resistance and steatohepatitis.
Finally, the role played by thrombin and coagulation status in the development of
hepatic fibrosis has been studied. Genetically determined thrombophilia due to the
Factor V Leiden mutation has been shown to accelerate hepatic fibrosis and
anticoagulation to slow tissue fibrogenesis. Thus, these studies confirm that NAFLD
and progressive hepatic fibrosis are complex disease traits, have generated novel models
for a spectrum ofNAFLD phenotypes and have demonstrated that there is an intimate
relationship between the activity of the coagulation cascade and the genesis of hepatic
fibrosis that may in the future be exploited as a potential therapeutic avenue.
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SECTION I: GENERAL INTRODUCTION
1.1 Common Liver Diseases as Complex Disease Traits (QTL)
Since 1996 the incidence of liver related deaths in the UK has risen by almost SO%
from 8.6 to 12.7 deaths per 100,000 of the male population. In 2001 chronic liver
disease was responsible for 7% and 6% respectively of UK men and women dying
under 4S years of age (ONS data); more men than died of Parkinson's disease and
more women than died of cancer of the cervix. According to the Office for National
Statistics, liver disease is now the fifth most common cause of death in the UK after
heart disease, stroke, chest disease and cancer (http://www.statistics.gov.uk/).
However, unlike the other main causes of death, liver disease mortality rates are
increasing rather than declining. The reason for this rise has not been fully explained
but coincides with a global epidemic of obesity. In Europe, the MONICA study
demonstrated that more than half the adult population between 3S and 6S years of age
are either overweight or obese l . 2. This rise in obesity affects all age groups with a
marked increase in adolescents reported in recent years3• Obesity is causally linked to
diabetes, hypertension, ischaemic heart disease and NAFLD.
During the last twenty years, the identification and study ofgenes that are responsible
for monogenic diseases (e.g. sickle cell anaemia and cystic fibrosis) has almost become
routine. These Mendelian single gene disorders are relatively rare and, whilst the
impact of such genetic variants may be devastating for an affected lineage or an
individual, they account for only a fraction of the disease burden within the
population4• In contrast, environmental and dietary factors are frequently cited as
major aetiological factors in the development of the more common human diseases
that are responsible for the bulk of the morbidity and mortality within a populationS.
The role played by genetic factors in the pathogenesis of common diseases (e.g.
diabetes mellitus, cirrhosis, atherosclerosis, hypertension, asthma and most cancers) is
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becoming more widely appreciated. These multifactorial non-Mendelian traIts
('complex disease traits') are determined by allelic variation at many genetic loci acting
in concert with a variable contribution from environmental factors6• Complex traits
may be dichotomous (e.g. cancer is present or absent) or continuous variables (e.g.
blood sugar and lipid levels or blood pressure). The genetic loci that influence
phenotype are termed 'Quantitative Trait Loci'. The apparent lag In our
understanding of the pathogenesis of society's more prevalent diseases may be
explained by the fact that the allelic variants that influence the genesis of these
conditions may have only a very slight effect in an individual but can have a substantial
influence over the health of a population. The causative genetic variants will be both
common in the human population and will be present in affected and unaffected
individuals. The metabolic effects of these variants are subtle and can be further
modulated by interactions with environmental factors and other susceptibility genes4•
The majority of liver related morbidity and mortality is due to disease processes that
culminate in hepatic fibrosis and cirrhosis. Hepatic fibrosis is the result of sustained
wound healing in response to chronic liver injury. This injury may be produced by a
variety of pathogenic insults including viral, toxic, autoimmune, metabolic and
cholestatic disease? The most common causes of hepatic fibrosis in industrialised
countries are chronic hepatitis C infection (HCV), alcoholic steatohepatitis and non-
alcoholic steatohepatitis. Unchecked, activated hepatic stellate cells deposit
extracellular matrix components including collagen types I and III, proteoglycans and
glycoproteins that accumulate within the hepatic parenchyma? As the degree of
fibrosis progressively increases, the hepatic architecture becomes distorted and
regenerative nodules develop marking the evolution of cirrhosis. Hepatocellular
dysfunction and increasing vascular resistance within the liver progress until hepatic
insufficiency and portal hypertension develop8. This carries with it a significant burden
in terms of morbidity (e.g. variceal haemorrhage, ascites, encephalopathy, hepatorenal
syndrome, hepatocellular carcinoma) and mortality.
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Table I: Genetic and Environmental Co-factors Associated with Hepatic Fibrosis
(Modified and Expanded from ReferenceS)
AETIOLOGY PUTATIVE GENETIC FACTORS ENVIRO"NMENTAL--FACTORS -~-",
Chronic Hepatitis C Infection HFE Hereditary Haemochromatosis Alcohol intake l2, 13
Angiotensinogen Angiotensinogen Co-infection with HIV +/- HBV
TGF-~ I Transforming Growth Factor ~ I Age at time of infection 12. 13
TNF-a Tumour Necrosis Factor a Liver transplantation
ApoE Apolipoprotein E Diabetes mellitus
MEH Microsomal epoxide hydroxylase Degree of Steatosisl4-18
MCP-I, MCP-2 Monocyte chemotactic proteins types I and 2 Body Mass Index l7
Factor V Leiden Factor V Leiden9• 10
CPT IA Carnitine palmitoyltransferase IA II
DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 11
Male Gender l2. 13
Alcohol intake
Recurrent alcoholic hepatitis
Body Mass Index l9
Diabetes mellitus l9
Degree of Steatosis20• 21
Hereditary Haemochromatosis
Angiotensinogen
Transforming Growth Factor ~ I
Interleukin 10
Interleukin I~
Alcohol dehydrogenase
Aldehyde dehydrogenase
Cytochrome P450
Tumour Necrosis Factor a
Cytotoxic T lymphocyte antigen type 4
Transporter-associated-antigen-processing 2
Manganese superoxide dismutase
Age22
Increasing Obesity22
Diabetes mellitus22
". • _ _ _ • ~." Hypertriglyceridemia ,,,"",,,,,,,,_,,,,,
HFE
Angiotensinogen
TGF-~I
IL-IO
IL-I ~
ADH
ALDH
CYP2EI
TNF-a
CTLA-4
TAP2
MnSOD
Non-Alcoholic Steatohepatitis
Alcohol Related
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In general, the progression to cirrhosis is a slow process that may require 30-35 years
before functional decompensation occurs. However, there is considerable inter-patient
variability observed in the rate of disease progression, irrespective of aetiology. Thus,
the processes that facilitate development of liver fibrosis exemplify a complex genetic
trait that may be modulated by genetic and environmental factors. Epidemiological
studies have identified a number of putative genetic and environmental factors that
may influence disease progression. These include polymorphisms in a range of
candidate genes (summarised in Table 1).
1.2 The Mouse as a Model for Studying Complex Liver Diseases
Polygenic inheritance of common diseases is difficult to study in humans due to
genetic heterogeneity within populations, epistasis, gene-environment interaction and
the low frequency of familial cases of diseases compared with the high overall
frequency in the background populations. For this reason it is necessary to study model
organisms in which physiological and pathophysiological processes may be dissected
under environmentally and genetically controlled conditions.
The laboratory mouse, Mus musculus, has been widely adopted as the primary model
organism for most research. It is a mammal and so shares many physiological,
anatomical and metabolic similarities with the human. Experience has shown the
mouse to be a reliable and faithful surrogate for studying human biology in a variety of
areas including behaviour, embryonic development, cancer and metabolic disease23•
The study of mouse models has enabled researchers to elucidate the action of genes at
different points throughout the natural history ofprogressive liver disease. Indeed, the
role played by many of the genes listed in Table 1 has been confirmed in transgenic
mouse models of hepatic fibrosis. A unique advantage of working with mice is that
there are many standardised and well characterised inbred strains (e.g. C57BL/6,
BALBIc, and C3H) that have a fully recorded pedigree. If a single inbred strain is used
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in an experiment much genetic heterogeneity can be eliminated as a variable24. Thus,
one can control both the genetic background (which may contain susceptibility alleles)
and, under SPF conditions, the environment. This allows researchers to study the
effects ofan intervention on a single homogeneous population.
There are well established genetic linkage maps of the mouse genome that can be used
to seek linkage between genetic markers and phenotypic characteristics25. The mouse
genome of the C57BL/6] strain is approximately 2.5 Gigabases in size and contains
about 30,000 genes. 99% of these genes have sequence homology to genes in the
human genome and 96% are found in syntenic regions26. Completion of the mouse
genome sequence has paved the way for an expansion in comparative genomic study
and modelling human diseases26, 27. Once disease loci have been mapped to a genomic
region, the candidate genes may be selected and the homologous human gene
identified. The mouse provides a highly genetically tractable organism. The
background inbred strains are both genetically homogeneous and well phenotypically
characterised and the majority of its biological processes are similar to those in man.
1.3 The Spectrum of Clinical NAFLD
N on-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver disease
encompassing steatosis (fatty change), non-alcoholic steatohepatitis (NASH) and
cirrhosis in the absence of alcohol abuse. NASH has been reported worldwide and is
increasingly recognised as the leading cause for liver dysfunction and cirrhosis in the
non-alcoholic, viral hepatitis negative population in Europe and North America28, 29.
Population studies show that NAFLD is strongly associated with obesity30-33,
dyslipidaemia33, 34, insulin resistance33-35 and type II (non-insulin dependent) diabetes
mellitus (NIDDM)33, 34. Indeed, insulin resistance is associated with NASH even in
subjects with apparently normal glucose tolerance35. Most authors now consider
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NAFLD to be an hepatic manifestation of the 'metabolic syndrome' (further discussed
in section 1.4 below) 34, 36.
NASH is progressive, leading to significant morbidity and may be a major cause of
what was previously described as 'cryptogenic cirrhosis'37-39. Irrespective of aetiology,
the rate of progression of hepatic fibrosis is accelerated when there are multiple
coincidental insults (e.g. alcohol intake and chronic viral hepatitis 12 or
haemochromatosis40). Historically, steatosis was considered a relatively benign disease
in the majority of patients. There is now good evidence that, besides being a
pathogenic process in its own right, NAFLD represents an important cofactor that
may determine the rate of progression of fibrosis in a range of liver diseases. As well as
influencing the progression of steatohepatitis to fibrosis41 , the extent of hepatic
steatosis has been shown to influence the progression of several liver diseases including
alcoholic liver disease2o, 21 and chronic hepatitis C 14, 17. 42, 43. A recent meta-analysis
examining the relationship between steatosis, inflammation and fibrosis in H CV has
determined by multivariate analysis that steatosis was significantly associated with viral
genotype 3, increased body weight, diabetes, hepatic inflammation and more advanced
fibrosis and that steatosis may compound the effects ofvirally induced inflammation43.
There is also evidence to suggest that the presence of obesity44 and/or hepatic steatosis
may impair the efficacy of interferon-alpha/ribavarin based anti-viral therapy4S-48.
Thus, lone NAFLD may progress to cause hepatic compromise. Where NAFLD is
associated with a coincidental second insult there is an accelerated progression of
fibrosis and anti-viral therapies that target a major cause ofprogressive liver disease are
rendered less effective by NAFLD. The rising prevalence of diabetes, obesity and
NAFLD, means that a greater proportion of the general population possess a cofactor
promoting progressive liver disease. This cofactor 'sensitises' the liver; individuals who
may not otherwise have progressed to end-stage liver disease as a result of alcohol abuse
or chronic viral hepatitis, progress more rapidly and become clinically apparent. The
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treatment costs incurred are consuming an ever-increasing proportion of the
healthcare budget in industrialised countries such as the United Kingdom.
1.4 Insulin Resistance & the Metabolic Syndrome
There is considerable variation in the sensitivity to insulin-mediated glucose disposal
within the healthy population49. Insulin resistance (IR) is said to be present when
either a higher than normal insulin concentration is needed to achieve a normal
metabolic response (i.e. right shift of the insulin response curve) or normal insulin
concentrations fail to achieve a normal metabolic response (i.e. a reduced maximal
response to a given level of stimulation)5o. Overt type II diabetes mellitus is said to
develop when insulin-resistant individuals cannot maintain a sufficient level of
hyperinsulinaemia to compensate for insulin resistance5l .
First described over 80 years ago52, the 'metabolic syndrome' (also referred to as
'syndrome X', 'the insulin resistance syndrome' or 'the deadly quartet'), defines a
constellation of metabolic disturbances (glucose intolerance, insulin resistance, central
obesity, dyslipidaemia and hypertension) that predict a high risk of developing type II
diabetes mellitus and cardiovascular disease53. 54. The most commonly adopted criteria
for the metabolic syndrome are shown in Table 2.
Comparative studies have shown that, whilst diagnostic criteria cover broadly the same
indices, differences in diagnostic thresholds have meant that studies can not be directly
compared and that there is only approximately 50% overlap in the identification of
affected individuals between criteria54. 55. Thus, the IDF (Table 2) criteria have been
established as a single internationally adopted definition for future studies54.
23
Table 2: Proposed Diagnostic Criteria for the Metabolic Syndrome
WHO Proposal (1999)56
Altered glucose regulation
(Impaired fasting glucose. impaired
glucose tolerance. type 2 diabetes)
or
Insulin resistance
(Clamp measurement: glucose uptake
below lowest quartile for background
population under study)
NCEP Proposal (2001)57 IOF Proposal (2005)54.58
Abdominal obesity
(Waist circumference >94 cm [M],
>80 [F] for Caucasians. Values
specified for other ethnic groups)
PLUS two or more of the
following criteria:
a. Impaired glucose tolerance
(2h glucose during OGTT: I 10-125
mgldL)
b. Arterial pressure
~ 140/90 mmHg or drug treated
c. Central obesity
(Waist-to-hip ratio >0.9 [M],
>0.85 [F] or BMI ~30)
d. Dyslipidaemia
(Triglycerides ~ 150 mg/dL
(l.7mmoI/L) or fib rate-treated or
HDL cholesterol <35 mg/dL (0.9
mmol/L) [M], <39 (1.0 mmol/L) [F])
Three or more of the following PLUS two or more of the
criteria: following criteria:
a. Blood glucose a. Blood glucose
~ I 10 mg/dL or treated for diabetes ~ 100 mg/dL (5.6 mmol/L) or treated
for diabetes
b. Arterial pressure b. Arterial pressure
~ 130/85 mmHg or drug treated ~ 130/85 mmHg or drug treated
c. Waist circumference
> I02 cm [M], >88 [F]
d. Triglyceride levels c. Triglyceride levels
~ 150 mg/dL (l.7mmoI/L) or fibrate- ~ 150 mg/dL (1.7 mmol/L) or fibrate-
treated treated
e. Insulin resistance
(see above)
f. Microalbuminuria
(Albumin excretion rate ~20 f-lg/min
or albumin/creatinine ~30 mg/g)
e. HDL cholesterol levels
<40 mg/dL (1.03 mmol/L) [M],
<50 (1.29 mmol/L) [F]
d. HOL cholesterol levels
<40 (1.03mmol/L) mg/dL [M],
<50 mg/dL (1.29 mmol/L) [F])
Abbreviations: WHO, World Health Organization; NCEP, National Cholesterol Education Program;
IDF, International Diabetes Foundation. Table modified from reference so
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The pathogenic trigger for the metabolic syndrome has yet to be determined.
However, insulin resistance and visceral (central) obesity have been proposed as
precipitating factors by several investigators58 and, as would be expected in a complex
trait, these factors are likely to be modified by genetic or ethnic variations and
environmental context54, 59. As with NAFLD, the metabolic syndrome received little
attention as a pathogenic entity until the late 1980's. This changed when studies began
to demonstrate a rapid increase in the prevalence of obesity and diabetes60 This is
exemplified by the prevalence of adult obesity (body mass index >30) in England and
Wales which has risen from 6% of men and 8% ofwomen in 1980 to 17% of men and
20% of women in 19971. The most recent data (2004) places the adult obesity
prevalence for England and Wales at 23.6% of men and 23.8% of women61 . Causing
concern for future health, the prevalence of childhood obesity has also risen
significantly (over 10 years from 1995 to 2004, the prevalence for boys aged 2-15 has
risen from 11% to 19% and for girls from 12% to 18%)61. Obesity and diabetes are now
so common that they are beginning to replace under-nutrition or infectious diseases as
the major global contributors to ill health60.
1.5 Pathogenesis of NAFLD
The development of NAFLD is determined by the interaction of genetic and
environmental factors62. Complex, polygenic disease traits, like NAFLD and insulin
resistance, are now the focus of much research. Such diseases are difficult to study in
humans due to genetic heterogeneity within populations, epistasis, gene-environment
interaction and the low frequency of familial cases of diseases compared with the high
overall frequency in the background populations. Despite some recent advances in
elucidating the genetic contribution and pathogenesis of related conditions, such as
insulin resistance and type II diabetes mellitus63, 64, our understanding of the
pathogenesis of steatosis and steatohepatitis remains incomplete65. The use of animal
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models in this field has proved invaluable. Indeed, it was work describing inducible
steatohepatitis in an animal model that led Day and James to propose the 'two hit'
hypothesis for the pathogenesis of NASH which remains a foundation for research in
this field66• The first hit, steatosis, sensitises the liver to the induction of inflammation
by a second pathogenic insult that promotes oxidative stress and hence steatohepatitis
(see Figure 1). This model has subsequently been revised in recognition that a
combination of 'second hits' (both environmental and genetic) may lead to the
development ofsteatohepatitis62•
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t Oxidative Stress & Lipid Peroxidatlon
• MCD Diet
• MTP -1- mouse
Pro-inflammatory Cytokine Release
'TNFa
'TGFI3
Lipopolysaccharide
Ischaemia-Reperfusion Injury
FIRST HITS
t LCFA delivery to the liver
• High Fat Diet
• High Carbohydrate Diet
• CD36 -1- mouse
de novo LCFA & TG Synthesis
• Ob/Ob mouse
• DblDb mouse
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• PEPCK-NSREBP-1a mouse
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Figure I: The Original 'Two Hit' Hypothesis for the Pathogenesis of NAFLD
The progression from normal healthy liver to steatohepatitis progresses in a stepwise fashion
involving first the development of obesity and insulin resistance (which leads to fatty change)
and later hepatic inflammation. Some of the available models and pathogenic processes are also
summarised.
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1.5.1 Steatosis and Insulin Resistance
The liver plays a central role in whole body lipid and carbohydrate metabolism
(summarised in Figure 2). Although the liver acts as a metabolic hub and is arguably
the primary metabolic effector organ, it does not operate in isolation. Interaction
between the liver and the two other metabolically active insulin sensitive tissues
(muscle and adipose tissue) have profound affects on metabolismso. In healthy
individuals, muscle is a major site for insulin mediated glucose disposalso, whilst
adipose tissue stores metabolic energy as lipid. Disruption of the normal mechanisms
for synthesis, transport and partitioning of fatty acids and triglycerides are the basis for
the development ofNAFLD. Steatosis occurs when the rate of import or synthesis of
fatty acids by hepatocytes exceeds the rate of export or catabolism67, 68. The
accumulation of lipid within the liver may be produced by disrupting the normal
physiological balance in any of four main ways:
L Increased delivery and uptake into hepatocytes offatty acids due to excess dietary
intake or release offtom adipose tissue stores.
As already mentioned in section 1.3, the development of steatosis is closely related to
the development of obesity and particularly insulin resistance, a near universal finding
in patients with NAFLD62. As hepatic steatosis can itself induce insulin resistance,
there has been debate over where the primary site of insulin resistance in NAFLD may
lie. Adipose tissue synthesises biologically active products including mediators of
carbohydrate metabolism (leptin, adiponectin and resistin), lipid metabolism
(apolipoprotein E and lipoprotein lipase) and adipocytokines (TNFa, IL-6 and
TGF~)69. Numerous factors including hyperinsulinaemia, hyperglycaemia, free fatty
acids, tumour necrosis factor-alpha (TNFa) and transcription factors may alter the
insulin signalling pathways down stream of the insulin receptorso• As obesity develops,
adipose tissue TNFa expression has been shown to rise in patients and experimental
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models. This acts both in an autocrine and paracrine fashion activating IKB kinase ~
(IKK~) and inhibiting tyrosine phosphorylation of insulin receptor substrates (IRS-1
and IRS-2). Insulin mediated suppression of hormone sensitive lipase (HSL) fails and
release of fatty acids into the circulation increases62, 70. Stable isotope tracer studies
demonstrate that 59+9.9% of total hepatic triacylglycerol in NAFLD is derived from
adipose tissue stores and a further 14.9+7% from the diet71 • Studies in mouse models
have shown that disruption of the type 1 TNFrx receptor gene72, the IKK~ gene or
administration of salicylates inhibits IKK~ activity73 and ameliorates insulin resistance.
However, there remains debate as to whether steatosis also abates65. Thus, peripheral
insulin resistance leads to failure to suppress lipolysis in adipose tissue and the release
of free fatty acids. This promotes hepatic steatosis and secondary insulin resistance and
may exacerbate skeletal muscle insulin resistance50, 74. (Glucose clearance by skeletal
muscle is reduced by nearly 50% in non-diabetic NAFLD patients as assessed by a
euglycaemic insulin infusion clamp technique75).
A potential explanation for the strong clinical association between central obesity
(characterised by predominant fat deposition in omental and mesenteric stores) and
steatosis is that the central adipose stores release high concentrations of fatty acids and
TNFrx directly into the portal circulation. This, coupled with TNFrx mediated up-
regulation ofhepatic fatty acid translocase (CD36)76, leads to enhanced lipid uptake by
the liver.
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Figure 2: Hepatic Lipid Metabolism and the Development of Steatosis
In the absorptive state dietary triglycerides are transported in the circulation as chylomicrons,
LPL mediated degradation releases LCFA. In the post-absorptive (fasting) state, insulin levels
fall and HSL releases LCFA from adipose tissue. In addition to absorbing circulating LCFA,
hepatocytes synthesise LCFA from dietary carbohydrate under control of SREBP-I c and
ChREBP.
Hepatic clearance of fatty acids depends on oxidation in the mitochondria and peroxisomes (~­
oxidation) or microsomes (w-oxidation) to generate Acetyl CoA for entry into Krebs cycle.
Excess fatty acids are re-esterified to triglyceride for export into the circulation as VLDL.
Points at which disruption may produce NAFLD are highlighted and discussed in the text.
(LPL, Lipoprotein lipase; HSL, Hormone sensitive lipase; ChREBP, Carbohydrate response
element binding protein; SREBP-I c, Sterol regulatory element binding protein Ic; PPARa,
Peroxisome proliferator activated receptor a; CPT I, Carnitine palmonitoyl transferase I;
MIT, Microsomal triglyceride transfer protein; ApoB 100, Apolipoprotein B100; VLDL, Very
low density lipoprotein).
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II. Increased de novo hepaticfatty acid and Triglyceride (TG) synthesis,
High plasma glucose and insulin levels following a carbohydrate meal normally trigger
rapid synthesis of fatty acids within hepatocytes. Accumulation of excess oleic acid (a
product of de novo fatty acid synthesis) has been demonstrated in both humans and
murine models of steatosis77. 78. The lipogenic actions of insulin are not compromised
in insulin resistant states79. The down stream effector through which insulin promotes
hepatic lipid synthesis is the transcription factor sterol regulatory element binding
protein-l (SREBP-l). Three SREBP isoforms, SREBP-la, -lc & -2, have been
described, each has a different role in lipid metabolism (see Table 3). SREBP-lc
induces expression of >30 genes that' effect the uptake and synthesis of fatty acids,
triglycerides, cholesterol and phospholipids80. Rising glucose levels can also activate de
novo hepatic lipid synthesis via carbohydrate response element binding protein
(ChREBP)81.
In obese individuals there is greater postprandial hyperglycaemia, and further
pancreatic insulin release82. This, together with the increased release of TNFet from
adipose tissue and consequent insulin resistance, drives hepatic fatty acid synthesis
from acetyl CoA. The conversion of fatty acids to triglycerides by glycerol phosphate
acyltransferase (AGPAT) within hepatocytes is non-rate limiting, consequently
increased availability of fatty acids will lead to increased hepatocyte TG synthesis and
accumulation68. In healthy subjects de novo lipid synthesis contributes <5% of the
hepatic triacylglyceride pool, this has been shown to increase to 26.1 +6.7% in
NAFLD71 .
III. Failure ofVLDL synthesis and triglyceride export.
Hepatic clearance of fatty acids may be accomplished by either esterification to TG
and export as very low density lipoprotein (VLDL) or by fatty acid oxidation. The rate
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limiting step in the assembly ofVLDL particles (composed of Apolipoprotein B-IOO,
triglyceride or cholesterol esters and phospholipids83) is performed within the
endoplasmic reticulum by microsomal triglyceride transfer protein (MTTP). In man
studies have established that mutations in the Mttp gene are responsible for the
autosomal recessive condition abetalipoproteinaemia, a condition which IS
characterised by the development of a severe NAFLD that may progress to
cirrhosis84. 85. Several commonly used drugs (including amiodarone, doxycycline and
tetracycline) been shown to inhibit MTTP activity in animal models of drug induced
steatosis68. 86. Similarly, reduced expression of Apolipoprotein B may impair VLDL
synthesis and allow NAFLD to develop87.
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Table 3: Selected Transcription Factors Implicated in the Pathogenesis of NAFLD
Transcription Factor
Peroxisome proliferator
activated receptor a
(PPARa, NRICI)
Endogenous Agonist
Fatty acids, oxidised phospholipids,
leukotrienes (LTB4)
Exogenous Agonist
Fenofibrate, Clofibrate,
Wy-14643 (Pirinixic acid)
Target Genes
Acyl CoA synthase, Fatty acid
transporter I, CPT I, ABCAI
Effects
i Fatty acid uptake, activation to acyl CoA &
mitochondrial ~-oxidation.
(PPARy, NR IC3)
Peroxisome proliferator Fatty acids, Prostaglandin J2 Thiazolidinediones (e.g. Lipoprotein lipase, Fatty acid Adipocyte differentiation. i LPL mediated fitty--
activated receptor V Rosiglitazone, Pioglitazone, transporter I, Acyl CoA synthase acid release from chylomicrons. i Adipose tissue
Troglitazone) fatty acid uptake & lipogenesis. i Adiponectin
production
Sterol regulatory element
binding protein Ia
(SREBP-I a)
Insulin & sterol depletion lead to i
transcription and activation
HMG CoA synthase, HMG CoA
reductase, Fatty acid synthase
i Activates both cholesterol synthesis & i fatty
acid / triglyceride synthesis
Sterol regulatory element
binding protein Ic
(SREBP-I c)
Sterol regulatory element
binding protein 2
(SREBP-2)
Carbohydrate response
element binding protein
(ChREBP)
Insulin & LXRa activity lead to i
transcription and activation
Insulin & sterol depletion lead to i
transcription and activation
Glucose
Glucokinase, Acetyl CoA synthase i Fatty acid / triglyceride synthesis; i Lipogenesis
& carboxylase, Fatty acid
synthase, ATP citrate lyase
HMG CoA synthase, HMG CoA i Cholesterol Synthesis
reductase, LDL receptor
Liver pyruvate kinase, Fatty acid i Lipogenesis
synthase, Acetyl CoA carboxylase
V>
V>
Liver X receptor 0(
(LXRa, NRIH3)
Cholesterol derived Oxysterols &
LCFAs
T090 1317, GW3965 CYP7AI, ABCAI, ABCGI,
SREBP-I c, Lipoprotein lipase,
CETP, ApoE
i Fatty acid synthesis, i Bile acid synthesis, i
Lipoprotein assembly
IV. Impaired mitochondrialfatty acid ~-oxidation.
The alternate route for disposal of fatty acids, fatty acid oxidation, takes place in three
cellular organelles: mitochondria, peroxisomes and the endoplasmic reticulum
(microsomes)88. The control of fatty acid oxidation is primarily regulated by the
ligand-activated transcription factor peroxisome proliferator activated receptor-alpha
(PPARa) which serves as an intracellular lipid detector. Upon activation, PPARa
complexes with retinol X receptor and binds to target gene PPAR response element
(PPRE) sequences to trigger gene transcription and stimulate lipid catabolism89.
Mitochondrial ~-oxidation is the main route for the metabolism of short, medium and
long chain fatty acids under normal physiological conditions9o. However, this process
may be disrupted at several key enzymatic stages.
Carnitine palmonitoyl transferase 1 (CPTl) mediated trans-esterification and import
of fatty acids into the mitochondrial matrix is the rate limiting and regulatory step in
this process. CPTl is inhibited by malonyl CoA, the first intermediate in fatty acid
synthesis and so is sensitive to the effects of up-regulated hepatic fatty acid synthesis91 ,
92. Once inside the mitochondrial matrix, acyl-CoA fatty acids are degraded by four
sequential enzymatic reactions to release NADH, FADH2 and acetyl-CoA (which
then enters the tricarboxylic cycle). Mitochondrial trifunctional protein (MTP) is a
hetero-octamer composed of four a and four ~ subunits associated with the inner
mitochondrial membrane that catalyses the final three of these reactions93. If CPTl,
and hence the oxidative capacity of the mitochondria, become overwhelmed, lipid
accumulates and alternative oxidative pathways, in other subcellular organelles, process
a greater proportion of the fatty acid load. As is discussed below, this can lead to
steatosis and an increase in the production of free radicals and other reactive oxygen
species. Mutations affecting the activity of MTP may also lead to the development of
steatosis. In man, autosomal recessive inherited mutations in MTP are associated with
a steatotic Reye-like syndrome, cardiomyopathy or sudden death. There is also
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evidence that mutation of foetal MTP carriage is associated with HELLP syndrome
and acute fatty liver ofpregnancy93.
1.5.2 Steatosis to Steatohepatitis
The two hit hypothesis dictates that, once steatosis has developed, the liver is
'sensitised' and so an inflammatory response may be precipitated by a variety of
stimuli66. As is the case in the histologically similar condition alcoholic steatohepatitis,
two mechanisms are thought to be pivotal to the genesis of non-alcoholic
steatohepatitis:
I Oxidative stress, lipidperoxidation and cell death
Oxidative stress has been implicated as an aetiological factor in many progressive liver
diseases including alcoholic steatohepatitis, Wilson's disease and hepatitis C 94. It is also
the mechanism of hepatic damage induced by the toxins such as carbon tetrachloride
(commonly used to induce liver fibrosis in research models). Suggesting a common role
in disease progression, the presence of biological markers of oxidative stress has been
demonstrated in NAFLD patients and animal models of steatohepatitis95,96.
A major source of reactive oxygen species (ROS) within hepatocytes is oxidation of
fatty acids. These include singlet oxygen molecules, hydrogen peroxide, hydroxyl
radicals and superoxide anions. As described above, mitochondrial ~-oxidation is the
main route for the metabolism of short, medium and long chain fatty acids under
normal physiological conditions9o. Within mitochondria, the electron transport chain
safely dissipates the majority of electrons released; however some still react to form
superoxide anions and other ROS. As described above, the enzymes that mediate
n1itochondrial ~-oxidation are regulated by PPARa, however, increased PPARa
activity preferentially induces extra-mitochondrial ~-oxidation and w-oxidation
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pathways88. 97. Thus, as mitochondrial oxidative capacity becomes overwhelmed,
alternative pathways in the peroxisomes (~-oxidation) and endoplasmic reticulum
(cytochrome P450 enzymes -4A and -2El catalysed w-oxidation) assume a greater role
in hepatic fatty acid oxidation. Insulin resistance further enhances CYP2E 1 mediated
w-oxidation. Peroxisomal ~-oxidation is not linked to the electron transport chain and
so generates hydrogen peroxide. Similarly, w-oxidation produces highly cytotoxic
dicarboxylic acid and other sources ofROS that further contribute to cellular oxidative
stress90• At times of hepatic fatty acid overload and mitochondrial dysfunction (e.g.
diabetes mellitus and obesity), these physiologically minor pathways increase the
hepatocyte ROS load.
When the production of ROS exceeds the antioxidant capacity of the cell, cellular
macromolecules are damaged. This includes damage to nuclear and mitochondrial
DNA, phospholipid membrane disruption by lipid peroxidation and the release of
proinflammatory cytokines98. 99. The production of oxidative stress is further amplified
by mitochondrial damage that induces loss ofcytochrome c which disables the electron
transport chain94. 100. Several different mouse models of steatohepatitis (including
MCD diet and ob/ob mice) are characterised by increased ROS production,
mitochondrial DNA damage (as assessed by mitochondrial 8-hydroxy-2'-
deoxyguanosine levels) and reduced expression of the DNA mismatch repair enzyme
MutylOl. Lipid peroxidation of polyunsaturated fatty acids generates toxic aldehyde
by-products including malondialdehyde (MDA) and hydroxynonenal (HNE) that are
more persistent than ROS and so damage more distant intracellular organelles and may
cause cell death. These products directly activate fibrogenic hepatic stellate cells and
are chemotactic for neutrophils, recruiting immunologically active cells into the
inflammatory process96. ROS may also induce Fas ligand expression on hepatocytes
and promote paracrine induced apoptotic cell death99•
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II. Pro-inflammatory cytokine mediated hepatocyte injury
Many of the proinflammatory cytokine abnormalities that were first described in
alcoholic liver disease have now been reported in NASH 102• The association between
TNFrx expression and insulin resistance has already been described. Studies also
demonstrate greater expression of TNFrx and TNFrx type 1 receptor in patients with
steatohepatitis than those with steatosis alone103. 104. In addition, products of lipid
peroxidation (e.g. 4-hydroxynonenal) have been shown to increase TGF-~l expression,
promoting hepatic fibrogenesis.
1.6 Focus of Study in this Thesis
The focus of this thesis centres upon the identification and characterisation of novel
mouse models of steatosis, steatohepatitis and liver fibrosis. As will be discussed in the
following section, a significant 'phenotype gap' exists between the currently available
murine models of NAFLD and the human disease process. At a time when the
prevalence of obesity, the metabolic syndrome and NAFLD is rising rapidly, the
available tools for the study of these important diseases are insufficient to the task.
This thesis describes the results of genetic and environmental manipulation of inbred
strains of mice to identify new disease models that may better serve the study of
NAFLD. Global hepatic gene expression is characterised in one model identified in
these studies, demonstrating how specific genetic derangements may produce the
disease phenotype.
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SECTION 2: IDENTIFICATION OF A NOVEL MODEL OF
NON-ALCOHOLIC STEATOHEPATITIS USING A
PHENOTYPE-DRIVEN MUTAGENESIS SCREEN
2. I Background
2.1.1 Existing Mouse Models of NAFLD
The study of existing animal models (summarised in Table 4) has provided vital
insights into the pathogenesis of steatosis and steatohepatitis, but these remain
incompletely understood6s• The literature contains numerous different rodent models
that exhibit histological evidence of hepatic steatosis. The features of true
steatohepatitis, that should include ballooning hepatocyte degeneration in addition to
simply fatty change and an inflammatory infiltrate105, are less frequently demonstrated.
No existing model exhibits the entire NAFLD phenotype as encountered in clinical
practice and many differ from the human disease in all but gross histological
appearance. These inconsistencies and the lack of a reliable model of progressive
fibrosing steatohepatitis have hampered research in this field.
Research models ofNAFLD may be divided into two broad categories, those caused by
either spontaneous or induced genetic mutation and those with an acquired NAFLD
phenotype. The latter group may be produced by either dietary or pharmacological
manipulation. The bulk of published research has employed genetically determined
leptin deficiency (ob/ob) and resistance (db/db) or the dietary methionine/choline
deficient model (MCD). These models differ significantly from the human phenotype
in a number of pathogenically important ways and have led some to question whether
observations made using many of these models are truly applicable to man. I will briefly
describe the established models and summarise those models that have been described
since Koteish and Diehl reviewed this field67•
38
'-'>
""
Table 4: Current Mouse Models of NAFLD
Model
Genetic: Increased lipid import/synthesis
ob/ob mouse
db/db mouse
Yellow-Obese Agouti (AY) mouse
CD36 -/- mouse
Liver Specific Pten Deletion
PEPCK-NSREBP-I a mouse
aP2-NSREBP-1 c mouse
aP2-Diptheria toxin mouse
Genetic: Reduced lipid export/catabolism
PPARa -/- mouse
Acetyl CoA oxidase -/- (AOX -/-) mouse
Aromatase (Cyp 19) deficient mouse
MTP -/-
Juvenile Visceral Steatosis UVS) mouse
Environmental: Increased lipid import/synthesis
High Fat Diet
High Sucrose/Fructose Diet
Argenine Deficient
Environmental: Reduced lipid export/catabolism
Methionine/Choline Deficient Diet (MCD)
Steroids, Oestrogen, Tamoxifen
~ 11\
Description ~ c:
·iii
-
11\ .. 0
:t: ~ a- lo..c ~ .cC 0 ...J u.
Leptin deficient. Steatosis may progress to NASH after 'second hit'. Y Y 1
Leptin receptor deficient. Steatosis may progress to NASH after 'second hit'. Y Y i
Hyperphagic: no hypothalamic appetite suppression by melanocortin. Y Y - N
Reduced peripheral lipid uptake increases FFA delivery to liver. Steatosis. N N
-
N
Increased hepatic fatty acid synthesis due to disinhibition of fatty acid synthesis. N N 1 N
Lipoatrophic model. Hepatic SREBP-I a overexpression. Develops steatosis. Y N 1 N
Lipoatrophic model. SREBP-I c overexpression in adipose tissue. Steatosis. Y N 1 N
Lipoatrophic model. Transgenic expression of diphtheria toxin in WAT. Y N 1 N
Impaired mitochondrial l3-oxidation. Develops steatosis. N N - N
Defective l3-oxidation leads to transient steatosis. N N - N
Female mice lack oestrogen. Develops steatosis. N Y - N
Key enzyme for mitochondrial l3-oxidation deleted. Develops steatohepatitis. Y ?
Carnitine deficiency 1 fatty acid transport into mitochondria for l3-oxidation. N N - N
Increased adiposity, FFA and insulin resistance. Steatosis and NASH. Y Y i
Hepatic enzyme induction and increased fatty acid synthesis. Steatosis. Y Y i
Increased lipid synthesis. Steatosis due to abnormal orotic acid metabolism. N N - N
Impaired mitochondriall3-oxidation. Develops steatosis, NASH and fibrosis. N N - Y
Impaired mitochondrial l3-oxidation and reduced hepatic triglyceride secretion. Y Y
2.1.1.1 A Model of Genetically Determined Leptin Deficiency: the ob/ob mouse
The oblob mouse carries a spontaneous mutation first observed whilst intercrossing
inbred mouse strains l06. This autosomal recessive trait renders animals hyperphagic,
inactive, obese and severely diabetic with marked hyperglycaemia107, 108. Histological
features include enlarged islets of Langerhans (consistent with compensatory
hyperplasia due to insulin resistance) and hepatic fat depositionl09• Early parabiotic
experiments demonstrated that obiob mice were unable to produce a satiety factor but
could respond to such a factor from a donor animal110, Ill. Positional cloning identified
the leptin gene on chromosome 6 as the site of the ob mutation l12, 113. This 16kDa
adipokine is produced by white adipose tissue and acts on the hypothalamic ventral
median nucleus to produce its prominent anorexic effects. In physiological states,
leptin mediates an innate adaptive neuroendocrine response to starvation. As adipose
tissue is depleted leptin levels fall. This drives a desire to seek food and suppresses the
thyroid, growth hormone, adrenal and reproductive endocrine axes l14. Leptin
influences numerous physiological processes and can directly affect the inflammatory
response. Leptin deficient oblob mice exist in a state of perceived starvation11S. When
given free access to standard chow, young obiob mice overeat, become obese and
develop steatosis.
Reflecting the plural activity of leptin, the obiob mouse is a complex model of obesity
related steatosis. Lipid and carbohydrate metabolism is deranged in several ways. The
expanded white adipose tissue mass in oblob mice and increased expression ofTNFa
promote adipose tissue lipolysis releasing LCFAs. Increased circulating LCFAs are
delivered to the liver (Figure 2 on page 30, *1). In addition, SREBP-1c is activated
and accumulates in obiob hepatocyte nuclei promoting fatty acid synthase activity and
de novo synthesis (Figure 2 on page 30, *2)116. The increased synthesis and storage of
lipid in the liver coincident with expanded adipose tissue stores contributes to hepatic
steatosis and obesity.
There is conflicting evidence regarding activity of hepatocyte fatty acid oxidation
pathways in ob/ob mice (Figure 2 on page 30, *3). Supporting the view that ~­
oxidation may not be appropriately up regulated in this setting, increased PPARa
activity in obiob mice has not been demonstrated67. Although one proteomic study
comparing obiob and lean mice demonstrated increased expression of peroxisomal 3-
ketoacyl-CoA thiolase band acyl-CoA oxidase and mitochondrial acyl-CoA
dehydrogenase117, other studies indicated that there was little increase in
mitochondrial ~-oxidation In ob/ob mice 118. However, investigators have
demonstrated increased microsomal w-oxidation activity (CYP2EI and CYP4A) 119.
Taken together, these findings suggest that there is only a small increase in
mitochondrial ~-oxidation in ob/ob mice, insufficient to dispose of the greater fatty
acid load. This necessitates the activation of the alternate microsomal w-oxidation
pathways.
Unlike the human NAFLD population, ob/ob mice do not spontaneously progress
from steatosis to steatohepatitis. Ob mice require a 'second hit' to be administered to
trigger progression to steatohepatitis. This may be provided by exposure to small doses
of lipopolysaccharide endotoxin (LPS) that are insufficient to cause ill effects in
control animals 120, 121, ethanol exposure or hepatic ischaemia-reperfusion challenge
which all provoke a severe steatohepatitis and frequently acute mortality67, 122. These
findings underpin the assertion that steatosis sensitises the liver to oxidative stress and
free radical mediated damage66,120.
2.1.1.2 A Model of Genetically Determined Leptin Resistance: the db/db mouse
Mutations in the diabetes (db) gene, mapped to mouse chromosome 4, result in an
autosomal recessive diabetic, obese phenotype similar to the ob/ob mouse l23• The
dbldb n10use (and the fal fa rat) have normal or elevated levels of leptin but are
resistant to its effects. Studies have shown that the db gene encodes the leptin receptor
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(OB-R) which is structurally similar to a class I cytokine receptor 124. On binding
leptin, the receptors form tetrameric complexes (two receptors with two molecules of
leptin) and the intracellular domain undergoes ligand induced conformational change.
Several alternative splice variants with a single transmembrane domain and a
cytoplasmic region ofvariable length have been described11s• The short OB-Ra isoform
has not been shown to have any signalling activity. In contrast, the OB-Rb isoform has
a long intracytoplasmic region that contains signal tr~nsduction motifs that activate
the JAK/STAT protein kinase signal transduction cascade12s. C57BL/Ks db/db mice
carry a sequence insertion at the 3' end of the mRNA transcript exactly where the OB-
Ra and OB-Rb transcripts diverge. This insertion contains a stop codon that leads to
the premature termination of the OB-Rb long intracellular signalling domain, loss of
function and, consequently leptin resistance126•
2.1.1.3 Models of Genetically Determined Increased Circulating LCFAs
The models described so far demonstrate the genesis of steatosis associated with
obesity but fatty acid delivery to the liver in excess of oxidative requirements can
induce steatosis, irrespective of adipose tissue mass. This has been demonstrated by
modifying how fatty acids are partitioned between body tissues in non-obese animals.
The transmembrane protein CD36 (fatty acid translocase) is an important fatty acid
transporter expressed in peripheral tissues including muscle and adipose tissue. CD36
null mice exhibit elevated circulating LCFA and TG levels and hepatic insulin
resistance due to impaired fatty acid storage. Affected mice develop steatosis and fail to
suppress hepatic gluconeogenesis127. 128. In contrast, hormone sensitive lipase deficient
animals and mice with targeted over expression of muscle lipoprotein lipase have
reduced levels ofcirculating LCFAs and are not steatotic129. 130.
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2.1.1.4 Models of Acquired Increased Hepatic LCFA Uptake and de novo Lipogenesis
The strong association between obesity and NAFLD has prompted the study of the
effects of diet on the development of steatosis and steatohepatitis in mouse models.
Increased dietary supply of fat or carbohydrate to the liver may promote steatosis by
increasing hepatic lipid uptake or de novo synthesis (Figure 2 on page 30, * 1 and *2).
HFD fed C57BL/6 mice are considered a valuable tool for investigating the metabolic
syndrome131, 132. This may in part be explained by a recently identified spontaneous
mutation in the nicotinamide nucleotide transhydrogenase gene carried by C57BL/6]
mice which impairs insulin secretion133, 134. With aging, C57BL/6 mice have been
shown to develop obesity, hyperinsulinaemia and glucose intolerance irrespective of
diet. This phenotype may be exacerbated and a mixed micro- and macrovesicular
steatosis provoked by feeding a 55 kcal% HFD for 6 months 135. These changes were
associated with increased expression of SREBP-Ic, SREBP-2 and stearoyl-CoA
desaturase 1 (an enzyme marker of hepatic lipid synthesis) 135. Studies using
gastrostomy based HFD overfeeding of C57BL/6 mice have demonstrated NAFLD
(with insulin resistance, obesity, glucose intolerance and raised plasma ALT levels) was
associated with increased expression of SREBP-Ic, PPARy and LXRa but reduced
expression of PPARa136. Diets with elevated carbohydrate content have also been used
to provoke steatosis in mouse models. C57BL/6 mice fed a 65% sucrose diet for 8
weeks have been shown to exhibit obesity, insulin resistance and macrovesicular
steatosis 137.
Studies have shown that HFD and/or high sucrose diet induced steatosis in C57BL/6
mice led to hepatic NKT cell depletion (a similar Th-l polarisation to that seen in
ob/ob mice) and exaggerated LPS sensitivity138. This observation was significant
because it confirmed that pathogenic processes underlying increased LPS sensitivity in
ob/ob mice may be replicated in an aetiologically appropriate model to man. However,
the mechanisms for the NKT cell depletion remain undefined139. HFD induced
steatohepatitis has also been associated with increased hepatic expression of the
.+3
endotoxin induced macrophage receptor with a collagenous structure (MARCO) and
increased portal endotoxin levels in some mouse strains, suggesting that HFD may not
only sensitise the liver to LPS but also increase portal delivery ofLPS140.
2.1.1.5 Models of Genetically Determined Hepatic Lipogenesis
Targeted over expreSSIon of the insulin controlled transcription factor SREBP-l
promotes hepatic lipogenesis. Two non-obese transgenic mouse models (PEPCK-
nSREBP-la mice and aP2-nSREBP-lc mice) with severe hepatic steatosis have been
described141,142. PEPCK-nSREBP-l a mice over express a truncated version of SREBP-
la in the liver under the control of a phosphoenolpyruvate carboxykinase promoter141 .
These animals exhibit histological steatosis but not steatohepatitis or dyslipidaemia
although ALT levels are elevated. aP2-nSREBP-lc mice over express SREBP-lc in
adipose tissue. These animals have a lipoatrophic phenotype associated with
steatosis142• Studies have shown that SREBP-l mediated hepatic lipogenesis proceeds,
even in the presence ofprofound insulin resistance1l6.
Carbohydrate mediated lipogenesis is transcriptionally regillated by the Carbohydrate
Response Element Binding Protein (ChREBP) 143. Targeted disruption of the
ChREBP gene in a mouse model has been shown to produce a 50% reduction in the
expression of key enzymes that mediate lipogenesis l44. These data suggest that both
hyperglycaemia and hyperinsulinaemia (even on a background of insulin resistance)
promote hepatic steatosis.
Phosphatase and tensin homolog (Pten) is a ubiquitously expressed tumour suppressor
gene with enzymatic phosphatase activity. A key substrate is the lipid second messenger
phosphatidylinositol-3,4,5-triphosphate (PIP3), generated by the action of PI3Ks and
activated by a range of stimuli, including various cytokines and insulin145. Studies
indicate that Pten deletion disinhibits PIP3 signalling via Akt to activate Foxol,
SREBP-l c and PPARy thus increasing hepatic lipogenesis and oxidative stress 1-t6 • Thus,
hepatocyte specific deletion of the Pten gene has been shown to produce florid hepatic
triglyceride accumulation and histological features of steatohepatitis which progresses
to fibrosis and often to tumour developmentI4S-147. Despite the strong morphological
phenotype, these animals do not develop any of the associated features of N AFLD
such as obesity, diabetes, insulin resistance or dislipidaemia l4S,146.
The study of rodent models has also identified that Peroxisome Proliferator Receptor y
(PPARy) contributes to the development of steatosis and that liver specific deletion of
PPARy reduces steatosis.
2.1.1.6 Models of Genetically Determined Reduced Beta-Oxidation
Several induced and spontaneous genetic mutations that are associated with steatosis
due to defective ~-oxidation have been described. The mutations all affect key
regulatory transcription factors, the import of LCFAs into mitochondria and
enzymatic activity within the oxidative cascade. Although these models establish
causality in that these mutations may provoke steatosis, few exhibit steatohepatitis or
provide a stable tool for NAFLD research. This problem with these models is
exemplified by the naturally occurring]uvenile Visceral Steatosis OVS) mouse. In this
model, systemic carnitine deficiency is caused by a mutation in the carnitine
transporter gene (Octn2) and leads to failure of fatty acid transport into mitochondria
for ~-oxidation148. This model has been shown to develop extreme steatosis within days
of birth. Similarly, Acyl-CoA oxidase (AOX-1-) mutant mice carry a deletion in a key
enzyme in peroxisomal ~-oxidation. Initially animals are phenotypically normal but
over an 8 week period, develop severe steatosis that then spontaneously resolves as
steatotic hepatocytes are replaced. Mice carrying a homozygote PPARa. knockout do
not accumulate fat under normal fed conditions but fail to up regulate fatty acid
oxidation and so develop severe steatosis when fatty acid delivery to the liver is
. d b f . 67, l-t9Increase y astlng .
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A recently described model of NAFLD exhibits a strong phenotypic resemblance to
the human disease. Mitochondrial trifunctional protein (MTP) is a key enzyme
mediating mitochondrial ~-oxidation. Homozygous carriage of an MTPa mutation
causes perinatal death. Recently published data demonstrated that carriage of the
heterozygous mutation was associated with a progressive, age related, elevation of
serum ALT levels. By 9-10 months mutant mice exhibited hepatic steatosis, basal
hyperinsulinaemia and evidence of insulin resistance and impaired glucose tolerance
during glucose tolerance testing93, 150. Mutant animals were also shown to have higher
antioxidant activity of total superoxide dismutase and lower glutathione levels as well
as increased CYP2E1 expression, consistent with increased hepatic oxidative stress.
2.1.1.7 Models of Acquired Reduced Beta-Oxidatio,n (Methionine/Choline Deficiency)
Impaired ~-oxidation may be induced by drugs including the oestrogen antagonist
T amoxifen or the CPT1 inhibitor Etomoxir67 however the main research model in
which an acquired defect in mitochondrial ~-oxidation is used to induce steatosis is
based on feeding a diet deficient in methionine and choline. The MCD model is
arguably the only established model with which to study the inflammatory and fibrotic
elements of the NAFLD spectrum.
Choline is an FDA classified essential nutrient with roles in cell membrane integrity,
transmembrane signalling, phosphatidylcholine synthesis, neurotransmission and
methyl metabolism. The role of dietary choline deficiency in promoting hepatic
steatosis and reduced plasma VLDL levels is well established in the literature (reviewed
in 151). The effect of choline was thought to be due to impaired synthesis of
phosphatidylcholine resulting in diminished VLDL assembly and secretion and
consequently reduced triglyceride clearance152 (Figure 2 on page 30, *4). Recent
observations have cast doubt on this explanation, suggesting further mechanistic study
is required to define the role ofcholine deficiency in steatosis153.
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Mice fed a diet that is deficient in both choline and the essential amIno acid
methionine (MCD) are reported to develop inflammation and hepatic fibrosis in
addition to simple steatosisl 54. The magnitude of the effect of this diet varies according
to the species, strain and gender of animals studiedl55. Evidence suggests that MCD
impairs mitochondrial ~-oxidation and leads to induction of alcohol-inducible
CYP2EI expression154 - a finding later confirmed in a cohort of NASH patients l56
(Figure 2 on page 30, *3). These findings support the hypothesis that alcoholic and
non-alcoholic steatohepatitis may share pathogenic mechanisms. Reactive oxygen
species produced by CYP2EI w-oxidation, coupled with depletion of hepatic anti-
oxidants (e.g. reduced glutathione and s-adenosylmethionine), promote oxidative stress
and induces a histological steatohepatitis. The histological features produced by M CD
are associated with elevated plasma TNFa levels l57 and may be ameliorated by
treatment with pentoxifyllinel58. The MCD diet induces significantly greater ROS
production, mitochondrial DNA damage and apoptotic cell death than many of the
other mouse models ofNAFLD 101.
2.1.1.8 Combined Models of Genetically and Environmentally Determined NAFLD
Several groups have attempted to combine genetic and dietary manipulation to
produce a more severe, accelerated, steatohepatitis or fibrosing steatohepatitis. The
literature reports a number of such combination models including Abcbll mutant
mice fed an MCD diet l59, Apolipoprotein E mutant mice fed an high fat diet l60 and
PPARa null mice fed MCD I61 . These models are all characterised by development of
histological steatohepatitis.
Feeding steatotic db/db mice the MCD diet is shown to produce an accelerated
fibrosing steatohepatitis l62. In this model, hepatic pro-collagen type 1 mRNA levels
were found to be 10 fold increased in db/db mice whilst non-steatotic db/m mice had
a 4 fold rise and ob/ob mice showed no increase in fibrogenesis with MCD feeding.
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The authors concluded that the db/MCD combined model represented an obese,
diabetic experimental model of progressive steatohepatitis. However, the aetiology in
this model is clearly not representative of the true physiological mechanism
encountered in clinical practice.
2.1.1.9 The Phenotype Gap
All the lines described above exhibit some features that may be consistent with the
human NAFLD phenotype. However, none exhibit the full constellation of features
and many differ significantly from the human disease. Even the most widely adopted
models are severely flawed. This is exemplified by the failure of the Ob mouse to
progress spontaneously to steatohepatitis and its leptin deficiency phenotype which is
diametrically opposite to that seen in NAFLD patients. Thus, a phenotype gap exists
between available models and the human disease. This is hampering research at a time
when the prevalence ofobesity and NAFLD is rapidly increasing.
The present study seeks to address this deficiency by looking to identify novel models
of NASH. This is achieved both by dietary manipulation (described in Section 4) and
by using a random N-ethyl-N-nitrosourea (ENU) chemical mutagenesis screen.
2.1.2 Ethyl-Nitrosourea: A Potent Chemical Mutagen
With the human genome project nearing completion, the next challenge for geneticists
is to develop methods of systematically identifying the function of each gene163•
Following success mapping many Mendelian disease traits, Complex Disease Traits are
now the focus of much research. The recently completed genome sequence2S,26 and
existing genetic linkage maps make the laboratory mouse, Mus musculus, an ideal
model organism for comparative genomic study and modelling human disease26. 27.
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Phenotype-driven mouse mutagenesIs represents an effective method for the
identification of novel genes and metabolic pathways underlying disease states 164•
The identification of N-ethyl-N-nitrosourea (ENU) as a highly potent mutagen in
mouse spermatogonial stem cells 165, 166 made employing random chemical mutagenesis
as a tool to generate novel mutant mouse lines a viable proposition167• ENU is an
alkylating agent that forms adducts by transferring an ethyl group to oxygen or
nitrogen radicals in the DNA molecule 168 • DNA adducts lead to base mispairing and
consequently genome wide, random point mutations such as base-pair substitution or
deletion occur168, 169. Using repeated dose regimens, the per locus mutation rate ofENU
has been estimated to be between 1 in 175 to 1 in 1000 gametes screened166, 170
(although estimates vary depending on strain of mouse and type of assay used to
determine the presence of a given mutation171 ). It is estimated that dominant
mutations occur at ",25% of this rate 170• ENU has a propensity to induce A-T to T-A
transversions (44%) and A-T to G-C transitions (36%) 167, this may favour mutation of
A-T rich genes. While targeted null mutations have proved a useful tool, approaches
such as ENU mutagenesis are helpful in elucidating complex human diseases and traits
because base-pair changes accurately model mutations found in naturel72• These
mutations may be gain of function, loss of function, hypomorphs or hypermorphs.
Since mutations occur at random, no assumptions are made about the genes involved
in specific disease processes. Subtle mutant alleles on a standard genetic background
allow researchers to more easily analyse the consequences ofcompound genotypes27•
2.1.2.1 ENU Mutagenesis Screening Strategies
The products of ENU mutagenesis may be studied in either phenotype driven or
genotype driven mutagenesis screens. In a phenotype driven screen, male animals are
exposed to ENU and, once fertility is regained, are mated and their offspring screened
for phenotypes of interest. These are then backcrossed to demonstrate heritability of the
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phenotype. A causative dominant mutation may then be localised by linkage analysis
(see Figure 3). The mapping of the causative mutation is facilitated by mating the
END exposed male animal to a female of a different strain, thus the F1 offspring will
be heterozygous at every location173.174. This approach has previously been successfully
employed in the study of quantitative traits including type II diabetes where END
induced mutations in the glucokinase gene have been rapidly identified17s. Published
data suggests that about 2% of progeny from such screens carry a heritable mutant
phenotypeI63.176.
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Figure 3: A Phenotype Driven Strategy for Identifying ENU Induced Mutations
The route to identification of ENU induced mutations in a phenotype driven mutagenesis
screen. Modified from reference 171
In a genotype driven screen, male animals are exposed to END and their male offspring
are culled and used to construct sperm and DNA archives in parallel. The DNA
archive may then be screened (e.g. by denaturing high-performance liquid
chromatography) to identify mutations in a given gene of interest. When a mutation is
identified, the affected animal can be rederived by in vitro fertilisation techniques and
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studied to determine the phenotypic effect of the mutation170, 177. This has been
successfully applied to identify animals with mutations in nicotinamide nucleotide
transhydrogenase affecting insulin secretion134.
The MRC Mouse Mutagenesis Project based at the MRC Mammalian Genetics Unit
(MGU), Harwell includes both a well established large-scale phenotype driven ENU
mutagenesis screen for dominant mutations and a 5,000 animal archive for genotype
driven research. With an archive of this size, and a per locus mutation rate of
1.08 x 10-3, the calculated probability of identifying a mutant allele in a given gene
approaches 100%170. Both these screening routes allow the generation and
identification of allelic series mutations within genes which may further inform our
understanding ofprotein-protein interactions or function.
The genetic characteristics of models identified from ENU screens may not necessarily
reflect the complex genetics of the human disease but rather may help identify genes
and metabolic pathways that are involved in the development of, for example,
NAFLD. Even if the specific genes identified are not the genes found in the human
population, they are potentially still in biologically and physiologically relevant
pathways and may be targets for therapeutic intervention. The aim of ENU
mutagenesis is to reduce the complexity to single or perhaps digenic gene involvement
(in a particular controlled genetic context) so that we can study the pathways involved.
Further, ENU mutagenesis offers the prospect of generating novel mouse models of
human disease that may be used for further study in a number of areas including cell
biology, metabolism and therapeutics.
2.1.2.2 'Sensitised' ENU Genetic Modifier Screens
Combining induced mutations has previously been described using mouse models of
insulin resistance produced by targeted deletion. Heterozygote deficiency of either the
Insulin Receptor (IR+1-)178 or Insulin Receptor Substrate 1 (IRS-l +1-)179 genes IS
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phenotypically silent whilst homozygous carriage of either mutation induces a severe
phenotype, characterised by death within 72 hours of birth or severe growth
retardation respectively. Exemplifying the potential for epistatic interaction between
these genes, combined heterozygous carriage of both IR+/- and IRS-l +/- mutations
produces a viable animal that exhibits marked insulin resistance and overt diabetes 180.
A phenotype driven ENU screen may be further sensitised to detect either mutations
in a given metabolic pathway or mutations that modify the affect of another gene by
performing mutagenesis on animals with a pre-existing mutation. In this way epistatic
interactions may be exploited in an ENU mutagenesis programme to detect mutations
that alone may be silent but can act in synergy to produce a detectable phenotype. This
approach has previously been used in the study of eye development in the fruit fly
Drosophila melanogaster181 • The first study reporting successful application of this
approach in a mammal was published by Carpinelli et al during the course of this
project182• They undertook a sensitised ENU screen to investigate genetic modifiers of
platelet production on a background of genetically determined thrombocytopenia
caused by homozygote deletion of the thrombopoietin receptor gene (Mpl-/-). This led
to the identification of mutations in the Myb gene that ameliorated the
thrombocytopenia in these mice182•
2.2 Aims & Objectives
The aims of this study were the generation and phenotypic characterisation of new
mouse models that accurately replicate the phenotype of NAFLD as encountered in
clinical practice. Whilst, a disease model may not replicate the entire constellation of
features seen in a complex disease trait, the cardinal features of the human progressive
NAFLD phenotype that the 'ideal' animal model would exhibit include:
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1. Insulin resistance/impaired glucose tolerance,
2. Increased body weight (although not extreme obesity),
3. Dyslipidaemia,
4. Histological steatosis,
5. Spontaneous histological progression from steatosis to steatohepatitis without
the requirement for further pathogenic challenge,
6. Biochemical evidence of hepatic inflammation (detectable, sustained plasma
transaminase elevations),
7. Potential to develop hepatic fibrosis.
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2.3 Methods
2.3.1 Animal Husbandry & Ethical Considerations
All research using live animals was approved by the local ethics committee and was
carried out under Home Office supervision in accordance with the Animal (Scientific
Procedures) Act 1986 taking care to minimise any distress caused to the animal.
Procedures were initially performed under the authority of licence 30/1631 'Genetic
Dissection of Diabetes' and later licence 30/2161 'Genetics of Diabetes & the
Metabolic Syndrome'. Animals were housed under standard conditions (12 hour
light/dark cycle, temperature 21 + 2°C, humidity 55 + 10%) and provided with a
standard commercial diet ('MRC-Standard Diet' Table 64 on page 221; SDS, UK) at
all times unless otherwise stated and given access to drinking water ad libitum.
In accordance with the requirement to address methods ofReduction, Refinement and
Replacement to minimise the use of animals in experimentation183, where practical,
collaborative research was undertaken and animals were sourced from established
mutagenesis programs by the addition of targeted phenotype specific screens to the
existing 'pipelines'.
2.3.2 Ethyl-Nitrosourea Mutagenesis
Due to the inherent risks associated with handling this highly carcinogenic agent, the
administration of ethyl-nitrosourea (ENU) to male mice was performed by specially
trained technicians following a standard operating procedure (MRC #8501/HAR
revision 3.0). The procedure was performed in a fume hood within a designated
'carcinogen suite' in the animal house. 19 N-ethyl-N-nitrosourea (Sigma, UK #N3385)
was dissolved in 10ml ethanol (absolute ethanol 99.86% v/v minimum) and the
solution diluted by the addition of90ml Phosphate/Citrate buffer (Table 5).
54
Table 5: Preparation of Phosphate/Citrate Buffer for ENU Mutagenesis
Components
Sodium citrate (Na3C6Hs0 7)
Sodium phosphate (NaH 2P04)
Water
IM Citric Acid
Total Volume
Amount added
2.94 g
2.4 g
200 ml
Adjust pH to 5.0
200.0 ml
The concentration ofENU (mg/ml) in the final solution was confirmed by measuring
light absorbance at 398nm in a Beckman DU-600 spectrophotometer (Beckman-
Coulter Inc., USA). Male animals of known weight aged 10-12 weeks were injected
with ENU at a dose of 100mg/kg. All ENU contaminated equipment was soaked in
20% sodium thiosulphate solution (20% Na2S203 in O.lM NaOH) for 24 hours to
inactivate the ENU before safe disposal.
This procedure was repeated once, 7 days later. Animals were singly caged until they
had regained fertility, at approximately 6 weeks from the date of last injection, when
they were mated to unmutagenised C3H/HeN female mice (Charles River, UK).
Approximately 30-50 F1 offspring were produced from each mutagenised male.
2.3.3 Phenotypic Screening Strategy
The successful identification of mutant animals is dependent on the correct selection
and implementation of serial phenotypic screens. The MRC Mammalian Genetics
Unit (MGU) mutagenesis program encompasses a battery of phenotypic screens
designed to identify mutants with morphological, neurological, behavioural and
biochemical phenotypic abnormalities l63, 184. Elements of these established screens and
purpose specific phenotypic screens were employed to seek mutant lines with heritable
NAFLD phenotypes.
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The NAFLD phenotype is characterised by impaired glucose tolerance/insulin
resistance, dyslipidaemia and elevations in plasma Alanine transferase (ALT) or
Aspartate transferase (AST) levels (section 1.3). Thus, identification of a biochemical
(ALT/ AST elevation or dyslipidaemia) or impaired glucose tolerance phenotype was
used as a primary screening tool. Animals found to have a robust, heritable glucose
tolerance or biochemical phenotype were then assessed using a secondary histological
screen to determine if NAFLD was present. This two-step screening strategy was
adopted as it offered an acceptable balance between identification of mutant
phenotypes and what was technically and economically practical. A primary
histological screen was not considered to be viable as it would necessitate killing
animals at screening, making onward breeding only possible by resource hungry in vitro
fertilisation techniques. Animals derived from two distinct mutagenesis studies (an un-
sensitised study and a sensitised study) were investigated in this project as summarised
in Figure 4 and discussed below.
Primary Screen
UN-SENSITISED
MUTAGENESIS STUDY
*Balblc x C3H
1
Biochemical
(ALT, AST, Glucose, Lipids)
1
SENSITISED
MUTAGENESIS STUDY
*C57BU6 IR+1- x C3H
1
Glucose Tolerance
(IPGTT)
1
Secondary Screen 1 Liv_e_r_Hi_st_ol_ogy ---'
1
Extended Phenotype Analysis
1
Figure 4: Overview of ENU Mutagenesis Phenotype Screening Strategy
Animals from each mutagenesis study underwent two phenotypic screens to identify those
with NAFLD like phenotypes. Animals selected for further study entered an extended
phenotype analysis that examined further biochemical parameters and response to high fat diet
as appropriate. IPGTT, intraperitoneal glucose tolerance test.
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2.3.3.1 Un-sensitised Mutagenesis Study
The un-sensitised mutagenesis study derived animals from the general MRC MGU
biochemical mutagenesis program l63, 185, 186. In this program, male BALB/c mice were
exposed to ENU as described in section 2.3.1 and crossed to unmutagenised C3H
females. At age 8-12 weeks, 1,961 F1 offspring were screened to identify animals with
biochemical abnormalities. Primary biochemical screening was performed by
experienced technical staff as part of the general MRC MGU mutagenesis program.
This work has previously been described and falls outside the scope of this thesis l86. A
threshold of> 2 standard deviations above the population mean was used to select mice
for inheritance testing. Affected animals were backcrossed to C3H and the backcross
(BC 1) offspring tested to determine if the trait was heritable.
Mouse lines identified by the MGU screen that had biochemical features consistent
with a NAFLD phenotype were adopted for study in this project. Specifically, mice
with persistent elevation of markers of hepatic inflammation (ALT/ AST), impaired
glucose tolerance or dyslipidaemia were selected. These lines underwent a secondary
histological screen to determine ifNAFLD was in fact present.
2.3.3.2 Sensitised Mutagenesis Study
As has been discussed in section 1.5, insulin resistance is considered to be one of the
cardinal pathogenic features of NAFLD and type II diabetes mellitus. A mutagenesis
screen sensitised to detecting phenotypes with reduced insulin sensitivity had been
initiated by Dr M. Goldsworthy as part of an ongoing research program into diabetes
mellitus within the MRC MGU. In collaboration, this screen was adapted to enable
detection of mice with NAFLD and a sensitised mutagenesis study was carried out (see
section 2.1.2 for a description of the genetic basis ofsensitised mutagenesis).
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ENU mutagenesis was performed on male C57BL/6J mice heterozygous for a targeted
mutation in the Insulin Receptor gene (IR+I-) derived from a colony that had been
purchased from the Jackson Laboratory, USA (congenic strain B6; 129S4-InsrcmlDac/J,
#002426)178. A smaller sensitised screen was performed using male C57BL/6J mice
heterozygous for a targeted mutation in the Insulin Receptor Substrate-l gene (IRS-
1+1-)179. ENU was administered as described above (2.3.1) and mice were then crossed
to unmutagenised C3H females. 30-50 F1 offspring were produced from each
mutagenised male.
The offspring from the sensitised ENU mutagenesis program independently segregate
both the IR or IRS-l heterozygote mutation and also any new ENU induced
mutation. Figure 5 illustrates how, following Mendelian principles, 25% of these
offspring would be expected to carry two mutations, 25% to carry no mutation, and
the remaining 50% to carry one mutation.
ENU 2 x 100mg/kg
/l
X
C3H
F1
4'
IR +/- ENU +/. C3H
BC1
IR ./+ ENU·j. IR ./. ENU ./. IR ./. ENU +'+ IR +1+ ENU +1+
Figure 5: Schematic of Sensitised ENU Mutagenesis Breeding Program
Male C57BU6-IR+I- mice were exposed to ENU and crossed to unmutagenised C3H females.
All offspring independently segregate the IR+I- mutation and any new ENU induced mutation.
FI offspring underwent IPGTT phenotype screening. Animals with a persistent glucose
tolerance abnormality entered inheritance testing and were backcrossed to C3H female mice
to produce Backcross I (BC I) generation offspring. These were in turn screened by IPGTT.
58
The F1 offspring were screened for an impaired glucose tolerance phenotype at age 12
and 24 weeks by intraperitoneal glucose tolerance test (IPGTT). This method is
described below in section 2.3.5. A non-ENU mutagenised control population of mice
from the same genetic background (C57BL/6-IR+I- x C3H), which therefore also
segregate the heterozygote insulin receptor mutation, was established and tested in
parallel. Blood glucose values >2 standard deviations above the mean of the control
group were considered significantly elevated. Animals found to have significant
phenotypic abnormalities entered inheritance testing and were backcrossed to C3H
females. The secondary histological screen was then performed to determine if
NAFLD was present.
2.3.4 Biochemical Screening
Biochemical screening of F1 offspring from ENU mutagenised male mice was the
primary screening tool used in the un-sensitised screen (Figure 4). The same method
was also used to test selected lines identified as part of the sensitised study to further
characterise their biochemical phenotype.
Blood samples were collected in lithium-heparin tubes (Microvette CB300, Sarstedt,
Germany) taking care to minimise haemolysis and immediately centrifuged at 3,000
rpm for 10 minutes in a bench-top centrifuge. The cellular pellet was discarded and the
plasma analysed in an AU400 (Olympus Diagnostic Systems, UK) automated clinical
chemistry analyser equipped with an ion selective electrode. If sufficient plasma was
available, up to seventeen biochemical tests were performed including Renal (sodium,
potassium, urea & creatinine), Hepatic (albumin, ALT, AST, alkaline phosphatise &
bilirubin) and Metabolic (glucose, triglycerides & cholesterol) parameters.
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2.3.5 Intra-peritoneal Glucose Tolerance Test
An intraperitoneal glucose tolerance test (IPGTT) was the primary screening tool used
in the sensitised screen (Figure 4). Following an overnight fast, mice were weighed.
Animals were placed in a restraint tube, local anaesthetic cream (Lidocaine 1%)
applied to the tail and, after 10 minutes, an initial 30~1 blood sample collected in a
lithium-heparin tube (Microvette CB300, Sarstedt, Germany) via a small incision in
the lateral tail vein. The mice then received an intraperitoneal injection ofglucose. The
dose of glucose administered was adjusted for body weight (2g/kg body weight as 20%
glucose diluted in 0.9% saline). Further blood samples were collected 60 and 120
minutes after the intraperitoneal injection. Samples were stored at 4°C until plasma
was obtained by centrifugation ofwhole blood at 3,000 rpm for 10 minutes in a bench-
top centrifuge. Approximately 10~1 of plasma was obtained from each sample. Plasma
glucose concentration was then determined using an Analox GM9 Glucose Analyser
(Analox, UK). Values >2 standard deviations above the mean of an unmutagenised
control population (CS7BL/6-IR+1- x C3H) were considered significantly elevated.
2.3.6 Determination of Plasma Insulin Concentration
As described in section 2.3.7, blood was collected by cardiac puncture when animals
were culled taking care to minimise haemolysis. Samples, collected in lithium-heparin
tubes (Microvette CB300, Sarstedt, Germany), were stored at 4°C until plasma was
obtained by centrifugation ofwhole blood at 3,000 rpm for 10 minutes in a bench-top
centrifuge. Insulin levels were measured on a subset of samples using a commercial
colorimetric solid phase ELISA kit (Ultrasensitive Insulin ELISA #10-1132-0 1,
Mercodia AB, Sweden) according to the manufacturer's instructions.
Enzyme conjugate solution was prepared by mixing 1.2ml of 11x concentrate with
12ml of Enzyme conjugate buffer and a Wash buffer was prepared by diluting 40ml of
21x concentrate with 800ml de-ionised water. Analysis was performed in a 96 well
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format. In duplicate, 5111 aliquots of sample serum or recombinant human insulin
standard ofknow concentrations (0, 0.15, 1,3, 10 & 20 mUll) were added to each well
of the ELISA plate. Following the addition of 100111 of enzyme conjugate solution to
each well, the plate was incubated on a plate shaker at room temperature for 1 hour to
allow insulin to bind to peroxidase-conjugated anti-insulin antibodies bound to each
well. Reagents were removed from each well by aspiration with a pipened and the
membrane washed by repeated (Sx) application and aspiration of 350111 aliquots of
wash buffer. 200111 of 3,3',S's'-tetramethylbenzidine (TMB) substrate were added to
each well and the plate incubated in the dark for a further 30 minutes on a plate shaker
at room temperature. 50111 of O.SM sulphuric acid was added to each well to stop the
reaction and light absorbance measured at 4S0nm wavelength in a SpectraMax 190
microplate spectrophotometer (Molecular Devices, USA). A standard curve was
generated by plotting absorbance values against concentration for the human insulin
standards and the insulin concentration of the serum samples determined. Where
necessary, samples with very high insulin concentrations were diluted 1: 10 vIv with the
zero calibrator solution and reprocessed.
2.3.7 Liver Histology
Mice were culled by overdose of anaesthetic administered by intraperitoneal injection
(0.2ml Sagatal, Pentobarbitone sodium 60mg/ml, Merial Ltd., UK). Cardiac puncture
and exsanguination were then performed to collect blood for biochemical analysis.
Liver, pancreas, muscle, brown and white fat were quickly collected and preserved in
10% formalin andlor snap frozen in liquid nitrogen and stored at -80°C as a resource
for subsequent RNA and protein analysis. Formalin fixed tissue was processed into
paraffin wax and sections were stained with Haematoxylin & Eosin and Chromotrope
Aniline Blue (CAB) trichrome.
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All sections were jointly examined by light microscopy with a histopathologist (Dr R.
Goldin). The degree of steatosis and steatohepatitis were assessed using the recently
validated NIDDK NASH Clinical Research Network histological classification (a
modified Brunt semi-quantitative steatohepatitis score) 187. 188. Briefly, this measures
the degree of steatosis (0-3), fibrosis (0-4), inflammation (0-3) and hepatocyte
ballooning degeneration (0-2) observed and is summarised in Table 6.
Table 6: The NIDDK NASH Clinical Research Network Histological Classification
Steatosis
o
I
2
3
Fibrosis
Less than 5% of lobular parenchyma involved
5-33% of lobular parenchyma involved
33-66% of lobular parenchyma involved
More than 66% of lobular parenchyma involved
o
I
Normal connective tissue
A i Zone 3 Mild Perisinusoidal Fibrosis
B i Zone 3 Moderate Perisinusoidal Fibrosis
C Periportal Fibrosis only
2 Perivenular and pericellular fibrosis confined to zones 2 & 3 ± periportal fibrosis
3 Bridging or extensive fibrosis with architectural distortion; no obvious cirrhosis
4 i Cirrhosis
Inflammation
o ! No hepatocyte injury or inflammation
I I Less than 2 foci per 20x field
2 i 2-4 foci per 20x field
3 I More than 4 foci per 20x field
Hepatocellular Injury (i.e. Hepatocyte Ballooning Degeneration)
o None
I i Few
2 I Many
The authors of this score report that the five features best associated with NASH are Ballooning
hepatocyte degeneration, Fibrosis, Lobular Inflammation, Steatosis and Acidophil bodies. Zone 3
Ballooning degeneration is considered a gold standard for diagnosis.
2.3.8 Measurement of Pancreatic Islet Area
Pancreatic tissue was collected and processed as described above. Sections were stained
with Haematoxylin & Eosin. An average of 5 non-overlapping fields (lOx objective)
distributed throughout each section were randomly selected and digital images
captured. Images were analysed using Photoshop CS2 software (Adobe, USA). The
mean area of pancreatic islets within the pancreatic stroma was calculated. This was
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expressed as a percentage of the total area of pancreatic tissue examined to provide a
relative measure of islet area.
2.3.9 High Fat Feeding
IGT/6 backcross 3 (BC3) mice were classified as 'affected' (defined as tl20 blood
glucose levels>2SD above the control mean) or 'unaffected' according to the results of
their 12 week IPGTT result taken whilst fed standard chow. The hypothesis that
affected IGT/6 mice were more sensitive to dietary factors that may exacerbate their
impaired glucose tolerance/NAFLD phenotype than unaffected littermates was tested.
From the age of 12 weeks, male affected IGT/6 BC3 mice and unaffected littermates
were randomised to receive either a nutritionally replete pelleted high fat diet
containing 45 kcal% fat (Research Diets Inc, USA) or standard pelleted chow
containing 11.5 kcal% fat (SDS, UK). Full details of diets are provided in Table 64 on
page 221 where they are designated as 'MRC-High Fat Diet' and 'MRC-Standard
Diet' respectively. Mice had IPGTTs repeated 4 and 12 weeks after randomisation (age
4 and 6 months) and were weighed regularly during the experiment to monitor
changes in body weight. Animals were culled at age 10-12 months, tissues collected for
histological analysis as described above and blood collected for biochemical analysis.
2.3.10 DNA Extraction
Genomic DNA was extracted from tail tip biopsies (length 0.4-0.6 cm) taken from 44
backcross 1 (BC1) and 27 backcross 2 (BC2) IGT/6 mice and unmutagenised mice
from the background strains (C57BL/6, C3H and F1 progeny). A commercially
available DNeasy Mini kit (Qiagen, USA) was used for this procedure (see Figure 6)
according to the manufacturer's instructions.
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Tissue was placed in a l.5ml Eppendorf tube to which I80~ Buffer ATL and 20/11
Proteinase K (600mAU/ml) were added. The reagents were mixed by vortexing and
incubated at 55°C overnight until the tissue sample had completely lysed. Buffers AL-
ethanol, AWl-ethanol and AW2-ethanol were prepared by addition of ethanol
(absolute ethyl-alcohol 99.86% v/v minimum, Hayman Ltd., UK) to the three buffer
concentrates as per the manufacturer's instructions. After lysis was complete, the
sample was mixed thoroughly by vortexing for IS seconds, 400~ AL-ethanol buffer
was added (total volume 600/11) and the reagents mixed again by vortexing for IS
seconds.
TIssue sample
f lyse
~
~
rg BindDNA
!~
Ready-Io-use DNA
Figure 6: Schematic of DNA Extraction Using DNeasy Kit (Qiagen, USA)
As described in the text, tissue was lysed by incubation with Proteinase K and the DNA bound
to a membrane within the spin column. Contaminants were washed away by serial application
of wash buffers before the purified DNA was eluted from the membrane. Image modified from
manufacturer's product literature with permission.
The 600~ reagent mixture was then applied to a DNeasy Mini spin column and
centrifuged at 8,000 rpm for 1 minute in a bench-top centrifuge. This allowed the
selective binding of DNA to the silica-gel membrane within the column. The
centrifugate was discarded. Contaminants were washed away by application of 500/11 of
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AWI-ethanol buffer, centrifugation at 8,000 rpm for 1 minute and application of
SOOfJ-l AW2-ethanol buffer. The column was centrifuged again at 14,000 rpm for 3
minutes to dry the membrane and the centrifugate discarded. The purified DNA was
eluted from the membrane by incubating the column for 1 minute in the presence of
200fll AE buffer followed by centrifugation at 8,000 rpm for 1 minute.
Extracted DNA was then quantified and checked for purity by measuring light
absorbance at 260/280nm (background correction at 320nm) in a SpectraMax 190
microplate spectrophotometer (Molecular Devices, USA). SoftMax Pro software
(Molecular Devices, USA) were used to determine DNA concentration for each
sample. Samples were diluted to a standard DNA concentration of Sng/fll with
nuclease free water and stored at -20°C.
2.3.1 I Genotyping to Determine Insulin Receptor Status
Homozygote (wildtype) or heterozygote carriage of the insulin receptor gene was
determined by genotyping each animal and comparison to CS7BL/6 and IR+I- control
animals. Primers, oIMROO13 (S'-CTTGGGTGGAGAGGCTATTC-3') and
oIMR0014 (S'-AGGTGAGATGACAGGAGATC-3') were used to amplify a 280
base pair region of DNA containing a neomycin cassette introduced as part of the
original targeting vector. Primers oIMROO 1S (S'-CAAATGTTGCTTGTCTGGTG-
3') and oIMR0016 (S'-GTCAGTCGAGTGCACAGTTT-3') served as a positive
internal control to amplify a 200 base pair region of the T-cell receptor delta (Tcrd)
gene. Primers were synthesized to order by Sigma Genosys, UK.
DNA was extracted from tail tip biopsies as described above. Prior to use, DNA
(Sng/fll) was thawed and diluted to Ing/fll with nuclease free water. PCR reactions
were prepared using GeneAmp PCR reagents and AmpliTaq Gold DNA Polymerase
(Applied Biosystems Inc, USA) as detailed in Table 7. Water was substituted for DNA
in negative control reactions.
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Table 7: Composition of PCR Reaction to Determine Insulin Receptor Status
Reagent
DNA (I ngl~,J1)
dNTP (lOx, 1.25 mM)
MgCl2 (25mM)
PCR Buffer* (lOx)
AmpliTaq Gold (5 U/jJl)
Primers olMROO 13 & olMROO 14 (2jJM)
Primers olMROO 15 & olMROO 16 (2jJM)
Nuclease-free Water
Total Volume
Volume per Reaction h,d)
5.0
2.5
2.5
2.5
0.1
1.0 each
0.6 each
9.2
25.0
Final Concentration
0.2 ng/jJl
0.125 mM
2.5 mM
Ix
0.02 U/jJl
0.08 jJM
0.048 jJM
* lOx PCR Buffer contains 100 mM Tris-HCI, pH 8.3; 500 mM KCI; 15 mM MgCI2; 0.1 %w/v Gelatin.
The 25/11 volume PCR reactions were prepared in 96-well plate format and run in a
DNA Engine thermal cycler (BioRad Inc., USA) using 'RH55' cycling conditions as
described in Table 8.
Table 8: 'RH55' PCR Thermal Cycler Settings
Reaction Step TempoC Time
Initial activation step 94°C 10 minutes
Cycle (x30) Denature 93°C 30 seconds
Anneal 55°C 30 seconds
Extend 7rC 60 seconds
Final extension step 7rC 5 minutes
Hold 15°C Indefinite
Electrophoresis ofPCR products was performed on a 2% Agarose gel (100ml1x TAE
buffer to 2g Agarose and 4[11 Ethidium bromide) in a TAE buffer solution at room
temperature. A 100 base pair DNA ladder (l[1g//1l, #15628-050 Gibco, USA) was
loaded into the first and last well of the gel to measure DNA fragment sizes. Five
microlitres of the PCR product and 1[1l ofxylene orange loading dye were loaded into
each well. The gel was run at a constant potential difference of 100 volts (maximum
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current) for 45 minutes at room temperature after which the migration of the PCR
product was determined using ultraviolet light and a photograph of the gel taken. The
fragment sizes were determined by comparison to the DNA ladder to determine the
genotype of the animals.
2.3.12 Microsatellite Linkage Analysis
The location of the ENU induced, dominantly inherited causative mutation was
sought by linkage analysis to genomic markers of known position (as discussed in
section 2.1.2). Microsatellite markers that were polymorphic between the C57BL/6
and C3H strains were identified from data published by the Whitehead/MIT Centre
for Genome Research 189, 190. 136 simple sequence length polymorphism (SSLP)
microsatellite markers, distributed throughout the mouse genome at approximately
20cM intervals (Table 9 and Figure 7), were selected and appropriate fluorescently
labelled oligonucleotide primers ordered (Sigma Genosys, UK).
Each marker was labelled with a blue (FAM), green (HEX) or red (ROX) fluorescent
dye to allow automated detection of PCR product. Where possible primers were split
into panels with dissimilar PCR product sizes and colours of fluorescent label so that,
when analysed simultaneously, the PCR products could be clearly resolved on an ABI
PRISM 3100 genetic analyser using ABI Genescan and ABI Genotyper software
packages (Applied Biosystems Inc, USA).
67
C~.z1/;T~~7
C ~2U.:--r2e.)
r-~:v~n;
D12lJrnro
D~2V:72' ~
DL7V:i;4J
DI2W7'O~,
CHR08
CHR12
U
11
:",0
2~.O -
t''"i!-·Mli13-4
\.. 075MIT'0~
t)"e-VIT,,:'
CHR15
CHR07
CHR11Z41r::'lwn<~'c. :'<Vll~3-
, cO rnMIT271
2E~ ~ D'.".'V.1T23-4).0 C' "'IT?;
:·:,C D~~ VIT":;
,x; c-' '1!lr:2_
";":-C C· ~ ~!lr:~.
OS,2
D~*\HT~, )::
D~4MIT~: "
C~ 4~/lT3:
D~4MlT::!
Di"MtT~:(;2
G~~}/lr~:
'/ C:<'4~'lT2,~
D"4Mlr~2
',- D"·4VIT2e:
O~4UIT9;
CHR14
CHR06
3,0
10.0
CHR02 CHR03 CHR04
3~.7 '"' r;:~}lT4% ~,2 I C3WT:,? Ir-'"4!'C' :':~}lT2i ,> :~_Ufr::~ C4\A:7·S:4:,e J: '\'- :Z1}iT27; « :;J\'{IT~~ ../ '-'-C-4M':'.~:\.4 ... '- ::2)}Jr~s 4:; C2NID7 3:- D~VT70~~.~ \ .. D~J!IT~2 5~ D:!VIT~2 42 -D41:;T~.7SiB .-/' '- C1WT4ee it :Y/liE-~ t·: [;4',.."2::107,( ./ :::).'IT2X :,3. D~Alre7
Cl~lF'13
Ct2;M1T.9
()t1~"':~:':;1
D~lJ.!'!":· ~
"'- CUfI,243
C,MI'17,
/" DJUJ71~~
c:Vrt~,2,-:'
DtVIT~:?
O'l!IH24
C'MI7!~~,
O'1tIT2:~
-C'l/17':f.
CHR01
t""!
CHR13
CHR05
Figure 7: Chromosomal Distribution of Informative Microsatellite Markers
Windows QTL Cartographer 2.0 software output showing relative position of microsatellite
markers on each chromosome. Distances measured in centimorgans (cM).
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Table 9: Details of the SSLP Microsatellite Markers Used for Linkage Analysis
MARKER MARKER POSITION t PRODUCT PRIMER SEQUENCE
SIZE (bp)
Chr eM mb 86 C3H FORWARD REVERSE
. - GGCTTCTGCAGGATATCTGCDIMIT316 7.90 10.49 150 141 GCCTTTCCAGGTTTCTTAAGG
DIMIT211 15.00 25.76 158 166 GTTATTCATCAAAATACAGATGGCC TCTGCTGCTAAGTAGAATGAATGC
DIMIT243 19.50 35.35 145 133 CCAGGGCAATTGGATACAAT GTTGTGCCAAAATGGAGGAC
DIMITI78 34.80 69.02
- -
TGTGTCCCTATAATACACACTCACG TTCCCATTAATGATTTGAGATAAGC
DIMITI36 59.60 101.83 99 105 TAGCCCTACACACTGTAGAAATGC TGAACACAAAGTAGTAAATGCGTG
DIMIT387 62.00 115.37 132 145 CCACTTTGCGATCTCTTCAT ATTGTGGCTTAACTACAAAAATAATTC
DIMITI39 65.00 126.35 242 231 CGACATTATCACTTCAGAGTTTGA GAGTTCCAGCCCACTGAGAG
DIMIT424 81.60 160.66 128 133 TCTACTCCTGCAGTTTATTAATGGG ATAAAGTGCTACAGGCAATCTGG
DIMIT355 97.00 173.34 110 95 TAGAAAGACCTTTTCTCAAATAGTGTG TAGGAACTGTTTTGTTGTTTTACACA
DIMIT221 102.00 184.72 116 118 GGATTGCTATAACAGGAGCAGG ATGGCAGAAGATGGATGAGG
DIMITI55 112.00 194.17 250 213 ATGCATGCATGCACACGT ACCGTGAAATGTTCACCCAT
D2MIT458 2 31.70 50.79 18 95 GTAGTTGAGGAAGACAATTGACACA AGTGCTGTCCTCTGGGCTTA
D2MIT37 2 45.00 74.39 69 177 TGTGCAAGCCAGAAAAGTTG GAAGGGGATTGTAAATTGGTACC
D2MIT272 2 47.50 90.22 18 114 CTCACATTCTGCTTTTCCTGC TACTGTACTGATCTGATCATTCCTACA
D2MIT58 2 51.40 107.88 34 128 ATAGTTGGTTTTTGTTGCTATTGC TGCATTTGCAACATACCCC
D2MIT62 2 65.00 117.63 61 145 GGATACCGTTTGGAAAGTAAACC GCAAGAAGCACAGGAGGC
D2MIT456 2 86.30 168.45 24 172 TTGCTTGAGCAATGGCTATG GGGAAAAGAACCAAGTTCTGC
D2MIT200 2 107.00 179.51 37 126 ATGGCCTCTGCTAAATGGTG GCTAGCAGGAGCGTCATAGG
D3MIT239 3 16.50 35.30 96 168 TTTCGGTCATATTCTTTCTTCTCC AGTAGTTGGTCAACACAAAAGTGTG
D3MIT25 3 29.50 56.43 35 133 GTCTGGGTCGTCAGTGGC TGGAGGCTACCATCTCCAAG
D3MIT49 3 41.00 88.99 22 106 CTTTTCTCGCCCCACTTTC TCCTTTTAGTTTTTGATCCTCTGG
D3MIT77 3 49.70 101.45 49 163 TCCTGCTGACACCACCAAG AGCACCTACATTTTCCGCAA
D3MIT42 3 58.80 120.24 86 190 TGACCTCCAGAGAGTCTTCCA TAAGCAGCTGAGACTCAAGTGG
D3MIT86 3 76.20 146.32 56 166 TGCTCAACATAAAATGTCTGGC AAGCACAGAAACATCTCTCACG
D3MIT87 3 83.50 152.22 47 151 TTTGTGTGGCAATGGCTG TATCCTAAACCAGAAGGTGGTTG
MARKER MARKER POSITION t PRODUCT
SIZE (bp)
PRIMER SEQUENCE
-.J
o
Chr eM mb B6 C3 H FORWARD REVERSE
D4MIT235 4 1.90 8.26 112 95 AGGCCAAAGGTTGGATTTCT GAGACTTGAAATTGAAGCATTTAGG
D4MITI93 4 7.50 32.45 136 120 TATTTTAATTTTAGCCCATCAGGG AAAGACATACAATTGATCCACAGG
D4MIT214 4 17.90 45.57 123 141 CCCTACAAGTTGTCCTCTGACC CACCAGTGTTGAGAGCAGGA
D4MITI78 4 35.50 66.27 144 165 GCCCTGAAGGTAAATCAGTAACT GCTCAGGAGGTACATTGCCT
D4MIT327 4 42.50 85.44 103 92 GAACACAAACATACAGAGACAAACG CATCATGCACCACTACACCTG
D4MIT203 4 60.00 128.60 112 122 GAATTCTTCCTGGGCCTTTC CAAGAGCCCAGGTGTGGTAT
D4MITI70 4 66.60 137.50 103 112 TTCCATCGAGTGACTTGATCC CAGAGTGGCTGTCATCTGGA
D5MIT348 5 8.00 23.39 120 125 CTGACCAGAACACAGCATAGTACA TTTAAAATAGGAAAAGCATTCTTTCC
D5MIT353 5 24.00 39.13 I 18 128 TTCCTCCCAAGATCCAAAAA CCTCAACCCCAAACTCAAAA
D5MITI97 5 36.00 63.44 152 117 TCAGTGATAATGACATGGTAGAAGTG AGAGGGTTTCCTTCCCCC
D5MITI35 5 42.00 73.65 243 218 TACACAGGGAAAGGACAGGG AGGGAGATTTTGGATTAGAGGC
D5MIT205 5 45.00 92.47 150 168 GAGACGGCAGTTGGAGAGTC GGCTAAGTGATAATCATTGCAGG
D5MIT25 5 61.00 112.99 230 226 GTCTTACTCCTGCCTGAACCC TTACCTTACACTGAGACCAGAAAGC
D5MIT292 5 80.00 139.69 109 123 GTCTTACTCCTGCCTGAACCC TTACCTTACACTGAGACCAGAAAGC
D6MITI59 6 7.00 29.80 114 140 CATATTCAAGACGGAGACTAGTTCC CACATGAAACACATGCACACA
D6MIT268 6 15.60 34.83 - - AGTCAGAATATGGCAAGTCAGTG TTTCAGAGTCTTTCTTTCAGTATCTCC
D6MIT316 6 28.00 55.70 92 88 TCATGCAGACAAACTCCTCG GCTCATTTCACTGCCCATCT
D6MITI88 6 32.50 75.79 132 158 CTTTAGTCATTATTAGGATTGCCTATG TGGGATAGCATTGGAAACGT
D6MIT289 6 62.30 129.53 150 154 TGGAGATCCACGGCATTG CTAGATTGAAGAATTCCTGGACC
"'D7Mifi-iTr--'-'-i"----')"A-0--T5.76--I'5-2---T91 TTGGGTTTGTACTACCTAGATACCTC CCTCTAGG'GCTCTTGCACAC------,·----
D7MIT25 7 16.00 - 107 91 AGGGGCACATGTTCAACTATG GGTTGTTTCCAGCTTTGGG
D7MIT230 7 24.50 43.62 107 90 GGGTTAACTGCTTTTTAAAAGTGC ACTTCTGCATGTTGCCCTCT
D7MIT23I 7 27.80 60.43 - - ATGCTCCAACTTGTGTGCAC ATGCAATGCCCTCTGCTG
D7MIT373 7 49.90 90.11 198 212 GCTGCTGAGCGTTTGTCTTA CTAGCATGGTGCATTTGAAGA
D7MIT28I 7 52.40 106.07 112 137 TTCCTCTACCTCCTGAGCCA GCCACAAGGAAGACACCATT
D7MITI05 7 63.50 122.61 257 241 AGCAAAGTAAGGCAGACTTTGG AGGAGAGGCAGAACATGGAA
...-•....•.•- _ _-- _._ - -_ .
--..I
-
MARKER MARKER POSITION t PRODUCT PRIMER SEQUENCE
SIZE (bp)
Chr eM mb B6 C3H FORWARD REVERSE
D8MITI43 8 8.00 22.60 280 268 AGCCTGAGGTTATGTTTTTTGC GGCCCTCAGGTTTTCTCTCT
D8MIT289 8 11.00 27.57 150 118 AAAAAGAAAAGAAGGCTTAGTAATGTG CTTGCTATTCATTGCAAAATTCC
D8MIT29I 8 15.50 31.13 96 94 GTTTAGTGTGTTTGTATGAGCATGC AACAAGAATGAAGTGTTCATGCA
D8MITI00 8 31.00 55.72 III 103 AGGGGCACATGTTCAACTATG GGTTGTTTCCAGCTTTGGG
D8MITI29 8 31.50 58.86 108 119 GTCAAAGGTAAAACATATGGACACA ACCGTGCAGGTTCTCTGC
D8MIT249 8 37.00 80.15 145 186 AAACTCACACACACAGAGACAACA GCCCCAGTGTGACTAAGGAG
D8MITI83 8 47.00 100.33 150 156 TCTCAAATAACTATCAACTCTTAGGGG TCTTTGAACTGGCTATAATCACTCA
D8MIT92 8 71.00 125.98 160 162 CTCAGGCTATCTTGGACATGC TGGCTCACATCTGTGCTTTC
D8MIT279 8 71.00 125.64 85 83 ACTTTTTTTCCTTTTTGAAATTGTG TCTATAAACAAAGCCCCCCC
D9MITI71 9 28.00 49.64 253 229 GGTTGCTCTTTTGTTGTTGTTG AGGTATGTAGACTCCTTACTCATCTGG
D9MITI04 9 35.00 66.05 125 116 TTAATTGAGACGCACTTTGGG AGGGGTCATTAGAGTTGGGG
D9MIT236 9 43.00 80.30 143 127 GGGAACTACATACACGAAATTGG AGTTATCAGTCGTCGTCCTAAGTG
D9MITI82 9 55.00 101.48 108 123 GTGAAATTGGTTATGTAAATGTCTGA GAGATGACTAGGGTGAACTGGG
D9MIT311 9 65.00 116.51 144 123 CAGAAAACACTAATGTTTTGTATCTCA AGAAAACCACCTACCTACCTACACA
DIOMIT80 10 4.00 11.52 150 137 CAAAAAAAACCCTGATTCTACCA GTGTGCATATGGCAGTAACTTTG
DIOMIT42 10 44.00 82.54 199 207 GCATTCAGAAGCTGGAAAGG TGCCCAGCATATGTTTAAAGG
DIOMITI2 10 56.00 99.45 236 215 ATGTCCAAAACACCAGCCAG GGAAGTGATGGAGCTCTGTT
DIOMIT271 10 70.00 124.04 110 96 ACAACCAAAGGTCTTTGTAGAAGA AATATATAGGCACACCTTAATAGCCA
_._--_.._...... .
12.21 TCCCAGAGGTCTCCAAGACA CCACAGTGTGTGATGtCTTCDIIMIT2 II 2.40 103 119
DIIMIT53 II 16.00 32.17 229 243 GTGGATACAGAGTGGATACAGGG GTAACCAAGATGCAAGGGGA
DIIMIT271 II 21.00 45.57 116 110 TCTCCACACATTCACCATGG CTTCCTCAATTGCTCTTGCC
DIIMIT23 II 28.10 53.99 125 120 AAAGCAGAGAAGTCTCACCCCT GCACACAGTCATGCAGCAC
DIIMIT29 II 40.00 69.52 159 166 TTGAGGCATGAGGGGATTAG TTTCCGTCATTGCTAAAGGG
DIIMITI79 II 52.00 89.66 163 139 TTTGGCATTCACATGTAGGTC TTGCTTTATAATCTTTCTCTGTGTG
DIIMIT224 II 66.00 108.30 144 157 TTCTCAGGGGCGTAATTCAC GTACACAGTAAACAATAGGCATTGTG
DIIMIT214 II 70.00 114.85 183 168 CATACAGCCTTCAACAATGACA ACTGCATACATGTGCACTCATG
_....................._. ._-_........_---_.... ..__ ..__..................................... .......................__._......._......_-_ .....
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MARKER MARKER POSITION t PRODUCT PRIMER SEQUENCE
SIZE (bp)
Chr eM mb 86 C3H FORWARD REVERSE
DI2MIT37 2 1.00 4.54 141 118 AAGTTTGAACACAGAACACTCAGC TCTGGTTTGCAGGAAGCC
DI2MITI03 2 1.00 5.18 127 129 ACTATGGTGAAATCATACCCACG ATCAATGGATCTTTTTTGGTGG
DI2MIT215 2 2.00 6.86 126 134 AATTTATATTGGAGAGAGAGGGGG TGATGTTTTTACATTAATTGTTCTCTC
DI2MIT240 2 3.00 10.56 III 98 CTAGCAAAAGTAAAGGCTTTCAGG GCAAGGAGTTAATGCTTTCCC
DI2MITI05 2 6.00 21.86 135 105 TACACACATACACATGCTCATATGC TGTCCCTATAGAGAACCCTAATGC
DI2MIT235 2 19.00 39.50 146 154 GTAGTTGAACCCTACTACCTCCTCA GGGAATAAGACAGAAAGACAGGA
DI2MIT89 2 28.00 56.25 128 117 CTCCTTGACATCCGGGAATA CTGTTCAAGTGCCCACCC
DI2MIT34 2 29.00 66.63 188 203 GACCACCAGGGCTATTACACA TGCCAATCTTCACTCATGTACC
DI2MIT5 2 37.00 77.78 176 162 CACATAGACCAGACAGGCATGCGT CAAGGTCACGTTGCTAGCTAGGAA
DI2MIT259 2 45.00 87.26 123 107 TACCTTGAGAAAAGTATGGAGAAATG TAGCAACATGTAAAAGCATGATACC
DI2MITI67 2 52.00 100.53 188 182 AGAAGAAATACAGTTGTTGGAGCC CTGGAGCAGACTGCAGTGAG
D6MITI95 2 63.80 -6 3.07-12 151 144 AACAGCAGTTTCCTCCCCTT TCTTCTGGTGTGACAGTGTACTCA
DI2MIT263 2 58.00 109.00 109 125 TCAGATCTCAGCAGATAAATACTTGG TCCCCTGGAGCATATTTGAC
-D I3MiTS-7--..... 13 9.00 16.46 136 GATATACTTGTTTGCACACTTGGG AGAGAGTATGTGCCACCATGG -----_.--_..144
DI3MITI3 13 35.00 55.10 - 130 CTGTGGTAAGTCCAGATTTG GGAAAGAGTAGGAAGATGCC
DI3MIT9 13 45.00 77.18 121 137 GGGTTCCAGATTGAGTGGAA TTGCCAAAGTGTCAAAATCA
DI3MIT202 13 47.00 87.60 149 147 TGACTCAAAAAGGTAGATAGATGGC GATGCTATGTGTACATGCTTGTAGG
DI3MITI48 13 59.00 105.06 137 119 TGCTTGTGCTCATGCATACA AAAGGAAGGTGGCAAGTAATAGG
DI3MIT262 13 68.00 109.21 122 113 CTGCGGCTGTAGGTTAAGTATG AGGCTGCTGCTAACAGATGG
DI3MIT77 13 73.00 113.36 276 265 TCTTTGAAGTCCCTTTCAAAGC ATAGCACTGCACTCATGCTCA
DI3MIT35 13 75.00 - 198 183 GATTTTCCAGGTAAGTGGCG CACATTCACTGTGAGTGCACA
._--~_ ..-[5 4MiTT09-·----·i~f--·---I"60 11.03 117 121 GAATTATCTGGAACTTACTTCCTTTTT TCTGATGGTGCTTATATGCC-C---·---·----
D 4MITI4 14 10.00 27.80 262 244 GCACATTCCAAAACACATGC GGGATGGTGTCAATCAATCC
D 4MIT60 14 15.00 42.18 136 113 AGGCTGCCCATAAAAGGG GTTTGTGCTAATGTTCTCATCTGG
D 4MIT215 14 22.50 52.90 125 132 TTTTAATTTGTGTGTGACTGAGTGG ACATGCCTGTGAGGTGAGC
D 4MITI60 14 40.00
-
137 158 CAAAATTAGCAAGGATTCCAGG AGTTTAATCTCTTGGCTTTTGGG
D 4MIT35 14 44.00 73.5 I 223 221 TGTGACTCTAGCTTTGAGTGAGTG AGGCCACCCAGTGTATCAAG
D 4MIT92 14 45.00 85.58 89 125 CTGCTGCAGAATTAATTGATTTT GGATATATGGATTTATACAGACACACA
D 4MIT265 14 48.00 95.86 147 175 TCAAGAAATGACTCTTATCTACACACA AACAGCAAGATGTCAGCAAGA
D 4MIT97 14 58.00 112.99 149 151 TCAGTCCAAACTCTGTTAATCTTCC CAGCTCCACATTTTTGCTCA
-.J
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MARKER MARKER POSITION t PRODUCT PRIMER SEQUENCE
SIZE (bp)
Chr eM mb 86 C3H FORWARD REVERSE
DI5MITI30 15 14.50 20.77 181 195 CATATTTTGCAATTTTTAGTAATAGGC CAACACAGAAATAAAAGTGAGAGAGG
D 5MIT204 15 18.90 32.99 142 138 GACTTTGTCTTATGTGATATGGTGTG TTCTAGACTTGCCTAACATGAAACA
D 5MITI00 15 21.00 51.14 108 110 CAAGACCGAGCCAAAAACTC ACCTCAGATTACTGATGTGGGG
D 5MIT88 15 27.60 61.36 211 200 TAGCAATCACAGGAGGAATTAGG TTACTGAACTTAAGAACTGGAATCATT
D 5MITI34 15 46.00 83.13 148 152 GCCAAGTTTGGGGTTTTTGT AGATAGCAATCTGTCTCCCTGC
D 5MITI05 15 47.90 72.53 124 130 ACTGGCTTATCTAGCATTCTCCC CATATTGTCTTATCAGCCATGTCC
D 5MITI61 15 69.20 97.08 96 115 TCTGTTTTGTTTGTTCGTTTGC TAAAATCTCCCTGTATACAAGTCTGTG
D 6MITI82 16 3.40 5.35 219 184 GCACATTACACATGCATATCTGC GTTCTGATCTCCAAGTTCAGGC
D 6MITI46 16 16.90 22.51 197 195 CTTATGGATGTTACCTGCATAGATG TTAGGAAAGTTGAGAAGCACTGC
D 6MITI25 16 29.00 41.24 148 140 CAGAGATTACAAGCATACATCTTAGC CAAACAACAAAACACATTCAACTC
D 6MITI39 16 43.00 64.67 147 171 GTATGTAAGGAATGGTCAAATTCTTG TCATTGTGATTGTGAAAGAATGC
D 6MITI89 16 55.20 81.64 256 246 ACAGTGTTTGTTTGTTTGTTTGTG CAGTACAGGAAGTCTTTGCATCC
D 6MIT86 16 66.00 92.30 127 121 TAATGTGGCAAGCAACCAAA GCATGTTTCCATGTGTCTGG
D 7MIT57 17 7.60 8.50 303 319 GCTGATAAACGTGGTGGCTT GTTTAGTGGCTTCAAGTCACCC
D 7MIT46 17 10.00 23.17 242 218 TCCACCCCACTACCTGACTC CCCTTCTGATGACCACAGGT
D 7MITI80 17 29.40 48.96 149 151 AGACACTGTCTAAAAACACAAGATGG TTGTGTTCATATGCATGTGTGC
D 7MITI93 17 41.50 65.27 188 180 CACCTGTCCCCAAACAAAAC GAAGATCTGGACATGCTCAGTG
D 7MIT243 17 55.70 79.34 98 96 CACTTTCTTTCCATTTATGTCTATGG TGTAACTTATTCAACTGATCACTGTCA
o--sMiT64---fs--ioo 6.15 151 168 TCAGATTCACTGCTAAGTCTTTTC AGCAAGAAAAGCAGGTGAGG
D 8MITI35 18 16.00 38.75 136 120 GGCCTCTCTCTGAACGTGAC GAACTACATAGATACAAATGAGCCTCC
D 8MITI47 18 16.00 26.50 150 147 GTAAGTCACTAGGAGCCATGTTTC AGAACATGGTAGAGCACTGCTG
D 8MIT55 18 25.00 53.38 163 169 ACAGATGTTCCCCAGCATTC TGAGTGTGAGATCAGCCTGTG
D 8MIT207 18 41.00 68.88 117 129 TGGTTGACTGATAGAAAATATGAACC GTGCCAGCATGCATACATG
D 8MITI44 18 57.00 85.67 176 172 TAGGGTTTTTTTTTTCTTTTTCTCC GATAAAAAAATATGTTCACAAAACGC
D 9MIT56 19 5.00 9.13 125 114 CTGAATGTGTATGTGTGCAAGTATG ATTATGAATTCAAGACTAGCCTAGGA
D 9MIT41 19 16.00 17.92 159 171 AGCCCTCCACCCAGTTTC TCTGGGGAAAAAGGATGAGA
D 9MIT63 19 24.00 35.38 169 163 CGCTTTCTTTGACTGGAATG GTCCTTTCACTTTCCACATGTG
D 9MITI9 19 26.00 38.98 142 117 CCTGTGTCCATACAGGCTCA ACCATATCAGGAAGCACCATG
D 9MITI03 19 52.00 53.34 124 130 CCCATGTCCTTTGTTTCCC GAAGCGCTATCACTGGATCC
t Marker positional information is derived from Ensembl build v37 (February 2006)191. Reported distances are relative to the 3'-end ofthe chromosome.
To minimise the number of PCR reactions that were performed, each primer panel
was sub-divided into several pools so that genomic DNA could be amplified in
multiplex PCR reactions containing several primer pairs at a time. This allowed a panel
containing up to 8 primer pairs to be amplified in only 1-3 PCR reactions for each
DNA sample. Primer pools were prepared at lOx concentration (2[lM) as shown in
Table 10 and are listed in Table 15 on page 77.
Table 10: Preparation of a lOx Concentration (2IJM) Primer Pool*
Reagent
Each Forward Primer (I OO~M stock, IOOpmol/~l)
Each Reverse Primer (I OO~M stock, 1OOpmol/~l)
Nuclease-free Water
Total Volume
Volume (~I)
10.0
10.0
Variable
500.0
*This allows preparation of a pool containing a maximum of 25 primer pairs.
All primer pools were tested with control DNA to ensure that the primer target
sequences could be successfully amplified in a multiplex format and that they could be
easily differentiated. A small number of primer pairs were found to amplify poorly
under multiplex PCR conditions. These primers were therefore amplified individually,
described in 2.3.12.2. As is described below, each panel was then assembled by mixing
together its constituent PCR products (detailed in Table 15) prior to analysis using an
ABI PRISM 3100 genetic analyser (Applied Biosystems Inc., USA).
2.3.12.1 Multiplex peR Method
DNA was extracted from 44 BC1 and 27 BC2 IGT/6 mice and from unmutagenised
CS7BL/6, C3H and F1 inter-cross control animals as described in section 2.3.10. Prior
to use, the Sng/til stock DNA was thawed and diluted to 1ng/[l1 with nuclease free
water. Mutiplex PCR reactions were prepared using Qiagen Multiplex PCR reagents
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(Qiagen, USA). An optimised PCR reaction mIxture, detailed In Table 11, was
identified and used for all multiplex reactions.
Table I I: Optimised Reagent Mixture for Multiplex PCR Reactions
Reagent
Qiagen PCR MasterMix (2x)*
DNA (I ng/~I)
Pooled Primers lOx (2 ~M solution)
Total Volume
Volume per Reaction (J,JI)
6.0
4.8
1.2
12.0
Final Concentration
Ix
0.4 ng/~I
0.2 ~M
*Qiagen MasterMix comprises HotStarTaq DNA polymerase, dNTP mixture and a PCR buffer
containing 6 mM MgCl2• pH 8.7 at room temperature.
The 12~1 volume PCR reactions were prepared in 96-well plate format and run in a
DNA Engine thermal cycler (BioRad Inc., USA) using the cycling conditions shown in
Table 12.
Table 12: Optimised Qiagen Mutiplex PCR Cycling Conditions
Reaction Step
Initial activation step
Cycle (x3s)
Final extension step
Hold
Denature
Anneal
Extend
Temp °C
95°C
94°C
61°C
7rC
60°C
16°C
Time
15 minutes
30 seconds
90 seconds
60 seconds
30 minutes
Indefinite
2.3./2.2 Monoplex peR Method
Those primer pairs that did not amplify well in multiplex reactions were amplified
individually using GeneAmp PCR reagents and AmpliTaq Gold DNA Polymerase
(Applied Biosystems Inc, USA). The majority of samples were successfully amplified
using a standard PCR reaction mixture containing 1.5 mM magnesium chloride as
detailed in Table 13.
75
Table 13: Monoplex Genotyping PCR Reaction Mixture
Reagent
DNA (Ingft,.II)
dNTP (lOx. 1.25mM)
MgCI (25mM)
Buffer (lOx)
AmpliTaq Gold
F* & R Primers lOx (2 ~M solution)
Nuclease-free Water
Total Volume
Volume per Reaction (J,JI)
4.8
1.5
0.9
1.5
0.1
1.5 each
3
14.8
Final Concentration
0.32 ng/~1
0.125mM
1.5 mM
Ix
0.2 ~M
Reactions were run in 96-well plate format on a DNA Engine thermal cycler (BioRad
Inc., USA). The optimised PCR cycling conditions ('MS55') are shown in Table 14.
Where it was necessary to vary these conditions to ensure a PCR reaction worked,
details are provided in Table 15.
Table 14: 'MS55' PCR Thermal Cycler Settings
Reaction Step Temp °C Time
Initial activation step 94°C 9 minutes
Cycle (x37) Denature 94°C 30 seconds
Anneal 55°C 45 seconds
Extend 7rC 60 seconds
Final extension step 7rC 5 minutes
Cool 4°C 10 minutes
Hold 15°C Indefinite
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Table 15: Composition of PCR Reaction Pools and Microsatellite Marker Panels
PANEL MARKER DYE POOL* PCR CONDITIONSt PREPARATION OF
ANALYSIS PANELS BY
COMBINING PCR POOLS
DI4MITI09 G Solo
DI6MITI46 R Solo
DISMITIOO B IA
D2MIT37 G IA
DI7MITS7 B IA
D2MITS8 B IB
D6MIT316 G IB
MSSS
MSSS
2~1 of DI4MITI09
+ 3~1 of DI6MIT 146
+ I ~I of Pool IA
+ 3~1 of Pool IB
2 DIOMIT42 G Solo
DIIMIT214 B 2A
D 12MIT263 B 2A
D 14MIT97 G 2A
D ISMIT204 B 2A
D 18MIT207 G 2A
DSMIT2S G 2A
MSSS 2.SmM MgCl 3~1 of DIOMIT42
+ I ~I of Pool 2A + 3~1 Water
3 DIIMIT29 G 3A
DIIMITS3 B 3A
DI7MITI93 G 3A
D3MIT87 B 3A
D 17MIT243 G Solo
DI8MITI44 B Solo
MSSS
MSSO* 2.SmM MgCl
II.lI of Pool 3A
+ 3~1 of D 17MIT243
+ I~I ofDI8MITI44
I ~I of Pool 4A
+ 3~1 of Pool 4B
+ 2~1 of Pool 4C
4 DI6MITI89 G 4A
DI7MITI80 G 4A
DIMITI36 B 4A
D7MIT373 B 4B
D9MIT I04 G 4B
DI2MITI67 R 4C
DIMIT424 R 4C
DI7MIT46 R 4C
·····s·--··············-····-·..tYi··oR·ITij·j···..··-B-··--·-··--5010--·-··-·--·-·1'1555----.··-·-····---·-·-···········-·-·--·---TiJlof·iSToMit-ir·j·····-·-·············· .
D I IMIT224 R Solo MSSS 2.SmM MgCl + 3~1 of D I IMIT224
D4MIT 170 G Solo MSSS + 2~1 of D4MIT244
D 14MIT21S G SA + I ~I of Pool SA
D 14MIT3S G SA
DISMITIOS B SA
DIMITI39 B SA
D3MIT42 B SA
DSMIT20S G SA
6 D 13MIT3S R 6A
DIMit316 G 6A
D 16MIT86 R 6A
D ISMIT88 G 6B
DISMITI30 B 6B
DI9MIT41 G 6B
D7MIT2S B 6B
I ~I of Pool 6A
+ 3~1 of Pool 6B
7 DI6MITI82 R 7A
DIMIT387 R 7A
DISMITI34 G 7B
D7MITIOS G 7B
D 18MITSS R 7C
3~1 of Pool 7A
+ I ~I of Pool 7B
+ 2~1 of Pool 7C
8 DIIMITI79 R Solo
D 12MIT34 B 8A
2~1 ofDIIMITI79
+ I ~I of Pool 8A + 3~1 Water
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DIMIT221 G 8A
D4MIT214 B 8A
D4MIT327 B 8A
DsMITI3s G 8A
D8MITI83 G 8A
9 DIOMITI2 B 9A 3~1 of Pool 9A
DI4MIT26s B 9A
DI4MIT92 B 9A
D8MITI43 G 9A
D3MIT239 G 9A
D4MIT203 R 9B + I ~I of Pool 9B + 3~1 Water
DIMIT211 R 9B
10 DIMITlss G OA I ~I of Pool lOA
D7MIT230 B OA
D8MIT249 B OA
DIIMIT2 G OB + 3~1 of Pool lOB + 2~1 Water
DsMIT348 B OB
II D3MIT86 R IA 4~1 of Pool If A
DI8MITI3s R IA
DI4MITI4 B IB + 2~1 of Pool II B + 2~1 Water
DI6MITI39 G IB
DI9MITI9 G IB
12 DIIMIT271 G 2A I ~I of Pool 12A + s~1 Water
DI3MITs7 G 2A
DI9MITI03 G 2A
DIMIT243 B 2A
D2MIT62 R 2A
D6MIT289 B 2A
13 DI2MIT2s9 B Solo 3~1 of D 12MIT2s9
DI2MIT89 G 13A + I ~I of Pool 13A 2~1 Water
DI8MITI47 G 13A
D3MIT2s R 13A
D4MIT23s G 13A
14 DIOMIT80 B 14A I ~I of Pool 14A
D6MIT268 G 14A
DI6MITI2s G 14A
D2MIT272 B 14A
D4MITI78 G 14A
D6MITI88 R 14B + 3~1 of Pool 14B
DI4MIT60 R 14B
15 DisMITI61 B Solo MSss
DI2MIT240 G SA I ~I of Pool IsA + 3~1 Water
DsMIT3s3 G SA
D6MITIs9 B SA
D7MITI91 B SA
16 DI8MIT64 B 6A I ~I of Pool 16A
DI9MITs6 G 6A
D4MITI93 B 6A
D3MIT77 R 6B + 3~1 of Pool 16B + 4~1 Water
D9MITI82 R 6B
17 DI3MIT9 G 7A I ~I of Pool 17A + 3~1 Water
DI9MIT63 B 7A
DIMIT3ss G 7A
D3MIT49 B 7A
18 D7MIT23I R 8A 3~1 of Pool 18A
DI3MIT202 B 8B + I ~I of Pool 18B
D8MITI29 B 8B
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D9MITI71 B 18B
DIMITI78 G 18C
DI3MITI3 G 18C
+ 21J1 of Pool 18C
31J1 of Pool 19A
+ IIJI of Pool 19B + 31J1 Water
MS5519 DI2MIT5 R Solo
D2MIT200 B 19B
D5MIT292 G 19B
20···........····-t5T·2M(r2J:s..···..·..C;..·..· ··..-·..·..20A ··· _ - ··--·· ..·· ·- --·.. ·..··..·-TjJrC;rpC;-01-20·A..- ..-·-·--···--._-
D2MIT456 G 20A + 21J1 of Pool 20B + 21J1 Water
D2MIT458 B 20A
D7MIT28I G 20A
DI4MITI60 B 20B
D9MIT236 R 20B
21 D6MITI95 B 21A
DI2MIT37 G 21A
DI2MITI03 B 21A
IIJI of Pool 21A + 31J1 Water
22 DI2MIT215 G 22A
DI2MITI05 B 22A
IIJI of Pool 22A + 31J1 Water
23 D8MIT I00 G 23A
D8MIT289 G 23A
D8MIT29I B 23A
IIJI of Pool 23A + 31J1 Water
24 DIIMIT23 G 24A
D5MIT 197 R 24A
D9MIT31 I G 24A
25 DI3MITI48 B Solo MS55 IIJI of D 13MIT 148 + 41J1 Water
26 D 13MIT77 B 26A
DI3MIT262 G 26A
27 D8MIT92 27A
D8MIT279 27A
IIJI of Pool 25A
* 'Solo' designation indicates that the primers were amplified individually.
t Details of monoplex PCR conditions and alterations from those given in Table 13 or Table 14.
:j: As thermal cycler program 'MS55' in Table 14 but the Anneal step was at 50°C for 45 seconds.
2.3.12.3 peR Product Size Analysis
The PCR products from each reaction were combined to make the 27 marker panels as
detailed above in Table 15. For each animal, 1rtl of each primer panel mixture was then
added to 9.2rtl of Hi-Din< Formamide (#4311320, Applied Biosystems Inc, USA) and
0.8rt! of NED labelled size standard (final volume llrtl) in an ABI 96 well plate. The
plate was spun briefly in a centrifuge to ensure that all samples were collected at the
bottom and then PCR product sizes were resolved using an ABI PRISM 3100 genetic
analyser (Applied Biosystems Inc, USA).
Data were analysed with ABI Genescan and ABI Genotyper 3.7 software (Applied
Biosystems Inc, USA). For all 136 microsatellite markers, each individual BCl and
BC2 animal was classified as C3H homozygote or C57BL/6-C3H heterozygote
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according to the PCR product sizes measured (expected PCR product sizes for each
strain are provided in Table 9). In this way the presence or absence at each locus of
CS7BL/6 DNA, potentially carrying the causative ENU induced dominant mutation,
was determined. Data was collated using Microsoft Excel (Microsoft Corporation,
USA) and linkage between markers and phenotypes (including glucose tolerance, body
weight and NAFLD) sought using MapManager QTXl92 and Windows QTL
Cartographer 2.0 software193 and by direct examination ofhaplotype patterns.
2.3.13 Statistical Analysis
Data were collated in Microsoft Excel (Microsoft Inc, USA) and statistical analysis
performed using SPSS version 12 (SPSS, USA). Quantitative data are expressed as
mean + standard error of the mean (SEM) unless otherwise stated. Normally
distributed continuous variables were compared by Student's t-test or ANOVA.
Ordinal and non-normally distributed variables were tested using the non-parametric
Mann-Whitney U or Kruskall-Wallis tests as appropriate. Two-tailed p-values are
shown unless otherwise stated. Statistical significance was accepted at p<O.OS.
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2.4 Results
2.4.1 Un-sensitised Mutagenesis Study
Approximately 1,960 F1 (BALB/c x C3H) mice underwent biochemical screening as
part of the MRC MGU mutagenesis program186. Some animals from this program
were also tested for impaired glucose tolerance by IPGTT.
2.4.1.1 Biochemical (ALT/AST) Phenotypes
In the unsensitised study, five F1 offspring were identified with persistent significant
elevations of ALT or AST in the primary biochemical screen (Table 16). These
animals were backcrossed to C3H and their offspring assayed for inherited ALT / AST
elevations.
Table 16: Results of Primary Screen for Biochemical (ALT/AST) Phenotype
FI Founder ALT* AST* Inheritance Testing
MUTN/975.5c 237, 178, 125 183, 135, 104 10 BC I mice tested: Not inherited
MUTN/1069.li 129, 192, 136 X, 130, 113 Poor breeder, only one BC I mouse tested: Normal
MUTN/990.2j 166,214,129 148, 149, 105 40 BC I tested: 3 had ALT elevations (range 85-91 )
MUTN/975.8d 205,447,49 136,386,48 15 BC I tested: I transient raised ALT: Not inherited
MUTN/ I065.8d 267, 320 145, 172 Be I tested: No inheritance
*Animals tested three times. Normal ranges: ALT 41 ±O.55 U/I and AST 58±O.64 U1I186.
Inheritance testing did not identify any mutant line with a robust, heritable
transaminase elevation that was of sufficiently high penetrance to be suitable for
further analysis. Inspection of the F1 biochemical test results in Table 16 also shows
that, even in the founder animals, the ALT and AST levels appear to reduce on
repeated testing which may suggest that changes were due to intercurrent illness. These
lines were not pursued further.
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2.4.1.2 Glucose tolerance and Cholesterol Phenotypes
Three lines of mice with robust, heritable impaired glucose tolerance phenotypes had
been identified from the unsensitised mutagenesis study. Data are summarised in
Table 17. The ENU induced mutation in the GENA/348 line has already been
mapped to the glucokinase gene175 however the causative mutations of the other two
lines are unknown.
Table 17: Results of Primary Screen for Raised Free-fed Glucose Phenotype
FI Founder Glucose* Cholesterol* Inheritance Testing Line
MUTNII 045.1 a 13.8, 13.3 4.7,4.8 Glucose phenotype inherited GENN263
MUTN/I 160.2d 15.4, 14.6 Glucose phenotype inherited GENN348
MUTN/1378.2f 19.7, 13.4 4.7,4.5 Glucose phenotype inherited GENN389
*Animals tested twice. Free-fed bleed normal ranges: Glucose 9.8±O.OS mmolll and
Cholesterol 3.8±O.O I mmo11l 186•
H&E stained liver tissue sections from each line were examined to determine if there
was any histological evidence ofNAFLD. Initial screening did not identify any samples
that had significant levels of steatosis.
Recently, the GENA/263 line was re-derived by IVF for transfer into the MRC Mary
Lyon Centre. During this process the line was bred onto a different C3H sub-strain
(C3H HM02) and so histological screening was repeated. This showed evidence of a
mixed macro- and micro-vesicular steatosIS In several animals but no
necroinflammatory infiltrate or hepatocyte ballooning degeneration (Figure 8). At the
time of writing, further characterisation ofNAFLD phenotype in this line is on-going
although it appears that, on the current C3H background the line develops steatosis
but not steatohepatitis.
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Figure 8: GENA/263 Liver Histology on Repeat Examination
GENA/263 was bred onto a different C3H sub-strain (C3H HM02) and histological screening
repeated. This showed evidence of a perivenous macro- and micro-vesicular steatosis but no
clear ballooning hepatocyte degeneration.
2.4.2 Sensitised Mutagenesis Study
Approximately 1,500 F1 offspring ofEND mutagenised male mice were generated and
assayed for impaired glucose tolerance in the sensitised mutagenesis study. Fifteen lines
with heritable impaired glucose tolerance phenotypes were identified by the primary
screen. The five lines with the strongest phenotypes (summarised in Table 18) were
selected to enter the secondary histological screen.
Table 18: Results of Sensitised ENU Mutagenesis Screen using IPGTT
Line +/-* Primary Screen (IPGTT) Secondary Screen (Histology)
IGT/3 IR Impaired glucose tolerance No NAFLD
IGT/4 IR Impaired glucose tolerance No NAFLD
IGT/6 IR Impaired glucose tolerance Histological evidence of NAFLD
IGT/IO IR Impaired glucose tolerance No NAFLD
IGT/IS IRS-I Impaired glucose tolerance No NAFLD
* Maintained on a C57BU6 x C3H background. Mice segregate a heterozygote mutation as
described in section 2.3.3.2.
H&E stained tissue ections from these lines were screened by light microscopy for
evidence ofNAFLD. Lines IGT/3, IGT/4, IGT/I0 and IGT/IS were not found to
xhibit any evidence of NAFLD during the secondary histological screen and were
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therefore excluded from further study within this program. The IGT/6 line was show
to exhibit histological features consistent with a diagnosis of NAFLD and so was
adopted for further study.
2.4.3 Phenotype of IGT/6 Mice
The IGT/6 line, first identified by the primary glucose tolerance screen (IPGTT at 12
weeks of age) in the sensitised ENU mutagenesis study, has been demonstrated to have
a heritable impaired glucose tolerance phenotype. The secondary histological screen
subsequently confirmed the presence of histological features consistent with NAFLD.
This line was therefore adopted for detailed analysis to fully characterise the disease
phenotype and to determine what transcriptome level changes were associated with the
insulin resistance and NAFLD phenotype. The IGT/ 6 phenotype is fully described
below.
2.4.3.1 IGT/6 Founder Animal
The male F1 founder animal (MEB/23b.2h), from whom all IGT/6 mICe are
descended, was identified by the 12 weeks of age IPGTT primary phenotypic screen.
At this age, the mutant animal was found to have impaired glucose tolerance relative to
populations of both CS7BL/6 x C3H and CS7BL/6-IR+1- x C3H unmutagenised
control mice. The results of the 12 week IPGTT are shown in Figure 9.
The mutant animal was shown to carry the heterozygote insulin receptor mutation.
MEB/23b.2h entered inheritance testing as described in the methods section and was
backcrossed to C3H females to generate the IGT/6 backcross 1 (BC1) generation. A
total of 44 male and 37 female BC 1 animals were produced. The founder animal died
unexpectedly limiting the production of BC 1 animals. Post-mortem, the carcass was
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destroyed by the other animals in the cage and so liver tissue was not available to
determine whether this mouse exhibited the histological NAFLD phenotype.
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Figure 9: Glucose Tolerance Phenotype of IGT/6 Founder Animal & Controls
The 12 weeks of age IPGTT results for the IGT/6 founder animal (MEB/23b.2h) and the mean
values for cohorts of C57BU6xC3H and C57BU6-IR+/-xC3H unmutagenised control animals
are shown. The time in minutes following the intraperitoneal injection of glucose solution is
shown on the x-axis (t = 0 represents the fasting blood glucose concentration).
2.4.3.2 Glucose Tolerance
The results of 12 and 24 week IPGTTs for IGT/6 Bel animals, performed as part of
the inheritance testing protocol, are presented in Table 19. By 12 weeks of age the
mean male IGT/6 t=120 minute blood glucose concentration was significantly
elevated over control animals (11.93+0.70 vs. 7.7+0.20 mmolll; p<O.OOl). This data is
graphically represented in Figure 10. The observed phenotypic differences persisted
when mice were retested at 24 weeks of age (Table 19) indicating that IGT/6 mice
have a heritable impaired glucose tolerance phenotype.
85
Table 19: Summary of Male IGT/6 BC I & Control Glucose Tolerance Test Data
Phenotype Parameter Control (SEM) IGT/6 (SEM) p-value*
12 Weeks N = 39 N = 29
Body Weight (g) 30.09 (0.36) 34.75 (0.70) <0.001
Fasting glycaemia (mmol/I) 6.34 (0.16) 6.55 (0.34) NS
Mean t=60 glycaemia (mmol/I) 11.67 (0.39) 18.56 (0.98) <0.001
Mean t= 120 glycaemia (mmolll) 7.7 (0.20) 11.93 (0.70) <0.001
Cumulative Glucose (mmol/I) 25.71 37.4
24 Weeks N = 38 N = 31
Body Weight (g) 35.85 (0.50) 38.41 (0.96) 0.022
Fasting glycaemia (mmol/I) 5.74 (0.24) 7.91 (0.47) <0.001
Mean t=60 glycaemia (mmolll) 13.3 (0.73) 21.56 (0.84) <0.001
Mean t= 120 glycaemia (mmolll) 8.35 (0.39) 14.21 (0.77) <0.001
Cumulative Glucose (mmolll) .J..7.39 43.68
* Significance tested with Student's t-test as data meets all necessary assumptions.
Subgroup analysis (Table 20) demonstrated that there was no significant difference in
glucose tolerance test results between IGT/6 mice that carried the heterozygote insulin
receptor mutation (IR+I-) and those that did not (IR+1+), suggesting that any sensitising
effect of the IR+1- mutation made little contribution to the glucose tolerance
phenotype in this line.
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Figure 10: Glucose Tolerance Phenotype of Male IGT/6 BC I Mice Age 12 Weeks
Results of IPGTT comparing male IGT/6 Be I mice with non-mutagenised mice from the
background strain. The mean blood glucose concentration of IGT/6 mice (n = 29) is
significantly higher than control animals (n = 39) at t=60 (I 1.67 vs. 18.56mmolll, p<O.OO I) and
t= 120 minutes (7.7 vs. 11.93mmol/l, p<O.OO I).
86
Table 20: Effect of Insulin Receptor Mutation Carriage on IGT/6 BC I Phenotype
Phenotype Parameter IGT/6-IR+J+(SEM) IGT/6-IR+J- (SEM) p-value*
12 Weeks N = 14 N = 13
Body Weight (g) 36.02 (1.0 I) 33.97 (0.97) NS
Fasting glycaemia (mmol/I) 7.01 (0.55) 6.14 (0.46) NS
Mean t=60 glycaemia (mmolll) 19.38 (1.40) 17.75 ( 1.60) NS
Mean t= 120 glycaemia (mmolll) 12.25 (0.94) 11.46 (1.23) NS
24 Weeks N = 12 N = 19
Body Weight (g) 42.37 (1.5 I) 35.90 (3.74) <0.001
Fasting glycaemia (mmolll) 8.07 (0.90) 7.82 (0.53) NS
Mean t=60 glycaemia (mmolll) 21.18 (1.26) 21.80 (1.15) NS
Mean t= 120 glycaemia (mmolll) 14.50 (0.96) 14.03 (1.12) NS
* Significance tested with Student's t-test as data meets all necessary assumptions.
Similarly, within the control group, there was no significant difference between glucose
tolerance of C57BL/6 x C3H and C57BL/6-IR+I- x C3H mice at either 12 or 24
weeks (Table 21).
Table 21: Effect of Insulin Receptor Mutation Carriage on Control Phenotype
Phenotype Parameter IR+J+ (SEM) IR+J- (SEM) p-value*
12 Weeks N = 21 N = 18
Body Weight (g) 30.88 (0.48) 29.16 (0.46) 0.006
Fasting glycaemia (mmolll) 6.65 (0.23) 5.99 (0.20) NS
Mean t=60 glycaemia (mmolll) 11.25 (0.54) 12.17 (0.54) NS
Mean t= 120 glycaemia (mmolll) 7.87 (0.28) 7.51 (0.28) NS
24 Weeks N = 22 N = 16
Body Weight (g) 36.35 (0.64) 35.16 (0.76) NS
Fasting glycaemia (mmolll) 5.83 (0.33) 5.63 (0.36) NS
Mean t=60 glycaemia (mmolll) 12.34 (0.68) 14.56 (1.41 ) NS
Mean t= 120 glycaemia (mmol/I) 7.98 (0.40) 8.85 (0.73) NS
* Significance tested with Student's t-test as data meets all necessary assumptions.
Affected BC 1 animals were agaIn backcrossed to C3H to provide further
recombinations for genetic mapping (section 2.4.5 below). Each generation continued
to exhibit significantly higher glucose levels than control when tested at age 12 weeks
although the phenotype weakened slightly with each subsequent backcross (Figure 11).
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Figure I I: Blood Glucose Concentration by Backcross Generation
Mean 12 week t = 120 blood glucose concentration weakened slightly with each backcross
generation but remained significantly higher than control at each generation (Backcross
I 1.93±0.70; Backcross 2 10.42±0.56; Backcross 3 9. I3±0.42; Control 7.70±0.20).
2.4.3.3 Body Weight
The body weight of animals was recorded when they underwent glucose tolerance
testing at 12 and 24 weeks of age. By 12 weeks of age, IGT/6 BC1 mice were found to
be 17% heavier than controls (34.75+0.70 vs. 30.9+0.36g; p<O.OOl), Figure 12. This
difference was maintained when animals were retested at 24 weeks ofage, see Table 19.
Subgroup analysis demonstrated that body weight was not influenced by carriage of the
IR+/- mutation at 12 weeks of age. However, by 24 weeks of age IGT/6 mice which
were homozygote wildtype (IR+/+) were significantly heavier than their IR+I- mutant
littermates (Table 20). This difference was also observed between C57BL/6 x C3H
and C57BL/6-IR+I- x C3H non-mutagenised control animals at 12 but not 24 weeks
(Table 20) although the disparity was less marked than with IGT/6.
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Figure 12: Body Weight Phenotype of IGT/6 Mice at Age 12 Weeks
Male IGT/6 mice (n = 29) are significantly heavier than control animals (n = 39) at 12 weeks of
age (30.09g vs. 34.75g, p<O.OO 1).
2.4.3.4 Liver Histology
Light microscopic examination ofliver tissue from male IGT/6 BCl mice culled at age
15 months demonstrated features consistent with NAFLD in 6 of25 animals (24%), 5
(20%) of these had active steatohepatitis. As illustrated in Figure l3A, this was
characterised by a mixed micro- and macrovesicular steatosis with an overall
macrovesicular predominance. Ballooning hepatocyte degeneration was demonstrated
in areas of more marked steatosis (Figure l3A) and was associated with a neutrophilic
necroinflammatory infiltrate (Figure 13B). Mild perisinusoidal fibrosis was seen in two
animals. Similar features were not seen in control animals (C57BL/6 x C3H or
C57BL/6-IR+/- x C3H) that had been housed under identical conditions to the same
age. The NAFLD phenotype was present a similar proportion of IGT/6 backcross 2
(B C2) animals.
89
The severity of NAFLD was formally assessed using the NIDDK histological score,
described in section 2.3.7. These data are summarised in Table 22 along with the
results ofeach animal's 12 week glucose tolerance test from the primary screen.
Table 22: Characteristics of IGT/6 BC I Mice with Histological NAFLD
Mouse 10 IR Wt (g)* Glucose (mmol/dl)* Histology Score
t=O t=60 t=120 S F 1 B
IGT/6.6h +/+ 33.52 4.88 21.94 15.16 I
IGT/6.4g +/+ 34.1 7.00 21.00 10.05 2 I
IGT/6.4e +/+ 38.5 6.88 20.16 13.11 3 I 2
IGT/6.lf +/- 39.47 9.44 19.94 13.16 I la 2
IGT/6.6f +/+ 38.49 4.27 16.72 10.38 2 I
IGT/6.le +/+ 46.72 10.88 22.94 17.11 I I
Controlt +/- 30.09 (0.36) 6.34 (0.16) I 1.67 (0.39) 7.7 (0.20) -
* Phenotype data from the 12 weeks of age primary screen. t Mean (SEM) for reference.
As detailed in Table 22, the majority ofBC1 animals with NAFLD did not carry the
heterozygote insulin receptor mutation (i.e. were ofIR+/+ status) whereas 13 of the 19
mice that did not have NAFLD were IR+/- (one PCR failed). The presence of a
relationship between insulin receptor status and developing the NAFLD phenotype
was tested using Fisher's Exact test because expected values fell below the threshold
required for a Chi-Squared test. Whilst more IGT/6 backcross 1 mice with NAFLD
were insulin receptor homozygote wildtype than would be expected by chance, this
difference fell at the limit of statistical significance (p = 0.050). This association was
not maintained when mice with NAFLD from the backcross 2 generation were also
considered and so may be spurious.
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Figure 13: Representative Liver Histology from IGT/6 Mice
A H&E stained section showing mixed microvesicular and macrovesicular steatosis and
ballooning hepatocyte degeneration (black arrow), the cardinal histological feature of
steatohepatitis.
B H&E stained section showing a neutrophilic inflammatory infiltrate (white arrow) associated
with macrovesicular steatosis within the hepatic parenchyma.
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2.4.3.5 Biochemistry
Biochemical analysis of plasma when the animals were culled at 15 months of age
demonstrated that, overall, IGT/6 mice had significantly higher AST levels than
control animals (Table 23). In contrast, HDL cholesterol and triglyceride levels were
lower than control.
Table 23: Summary of Male IGT/6 BC I & Control Biochemical Tests
Phenotype Parameter IGT/6 (SEM) Control (SEM) p-value*
N =21 N =8
ALT 33.42 (4.18) 29.00 (3.91 ) NS
AST 100.54 (16.23) 54.00 (6.77) 0.023
Total Cholesterol 3.66 (0.13) 3.53 (0.10) NS
HDL Cholesterol 2.06 (0.08) 2.40 (0.10) 0.028
Triglycerides 2.09 (0.14) 3.32 (0.46) 0.005
*Tested by Mann-Whitney U test as not all data normally distributed.
No significant differences between IGT/6-IR+/+ and IGT/6-IR+/- animals or between
C57BL/6 x C3H and C57BL/6-IR+/- x C3H non-mutagenised control animals were
detected on subgroup analysis.
Table 24: Biochemical Tests Results for IGT/6 Mice With & Without NASH
Phenotype Parameter
ALT
AST
Total Cholesterol
HDL Cholesterol
Triglycerides
IGT/6 NASH
N =5
46.20
111.80
4.04
2.37
1.82
(SEM)
(10.82)
(30.08)
(0.12)
(0.08)
(0.31 )
IGT/6
N = 14
27.57
101.88
3.56
1.96
2.25
(SEM)
(3.73)
(22.0 I)
(0.17)
(0.11 )
(0.17)
p-value*
0.05
NS
0.03
0.03
NS
* Tested by Mann-Whitney U test as not all data normally distributed
Total cholesterol levels were significantly higher in IGT/6-NASH animals than
control mice (4.04+0.12 vs. 3.53+0.10, P = 0.015). In addition, as demonstrated in
Table 24, IGT/6 mice with steatohepatitis had significantly higher blood ALT levels
than littermates without histological NAFLD. These mice also exhibited significantly
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higher total cholesterol and HDL cholesterol levels than unaffected littermates. No
significant differences in glucose tolerance or serum insulin levels were detected.
2.4.3.6 Insulin Resistance & Pancreatic Islet Area
Serum for insulin analysis was available for 16 male IGT/6 BC 1 mice at 15 months of
age, 11 were animals that had been shown to have impaired glucose tolerance
('affected') and 5 were unaffected. In comparison to their unaffected littermates,
affected IGT/6 mice were found to exhibit significantly greater hyperinsulinaemia
(Figure 14A). The majority of affected mice had free fed serum insulin levels of >20
ng/ml (mean 31.03+6.93 ng/ml), whilst unaffected littermates all had serum insulin
levels of <16ng/ml (mean 7.34+2.50 ng/ml). The highest insulin levels were seen in
IGT/6-IR+I- mice.
Pancreatic tissue samples, collected when mice were culled at 15 months, were available
for 25 male IGT/6 BCl mice and 4 control mice. However, 6 of the samples were too
small to provide the required number of microscopy fields for accurate digital analysis.
Inclusion ofsuch small samples could introduce sampling error and potentially bias the
data and so these were excluded from the analysis. Digital analysis of H&E stained
sections from the remaining animals demonstrated pancreatic islet cell hyperplasia in
affected IGT/6 mice (Figure 15A) but not in control animals (Figure 15B). Mean islet
area was found to be significantly greater in affected IGT/6 mice than controls; up to
25.91% of total pancreatic tissue in affected IGT/6 mice, <10% in the majority of
unaffected littermates and <3.0% in control animals (Figure 14B). A positive
correlation between blood insulin level and pancreatic islet area was demonstrated in
IGT/6 mice (Figure 16).
Taken together with the glucose tolerance data presented earlier, these data strongly
suggest that IGT/6 mice have a combined impaired glucose tolerance and insulin
resistance phenotype.
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Figure 14: Serum Insulin Concentration and Pancreatic Islet Size
A Those IGT/6 BC I mice identified with impaired glucose tolerance at 12 weeks of age
('Affected', n = I I) were also found to have significantly higher serum insulin levels than their
unaffected littermates (n = 5) when tested at age 15 months. Significance tested with Student's
t-test. Data shown as mean ± SEM.
B Islet area fraction for affected IGT/6 mice (n = 9), unaffected littermates (n = 10) and
C57BU6-IR+/- x C3H control mice (n = 4). ANOYA (p = 0.004) with post-hoc Bonferroni
analysis of pair-wise comparisons. Mean ± SEM presented.
A B
Figure I5: Pancreatic Islet Size
A H&E stained section of pancreas from an affected IGT/6 BC I mouse showing marked islet
hyperplasia (islets are indicated by arrows) which takes up much of the pancreatic section.
B Pancreatic section from a C57BU6-IR+/- x C3H control mouse showing only a few small
islets.
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Figure 16: Correlation of Pancreatic Islet Size & Blood Insulin Levels in IGT/6
Mice
A positive correlation between blood insulin levels and pancreatic islet hyperplasia was
demonstrated in IGT/6 mice. In general, affected IGT/6 mice have higher insulin levels and
larger islet areas than unaffected animals.
2.4.4 Response to High Fat Diet
A new animal facility (the Mary Lyon Centre) was opened at MRC Harwell during
the course of this experiment. Some of the mice that were being studied had to be used
as additional sperm donors for IVF matings due to problems re-establishing the colony
within the new unit. As a result, only partial phenotypic datasets were available for
some mice. Despite this caveat, these data offer further insight into the IGT/6
phenotype and so are presented here with details ofgroup sizes.
IGT/6 backcross 3 mice were classified as 'affected' or 'unaffected' according to the
results of their 12 week IPGTT result taken whilst fed standard chow. Following
randomisation to either standard (4.5% fat) chow or a supra-nutritional high fat diet
(HFD, 45% fat), mice were tested at intervals to determine whether this dietary
challenge would exacerbate the impaired glucose tolerance, body weight, biochemical
and NAFLD phenotype.
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2.4.4.1 Glucose Tolerance
Differences were tested by ANOVA (result p < 0.001) with Bonferroni post-hoc
analysis (Figure 17). Inspection of Figure 17 shows that, irrespective of study group, 12
weeks after randomisation HFD fed animals tended to have higher glucose levels than
their control diet fed counterparts. However, the increase in t = 120 minute glucose
levels over that of chow fed animals was 2-fold greater for affected mice (mean
difference 5.08+2.52, p=O.048) than unaffected mice (mean difference 2.55+ 1.24,
p=0.338). The combination of genetic and dietary factors was found to have had an
additive effect on glucose tolerance in affected IGT/6 mice which exceeded that seen
in unaffected littermates. Affected mice fed HFD had significantly worse glucose
tolerance than unaffected littermates given the same diet (18.49+2.26 vs. 13.41 + 1.12,
p=0.004).
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Figure 17: Effect of High Fat Diet on IGT/6 Glucose Tolerance
Mean ± SEM of t = 120 minute blood glucose levels in 24 week old IGT/6 Be3 affected and
unaffected littermates fed either standard chow or HFD for 12 weeks. Significance tested by
ANOYA (p < 0.00 I) with Bonferroni post-hoc analysis; one-tailed p-values shown.
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2.4.4.2 Body Weight
Overall, affected IGT/6 mice are heavier than their unaffected littermates (39.94+ 1.06
vs. 35.66+0.71, p = 0.001). Inspection of Figure 18 also reveals that, whilst all animals
fed HFD gained weight, the increase in weight over that of chow fed animals was
greater for impaired glucose tolerance affected mice (mean difference 5.10+ 1.78, P =
0.016) than unaffected mice (mean difference 2.75+ 1.36, P = 0.159) suggesting these
animals may be more sensitive to diet induced weight gain. The consumption of high
fat diet increased the weight of unaffected animals to levels similar to those ofchow fed
IGT/6 mutants.
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Figure 18: Effect of High Fat Diet on IGT/6 Body Weight
Mean ± SEM of body weight in 24 week old IGT/6 Be3 affected and unaffected littermates fed
either standard chow or HFD for 12 weeks. Significance tested by ANOVA (p < 0.001) with
Bonferroni post-hoc analysis; one-tailed p-values are shown.
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2.4.4.3 Biochemistry
Plasma was only available for biochemical analysis from a small cohort of animals when
they were culled at 12 months of age. Alanine transaminase (ALT) levels were used as a
marker of hepatic inflammation. Figure 19 shows that HFD fed affected IGT/ 6
animals had significantly higher plasma ALT levels than unaffected HFD fed
littermates (88.75+9.66 vs. 49.75+4.29, p < 0.001) or chow fed affected mice
(88.75+9.66 vs. SS.sO+ 1.50, p =0.040).
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Figure 19: Effect of High Fat Diet on IGT/6 Plasma AlT levels
Mean ± SEM of ALT levels in IGT/6 Be3 affected and unaffected Iittermates fed either standard
chow or HFD from age 12 weeks. Significance tested by ANOVA (p =0.003) with Bonferroni
post-hoc analysis; one-tailed p-values are shown.
The small difference in ALT levels between affected and unaffected chow fed mice did
not reach statistical significance. No significant difference in ALT levels was seen
between HFD and chow fed unaffected mice which further supports the conclusion
that affected IGT/6 mice are more sensitive to dietary induced hepatic inflammation.
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2.4.4.4 Liver Histology
Examination of H&E stained sections demonstrated that high fat diet feeding induced
steatosis in the majority of animals irrespective of their initial glucose tolerance levels.
Affected animals fed HFD exhibited more frequent inflammatory infiltrates and more
extensive hepatocyte ballooning than unaffected HFD fed animals and more extensive
NAFLD than chow fed unaffected littermates (Figure 20). These findings are
consistent with increased steatohepatitis as indicated by the increased ALT levels
observed in the high fat fed affected IGT/6 group that was described above.
Figure 20: Liver Histology showing Effect of HFD on an 'Affected' Male IGT/6
Mouse
Image shows liver histology in an 'affected' high fat diet fed IGT/6 mouse. There is a florid
mixed micro- and macro-vesicular steatosis with hepatocyte ballooning degeneration.
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2.4.5 IGT/6 Genotyping
The location of the causative ENU induced mutation was sought by microsatellite
linkage analysis as described in section 2.3.12. Mapping the causative mutation is
easiest when large numbers of early backcross generation animals are available. On
average, one recombination occurs with each meiosis (generation). Thus, the amount
of paternal (C57BL/6J) DNA halves with each generation. Compared to an F1
animal, only a quarter of the paternal DNA remains by the yd backcross generation,
and so one expects only 25% of the available C57BL/6-C3H polymorphic markers to
still be present. Examination of Figure 7 shows the microsatellite panel used in this
study contained an average of7 polymorphic markers per chromosome; by backcross 3
this would have fallen to an average of 2 markers per chromosome. As already
mentioned, the supply of informative early backcross animals was limited due to the
early death of the founder animal (MEB/23b.2h). Only 44 male BC1 animals were
available and so these were supplemented by 27 BC2 and 50 BC3 mice, detection
sensitivity falling with each generation. Initial analysis was performed using Windows
QTL Cartographer software.
No clear linkage could be established using the 12 week glucose tolerance or body
weight data over all three backcross generations (Figure 21). This was not significantly
improved by the addition of subsequent backcross generations. When the 24 week
data was studied, an area of weak linkage was observed on chromosome 12 centred on
marker D 12MIT167 (lod score 2.6). See Figure 22. Inspection of haplotypes for this
area suggested that this was a spurious finding (Figure 23).
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Figure 21: Linkage Analysis for Backcross I Mice using 12 Week Phenotype Data
The plots of lod score by chromosome position demonstrate that no clear linkage could be
established using the 12 week Be I data. No scores approached a 2.5 lod threshold.
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Figure 22: Linkage Analysis for Backcross I Mice using 24 Week Phenotype Data
The plots of lod score by chromosome position demonstrate an area of possible linkage on
chromosome 12 using the 24 week Be 1 data.
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Thus, no clear sustained linkage of phenotype (glucose tolerance, body weight or
NAFLD) to a genetic locus could be established using Windows QTL Cartographer
software. To try and identify areas of possible linkage the markers were arranged by
chromosomal location and sorted according to ascending values of 12 week t = 120
glucose trait, five areas where linkage may reside could be identified (Table 25 on page
105).
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Figure 23: Chromosome 12 Haplotypes Sorted by 24 Week Blood Glucose Levels
For each marker position, C3H homozygote DNA is represented as I and CS7BU6-C3H
heterozygote DNA as a 2. When the haplotypes on chromosome 12 are sorted according to
increasing 24 week t = 120 minute blood glucose concentration (mmol/I) it becomes clear that
the area of possible linkage (shown in red) is unlikely to be real and may in fact represent an
area with a negative additive effect (i.e. an area where carriage of CS7BU6 DNA is associated
with lower blood glucose levels).
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Each of these areas was too large to make the sequencing of candidate genes a practical
approach. It did not prove possible to narrow the area of linkage further with the
addition of the BC3 animals. However, areas of interest on chromosomes 7 and 8 were
still present. Although chromosome 8 contains the insulin receptor gene, it lies some
distance from the areas ofpotential linkage that were identified (Figure 24).
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Figure 24: Chromosome 8 Haplotypes Sorted by 12 Week Blood Glucose Levels
For each marker position, C3H homozygote DNA is represented as I and C57BU6-C3H
heterozygote DNA as a 2. When the haplotypes on chromosome 8 are sorted according to
increasing 12 week t = 120 minute blood glucose concentration (mmol/I), an area between
markers D8MIT I00 and D8MIT 183 (shown in red) appears to be consistently present in
animals with high glucose levels. This may be indicative of an area containing the causative
mutation but was of too great a length to make candidate gene sequencing viable.
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Table 25: Areas with Possible Linkage
Phenotype Chr Start Marker End Marker Length
BC I 12 week IPGTT I DIMITI78 DIMITI39 60Mb
BC I 12 & 24 week IPGTT 7 D7MIT25* D7MIT28I See *
BC I 12 & 24 week IPGTT 8 D8MITIOO D8MITI83 44.5Mb
BC I 24 week IPGTT 12 D6MITI95t DI2MITI05 21.8Mb
BC2 12 week IPGTT 8 D8MITI43 D8MITI29 37.4Mb
t This marker maps to chromosome 12 in Ensembl Build v38 (current).
* This marker not present in current Ensembl build.
Identification of the causative mutation in the IGT/6 line has not proved successful
although several candidate regions have been identified (Table 25).
In an attempt to overcome the shortage of early backcross animals, the IGT/6 line was
crossed onto another genetic background (129S6/SvEv). Mapping could then be
restarted at the Fl generation using markers polymorphic between C57BL/6 and
129S6/SvEv. When placed on the 129S6/SvEv background the glucose tolerance
phenotype became too weak to make this approach viable.
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2.5 Discussion
2.5.1 IGT/6: A Model of Steatohepatitis
The IGT/6 line F1 founder animal, identified by the 12 week pnmary glucose
tolerance screen, exhibited significantly impaired glucose tolerance. This trait was
proven to be heritable by backcrossing the F1 mouse to the maternal C3H strain and
was shown to exhibit a high level of penetrance in the first backcross generation
(2.4.3.2). The glucose tolerance phenotype was however, only detectable in male
offspring - suggesting that gender may influence glucose sensitivity. This gender bias
with relative sparing of female animals has previously been reported in mouse models
ofdiabetes and has been attributed to greater hepatic/adipose insulin sensitivity194.19S.
The extended phenotype analysis demonstrates that subsequent IGT/6 generations all
have a strong impaired glucose tolerance phenotype which is not dependent on
carriage of the IR+I- mutation (2.4.3.2). In addition, impaired glucose tolerance was
shown to positively associate with hyperinsulinaemia and pancreatic islet cell
hyperplasia; surrogate markers of insulin resistance (2.4.3.6). The body weight of
IGT/6 mice was also found to be significantly greater than control animals (2.4.3.3).
Histological examination of liver tissue revealed features consistent with NAFLD in
approximately a quarter of animals. The majority of these had features of active
steatohepatitis (2.4.3.4) of sufficient histological severity to be equated to Matteoni
classification group 3 in humans41 . Disease of this severity is histologically characterised
by fat accumulation, necroinflammation and hepatocyte ballooning degeneration and
is associated with an increased likelihood ofhepatic fibrosis progression or liver related
death in epidemiological studies41 . Those IGT/6 mice with histological steatohepatitis
also exhibited a biochemical steatohepatitis - significant elevations of ALT and AST
over control indicating active hepatic inflammation.
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A further important phenotypic characteristic of the IGT/6 line is that mice are more
sensitive to the deleterious effects of high fat diet in terms of impaired glucose
tolerance, weight gaIn and severity of steatohepatitis (as assessed by
inflammatory/ballooning histological score and plasma ALT levels) than unaffected
littermates (2.4.4).
2.5.2 Comparison of IGT/6 to Existing Mouse Models of NAFLD
As discussed in section 2.1.1 on page 38, numerous different rodent models that
exhibit histological evidence of hepatic steatosis have been described (Table 4 on page
39). Most of these lack features of true steatohepatitis (specifically ballooning
hepatocyte degeneration) and simply exhibit fatty change with or without an
inflammatory infiltrate105. No existing model exhibits the entire NAFLD phenotype as
encountered in clinical practice and many differ from the human disease in all but
gross histological appearance. The pre-eminent models ofNAFLD used in research are
the ob/ob mouse and MCD diet induced steatohepatitis. To establish its place as a
faithful and effective model ofNAFLD, the IGT/6 line will be compared to these.
2.5.2.1 IGT/6 versus the MCD Dietary Model
The MCD model (as fully described in section 2.1.1.7) is arguably the only established
model with which to study spontaneous inflammatory and fibrotic elements of the
NAFLD spectrum. Despite this, there is little evidence to support the assertion that
this model replicates either the phenotype or pathogenic mechanisms of metabolic
syndrome related NAFLD.
In contrast to human fatty liver disease or the IGT/6 line, animals fed the MCD diet
are cachectic (50% weight loss compared with control mice by ten weeks), have low
plasma triglyceride levels and reduced liver weight/body weight ratio. The histological
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distribution of hepatic steatosis differs from the pattern seen in humans where a
periportal rather than perivenous deposition is seen67. MCD fed mice also exhibit very
high plasma ALT levels, markedly more elevated than those seen in patients with
NASH. Further, the MCD diet model is not insulin resistant l96• Although there has
been some recently published data indicating that CYP2E1 expression and consequent
oxidative stress, may impair insulin signalling by reducing tyrosine phosphorylation
and increasing serine phosphorylation of IRS-1 197, this model lacks what is considered
by many to be a pivotal feature of the NAFLD phenotype. Whilst the IGT16
histological phenotype is not as florid as that induced by MCD, it more accurately
models the entire trait.
2.5.2.2 IGT/6 versus the Db/Db Mouse Model
As discussed in section 2.1.1.1, the obiob mouse remains the most commonly used
model ofNAFLD. Genetically determined leptin deficiency leads to failure of satiety.
An increase in hepatic synthesis and storage of lipid coincident with expanded adipose
tissue stores leads to steatosis and obesity. This model has been extensively studied,
although the ob mutation is not prevalent in the human obese, NASH population and
leptin levels correlate poorly with the development ofNASH198.
As a model of genetic leptin deficiency, the obiob mouse exhibits a spectrum of
phenotypic traits that include obesity, diabetes and steatosis. These are features that
are shared by the IGT16 line. However, leptin deficiency affects numerous other
physiological systems and these additional influences potentially interfere with and
distract from the metabolic syndrome/NAFLD phenotype that is the focus of study.
Some facets of the ob phenotype that are not shared by the IGT16 line are discussed
below:
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I. Thefailure ofthe ob/ob model to progress beyond simple steatosis.
Without the administration of a second environmental insult ob mIce do not
spontaneously progress to steatohepatitis. This observation was the inspiration behind
the influential 'two-hit' hypothesis66 that remains a foundation for research in this
field. However, in terms of the general utility of this model, this anomaly is a severe
limitation. The ob mouse can not be used to examine the mechanisms that permit the
spontaneous transition from simple steatosis to steatohepatitis, an important switch in
the evolution of human NAFLD. In contrast, this data shows that the IGT/6 line can
exhibit either lone steatosis or steatohepatitis (Table 22). As such the IGT/6 line
would be an appropriate tool with which to study of this key transitional phase
without the need for further manipulation of the model.
II Potentialfor Tissue Fibrosis
Another significant shortcoming in the ob/ob model is that it is resistant to the
development of hepatic fibrosis. Leptin deficiency suppresses both the innate
(monocyte/macrophage mediated) and acquired (T-lymphocyte mediated) immune
responses. Hepatic depletion of natural killer T cells (NKT cells) favours a pro-
inflammatory, anti-fibrotic type 1 T -helper cell (Th-l) lymphocyte polarisation and so
makes the steatotic liver vulnerable to LPS toxicity199. Studies demonstrate that leptin
is necessary for the release of TNFa and the activation of TGF~ in response to liver
injury. TGF~ has an important regulatory role in the development of liver fibrosis7.
Defects in the production or post-translational modification ofTGF~ limit its activity
and so limit fibrogenesis. Hence ob/ob mice are resistant to hepatic fibrosis, even when
exposed to carbon tetrachloride2oo-202.
Once again, the ob mouse is held up at a physiological checkpoint in the pathogenesis
of progressive NAFLD. The normal progression from inflammation to fibrosis must
be artificially reconstituted in this model by leptin supplementation or treatment with
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norepinephrine to reset the Th-I/Th-2 balance in favour of a profibrotic Th-2
response with increased IL-4, IL-IO and TGF~ cytokine levels203, 204. The effects of
leptin deficiency on so many aspects of physiology increase the complexity of studies
using this line. Similarly, the limited fibrotic capacity of a leptin deficient model means
that it is best suited to studies investigating the mechanisms behind the development
of steatosis. The IGT/6 line does not share this deficiency and indeed
immunohistochemistry suggests that some spontaneous stellate cell activation may be
found in IGT/6 animals with NASH (data not shown).
2.5.3 Difficulties Identifying the Causative Mutation in IGT/6
Attempts to identify the END induced mutation that is responsible for the IGT/6
phenotype have thus far proved un-successful. Despite a total of 117 animals over three
backcross generations being tested for linkage to genetic markers distributed
throughout the genome, no area that is consistently linked to the phenotype has been
identified. Several factors contributed to these difficulties, discussed below.
2.5.3.1 Limited Supply of Early Backcross Animals.
The process of genetic mapping has been hampered by limitations in the supply of
mice from early backcross generations due to the early death of the founder animal,
MEB/23b.2h. Further, as the death was unexpected, sperm could not be stored for IVF
rederivation to allow further informative offspring to be generated. The amount of
founder C57BL/6 derived DNA within the genome is halved with each generation
and so the density of markers distributed throughout the genome needs to increase to
ensure that areas carrying the founder DNA are not missed. The panel of microsatellite
markers available was powered for use at the backcross one/two generation level and so
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once available stock at these generations was exhausted, identification of the mutation
became increasingly difficult.
In an attempt to generate more mice at an earlier backcross generation, the IGT/6 line
was out-crossed to a third inbred strain (129S6/SvEv instead of C3H). The intention
being that, if the glucose tolerance phenotype remained sufficiently strong, mapping
the mutation could be restarted at the equivalent of the BC1 generation using markers
that were polymorphic between CS7BL/6 and 129S6/SvEv. However the glucose
phenotype was lost on this background and so this approach has not been pursued
further. Similar resistance to genetically induced impaired glucose tolerance on the
129/Sv background has also been reported by other investigators examining IR/IRS-1
double heterozygote mice2os.
2.5.3.2 Possible Modifier Genes Affect IGT/6 Phenotype
The glucose tolerance phenotype used to identify mutant animals was found to weaken
with each backcross generation (see Figure lIon page 88). The concept that genetic
background may influence the apparent phenotype, whether induced by naturally
occurring 206, 207 or targeted induced mutation208, is well established. Therefore, this
observation may be interpreted as demonstrating that the CS7BL/6 background was
more permissive to an impaired glucose tolerance phenotype than the C3H
background. Hence, as the total CS7BL/6 DNA content was halved with each
generation, quantitative trait loci that influenced the penetrance of the causative ENU
induced mutation were lost.
An alternative explanation for the weakening phenotype, which may also account for
the difficulties experienced in locating a single causative mutation, is that the IGT/6
phenotype may be the product of more than one ENU induced mutation, each
affecting a complementary metabolic pathway. As discussed in section 2.1.2, given a
per locus functional mutation frequency of 1.08 x 10-3 (as has been established using
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the two times 100mg/kg ENU dosing regimen 170) and given that dominant mutations
occur at approximately 25% of this rate 170, one can estimate that an F1 generation
animal will carry approximately 8 functional autosomal dominant mutations (and
approximately 24 recessive mutations). Mice from the first backcross generation will
carry approximately half this number. Epistatic interactions between independently
segregating ENU induced mutations and modifier loci derived from the background
strains may therefore both contribute to the disease phenotype and confound linkage
analysis.
2.5.3.3 Mapping Quantitative Traits
Whilst it is easy to segregate mutant from non-mutant animals for qualitative traits
such as dysmorphia or extreme alcohol preference, it becomes more difficult to
separate animals on the basis of quantitative traits such as glucose tolerance and body
weight. This is because, although a phenotype may be clearly different on a population
basis, there is often some overlap between the mutant and non-mutant quantitative
trait phenotypes (exemplified in Figure 10). Thus, distinguishing true mutant animals
from non-mutant littermates that are simply at the extremes of the normal range may
be impossible. When trying to detect areas of the genome that segregate with a given
phenotype, the inadvertent inclusion of non-mutant animals may distract attention
from an area of true linkage.
2.5.4 Securing IGT/6 as a Tool for Future NAFLD Research
The difficulties in identifying the causative genetic mutations responsible for the
IGT/6 phenotype do not negate the value of this model as a tool for physiological and
pharmacological investigation. Currently the line is being bred to congenic status
(using the glucose tolerance phenotype and subsequent histological confirmation of
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NAFLD phenotype) onto a C57BL/6 background and also by intercrossing IGT/6
littermates. The intention is that these two IGT/6 sub-strains will me made available
to the scientific community for future study.
2.5.5 GENA/263: A model of Steatosis
The second NAFLD model identified during this study was GENA/263. The
GENA/263 line, as established within the MRC MLC, exhibits histological features
consistent with steatosis associated with insulin resistance and impaired glucose
tolerance. The change in apparent phenotype occurred when the animal was bred on
to a different C3H sub-strain and exemplifies how small changes in modifier genes due
to genetic drift may have major implications on disease phenotype. Currently the
ENU induced mutation is being sought by linkage analysis.
2.5.6 Conclusion
These results demonstrate that ENU mutagenesis is a valid and powerful approach
that may be used to bridge the phenotype gap between the existing models of complex
diseases such as NAFLD and the human disease phenotype. Using both genetically
sensitised and un-sensitised ENU mutagenesis approaches two novel models ofNAFLD
(With impaired glucose tolerance/insulin resistance and increased body weight) have
been identified. In both cases the models were the product of a random mutagenic
process with no a priori assumptions about the role of specific genes in disease
pathogenesis. This increases the value of these models as their study will allow
hypothesis generation through discovery and provide new insights into how NAFLD
develops.
Of the twO, the IGT/6 model has been more fully characterised. The results of this
analysis support the contention that this model is a significantly more faithful
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replication of the human NAFLD phenotype than any of the current mouse models
and fulfils the majority of the criteria set out in section 2.2. This line has been adopted
for further study in this thesis.
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SECTION 3:
3.1 Background
GENE EXPRESSION PATTERNS IN NAFLD
3.1.1 Transcriptome Level Analysis of NAFLD Phenotype
Hepatic regulation of glucose and lipid homeostasis is influenced by a complex system
of hormones, hormonally regulated signalling pathways and transcription factors79.
The availability of high-throughput microarray technology has revolutionised the way
transcriptome level research is performed. The expression of thousands of genes may
be ascertained simultaneously to provide a 'snap-shot' of the transcription state of a
tissue. Gene expression profiles of diseased tissue may then be compared to those of
healthy tissue and pathologically significant changes identified.
3.1.2 Previous Microarray Studies
In addition to studies examining expression of small numbers of selected genes using
techniques such as rtPCR, several high throughput microarray studies have been
published over the last 5 years examining differential gene expression in human tissue
and mouse models of NAFLD (Table 26). Reflecting the speed of technological
advances in this field, numerous different array platforms (both custom-made and
commercial) and analytical techniques have been used. High throughput studies such
as these have contributed to our understanding of the pathogenesis ofNAFLD. These
will be discussed further in section 3.4.5 when they will be compared to the expression
profile of the IGT/6 line.
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Table 26: Microarray Studies in NAFLD Research
Author Year Tissue Study Groups Platform Ref
Ferrante 2001 Mouse Ob/Ob mouse vs. Control ± Leptin Cy5/Cy3 209
Liang 2001 Mouse Ob/Ob mouse vs. Control ± Leptin Cy5/Cy3 210
Sreekumar 2003 Human Cirrhosis (NASH, HCV, PBC, Control) HU-6800 211
Younossi 2005a Human Bariatric surgery (Control, Steatosis, NASH) Cy5/Cy3 212
Younossi 2005b Human Bariatric surgery (Control, Steatosis, NASH) Cy5/Cy3 213
Sato 2006 Mouse Pten ko vs. Control (10 & 35 weeks) Cy5/Cy3 214
Chiappini 2006 Human Cadaveric donors (Steatosis, Normal) HG-UI33A 215
3.1.3 Microarray Technology
3.1.3.1 The Affymetrix Gene Expression Microarray Platform
The Mouse 430 2.0 GeneChip microarray contains 45,101 'probe-sets', each relating
to a specific gene transcript. A single array chip enables the interrogation at the
transcription level of>39,000 independent gene and EST sequences. Each probe-set is
composed of 11-20 Perfect Match (PM) 2S-nucleotide probes that are complementary
to specific cRNA sequences and 11-20 Mismatch (MM) 2S-nucleotide probes that
differ at a single (13th) nucleotide from the PM probes and are designed to test for
background fluorescence due to non-specific binding.
Affymetrix data is generated by processing an image of the microarray (stored in a
.DAT file) to produce a .CEL file. This function is performed by the GeneChip
Operating Software (Affymetrix Inc, USA). For each probe on the array, the .CEL file
contains a single number defining its fluorescence intensity.
3.1.3.2 Data Analysis
The analysis of microarray data may be divided into two broad categories. These will
be briefly reviewed; further detail is provided in the methods section below.
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1. Pre-processing & Low LevelAnalysis
The primary aims of pre-processing are background correction, data normalisation (to
remove systematic variation between arrays), correction for non-specific hybridisation
and assimilation of probe fluorescence intensities into a single expression-level call for
each probe-set. Secondary goals may include log2 transformation of data and filtering
to reduce the size of the data-set being studied. The optimal biostatististical techniques
for microarray pre-processing remain an actively researched field that is rapidly
evolving. Numerous statistical algorithms that perform some or all of these tasks have
been described. The most widely adopted include MAS 5.0, PLIER, RMA and GC-
RMA. There have been several recent critical reviews comparing these and other
techniques but choice of algorithm remains largely down to investigator preference216-
219. GC-RMA has been shown to perform well over a wide range of gene expression
levels whilst remaining sensitive to changes in genes that are present at low expression
levels such as transcription factors22o.
II. High LevelAnalysis
Once a list of differentially expressed genes is identified, the data must be analysed
further to extract biologically relevant information. High level analysis encompasses
the annotation of probe-sets with details of the genes they represent and their
ontological classification based on current understanding of function. Further, the
data may be explored to identify patterns of gene expression that most strongly
differentiate the phenotypic groups and genes may be mapped onto previously
described metabolic pathways. These processes can inform hypothesis generation for
future studies and highlight the pathogenic mechanisms ofa disease.
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3.1.4 Aims & Objectives
The aim of this study was to elucidate the complex pathogenesis of NAFLD in the
IGT/6 model at the transcriptome level and to identify those changes in gene
expression that differentiate IGT/6 mice with a histological NAFLD phenotype from
those without.
Genes and pathways found to be differentially expressed in NAFLD will be compared
to those identified in the previous microarray studies in this field in order to identify:
1. Common patterns of differential gene expression between IGT/6 and other
disease models or patient groups.
2. Novel genes and metabolic pathways that are associated with the NAFLD
phenotype in this model and that may be candidates for investigation in
NAFLD patient populations.
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3.2 Methods
3.2.1 Selection of Specimens
To determine the differences in hepatic gene expression profile between IGT/6 mice
with an impaired glucose tolerance/insulin resistance phenotype ('IGT/6-DM') and
littermates that, in addition, exhibited histological evidence ofsteatohepatitis ('IGT/6-
NASH') a group of BC1 mice were selected for further analysis using microarray
technology.
Animal stock maintenance and phenotypic screening have previously been described in
section 2.3.1 on page 54. Animals were culled by intraperitoneal injection of a lethal
dose of Pentabarbitone (0.2ml Sagatal, Pentobarbitone sodium 60mg/ml, Merial Ltd.,
UK). Immediately after death liver tissue was harvested, half was snap-frozen in liquid
nitrogen and stored at -80aC as a resource for subsequent RNA extraction. As is
detailed in section 3.2.2 below, RNA was extracted from 5 male IGT/6-NASH mice
and 4 IGT/6-D M mice. All had been fully phenotypically characterised in terms of
glucose tolerance, body weight and liver histology. RNA was also extracted from 3
control animals, generated in parallel by backcrossing non-ENU mutagenised
C57BL/6 IR heterozygote mice to C3H females, all 3 exhibited normal glucose
tolerance and no histological evidence ofNAFLD.
Details of the twelve week glucose tolerance phenotype and post-mortem histological
steatohepatitis score of the animals in each experimental group are summarised below
in Table 27. There was no significant difference in insulin receptor status (p = 0.206)
or body weight between the three study groups (ANOVA p = 0.300) and there was no
significant difference in t = 120 minute glucose tolerance test results between IGT/6-
DM and IGT/6-NASH mice (p =0.296).
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3.2.2 RNA Extraction
Total RNA was extracted from snap frozen liver tissue using an RNeasy Mini kit
(Qiagen, USA) following the manufacturer's protocol, summarised in Figure 25. Prior
to commencing the procedure, RLT-~ME buffer was prepared by adding 1O~.l ~­
Mercaptoethanol (2-mercaptoethanoI98+%, Sigma, UK) to Iml RLT buffer (a highly
denaturing guanidine isothiocyanate buffer, Qiagen, USA). RPE buffer concentrate
was diluted by the addition of 4 volumes ethanol (absolute ethyl-alcohol 99.86% v/v
minimum, Hayman Ltd., UK) to 1 volume ofRPE.
Approximately 30mg of frozen sample tissue were ground to fine powder with a
mortar and pestle. During this process liquid nitrogen was added to the mortar to
prevent the sample thawing. 600t-t1 of RLT-~ME buffer was added and the tissue
suspension homogenised by repeated aspiration and ejection through a 21-gauge
needle into a sterile 2ml plastic syringe. The presence of the
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guanidine isothiocyanate buffer ensured that all RNases were
rapidly inactivated. The homogenate was transferred to a 1.5ml
Eppendorf tube and centrifuged at 13,000 rpm for 3 minutes in a
bench top centrifuge at room temperature. Supernatant (lysate)
was transferred into a fresh Eppendorf tube and the residue
discarded. An equal volume of 70% Ethanol (prepared from
absolute ethyl-alcohol 99.86% v/v minimum, Hayman Ltd., UK)
was added to the supernatant to produce appropriate binding
conditions. The reagents were mixed thoroughly by aspiration
with a pipette and applied to an RNeasy mini column so that
RNA could bind to the silica-gel membrane within the column.
Figure 25: Schematic Representation of RNA Extraction
Using RNeasy Mini kit (Qiagen, USA)
Image modified from manufacturer's manual with permission.
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The column was centrifuged at 10,000 rpm for 15 seconds and the flow-through
discarded. The column was washed by addition of 35°111 of RWI buffer followed by
centrifugation at 10,000 rpm for 15 seconds and disposal of the flow-through. A
solution containing 1°111 of RNase-free DNase (#79254 Qiagen, USA) and 7°111 of
RDD buffer was added to the column before incubation at room temperature for 15
minutes to ensure that the extracted RNA was not contaminated with genomic DNA.
Contaminants were washed away by addition of 35°111 of RWI buffer followed by
centrifugation at 10,000 rpm for 15 seconds and disposal of the flow-through. The
column was then placed in a new collection tube. 5°°111 diluted RPE buffer was added
to the column prior to recentrifugation at 10,000 rpm for 15 seconds. The follow-
through was discarded. This process was repeated with a further 5°°111 RPE buffer and
the column centrifuged at 10,000 rpm for 2 minutes and 13,000 rpm for a further
minute to dry the membrane. All flow-through was discarded. The purified total RNA
was eluted from the membrane into a nuclease free 1.5ml Eppendorf tube by
incubating the column for 4 minutes in the presence of 5°111 nuclease-free water and
spinning the column for 1 minute at 10,000 rpm. Care was taken throughout the
procedure to avoid any contamination of the samples.
The amount and quality of RNA extracted was assessed by measuring light absorbance
at 260/280nm in a Beckman DU-600 spectrophotometer (Beckman-Coulter Inc.,
USA). Messenger RNA (mRNA) constitutes approximately 1-3% of total RNA; the
rest is predominantly ribosomal RNA (made of 28s and 18s subtypes, sized 5kb and
2kb respectively in mammals). As the small proportion of mRNA within total RNA is
not easily detectable, the integrity of the extracted total RNA was assessed by
examining the electrophoretogram and the ribosomal RNA 28s/18s concentration
ratio as a surrogate (Agilent 2100 Bioanalyzer, Agilent Technologies, USA). The
extracted RNA was then stored at -80aC until required.
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3.2.3 Affymetrix GeneChip Eucaryotic Small Sample Target Labelling
Assay version II (Processing of RNA to Biotinylated cRNA).
Total RNA extracted as described above in section 3.2.2 was converted into biotin
labelled antisense cRNA according to a protocol adapted from the Affymetrix
GeneChip Eucaryotic Small Sample Target Labelling Assay version II (Affymetrix Inc,
USA). High quality total RNA with no evidence of DNA contamination or RNA
degradation on Agilent 2100 Bioanalyser electrophoretogram was used. The protocol
is described below and summarised in Figure 26. All reagents, pipette tips and tubes
used throughout the experiment were certified nuclease free.
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1. First Stand eDNA Synthesis
2. Second Strand eDNA Synthesis
5' 'D'U'ITUU AAAAA 3'
3' lllJ.lllllJ.WlL UUUUU 5'
FIRST CYCLE
5' =AAAM 3'B +--1~3'TiTTITTIrr:Iiiiiiiii~5'I
5' =AAAM 3'
3' lllJ.lllllJ.WlL TITTI - __ 5'
B
5' 1J'1'Tml'lj"[j' AAAM - __ 3'
3' lllJ.lllllJ.WlL TITTI - 5'
~~ ~~~~~u~ ~~~~~~~e_~~~:~~~~~_N_~ j} _
4. In vitro Transcription ~ Unlabelled Ribonucleotides I
3' lllJ.lllllJ.WlL UUUUU 5'
:~~~~~~u~~~~:~~~~~~~~~~~~~~~ j} _
SECOND CYCLE ~ Random Primers I
6. First Stand eDNA Synthesis
7. Second Strand eDNA Synthesis
8. Cleanup of Double Stranded eDNA
9. Biotin Labelling Antisense cRNA
10. Cleanup of Biotynilated cRNA
B +--1L3' ~TITTI~~5'I
3' 'D'U'ITUU AAAAA - -- 3'
5' .D.lJ.JllllJ. TITTI - __ 5'
B ~ Biotinylated Ribonucleotides
, - 0 _ 0 - 00000
3 .D.JJJJJ.lll UUUUU 5'
B
FRAGMENTATION & HYBRIDISATION
Legend
.D.lJ.JllllJ. RNA
.D.lJ.JllllJ. DNA
T7 Primer
Figure 26: Affymetrix GeneChip Eukaryotic Small Sample Target Labelling Assay
Version II Summary Figure
This figure summarises the ten steps that are involved in amplifying 100mg of total RNA to
generate a sufficient amount of biotinylated cRNA for fragmentation and hybridisation to an
Affymetrix GeneChip microarray. This process is described fully in the text. (Figure modified
from 'GeneChip Eukaryotic Small Sample Target Labelling Assay Version II Technical Note'
Affymetrix #701265 Rev. 2)
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1. First RoundAmplification: First Strand eDNA Synthesis
In the first step of the protocol, total RNA was reverse transcribed into the
complementary DNA sequence. Extracted RNA was diluted to a concentration of
200ng/!l1 with nuclease free (DEPC-treated) water. Reagent mixture A (see Table 28)
was prepared in 200!l1 nuclease-free PCR tubes.
Table 28: Microarray Reagent Mixture A
Components Volume added (~I) Supplier
Total RNA 0.5
T7-Oligo(dT) Promoter Primer (H PLC-purified)* 1.0
(200 ng/[-tl)
(5 pmol/[-tl) Affymetrix #900375
PolyA+ Control Mixturet
Total Volume
0.5
2.0
Microarray Centre
* Sequence 5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24-3' (Affymetrix, USA)
t The PolyA+ 'spiked-in' controls are synthesized by the Imperial College Microarray Centre from five Bacillus
subtillus transcripts followed by a polyA tract prepared from pBluescript ii KS (+) plasmids.
The reagents were mixed thoroughly by aspiration with a pipette, spun briefly to
ensure all liquid was forced to the bottom of the tube and incubated at 70°C for 6
minutes in a DNA Engine thermal cycler with a heated lid (BioRad Inc., USA) to
disrupt secondary RNA structure. Samples were then cooled to 4°C for a further 2
minutes.
Table 29: Microarray Reagent Mixture B
Components Volume added (~I) Supplier
RNase-free Water (DEPC-treated) 0.375 Ambion #9920
5x First Strand Buffer 1.0 Invitrogen*
Dn 0.5 (0.1 M) Invitrogen*
dNTP Mix 0.375 (IOmM) Invitrogen #18427-013
RNase Inhibitor 0.25 (40U/[-tI) Ambion #2684
Superscript II Reverse Transcriptase 0.5 (200U/I-tI) Invitrogen*
Total Volume 3.0
*These are components ofthe Superscript II Reverse Transcription kit # 18064-0 14 (Invitrogen, USA).
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Reagent mixture B (see Table 29) was prepared on ice and 3[1-1 of this mixture added to
each tube. The tubes were returned to the thermal cycler, incubated first at 42°C for 1
hour, then 70°C for 10 minutes (to deactivate the Superscript II reverse transcriptase)
and finally cooled to 4°C.
2. First RoundAmplification: Second Strand cDNA Synthesis
A second DNA strand, complementary to that synthesised in step one, was synthesised
using an E. coli derived DNA polymerase. Reagent mixture C (Table 30) was prepared
and 32.5[1-1 added to each of the reaction tubes from step one. The reagents were mixed
by aspiration with a pipette, spun briefly and incubated for 2 hours at 16°C in a
thermal cycler without a heated lid. The total reaction volume was 37.5[1-1 per tube.
Samples were frozen on dry-ice and stored at -80°C overnight.
Table 30: Microarray Reagent Mixture C
Components Volume added (~I) Supplier
RNase-free Water (DEPC-treated) 22.75 Ambion #9920
5x Second Strand Buffer 7.5 Invitrogen # 10812-014
DNA Ligase (E.coli) 0.25 (lOU /p.l) Invitrogen # 18052-019
dNTP Mix 0.75 (IOmM) Invitrogen #18427-013
DNA Polymerase (E.coli) 1.0 (IOU/l-d) Invitrogen # 180 I0-025
RNase H 0.25 (2U/fLl) Invitrogen # 18021-071
Total Volume 32.5
3. First RoundAmplification: Clean-up ofDouble Stranded cDNA
The samples were thawed and the 37.5[1-1 volume reactions from step 2 transferred into
1.5ml Eppendorf tubes on ice. 82.5[1-1 of nuclease-free water was added to each tube to
dilute the reaction mixture followed by 2[1-1 Glycogen (5mg/ml; Ambion #9510), 72[1-1
5M Ammonium Acetate (Ambion #9070G) and 480[1-1 ice-cold ethanol (absolute
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ethyl-alcohol 99.86% v/v minimum). The reactions were mixed thoroughly by
pipetting and the tubes incubated at -20°C for 1 hour to allow the double stranded
eDNA to precipitate. Glycogen acts as a carrier, enhancing precipitation ofeDNA.
The latter was pelleted by centrifugation at 14,000 rpm for 20 minutes at 4°C. The
supernatant was discarded and the eDNA pellet washed by resuspension in 800V-1 of
ice-cold 70% ethanol prior to recentrifugation at 14,000 rpm for 5 minutes at 4°C. All
remaining traces of ethanol were removed and the pellet air dried for'" 15 minutes at
room ternperature.
4. First RoundAmplification: in vitro Transcription
The double-stranded eDNA was then transcribed back into antisense cRNA. The
pellet was re-suspended in a 9V-1 solution of unlabelled ribonucleotides and reaction
buffer (reagent mixture D, Table 31) to which lV-I T7 Enzyme mix RNA polymerase
was added (Ambion #1334). The mixture was incubated at 37°C in a heat block for 5
hours. Each hour the tubes were gently agitated and spun briefly in a bench top
microcentrifuge to collect any condensation. The samples were frozen on dry-ice and
stored at -80°C overnight.
Table 31: Microarray Reagent Mixture D
Components Volume added (1"1) Supplier
RNase-free Water (DEPC-treated) 4.0 Ambion #9920
T7 ATP Solution 1.0 (75mM) Ambion*
T7 CTP Solution 1.0 (75mM) Ambion*
T7 GTP Solution 1.0 (75mM) Ambion*
T7 UTP Solution 1.0 (75mM) Ambion*
T7 lOx Reaction Buffer 1.0 Ambion*
Total Volume 9.0
*These are components of the MEGAscript T7 in vitro Transcription kit # 1334 (Ambion t USA).
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5. First RoundAmplification: Amplified cRNA Clean-up (QC)
The amplified cRNA from step 4 was cleaned to remove any residual free nucleotides,
etc. using components of an RNeasy Mini kit (Qiagen #74104, for details of reagents
see Appendix A). To each 1.5ml Eppendorf containing the products of in vitro
transcription, 90~ nuclease free water, 350~ RLT Buffer and 250~1 100% ethanol
were added. The reagents were mixed thoroughly by aspiration with a pipette, placed
on an RNeasy Spin Column and centrifuged at 15,000 rpm for 15 seconds at room
temperature. The cRNA binds to the membrane within the column and the eluate was
discarded. 500~1 RPE buffer was added to the column which was centrifuged again at
15,000 rpm for 15 seconds to remove any unbound material. This process was repeated
with a further 500~ RPE buffer being added to the column followed by centrifugation
at 15,000 rpm for 3 minutes to dry the membrane. The cRNA was eluted from the
membrane by incubating the column at room temperature for 4 minutes in the
presence of 30~1 nuclease-free water and spinning the column for 1 minute at 15,000
rpm. A further 20~1 of water was then added to the membrane which was incubated
for a further 4 minutes and centrifuged so that the total volume ofeluate was ""50~1.
Before proceeding to the second round amplification, the cRNA yield was measured
and quality control checks were performed to confirm that there had not been any
degradation of the sample during processing. Five microlitres cRNA solution was
added to 95~1 non-DEPC treated nuclease-free water and light absorbance measured at
260/280nm in a Beckman DU-600 spectrophotometer (Beckman-Coulter Inc., USA).
Total cRNA yield was calculated (expected yield 1-2~g from 100ng total RNA,
representing a 10-20 fold amplification) and the ratio of absorbance at the two
wavelengths was recorded (expected range 1.9-2.1). Integrity of the cRNA was further
assessed by examining the electrophoretogram using an Agilent 2100 Bioanalyser
(Agilent Technologies, USA).
Using the concentration values obtained from their light absorbance profiles, the
appropriate volumes of cRNA solution to contain 1~g of cRNA were then transferred
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into 1.5ml Eppendorf tubes. The cRNA was vacuum centrifuged at room temperature
to reduce the volume of the cRNA solution to ::; 4til. The samples were frozen on dry-
ice and stored at -80°C overnight.
6. Second RoundAmplification: First Strand eDNA Synthesis
Each cRNA sample (l!lg in 4!ll) generated from the first round of amplification was
mixed with l!ll (0.2!lg/!ll) Random Primers (Invitrogen #48190-011) and incubated at
70°C in a thermal cycler with heated lid for 10 minutes. Samples were cooled on ice for
2 minutes and then spun briefly in a bench-top microcentrifuge.
Reagent mixture E (Table 32) was prepared at room temperature with the enzyme
kept on ice until finally added. Five microlitres of mixture E was added to each sample,
the components were mixed by pipette and the sample incubated at 42°C for 1 hour in
a thermal cycler.
Table 32: Microarray Reagent Mixture E
Components Volume added (~I) Supplier
5x First Strand Buffer 2.0 Invitrogen*
DTT 1.0 (0.1 M) Invitrogen*
dNTP Mix 0.5 (IOmM) Invitrogen #18427-013
RNase Inhibitor 0.5 (40U/[-tI) Ambion #2684
Superscript II Reverse Transcriptase 1.0 (200U/[-tI) Invitrogen*
Total Volume 5.0
*These are components of the Superscript II Reverse Transcription kit # 18064-014 (Invitrogen, USA).
The samples were then mixed with ltil (2V/til) RNase H (Invitrogen, #18021-071)
and incubated at 37°C for a further 20 minutes. The samples were then heated to 95°C
for 5 minutes to inactivate the RNase H, cooled on ice for 2 minutes and spun briefly.
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7. Second RoundAmplification: Second Strand cDNA Synthesis
Each 11 fll sample from step 6 was mixed with 2fll T7 Oligo(dT) Promoter Primer
(diluted to 5pmollfll; Affymetrix #900375) and incubated at 70°C for 6 minutes in a
thermal cycler. Samples were then cooled on ice for 2 minutes, spun briefly and mixed
with 62fll of reagent mixture F (see Table 33). The final 75fll reaction was incubated at
16°C for 2 hours in a thermal cycler with a lid. The samples were frozen on dry-ice and
stored at -80°C.
Table 33: Microarray Reagent Mixture F
Components Volume added (",I) Supplier
RNase-free Water (DEPC-treated) 43.5 Ambion #9920
5x Second Strand Buffer 15.0 Invitrogen # I0812-0 14
dNTP Mix 1.5 (IOmM) Invitrogen #18427-013
DNA Polymerase (E.coli) 2.0 (IOU/rtl) Invitrogen # 180 I0-025
Total Volume 62.0
8. Second RoundAmplification: Clean-up ofDouble Stranded cDNA
The samples from step 7 were transferred into 1.5ml Eppendorf tubes and kept on ice.
2fll Glycogen solution (5mg/ml; Ambion #9510), 45fll 5M Ammonium Acetate
(Ambion #9070G) and 300fll ice-cold ethanol (absolute ethyl-alcohol 99.86% v/v
minimum) were added to each tube. The reagents were mixed thoroughly by aspiration
with a pipette followed by incubation at -20°C for 30 minutes to allow the double
stranded cDNA to precipitate.
The samples were centrifuged at 14,000 rpm for 20 minutes at 4°C, the supernatant
discarded and the cDNA pellet washed by resuspension in 800fll of ice-cold 70%
ethanol. The cDNA sample was spun down again at 14,000 rpm for 5 minutes at 4°C,
all remaining traces of ethanol removed and the pellet air dried for I"V 15 minutes at
room temperature.
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9. Second RoundAmplification: in vitro Transcription
Each sample pellet from step 8 was re-suspended in 38[11 of mixture G (Table 34) to
which 2~1 T7 Enzyme n1ix RNA polymerase was added (Ambion #1334). The samples
were incubated at 37°C for 5 hours. Each hour the tubes were gently agitated and spun
briefly in a bench top microcentrifuge. Thereafter the samples were frozen on dry-ice
and stored at -80°C overnight.
Table 34: Microarray Reagent Mixture G
Components Volume added (1'-1) Supplier
RNase-free Water (OEPC-treated) 22.0 Ambion #9920
HY Reaction Buffer (lOx) 4.0 Affymetrix*
Biotin-labelled Ribonucleotides (I Ox)t 4.0 Affymetrix*
OTT (lOx) 4.0 Affymetrix*
RNase Inhibitor Mix (lOx) 4.0 Affymetrix*
Total Volume 38.0
*Components ofthe ENZO BioArray HighYield RNA Transcript Labelling Kit #900 182 (Affymetrix. USA).
t The nucleotides Cytosine and Uracil are biotin labelled.
10. Second RoundAmplification: Amplified cRNA Clean-up (QC)
The highly amplified cRNA synthesised during the above series of steps was cleaned to
remove any residual free nucleotides, etc. using components of an RNeasy Mini kit
(Qiagen #74104, for details of reagents see Appendix A). To each 1.5ml Eppendorf
containing the products of in vitro transcription, 60[11 nuclease free water, 350~1 RLT
Buffer and 250[11 ethanol (absolute ethyl-alcohol 99.86% v/v minimum) were added.
The reagents were mixed thoroughly by pipette, added to an RNeasy Spin Column and
centrifuged at 15,000 rpm for 15 seconds at room temperature to bind the cRNA to
the membrane within the column. The eluate was discarded and 500[11 RPE buffer was
added to the column prior to recentrifugation at 15,000 rpm for 15 seconds. This
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process was repeated with a further 500fLl RPE buffer and the column centrifuged at
15,000 rpm for a total of 3 minutes to dry the membrane. Successive eluates were
discarded. The cRNA was eluted from the membrane by incubating the column for 4
minutes in the presence of 30/11 nuclease-free water and spinning the column for 1
minute at 15,000 rpm. A further 20/11 ofwater was then added to the membrane which
was incubated for a further 4 minutes and centrifuged so that the total volume of
eluate was "'50/11.
Before proceeding to the second round amplification, the cRNA yield was measured
and quality control checks were performed to confirm that there had not been any
degradation of the sample during processing. Five microlitres cRNA solution was
added to 95/11 non-DEPC treated nuclease-free water and light absorbance measured at
260/280nm in a Beckman DU-600 spectrophotometer (Beckman-Coulter Inc., USA).
Total cRNA yield was calculated (expected yield 40-1 OO/1g using l/1g cRNA from the
first round of amplification) and the ratio of absorbance at the two wavelengths was
recorded (expected range 1.9-2.1). Integrity of the cRNA was further assessed by
examining the electrophoretogram using an Agilent 2100 Bioanalyser (Agilent
Technologies, USA).
Using the concentration values obtained from the absorbance measurements, the
cRNA concentration ofeach sample was adjusted so that it was ~ 1.25/1g//11 by vacuum
centrifugation at room temperature where appropriate. The biotinylated cRNA
samples were frozen on dry-ice and transported to the Imperial College Microarray
Centre, MRC Clinical Sciences Centre, Hammersmith Campus for further
proceSSIng.
3.2.4 Further Processing of Biotinylated cRNA at the Microarray Centre
The biotinylated cRNA was subsequently processed using standard protocols by
experienced technical staff at the Microarray Centre in preparation for hybridisation
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to full genome scale Affymetrix GeneChip Mouse 430 verSIon 2 mIcroarrays as
described below.
1. Fragmentation ofBiotinylated cRNA Samples
Twenty micrograms of biotinylated cRNA (minimum concentration 1.25V-g/V-l) was
added to 4V-l 5x Fragmentation Buffer and the reaction made up to 20V-l with nuclease-
free water prior to incubation at 95°C in a thermal cycler with heated lid for 35
minutes. The samples were then spun to remove any condensation from the lid of the
tube. 15V-l aliquots of each fragmented cRNA sample were added to 285V-l of mixture
H (see Table 35) and mixed by vortexing for 30 seconds.
Table 35: Microarray Reagent Mixture H (cRNA Fragmentation)
Components Volume added «(A-I) Supplier
Hybridisation Buffer (2x)
Control Oligonucleotide B2*
Eukaryotic Hybridisation Controls (20x)* t
Herring Sperm DNA
Acylated BSA
RNase-free Water (DEPC-treated)
Total Volume
150.0
5.0
15.0
3.0
3.0
109.0
285.0
(3nM)
(IOmg/ml)
(IOmg/ml)
Affymetrix #900720
Affymetrix #90030 I
Affymetrix #900299
Promega #D 18 I I
Invitrogen # 15561-020
Ambion #9920
*These reagents were heated at 65°C for 5 minutes before being added to the master mix.
t Eukaryotic labelled cRNA control transcripts called BioB, BiDe, B;oD and ere derived from Bacillus subtiliis.
2. Hybridisation ofFragmented cRNA to GeneChip Microarrays
The fragmented cRNA samples were hybridised to Affymetrix GeneChip Test3 arrays
as a final quality control check. This scaled down array contains probe sets representing
a subset of characterised genes from various organisms including mammals, plants and
eubacteria. For each eukaryotic organism represented, probes derived from 5', middle,
and 3' portions of the gene are represented. Measurement of the signal from these three
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probe sets permits the identification of degraded samples that contain insufficient
target and so may result in poor expression array results.
The array chip was equilibrated at room temperature for 30 minutes, pre-wetted with
100fll (200fll for full genome arrays) Hybridisation buffer (Affymetrix #900720) and
incubated in rotisserie oven at 45°C, 60 rpm for 10 minutes. Fragmented cRNA was
heated to 99°C for 5 minutes in a thermal cycler with heated lid, cooled to 45°C for 5
minutes and centrifuged at 13,000 rpm for 5 minutes to remove debris. The buffer
solution was then removed from the array chip and 100fll (200fll for full genome array)
of the fragmented, biotin labelled, cRNA added. The chip was incubated in a rotisserie
oven at 45°C, 60 rpm for 16 hours whilst hybridisation took place.
Those samples that successfully passed the Test3 quality check were hybridised to full
scale Affymetrix GeneChip 430 2.0 mouse genome oligonucleotide arrays according to
the same protocol.
3. Washing, Staining & Scanning GeneChip Microarrays
Once hybridisation was complete, the excess fragmented cRNA was removed and
200fll Wash Buffer A (Affymetrix #900720) added to the microarray chip. Only the
washing and staining of the full scale whole genome chips will be described here. For
each chip, a Streptavidin-Phycoerythrin (SAPE) stain solution was prepared (Mixture
1, Table 36) and divided into two 600fll aliquots for use pre- and post-antibody
staInIng.
Table 36: Microarray Reagent Mixture I (SAPE Stain Solution)
Components Volume added (~I) Supplier
Stain Buffer (2x)
Acetylated BSA
SAPE
RNase-free Water (DEPC-treated)
Total Volume
600.0
48.0
12.0
540.0
1200.0
(50mg/ml)
(I mg/ml)
Affymetrix #900720
Invitrogen # 15561-020
Molecular Probes #5866
Ambion #9920
134
Antibody mixture J was prepared (Table 37). Washing and staining of both Test3 and
full genome scale arrays were performed in a Fluidics Station 450 (Affymetrix Inc.,
USA).
Table 37: Microarray Reagent Mixture J (Antibody Solution)
Components Volume added (!'tl) Supplier
Stain Buffer (2x) 300.0 Affymetrix #900720
Normal Goat IgG 6.0 (IOmg/ml) Sigma #1-5256
Biotinylated Antibody 3.6 (0.5mg/ml) Vector Labs #5800
Acylated BSA 24.0 (50mg/ml) Invitrogen # 15561-020
RNase-free Water (DEPC-treated) 109.0 Ambion #9920
Total Volume 600.0
The chips were scanned at 560nm and the fluorescence intensity of each probe
measured using GeneChip Operating Software (Affymetrix Inc, USA). Chip images
were stored as .DAT files and raw probe level data was saved in the .CEL file format.
These raw data files, generated by the Microarray Centre, were returned for analysis.
3.2.5 Data Analysis
Analysis was performed on a PC workstation running the Microsoft Windows XP
operating system (Dell Dimension 8400, Intel 3.0GHz Pentium 4 HT Processor with
1 GB RAM). The .CEL file data from the 12 microarray chips was collated and
analysed using Bioconductor release 1.7 packages221 (www.bioconductor.org) running
in the open source R software environment222 (release 2.2.1, www.r-project.org) and
Microsoft Excel software (Microsoft Corporation, USA). Customised scripts, based on
examples in the help files and vignettes that accompany each package, were written in
the R programming language to facilitate this analysis (Appendix B).
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3.2.5.1 Pre-processing & Low-Level Analysis
Prior to pre-processing and low-level analysis both the quality of the total RNA used
and the chip processing were assessed. Then, as discussed in section 3.1.3.2,
background correction, data normalisation (to remove systematic variation between
arrays), correction for non-specific hybridisation and assimilation of probe
fluorescence intensities into a single expression-level call for each probe-set were
performed.
1. RNA & Data Quality Control
The twelve raw .CEL data files corresponding to each of the RNA samples analysed
and a vector describing biological replicates and assigning each to a phenotypic
category ('Control', 'IGT/6-DM' or 'IGT/6-NASH') were imported into the
Bioconductor environment using the Affy package223• For the purposes of quality
control analysis only, the files were normalised using the MAS 5.0 algorithm
(Affymetrix Inc., USA) which by default determines a number of quality control
parameters. The Simpleaffy package was then used to report these quality control
metrics for each array chip including:
t. Average backgroundfluorescence signal intensity,
Uniformity across all chips in the experiment was confirmed. If outliers had
been detected it may have reflected unequal amounts of cRNA being
hybridized to the arrays, etc.
H. Scalefactor,
The MAS 5.0 algorithm was used to scale the signal intensity so each array
had the same mean. Arrays were tested to ensure that the 'scale factor' (a
measure ofan array's overall expression level) varied <3 fold across all chips.
tH. Number ofprobe-sets called Present,
MAS 5.0 flagged probe-sets as Present/Marginal/Absent according to
whether expression of PM probes differed significantly from their
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complimentary MM probes. The percentage present was tested to ensure it
was broadly similar across all chips.
tv. 3' to 5' ratiosfor GAPDHand ~-Actin,
Comparison of expression levels from probe-sets that target the 3' region,
mid- and 5' regions of the GAPDH and ~-Actin cRNA was used to
determine if transcripts had been truncated due to RNA degradation. As the
Small Sample processing protocol had been used (which contains an extra
amplification step that increases the frequency of short transcripts and
introduces 3' bias) a 3':mid ratio was adopted, as recommended by
Affymetrix. Respective values of <1.25 and <3 were sought for the GAPDH
and the ~-Actin ratios.
v. Valuesfor spike-in control transcripts
Additional labelled cRNA control transcripts (BioB, BioC, BioD and Cre) of
known concentration were added prior to array hybridization (see Table 35).
Fluorescence intensity of these primers is solely dependent only on the
hybridisation and array scanning steps. Detection of the BioB control was
checked for each sample to confirm that an acceptable threshold for signal
detection had been attained.
Taken together these data provided a final check to detect problems that may have
occurred during sample or chip processing. Ifany chips fell outside an acceptable range,
they were excluded so that data was not artificially skewed.
2. Generation ofProbe-LevelExpression Summary Values
The twelve raw .CEL data files corresponding to each of the RNA samples analysed
and a vector assigning each to a phenotypic category ('Control', 'IGT/6-DM' or
'IGT/6-NASH') were imported into the Bioconductor environment using the AJJY
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package223• Data were pre-processed according to the GeneChip-Robust Multi-array
Analysis (GC-RMA) method implemented in the gcrma package220• GC-RMA
performs a model-based background correction using only the perfect match probe
dataset (i.e. mismatch probe data ignored), followed by global quantile normalisation
to align values to a common scale and median polish summarisation to generate an
expression value for each probe set in lo~ space220•
This variant of the RMA expression index224 uses a model based on each probe's
sequence information to adjust for the effects of non-specific binding225• This differs
from the default, empirical, approach implemented by MAS 5.0 in which the MM
signals are simply subtracted to limit background noise. Much of the background
signal is due to partial nucleic acid homology between oligonucleotides with
incomplete complementarity. The magnitude of this effect is influenced by the base
composition of the nucleic acid sequences. Sequences rich in guanine (G) or cytosine
(C) lead to stronger hybridisation because each G-C pair forms three hydrogen bonds
whereas adenine (A)-thymine (T) pairs forms only two. In contrast, fluorescently
labelling the bases uracil (U) and C in amplified RNA appears to reduce binding
affinity226.
3. Probe Filtering & Comparative StatisticalAnalysis
Non-specific filtering was performed to exclude probe-sets from the analysis which did
not detect any gene expression or which were unlikely to exhibit significant variation
in expression level. Filtering was implemented using the Bioconductor gene.filter
package. Those probe-sets where less than a quarter of chips had expression levels
greater than an arbitrary normalised intensity threshold of 64 and where variation
across the samples was low (inter-quartile range <0.4) were excluded.
The Bioconductor package limma was used to identify statistically significant
differential expression between the study groups in the remaining probe-sets227. An
experimental design matrix was specified and the limma package used to fit a linear
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model to the data. Limma uses an empirical Bayes method to moderate the standard
errors of the estimated log-fold changes. This results in more stable inference and
improved power when the number ofarrays used is relatively sma1l227. Using these data,
three comparisons of differential expression were performed: IGT/6-DM vs. Control,
IGT/6-NASH vs. Control and IGT/6-NASH vs. IGT/6-DM. For each probe-set
comparison, the limma package generated an M-value (i.e. the log2-fold-change
between two conditions). The average expression level for a given gene across all the
arrays (A-value), the moderated t-statistic (a ratio of the M-value to its standard error)
and a p-value derived from the moderated t-statistic were also generated.
Lists of significant differentially expressed genes and their log2 transformed expression
values were output for further analysis directly from the limma package and also using
the a./fycoretools package. Estimates of false discovery rate for genes in each comparison
were made using Significance Analysis of Microarrays (SAM) software version 2.23
and the samr & siggenes packages running in the R environment228 •
3.2.5.2 High Level Analysis
Data exploration to identify biologically important features was performed using three
separate software environments. The main analytical processes performed are
summarised here.
1. Annotation ofProbes with Gene Transcript Information
The probes were annotated with gene transcript information based on the
Bioconductor mouse4302 metadata package (release 1.7, dated 14th October 2005).
This was manually updated for each significant cluster using data derived from the
Affymetrix N etAffx Analysis Centre229• Where a discrepancy between the two
annotation datasets was found for a given probe-set, the target sequence from which
the probes were derived was analysed using the NCBI BLASTn tool (version 2.2.13:
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www.ncbi.nlm.nih.gov/blast/) to identify where the sequences map in the current
mouse genome build. Each probe-set was annotated with details including gene name,
gene symbol, EntrezGene ID and key Gene Ontology classifiers.
2. Principal Components Analysis & Hierarchical Clustering
Principal Components Analysis (PCA) and Hierarchical clustering were performed
using TIGR MeV 3.1 sohware230. PCA is an exploratory multivariate statistical
technique for simplifying complex datasets231 . PCA reduces the dimensionality of a
data set by transforming to a new, smaller set of variables (the principal components)
that summarise the features of the data but remain mutually uncorrelated and
orthogonal. Principal components are ranked in order of variance; the first 2-3
components will capture the majority ofvariance within the dataset. It is often possible
to ascribe biological meaning to what the components represent231 . Thus, PCA
facilitates visualisation of large datasets, allows gene expression patterns to be studied
and when applied at the sample level, identifies correlations between samples or
conditions.
Hierarchical clustering is another technique to statistically group genes into clusters
that have similar expression profiles. This helps to identify trends in gene expression
between the study groups and highlights those genes that appear to respond similarly
in each study group.
3. Gene Ontology Classification
The Gene Ontology Consortium has developed a systematic approach to classifying
and annotating genes by dividing them into three groupings (Biological process,
Molecular function and Cellular component)232. However, the standard gene ontology
classifications may have an inherent flaw which can reduce their sensitivity for
detecting functional associations using automated techniques. This is because not all
aenes are associated with all the relevant ancestor nodes linked to the node with which
o
they are directly associated233• This is best explained using the hypothetical example
l-VI
proposed by the creators of the L2L software tool: 'a gene might be specifically associated
with [the term} "voltage-gated sodium channels" but not ''sodium channels': " .catIOn
channels': ''membrane transporters" or "homeostasis': For any given term (e.g. ''cation
channels')~ this meant that the list ofgenes directly associated with that term did not
necessarily include all the genes associated with its descendant terms (e.g. "voltage-gated
sodium channels')'. Whilst these associations may be explicit to a human, they are not
detected using an automated software classification technique.
L2L is a novel software tool that has been developed to address this potential flaw
(http://depts.washingron.edu/12l!)234. The L2L database contains a reworking of the
established gene ontology databases derived from NCBI Gene and the Gene Ontology
Consortium232 in which all descendent terms for each node are fully elucidated. In
addition, L2L contains a fourth database containing 592 lists ofdifferentially expressed
genes compiled from 130 published mammalian microarray studies covering a broad
range of tissues and interventions (updated and expanded January 2006) that may
offer further insights into biological relevance234.
Significantly up-regulated and down-regulated differentially expressed genes for each
comparison were submitted to L2L analysis for enhanced gene ontology classification.
Genes were mapped to nodes within the three gene ontology groupings. Nodes that
were significantly (p<O.O 1) enriched in each of the three comparisons guided the
determination of biological significance. Where appropriate, GO hierarchies were
further studied and tree diagrams plotted linking those nodes that were over-
represented using the European Bioinformatics Institute QuickGO database
(http://www.ebi.ac.uk/ego/).
4. Mapping Gene Expression onto BiologicalPathways
To gain further insights into how metabolic pathways within the liver of affected
animals were perturbed, differentially expressed genes for each comparison were
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mapped onto well characterised metabolic pathways using KEGG Pathway (Release
38.1)235 and GenMAPP 2.0 software236, 237. Specific attention was paid to those
pathways currently thought to be perturbed in the pathogenesis of NAFLD including
glycolysis, Kreb's TCA cycle, fatty acid synthesis, triglyceride synthesis, hepatic lipid
export as VLDL, fatty acid ~-oxidation and w-oxidation. Those metabolic pathways
found to be involved were then combined to generate a customised model based on
current literature and reflecting how key biological processes involved in the
pathogenesis of steatosis and steatohepatitis are altered in the IGT/6 model98,238.
3.2.6 Validation by rtPCR
3.2.6.1 Reverse Transcription for cDNA Synthesis
A subset of genes was selected for validation to confirm the results of microarray
analysis. Total RNA was diluted to a concentration of O.IS~g/[l1 with nuclease free
water (Ambion, USA). For each sample, l.S~g total RNA was reverse transcribed to
eDNA using a commercially available kit (RETROscript, Ambion, USA). The method
was as described by the manufacturer, full details of the reagents are given in
AppendixA.
Reactions were prepared in 200[11 nuclease free PCR tubes. Briefly, 2[11 SO[lM random
sequence oligonucleotide decamers (first strand primers) were added to 1.5[lg total
RNA in 1O~l nuclease free water and the mixture heated to 80°C for 3 minutes in a
DNA Engine tetrad thermal cycler (BioRad Inc., USA) to denature the RNA template
and remove any secondary structure which could impede the activity of the reverse
transcriptase. Reaction tubes were spun briefly and placed on ice. The remaining
reagents were then added (2[l110x RT Buffer, 4~12.SmM dNTP mixture, 10 units/l[ll
RNase inhibitor, 100 units/l [11 MMLV-RT) to a total volume of20[l1 and the mixture
incubated at 43°C for 1 hour. The reverse transcriptase was then denatured by heating
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to 92°C for 10 minutes. Samples were stored at -20°C until used In the rtPCR
reaction.
3.2.6.2 Determination of Relative Gene Expression by rtPCR
Separate quantitative PCR analyses was performed using TaqMan Gene Expression
Assay reagents and FAM-labelled primers (Applied Biosystems Inc, USA) specific for
Ceacaml, Fadsl, Ppara, Srebfl, Fg/2l, Vanin-l or Cd36 in a multiplex reaction with
VIC-labelled primers specific for the endogenous house keeping gene glyceraldehyde-
3-phosphate dehydrogenase (see Table 39 on page 144).
Three technical replicates of each sample were performed. ISng of template cDNA
(diluted with water to a total volume of 8[11) was mixed with 1[11 of experimental 20x
gene expression assay mix, 1[11 of gapdh 20x gene expression assay mix and 10[11 of
TaqMan MasterMix (total reaction volume 20[11). The rate of template amplification
was measured under standard conditions (Table 38) using a Chromo4 Real Time
Detection System (BioRad Inc, USA).
Table 38: TaqMan rtPCR Cycling Conditions
Reaction Step Temp °C Time
Amperase UNG Activation 50°C 2 minutes
Initial activation step 95°C 10 minutes
Cycle (x45) Denature 95°C 15 seconds
Anneal/Extend 60°C 60 seconds
Data were normalised to gapdh expression and analysed by the Comparative L\L\CT
method239 to determine the difference in expression between sample groups relative to
control animals.
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tTable 39: Fluorescently Labelled TaqMan Probes for Microarray Validation by rtPCR
Gene Symbol Primer 10 Exons Context Sequence Label
Ceacam I Ceacaml Mm00442360 m I 3/4 CAGGAAGTCTGGCGGGGGAAGTGAC FAM
Fatty Acid Desaturase I Fads I Mm00507605 m I 5/6 TTCCTGTGGAGCTCGGGAGGGAAAA FAM
Sterol Regulatory Element Binding Factor-I Srebfl MmOOSS0338 m I 1/2 GACATCGAAGACATGCTCCAGCTCA FAM
Peroxisome Proliferator Activated Receptor-Alpha Ppara Mm00440939 m I 7/8 GTGGAGATCGGCCTGGCCTTCTAAA FAM
Fatty Acid Translocase Cd36 Mm00432403 m I 8/9 AATGGCACAGACGCAGCCTCCTTTC FAM
Fibroblast growth factor 21 Fgf21 Mm00840 165--z I 1/2 GTCCAGAAAGTCTCCTGGAGCTCAA FAM
Vanin-I Vnnl Mm0049S965 m I 1/2 CAGCGAAGCAGGGTGCGCACATTAT FAM
Glyceraldehyde-3-phosphate dehydrogenase gapdh Mm999999 I5--Z1 2/3 - VIC
• All primers cross an exon-exon boundary and so, even if contamination had occurred, would not detect genomic DNA.
• Context sequence refers to the 25 base nucleotide sequence surrounding the probe Le. including the targeted exons (data provided by Applied
Biosystems Inc., USA).
• All of the inventoried TaqMan Gene Expression assays used have equal efficiencies (approaching 100% ± 10%) over a 6 log range of dilutions as
determined by the manufacturer. Hence, routine validation of assay efficiency before using the /J./J.CT method of relative fold change calculation was
unnecessary (ABI Technical Note #00113186, 2004 'Amplification Efficiency of TaqMan Gene Expression Assays')
• The VIC-labelled endogenous control (gapdh) gene expression assay was primer limited and so suitable for use in a multiplex reaction format.
3.3 Results
The results of these experiments fall into two broad categories, those that relate to
assessment of the quality and conduct of the study (which allow determination of how
reliable the data generated may be) and those directly related to the detection of
changes in gene expression - both will now be presented.
3.3.1 Data Quality Control Analysis
3.3.1.1 Total RNA & Amplified Biotin-Labelled cRNA Quality
As described in section 3.2.2, the total RNA extracted from the 12 mice selected for
gene expression profiling was tested to determine quality (Table 40). In addition, the
electrophoretogram of the amplified product was checked after steps 5 and 10 of the
amplification protocol to confirm selective amplification of mRNA without any
ribosomal RNA contamination. The cRNA yield after each round of amplification is
also shown (Table 40).
Table 40: Total RNA and cRNA Quality & Yield during Sample Amplification
# Fig* Mouse Total RNA cRNA Protocol Step 5 cRNA Protocol Step 10
28s/18s 260/280 rtg/ml 260/280 rtg/ml rRNA 260/280 rtglml rRNA
I B INSRB 1.8 .88 352.0 2.32 37.8 0.00 2.09 1758.3 0.00
2 D INSRB 1.9 .69 1224.7 1.93 157.2 0.00 2.08 1403.7 0.00
3 K INSRB 1.9 .90 252.5 2.06 42.0 0.00 2.11 1791.9 0.00
4 J IGT/6.IOc 2.2 .84 852.4 2.25 50.6 0.00 2.65 1491.8 0.00
5 F IGT/6.IOd 1.9 .73 1801.4 2.36 28.2 0.00 1.94 1987.1 0.00
6 C IGT/6.2d 2.2 .72 852.4 1.27 41.1 0.00 2.07 1457.6 0.00
7 E IGT/6.llb 2.0 .83 1477.3 2.14 56.2 0.00 2.08 1519.2 0.00
8 H IGT/6.4g 2.4 .82 770.6 2.33 35.5 0.00 2.10 1729.0 0.00
9 L IGT/6.4e 2.4 .59 237.5 2.01 169.9 0.00 2.09 1365.3 0.00
10 I IGT/6.lf 2.5 .77 245.3 1.92 34.2 0.00 2.15 1444.0 0.00
II G IGT/6.6f 2.3 .74 519.6 1.94 77.6 0.00 2.05 1468.4 0.00
12 A IGT/6.le 2.0 .78 879.7 4.11 46.9 0.00 2.05 1583.4 0.00
* Refers to total RNA electrophoretogram images presented in Figure 27.
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Figure 27: Electrophoretograms for total RNA used in Microarray Analysis
See Table 40 for details of which electrophoretogram corresponds to which total RNA
sample.
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The theoretical maximum 28s/18s ratio is "'2.7:1, in practice a ratio of> 1.9 is taken to
indicate high quality total RNA with minimal RNA degradation. Examination of
Table 40 shows that all total RNA samples were of high quality. Figure 27 shows the
electrophoretograms for each of the twelve total RNA samples used in this study. All
samples show crisp 18s and 28s peaks with no evidence of DNA contamination or
significant RNA degradation. No rRNA contamination of the amplified mRNA
samples was detected.
3.3.1.2 Bioconductor (Simpleaffy) Quality Matrices
All chip images were inspected to confirm that there were no scratches or local
anomalies that may skew the data. The main gene expression quality control matrices
are presented in Figure 28. The percentages of probeset 'present' calls, average
background fluorescence intensities and MASS scale factor are comparable across all
12 chips with no outliers.
Figure 29 shows the RNA digestion profiles of the 12 samples calculated from the 3',
mid- and 5' probesets that target the ~-Actin and GAPDH genes. The expected 3':5'
imbalance introduced by the RNA amplification protocol is observed. The plots are all
parallel, confirming that all samples are similarly affected and therefore the results are
not biased. Further, inspection of Figure 28 shows the 3':Mid ratios for both genes fall
within the target ranges of <3 and <1.25 respectively in all but one case. The BioB
spiked-in control was called present for every chip, confirming that the hybridization
and scanning steps were successful and ofhigh sensitivity.
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b. AFFX-b-Ac1inMurIM1248 QC Stats
0 AFFX-GapdhMur/M32599.
FFR2004092111 ABa. CEL 34.76% I 01:1.69.4
FFR2004092110Aaa.CEL 35.84% I 01:1.55.93
FFR20040921 09Aaa.CEl 35.25% r48.34
FFR20040921OBAaa.CEL 38.19% ~ 0 644.49
FFR2004092107Aaa.CEl 36.54% 1°643.46
JLD2005030817Aaa.CEL 35.45% 1°637.16
FFR200409210BAaa.CEl 34.14%
t M52.73
FFR20040921 05Aaa.CEl 33.91%
t Ob.56.8
FFR20040921 04Aaa.CEl 35.41% 1oA53.66
FFR20040921 03Aaa.CEl 36.66%
t 653.94
FFR2004092102Aaa.CEl 35.72% I en50.55
FFR20040921 01Aaa CEL 35.82%
r ~45.83
-3 -2 -1 0 2 3
Figure 28: Results of Simpleaffy Quality Control Matrices
Data are presented for each .eEl file. 3':Mid ratio for J3-Actin (L1) and GAPDH (0) as well as
the MASS scale factor (e) are graphically represented in the right hand column. A blue symbol
indicates that the measurement is within the target range. The percentage of Probesets called
present (left column, upper number) and the average background fluorescence intensity (left
column, lower number) are also provided.
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RNA digestion plot
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Figure 29: RNA Degradation Plot for Each Chip
All chips have approximately equivalent RNA degradation profiles. The 3':5' imbalance that is
known to be introduced by the sample amplification procedure is illustrated here. The 3':Mid
ratios fall within the acceptable range however.
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3.3.2 Pre-processing (Background Correction & Data Normalisation)
U sing the Bioconductor A./fy package, the GC-RMA algorithm was applied to the raw
.CEL file data to correct for variations in background signal and to normalise values so
that data could be compared between chips. The effect is demonstrated in Figure 30
which illustrates how chip level normalised .CEL file data became directly inter-
comparable. The intensity values for each probe in a probe-set were combined to
generate gene expression values for each probe-set and expressed in 10g2 space.
Boxplots of Raw Affymetrix CEl-level Data Boxplots of GCRMA Processed Data
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Figure 30: Effect of GC-RMA Normalisation on Chip Signal Intensity Distribution
The GC-RMA algorithm successfully normalised the data so that inter-chip comparisons could
be made.
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3.3.3 Microarray Probe-Set Filtering & Significance Testing
The sequential application of non-specific filters was designed to remove probe-sets
that were unlikely to represent significantly differentially expressed genes and thus to
enrich the proportion of informative probe-sets that pass on to statistical testing.
These reduced the number of probe-sets, and null hypotheses to be tested in each
comparison, by approximately 90% to 4,828.
Affymetrix Mouse 430 v 2 GeneChip
45,101 Probe-Sets
Normalise Expression Levels
GC-RMA & Convert values to Log2
Non-Specific Filtering
At least 25% chips with expression level> log2(64)
Inter-Quartile Range over all chips> 0.4
4,828 Probe-Sets
/1"'"
Test for Significant Differentially Expressed Genes
/ 1 ~
IGT/6-DM v Control IGT/6-NASH v Control IGT/6-NASH v IGT/6-DM
1,167 Pmb"S'"~P'i"S~ 636 Pco"",S",
1,892 Significant Probe-Sets
Figure 31: Data Processing Flow-Diagram & Probe-Set Filtering Results Summary
Following normalisation and non-specific filtering, a linear model was fitted to the remaining
4,828 probe-sets and statistically significant changes in expression between the three study
groups sought.
Significance testing excluded a further 2,936 probe-sets. Without the requirement for
an additional fold-change threshold to be reached, a total of 1,892 probe-sets were
identified that were considered to be significantly differentially expressed in at least
one of the three study group comparisons made. The breakdown of these comparisons
are summarised as a Venn diagram in Figure 32. In parallel, the data were analysed using
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the SAM algorithm to generate a q-value (the lowest false discovery rate at which the
gene is considered to be significant) 228, 240. These data are presented along side p-values
to assist in interpretation (fully detailed for each probe-set in Appendix C).
OM - CONTROL NASH - CONTROL
NASH - OM 2936
Figure 32: Venn Diagram of Differentially Expressed Genes by Comparison
2,936 probe-sets were excluded and 1,892 found to be significantly differentially expressed in
one or more of the three comparisons made. The number of probe-sets that were found to be
differentially expressed in more than one comparison is also shown.
When the additional requirement of at least a 1.5 fold-change was considered, a total
of 1,671 probe-sets were found to be differentially expressed over the three
comparisons (Table 41).
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Table 41: Number of Probe-Sets Identified as Differentially Expressed
Expression No Fold-Change Filter
All Increased Reduced
>1.5 Fold-Change Filtered
All Increased Reduced
Comparison
IGT/6-DM vs. Control
IGT/6-NASH vs. Control
IGT/6-NASH vs. IGT/6-DM
Total *
1167
969
636
1892
741
759
366
426
210
270
1069
836
459
1671
683
653
244
386
183
215
* Probe-sets may be differentially expressed in more than one comparison and/or have
increased expression in one comparison and reduced expression in another.
The significant probe-sets identified as differentially expressed were annotated with
gene sequence information and were subjected to high level analysis to identify
biologically relevant patterns ofexpression. No significant differences in the expression
of the insulin receptor probe-sets were found between the groups, confirming this was
not the causative mutation.
3.3.4 Gene Expression Clustering
Hierarchical clustering of samples based on expression of the 1,892 significant genes
indicated that, within each group, members exhibited homogeneous expression
patterns (Figure 33).
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Figure 33: Hierarchical Clustering of Samples
Clustering dendrogram showing samples resolved according to their gene expression profile.
153
The initial separation between samples discriminated between control and IGT/6
mutant animals. Subsequently the IGT/6 dendrogram separated according to IGT/6-
DM and IGT/6-NASH phenotypic sub-groups.
3.3.5 Principal Components Analysis
Principal components analysis was used to distil the variability in gene expression
within the dataset into 12 principal components. As is demonstrated in Figure 34 and
Table 42 the majority of the variability within the dataset (77.29%) can be summarised
within the first two principal components. When the 12 samples are plotted in two
dimensional space according to these first two components (Figure 35), it can be seen
that the constituent samples of each of the three study groups cluster together. As was
expected, addition of further dimensionality to the analysis provided little inter-sample
discriminatory benefit but increased the noise within the analysis.
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Figure 34: Plot of Principal Component against Eigenvalue
The majority (77.29%) of the variability within the dataset can be summarised within two or
three (82.05%) principal components. The remaining components contribute little to the total
variability observed.
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Table 42: Eigenvalue & Percentage of Variation for each Principal Component
Principal Eigenvalue % Variation
Component
I 5.330 65.54%
2 0.956 I 1.75%
3 0.387 4.76%
4 0.366 4.50%
5 0.255 3.13%
6 0.190 2.34%
7 0.165 2.03%
8 0.130 1.60%
9 0.126 1.55%
10 0.092 1.14%
II 0.079 0.97%
12 0.056 0.69%
Further inspection of Figure 35 and the profile plots for the first two principal
components (Figure 36) reveals that the distribution within these two dimensions may
be used to separate features as being characteristic of a given phenotypic category.
Figure 36A shows the first principal component is able to differentiate control from
mutant and illustrates that control mice have higher values within the first principal
component than mutant animals, irrespective of IGT/6 sub-group. Similarly, Figure
36B shows that the second principal component may be used to separate all three
groups: IGT/6-DM mice have higher values than control mice which in turn have
higher values than IGT/6-NASH animals. These findings may be applied to assist in
the exploration ofdifferentially expressed genes.
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Figure 35: Samples Plotted on a 20 View of the First Two Principal Components
Two dimensional plot of the first two principal components showing that members of the
three study groups form discreet clusters. The position on the x-axis (principal component I)
differentiates IGT/6 animals from the Controls whilst position on the y-axis (principal
component 2) differentiates all three phenotypic groups (IGT/6-DM, IGT/6-NASH and
Control) from each other.
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When expression data for the 1,892 significant probesets are plotted according to the
first two principal components (Figure 37), positive displacement along the y-axis is
indicative of genes that are expressed at higher levels in IGT/6-DM mice than control
animals and negative displacement indicates genes that are expressed at higher levels in
IGT/6 mice that develop NAFLD. Positive displacement along the x-axis is indicative
of genes that are expressed at lower levels in pooled mutant mice (values reflecting the
mean of all IGT/6 mice) than in control animals. The degree of displacement is
indicative of the magnitude of the difference in expression.
All 1,892 significant genes contribute to the inter-group variability and discriminative
power of the principal components analysis. Those probe-sets that most strongly
differentiate the three study groups and generate the greatest displacement along the
first two components in this analysis are highlighted in Figure 37 and are summarised
in Table 43.
157
;
••4 •• .):' _ •••• "j •
~
........... ··············T ·•.•....~ _ .
!
A
0.5
0.4
0.3
0.2
0.1
-0.0
-0.1
-0.2
-0.3
-0.4
-0.5
B
0.5
0.4
0.3
0.2
0.1
-0.0
-0.1
-0.2
-0.3
-0.4
-0.5
-0.6
PRINCIPAL COMPONENT 1
. I
. I
I I
-- +.- ~-. --· ··1----------+-·.;..· -------- --- -----
I I
I I
I . I
I . I •
...~ !-_.... ." ·f-······ .._....... .." ...•....••...~ ".~.- •......••-:.- , ·····t··· • . : - _ __ .
I I
I I
1 : : ;
I : I !.I , I
I , I
I > I
.. _}.. -1 j_I";
I I I
: : :
i
i
i
!
i
._-~---! _. ·-1.._····- --·..·1
i i l ..i_..-J...J ...L ,_. _
I , I
I ' I
I : I
. I ,i I
._._....._._._._....._ ..1.__..l. _._._.__;_. ._~._._t__._._. .__..j__....__..._._.
I :' ~ t i ~ ~
I i I :
IGT/6-DM CONTROL IGT/6-NASH
PRINCIPAL COMPONENT 2
I ,: j!! J' I'I i· I I.... I J' ;I ! J i! I !-t--~f-~+++1---+---"
I I 1 ! I
, I I :
..... ; 'j'" "1 t' .
I I
I
I! I
.. j 1" ..
. I
___L ._ :.l__._.._..l..;_-+---!-\
: I ': !
, I
j. • , I ~
, I
1 . I .
··-·---·:--·-·t------·--t ......---~- : "i-!- -'" _L _
. ; . I ; I
'''-'--r''''-T---''r'' i' "!- -..... --or !
1 I 1 ; ,
IGT/6-DM CONTROL IGT/6-NASH
Figure 36: Profiles of First Two Principal Components Plotted by Sample
A Within the first principal component, all IGT/6 mutant mice have depressed gene expression
levels relative to control animals.
B The second principal component shows that mice from the IGT/6-DM group have greater
scores than control animals and IGT/6-NASH mice. All three groups may be separated by this
component.
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Figure 37: Genes Plotted on a 20 View of the First Two Principal Components
Gene expression plotted according to the first two principal components. Positive
displacement along the x-axis (principal component I) indicates increased expression in
control animals over pooled mutant mice. Positive displacement along the y-axis (principal
component 2) indicates increased expression in the IGT/6-DM group over control whilst
negative displacement indicates increased expression in the IGT/6-NASH group over control.
Caution should be exercised in interpreting x-axis displacement as a mean value is shown
which may mask the true biological effect if IGT/6 subgroups differ in direction of change in
gene expression.
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Table 43: Outlying Genes of Interest Identified by Principal Components Analysis
Symbol Gene Name Entrez Function D-C N-C N-D
Gene#
AI I32709 'Expressed Sequence' 101494 Unknown (2.31 ) 4.00 ( 1.68)
ApoB Apolipoprotein B 238055 Very Low Density Lipoprotein assembly 1.45 -1.60 -3.05
Cyp2b9 Cytochrome P450 2b9 13094 Microsomal fatty acid w-oxidation 3.88 6.62 2.74
Cyp2bl3 Cytochrome P450 2b 13 292728 Mixed function oxidase (1.42) 3.00 (1.58)
Cyp2c39 Cytochrome P450 2c39 13098 Mixed function oxidase ( 1.90) 3.30 ( 1.4)
Cyp4al0 Cytochrome P450 4a I0 13117 Microsomal fatty acid w-oxidation (-2.25) ( 1.92) 4.17
Lcn2 Lipocalin 2 16819 Acute phase. function unresolved 5.84 2.96 -2.88
Mti Metallothionein I 17748 Antioxidant & Antiinflammatory 3.75 2.35 (-1.39)
Pexlla Peroxisomal biogenesis factor I Ia 18631 Peroxisome proliferation & fatty acid oxidation (-0.41 ) 0.59 1.00
Rgsl6 Regulator of G-protein signalling 16 19734 ?Promotes pro-fibrotic Th2 T-cell response (0.40) 3.26 2.86
Rora RAR-related orphan receptor alpha 19983 Cholesterol handling & antiinflammatory effects 0.88 -1.03 -1.91
Saal Serum amyloid A 20208 Acute phase. function unresolved 3.21 ( 1.27) -1.94
Serpina4 Serine peptidase inhibitor A4, ps I 321018 ?Kallistatin activity -2.70 -2.81 (-0.11 )
Tsc22d4 TSC-22 domain family 4 78829 Transcription factor 1.48 -2.29 -3.77
Ugt2b5 UDP glucuronosyltransferase 2. B5 22238 Xenobiotic & endobiotic elimination -3.40 -4.13 (-0.73)
Vnnl Vanin-I 22361 Pantetheinase activity producing cysteamine -1.77 ( 1.48) 3.25
• Fold change values for each comparison shown are log2 transformed.
• Comparative change in expression shown for D-C: IGT/6-DM vs. Control; N-C: IGT/6-NASH vs. Control; N-D: IGT/6-NASH vs. IGT/6-DM.
• Significance accepted at p < 0.05. values in parenthesis indicate significance not reached for that comparison.
3.3.6 Gene Ontology Classification
The product of a given gene performs one or more molecularfunctions, participates in
defined biological processes and may be located within particular cellular components.
Using the fully annotated L2L ontologies, sub-categories of each of these three main
groupings were sought that were significantly over-represented in the list of 1,892
genes described in section 3.3.3. A p-value < 0.001 was considered to indicate
significant enrichment whist balancing the need to control for multiple testini34.
3.3.6.1 Molecular Function Ontology Classification
857 fully annotated ontology terms were tested. The results of this analysis are
presented in Table 44 to Table 49. As is illustrated in Figure 38, many of the genes that
are up-regulated in IGT/6-NASH mice over control encode enzymes that perform
catalytic transferase activity (GO:OO16740) including the transfer of acyl- groups.
Genes included under this node include transglutaminase 2, citrate synthase and citrate
lyase. Other nodes that are over-represented include those that describe enzymatic
oxidoreductase activity (GO:0016491 & GO:0016614) and coenzyme binding,
specifically related to NADP metabolism (GO:0050661).
Table 44: IGT/6-NASH ys. Control Molecular Function Down-Regulated Ontologies
III
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GO List Name C) to- w « w a.
Translation Initiation Factor Activity GO:0003743 138 0.84 6 7.15 2.20E-04
Translation Factor Activity. Nucleic Acid Binding GO:0008135 213 1.30 6 4.63 2. 1OE-03
Translation Regulator Activity GO:0045 182 215 1.31 6 4.59 2.20E-03
Aspartic-Type Endopeptidase Activity GO:0004190 17 0.10 2 19.34 4.74E-03
Pepsin A Activity GO:0004194 17 0.10 2 19.34 4.74E-03
Signal Peptidase Activity GO:0009003 17 0.10 2 19.34 4.74E-03
DNA Helicase Activity GO:0003678 60 0.37 3 8.22 5.95E-03
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Table 45: IGT/6-NASH vs Control Molecular Function Up-Regulated Ontologies
!II
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Transferase Activity, Transferring Acyl Groups GO:0016746 280 6.65 19 2.86 5.14E-05
Oxidoreductase Activity, Acting on Paired Donors, GO:0016717 12 0.28 4 14.04 1.35E-04
With Oxidation of A Pair of Donors Resulting In The
Reduction of Molecular Oxygen to Two Molecules of
Water
Protein-Glutamine Gamma-Glutamyltransferase Activity GO:0003810 14 0.33 4 12.04 2.63E-04
Oxidoreductase Activity, Acting on CH-OH Group of GO:0016614 150 3.56 12 3.37 2.68E-04
Donors
Acyltransferase Activity GO:00084 I5 262 6.22 16 2.57 6.18E-04
Transferase Activity, Transferring Groups Other Than GO:0016747 262 6.22 16 2.57 6. I8E-04
Amino-Acyl Groups
Coenzyme Binding GO:0050662 126 2.99 10 3.34 8.98E-04
NADP Binding GO:005066 I 23 0.55 4 7.33 1.96E-03
Cofactor Binding GO:0048037 144 3.42 10 2.93 2.44E-03
Sodium:Potassium-Exchanging ATPase Activity GO:000539I 25 0.59 4 6.74 2.69E-03
Transferase Activity, Transferring Amino-Acyl Groups GO:0016755 25 0.59 4 6.74 2.69E-03
Cobalt Ion Binding GO:0050897 25 0.59 4 6.74 2.69E-03
Transition Metal Ion Transporter Activity GO:00469 15 42 1.00 5 5.02 3.09E-03
S-Acyltransferase Activity GO:0016417 13 0.31 3 9.72 3.20E-03
Carbohydrate Kinase Activity GO:OO I9200 43 1.02 5 4.90 3.42E-03
Antigen Binding GO:0003823 27 0.64 4 6.24 3.60E-03
ATPase Activity, Coupled to Transmembrane GO:0015662 114 2.71 8 2.96 6.00E-03
Movement of Ions, Phosphorylative Mechanism
Double-Stranded DNA Binding GO:0003690 70 1.66 6 3.61 6.42E-03
Protease Activator Activity GO:0016504 17 0.40 3 7.43 7.09E-03
Transferase Activity, Transferring Acyl Groups, Acyl GO:00469 I2 17 0.40 3 7.43 7.09E-03
Groups Converted Into Alkyl on Transfer
Protein Heterodimerization Activity GO:0046982 98 2.33 7 3.01 8.99E-03
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Figure 38: Molecular Function Hierarchy for Up-Regulated Terms Over-
Represented in IGT/6-NASH vs Control
Terms describing enzyme mediated catalytic transferase activity (acyl-group and carbohydrate
kinase) and oxidoreducatse activity are over-represented amongst genes identified as up-
regulated in IGT/6-NASH animals.
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Table 46: IGT/6-NASH vs IGT/6-DM Molecular Function Up-Regulated Ontologies
III
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Oxidoreductase Activity GO:0016491 985 11.2/ 32 2.85 2.40E-07
Oxidoreductase Activity, Acting on NADH or GO:0016651 124 1.41 10 7.09 1.83E-06
NADPH
NADH Dehydrogenase (Ubiquinone) Activity GO:0008137 83 0.94 7 7.41 4.82E-05
NADH Dehydrogenase (Quinone) Activity GO:0050136 83 0.94 7 7.41 4.82E-05
Electron Transporter Activity GO:0005489 436 4.96 16 3.22 5.53E-05
NADH Dehydrogenase Activity GO:0003954 86 0.98 7 7.15 6.06E-05
Sodium Ion Transporter Activity GO:0015081 90 1.02 7 6.83 8.09E-05
Oxidoreductase Activity, Acting on NADH or GO:0016655 92 1.05 7 6.69 9.31 E-05
NADPH, Quinone or Similar Compound As Acceptor
Oxidoreductase Activity, Acting on The Aldehyde or GO:0016624 10 0.11 3 26.36 1.67E-04
Oxo Group of Donors, Disulfide As Acceptor
Carboxylesterase Activity GO:0004091 36 0.41 4 9.76 7.39E-04
Serine Esterase Activity GO:0004759 36 0.41 4 9.76 7.39E-04
Hydrogen Ion Transporter Activity GO:0015078 258 2.94 10 3.41 8.61 E-04
Oxidoreductase Activity, Acting on The Aldehyde or GO:0016903 41 0.47 4 8.57 1.21 E-03
Oxo Group of Donors
Monovalent Inorganic Cation Transporter Activity GO:0015077 283 3.22 10 3.11 1.7IE-03
Transferase Activity, Transferring Acyl Groups GO:0016746 280 3.19 9 2.82 5.27E-03
Protein Phosphatase Binding GO:0019903 10 0.11 2 17.57 5.48E-03
Metal Ion Transporter Activity GO:0046873 186 2.12 7 3.31 5.78E-03
Lysophospholipase Activity GO:0004622 II 0.13 2 15.98 6.65E-03
Carnitine O-Acyltransferase Activity GO:OO I6406 II 0.13 2 15.98 6.65E-03
Disulfide Oxidoreductase Activity GO:0015036 34 0.39 3 7.75 6.78E-03
Phosphatase Binding GO:0019902 12 0.14 2 14.65 7.92E-03
Primary Active Transporter Activity GO:0015399 354 4.03 10 2.48 8. I3E-03
Table 47: IGT/6-NASH vs IGT/6-DM Molecular Function Down-Regulated Ontologies
III
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Lipid Transporter Activity GO:0005319 148 1.16 9 7.75 3.IIE-06
DNA Helicase Activity GO:0003678 60 0.47 4 8.49 1.30E-03
Helicase Activity GO:0004386 274 2.15 8 3.72 1.63E-03
Histone Acetyltransferase Binding GO:0035035 IS 0.12 2 16.99 6.04E-03
Basic Amino Acid Transporter Activity GO:0015174 16 0.13 2 15.92 6.87E-03
Protein Binding, Bridging GO:0030674 161 1.26 5 3.96 9.21 E-03
Table 48: IGT/6-DM vs Control Molecular Function Up-Regulated Ontologies
III
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Peptide antigen binding GO:0042605 6 0.1 2 14.3 7.61 E-03
Protei n-gl utami ne gamma-gl utamyltransferase activity GO:0003810 14 0.3 4 12.3 2.42E-04
Basic amino acid transporter activity GO:0015174 16 0.4 3 8.1 5.60E-03
Hexosaminidase activity GO:0015929 16 0.4 3 8.1 5.60E-03
Transition metal ion transporter activity GO:00469 15 42 1.0 7 7.2 4.82E-05
Transferase activity, transferring amino-acyl groups GO:0016755 25 0.6 4 6.9 2.49E-03
Cobalt ion binding GO:0050897 25 0.6 4 6.9 2.49E-03
Di-, tri-valent inorganic cation transporter activity GO:0015082 80 1.9 9 4.8 1.03E-04
Hydrolase activity, hydrolyzing O-glycosyl compounds 112 2.6 10 3.8 3.00E-04
Serine-type endopeptidase inhibitor activity GO:0004867 106 2.5 9 3.7 8.54E-04
Hydrolase activity, acting on glycosyl bonds GO:OO I6798 140 3.3 II 3.4 4.63E-04
Copper ion binding GO:0005507 98 2.3 7 3.1 8.05E-03
Lipid transporter activity GO:00053 19 148 3.4 10 2.9 2.56E-03
Endopeptidase inhibitor activity GO:0004866 173 4.0 II 2.7 2.58E-03
Protease inhibitor activity GO:0030414 173 4.0 II 2.7 2.58E-03
Metal ion transporter activity GO:0046873 186 4.3 II 2.5 4.46E-03
ATPase activity, coupled to transmembrane movement GO:0042626 266 6.2 15 2.4 1.61 E-03
ATPase activity, coupled to movement of substances GO:0043492 266 6.2 15 2.4 1.61 E-03
Hydrolase activity, acting on acid anhydrides, catalyzing GO:0016820 267 6.2 15 2.4 1.67E-03
transmembrane movement of substances
Serine-type peptidase activity GO:0008236 232 5.4 12 2.2 8.68E-03
ATPase activity, coupled GO:0042623 511 11.9 24 2.0 1.11 E-03
ATPase activity GO:0016887 578 13.4 26 1.9 1.31 E-03
Endopeptidase activity GO:0004175 639 14.8 28 1.9 1.29E-03
Peptidase activity GO:0008233 904 21.0 35 1.7 2.86E-03
Hydrolase activity GO:0016787 3387 78.7 107 1.4 1.22E-03
When IGT/6-NASH mice are compared to IGT/6-DM (Figure 39), oxidoreductase
activity is again over-represented amongst up-regulated genes (GO:0016491) as are
genes related to electron carrier activity within the oxidative phosphorylation pathway
(GO:0003954 and GO:0016655) such as NADH dehydrogenase (ubiquotone).
Reflecting the observed reduction in expression of apolipoprotein B, serum amyloid A
and apolipoprotein M, Table 47 also demonstrates that genes encoding effectors of lipid
transporter activity are under-expressed in IGT/6-NASH mice compared to
littermates with impaired glucose tolerance alone (GO:0005319)
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Figure 39: Molecular Function Hierarchy for Up-Regulated Terms Over-
Represented in IGT/6-NASH vs IGT/6-DM
Genes within the oxidative phosphorylation pathways and those encoding oxidoreductase
activity are over-expressed in mice with NAFLD.
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Table 49: IGT/6-DM vs Control Molecular Function Down-Regulated Ontologies
ell
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Palmitoyl-CoA hydrolase activity GO:0016290 10 0.1 2 15.0 7.42E-03
Ubiquitin activating enzyme activity GO:0004839 18 0.2 3 12.5 1.65E-03
NADH dehydrogenase (ubiquinone) activity GO:0008137 83 1.1 6 5.4 8.73E-04
NADH dehydrogenase (quinone) activity GO:0050136 83 1.1 6 5.4 8.73E-04
NADH dehydrogenase activity GO:0003954 86 1.1 6 5.2 I.05E-03
Sodium ion transporter activity GO:0015081 90 1.2 6 5.0 1.33E-03
Translation initiation factor activity GO:0003743 138 1.8 9 4.9 1.07E-04
Oxidoreductase activity. acting on NADH or NADPH, GO:0016655 92 1.2 6 4.9 1.49E-03
quinone or similar compound as acceptor
Oxidoreductase activity. acting on NADH or NADPH GO:0016651 124 1.6 6 3.6 6.53E-03
Heme binding GO:0020037 133 1.8 6 3.4 9.07E-03
Tetrapyrrole binding GO:0046906 133 1.8 6 3.4 9.07E-03
Electron transporter activity GO:0005489 436 5.8 19 3.3 9.17E-06
Hydrogen ion transporter activity GO:0015078 258 3.4 II 3.2 7.88E-04
Translation factor activity. nucleic acid binding GO:0008135 213 2.8 9 3.2 2.43E-03
Translation regulator activity GO:0045 182 215 2.9 9 3.1 2.58E-03
Structural constituent of ribosome GO:0003735 350 4.7 14 3.0 3.12E-04
Monovalent inorganic cation transporter activity GO:0015077 283 3.8 II 2.9 1.65E-03
Primary active transporter activity GO:0015399 354 4.7 12 2.5 3.21 E-03
Iron ion binding GO:0005506 390 5.2 12 2.3 6.80E-03
Oxidoreductase activity GO:OOI 649 I 985 13.1 23 1.8 7.91 E-03
3.3.6.2 Biological Process Ontology Classification
1,322 fully annotated ontology terms were tested for fold-enrichment. Analysis of the
biological process ontology was the most informative of the three categories in
elucidating the metabolic changes underlying the phenotypic differences observed.
Significantly enriched ontology categories are listed by direction of change in
expression for IGT/6-NASH vs. Control (up-regulated, Table 50 and down-regulated,
Table 52), IGT/6-NASH vs. IGT/6-DM (Table 53 and Table 54) and IGT/6-DM vs.
Control comparisons (Table 51 and Table 55). Where appropriate, genes that are
contained within enriched ontology categories and that were found to be significantly
differentially expressed are detailed.
167
It can be seen in Table SO (and Table 53) that IGT/6-NASH mice have significant
enrichment of nodes related to processes of carbohydrate metabolism (GO:0006092)
glucose catabolism (GO:0006007) and glycolysis (GO:0006096) compared to both
control and IGT/6-DM mice. Up-regulated genes whose products are represented by
these nodes include many of the main enzymes in the glycolysis pathway: glucose-6-
phosphate isomerase 1, phosphofructokinase, ftuctose-bisphosphate aldolase A, pyruvate
kinase. The ontology hierarchy showing how the terms describing these and other
associated genes are related is shown in Figure 40.
Table SO also shows that nodes defining an association between carbohydrate
metabolism, lipid metabolism and lipid biosynthesis (GO:0006629 and GO:0008610)
are enriched, indicating that expression of genes from these categories are also
increased in IGT/6-NASH mice. The enriched ontology hierarchy for lipid
metabolism is shown in Figure 41. Central to this association is the observed increase
in expression in IGT/6 mice of the nuclear transcription factor gene sterol regulatory
element bindingfactor 1 (Srebfl), an expression regulator ofeffector genes that mediate
lipid biosynthesis (GO:0006629). Further, increased expression ofdihydrolipoamide S-
acetyltransferase (the E2 component of the mitochondrial pyruvate dehydrogenase
complex), citrate synthase and ATP-citrate lyase are also represented by this node.
Expression of CD36 (fatty acid translocase) is also increased in IGT/6-NASH mice,
increasing the liver's capacity to take-up fatty acids from the circulation.
The pentose phosphate pathway generates NADPH within the cell and so is the
principal source of the metabolic reducing power required to fuel lipid and steroid
reductive biosynthesis. Nodes describing activity of the pentose phosphate pathway are
enriched over control (GO:0006089, GO:0006739 and GO:0006740) in IGT/6-
NASH mice (Table SO) and to a lesser extent in IGT/6-DM animals (Table 51). In
mice with NAFLD the enrichment is due to increased expression of many of the key
genes from the oxidative and non-oxidative phases of the pathway (including
16k
phosphogluconate dehydrogenase, hexose-6-phosphate dehydrogenase and ribose 5-
phosphate isomerase A) and cytokine-like nuclearfactor n-pac.
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Table 50: IGT/6-NASH ys. Control Biological Process Up-Regulated Ontologies
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Glucose Catabolism GO:0006007 112 2.66 16 6.02 1.11 E-08
Carbohydrate Catabolism GO:OO I6052 160 3.80 18 4.74 6.29E-08
Cellular Carbohydrate Catabolism GO:0044275 160 3.80 18 4.74 6.29E-08
Pentose-Phosphate Shunt GO:0006098 17 0.40 7 17.35 6.70E-08
NADP Metabolism GO:0006739 17 0.40 7 17.35 6.70E-08
NADPH Regeneration GO:0006740 17 0.40 7 17,35 6.70E-08
Hexose Catabolism GO:0019320 127 3.01 16 5.31 6.84E-08
Monosaccharide Catabolism GO:0046365 129 3.06 16 5.23 8.53E-08
Alcohol Catabolism GO:0046 I64 133 3.16 16 5.07 1.31 E-07
Main Pathways of Carbohydrate Metabolism GO:0006092 194 4.61 18 3.91 1.13E-06
Glucose Metabolism GO:0006006 170 4.04 16 3.96 3.60E-06
Nicotinamide Metabolism GO:0006769 29 0.69 7 10.17 4.18E-06
Energy Derivation By Oxidation of Organic Compounds GO:0015980 281 6.67 21 3.15 4.98E-06
Lipid Metabolism GO:0006629 1005 23.86 48 2.01 6.67E-06
Cellular Lipid Metabolism GO:0044255 797 18.92 40 2.11 1.22E-05
Pyridine Nucleotide Metabolism GO:0019362 36 0.85 7 8.19 1.93E-05
Hexose Metabolism GO:0019318 243 5.77 18 3.12 2.56E-05
Monosaccharide Metabolism GO:0005996 247 5.86 18 3.07 3.18E-05
Lipid Biosynthesis GO:00086 I0 396 9.40 24 2.55 3.65E-05
Oxidoreduction Coenzyme Metabolism GO:0006733 41 0.97 7 7.19 4.70E-05
Cellular Carbohydrate Metabolism GO:0044262 550 13.06 29 2.22 7.60E-05
Membrane Lipid Metabolism GO:0006643 222 5.27 15 2.85 3. I6E-04
JAK-STAT Cascade GO:0007259 75 1.78 8 4.49 4.13E-04
Peptide Cross-Linking GO:0018149 16 0.38 4 10.53 4.60E-04
Alcohol Metabolism GO:0006066 446 10.59 23 2.17 5.34E-04
Water-Soluble Vitamin Metabolism GO:0006767 62 1.47 7 4.76 6.66E-04
Carbohydrate Metabolism GO:0005975 757 17.97 33 1.84 8.01 E-04
Phospholipid Biosynthesis GO:0008654 103 2.44 9 3.68 8.07E-04
Regulation of Cell Adhesion GO:0030155 68 1.61 7 4.34 I. I6E-03
Vitamin Transport GO:0051180 23 0.55 4 7.33 1.96E-03
Vitamin Metabolism GO:0006766 76 1.80 7 3.88 2.22E-03
Cofactor Metabolism GO:0051186 327 7.76 17 2.19 2.43E-03
Phospholipid Metabolism GO:0006644 148 3.51 10 2.85 2.98E-03
Membrane Lipid Biosynthesis GO:0046467 126 2.99 9 3.01 3.27E-03
Cellular Catabolism GO:0044248 870 20.65 34 1.65 3.89E-03
Tyrosine Phosphorylation of Stat3 Protein GO:0042503 14 0.33 3 9.03 4.00E-03
Regulation of Tyrosine Phosphorylation of STAT Protein GO:0042509 14 0,33 3 9.03 4.00E-03
Regulation of Tyrosine Phosphorylation of Stat3 Protein GO:00425 16 14 0.33 3 9.03 4.00E-03
Catabolism GO:0009056 1005 23.86 38 1.59 4.11 E-03
Coenzyme Metabolism GO:0006732 290 6.88 15 2.18 4.42E-03
Regulation of Cell Shape GO:0008360 66 1.57 6 3.83 4.82E-03
Regulation of JAK-STAT Cascade GO:0046425 15 0,36 3 8.43 4.91 E-03
Glycolysis GO:0006096 91 2.16 7 3.24 6.06E-03
Carboxylic Acid Metabolism GO:0019752 744 17.66 29 1.64 7.44E-03
Nucleotide Metabolism GO:0009117 337 8.00 16 2.00 7.49E-03
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Table 5 I: IGT/6-DM vs Control Biological Process Up-Regulated Ontologies
III
QI ~
.c c
0 "'C QI~ QI E QIQ. ~
'; .c :::s~ v'; QI :::s v ';
0 ~ Q. ~ .£: >0 >< v C IGo List Name C) I- w <t w Q.
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Acute-Phase Response GO:0006953 34 0.8 15 19.0 3.79E-16
Transition Metal Ion Transport GO:0000041 77 1.8 12 6.7 2.24E-07
Transition Metal Ion Homeostasis GO:0046916 47 1.1 8 7.3 1.19E-05
Response to Other Organism GO:0051707 747 17.4 35 2.0 1.03E-04
Response to Biotic Stimulus GO:0009607 1277 29.7 52 1.8 1.06E-04
Response to Pest, Pathogen or Parasite GO:00096 I3 731 17.0 34 2.0 1.47E-04
Regulation of Cell Adhesion GO:0030155 68 1.6 8 5.1 1.81 E-04
Defense Response GO:0006952 1216 28.3 48 1.7 3.75E-04
Peptide Cross-Linking GO:0018149 16 0.4 4 10.8 4.24E-04
Immune Response GO:0006955 1128 26.2 45 1.7 4.48E-04
Pentose-Phosphate Shunt GO:0006098 17 0.4 4 10.1 5.44E-04
NADP Metabolism GO:0006739 17 0.4 4 10.1 5.44E-04
NADPH Regeneration GO:0006740 17 0.4 4 10.1 5.44E-04
Iron Ion Homeostasis GO:0006879 33 0.8 5 6.5 9,33E-04
Di-, Tri-Valent Inorganic Cation Transport GO:0015674 231 5.4 14 2.6 1.15E-03
Coagulation GO:0050817 134 3.1 10 3.2 1.22E-03
Regulation of Inflammatory Response GO:0050727 II 0.3 3 11.7 1.80E-03
Vitamin Transport GO:0051180 23 0.5 4 7.5 1.81 E-03
Di-, Tri-Valent Inorganic Cation Homeostasis GO:0030005 170 3.9 II 2.8 2.25E-03
Positive Regulation of Secretion GO:0051047 12 0.3 3 10.8 2.36E-03
Posttranslational Protein Folding GO:0051084 14 0.3 3 9.2 3.77E-03
Nicotinamide Metabolism GO:0006769 29 0.7 4 5.9 4.35E-03
Metal Ion Homeostasis GO:0006875 188 4.4 II 2.5 4.83E-03
Neutral Amino Acid Transport GO:0015804 16 0.4 3 8.1 5.60E-03
Homeostasis GO:0042592 307 7.1 15 2.1 6.09E-03
Regulation of Protein Secretion GO:0050708 17 0.4 3 7.6 6.68E-03
Cell Homeostasis GO:OO I9725 258 6.0 13 2.2 7.99E-03
Endocytosis GO:0006897 317 7.4 15 2.0 8.06E-03
JAK-STAT Cascade GO:0007259 75 1.7 6 3.4 8.08E-03
Iron Ion Transport GO:0006826 35 0.8 4 4.9 8.59E-03
Cation Homeostasis GO:0030003 205 4.8 II 2.3 9.03E-03
Pyridine Nucleotide Metabolism GO:0019362 36 0.8 4 4.8 9.49E-03
Cholesterol Metabolism GO:0008203 127 3.0 8 2.7 9.93E-03
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Figure 40: Biological Process Hierarchy of Carbohydrate Metabolism Related
Terms Over-Represented in IGT/6-NASH Mice
The relationship between enriched ontology nodes describing carbohydrate metabolism and
the pentose phosphate pathway that were identified in the array study are shown. GO
numbers and node names are also listed in the tables where details of degree of enrichment
are given.
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Figure 41: Biological Process Hierarchy of Lipid Metabolism Related Terms Over-
Represented in IGT/6-NASH Mice
The relationship between parent ontology nodes related to fatty acid biosynthesis and fatty
acid oxidation and carbohydrate metabolism are shown.
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Table 52: IGT/6-NASH vs. Control Biological Process Down-Regulated Ontologies
ell
Q) ..,
.Q C
0 "'C Q)lo.. Q) E Q)A. ..,
:ft v 'i .c j'i Q) j v 'i
0 ~ ~ ~ 'S: >0 >< v C I
Go List Name l' I- w < W A.
Response to Unfolded Protein GO:0006986 103 0.63 6 9.57 4.38E-05
Regulation of Protein Metabolism GO:005 I246 428 2.60 II 4.22 8. I5E-05
Regulation of Biosynthesis GO:0009889 291 1.77 9 5.08 8.95E-05
Regulation of Translational Initiation GO:0006446 84 0.51 5 9.78 1.73E-04
mRNA Metabolism GO:0016071 555 3.38 12 3.55 1.97E-04
Translational Initiation GO:00064 I3 139 0.85 6 7.09 2.28E-04
Regulation of Protein Biosynthesis GO:0006417 270 1.64 8 4.87 2.90E-04
Regulation of Cellular Biosynthesis GO:0031326 281 1.71 8 4.68 3.78E-04
Nucleosome Assembly GO:0006334 75 0,46 4 8.77 1.18E-03
Regulation of Translation GO:0006445 191 1.16 6 5.16 1.21 E-03
RNA Catabolism GO:0006401 77 0,47 4 8.54 1.30E-03
Chromatin Assembly GO:0031497 91 0.55 4 7.22 2,40E-03
DNA Alkylation GO:0006305 45 0.27 3 10.96 2.64E-03
DNA Methylation GO:0006306 45 0.27 3 10.96 2.64E-03
mRNA Catabolism GO:0006402 47 0.29 3 10,49 2.99E-03
mRNA Processing GO:0006397 486 2.96 9 3.04 3.35E-03
Biosynthesis GO:0009058 2004 12.19 23 1.89 3.57E-03
DNA Modification GO:0006304 52 0.32 3 9,48 3.98E-03
Purine Base Metabolism GO:0006144 16 0.10 2 20.55 4.20E-03
Translation GO:0043037 333 2.03 7 3,46 4.70E-03
Steroid Metabolism GO:0008202 262 1.59 6 3.76 5.76E-03
Bile Acid Metabolism GO:0008206 19 0.12 2 17.30 5.91 E-03
Cellular Biosynthesis GO:0044249 1735 10.56 20 1.89 5.97E-03
Purine Nucleoside Monophosphate Metabolism GO:0009126 21 0.13 2 15.65 7.20E-03
Purine Nucleoside Monophosphate Biosynthesis GO:0009127 21 0.13 2 15.65 7.20E-03
Purine Ribonucleoside Monophosphate Metabolism GO:0009167 21 0.13 2 15.65 7.20E-03
Purine Ribonucleoside Monophosphate Biosynthesis GO:0009168 21 0.13 2 15.65 7.20E-03
Amyloid Precursor Protein Metabolism GO:0042982 21 0.13 2 15.65 7.20E-03
Biopolymer Methylation GO:0043414 68 0,41 3 7.25 8,41 E-03
Sensory Perception of Sound GO:0007605 204 1.24 5 4.03 8.63E-03
Sensory Perception of Mechanical Stimulus GO:0050954 204 1.24 5 4.03 8.63E-03
Membrane Protein Ectodomain Proteolysis GO:0006509 24 0.15 2 13.70 9.35E-03
Lipid Metabolism GO:0006629 1005 6.11 13 2.13 9.97E-03
As has been described above, many genes related to lipid metabolism (GO:0006629)
are up-regulated in IGT/6-NASH mice. This ontology node also contains a group of
genes that exhibit reduced expression in NAFLD (Table 52). These genes include
Apolipoprotein B, an important component of very low density lipoprotein (VLDL)
particles without which hepatic lipid excretion is impaired; Apolipoprotein M,
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associated with the formation of LDL, HDL and triglyceride rich-lipoproteins; and
hepatocyte nuclearfactor 4, alpha (Hnf4a). Hnf4a is a key nuclear transcription factor
that controls the expression of many hepatic genes241 including the gene that encodes
the critical enzyme in VLDL assembly, microsomal triglyceride transfer protein
(MTP)242. Hnf4a has also been associated with the pathogenesis of type II diabetes
mellitus.
Data in Table 52 shows that, in IGT/6-NASH mice, more than the expected number
of genes represented by the bile acid metabolism node (GO:0008206) are down-
regulated. The genes Akr1d1 (aldo-keto reductase family 1, member D1 (delta 4-3-
ketosteroid-5-beta-reductase)) and bile acid coenzyme A are under expressed in mice
with NAFLD. Both these genes encode enzymes that are responsible for the catalysis of
reactions that remove toxins from the liver. Deficiency ofbile acid coenzyme A has been
associated with reduced protection against toxicity caused by accumulation of
unconjugated bile acids and non-esterified very long-chain fatty acids within the liver
parenchyma243 and so the reduced expression seen in IGT/6-NASH mice may further
predispose to hepatic damage.
Taken together, these findings indicate increased expression of genes that mediate
glycolysis, fatty acid synthesis (including activity of the pentose phosphate shunt) and
hepatic fatty acid uptake in mice with NAFLD compared to control animals.
Simultaneously, there is evidence of reduced hepatic lipid export capacity due to failure
to synthesise VLDL and reduced ability to resist hepatic toxicity. In contrast, IGT/6-
DM mice (that did not have evidence ofNAFLD) had no significant enrichment of
nodes representing glycolysis, fatty acid synthesis or uptake (Table 51). A lesser degree
of enrichment over control of nodes describing activity of the pentose phosphate
pathway (GO:0006089, GO:0006739 and GO:0006740) was observed. Of note,
enrichment of the cholesterol metabolism node (GO:0008203) was also observed.
Specifically, expression of genes encoding Apolipoprotein B, Scavenger receptor B1, 7-
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dehydrocholesterol reductase and Srebfl were increased in these animals over control.
Expression of Serum amyloid A 1 was also increased in this group as reflected by
enrichment ofnodes GO:0006953, GO:0050727 and GO:0051 047.
Examination of Table 53, where gene expression in IGT/6-NASH mice is compared
to that ofIGT/6-DM littermates, demonstrates that there is significant enrichment of
up-regulated genes in the glucose metabolism, glucose catabolism and the acetyl-CoA
metabolism nodes (GO:0006006, GO:0006007 and GO:0006084) in mice with
NAFLD. These include the genes glycerol-3-phosphate dehydrogenase 2 (electron
transport shuttle across mitochondrial membrane that recycles NADH to NAD+ so
that glycolysis may continue), pyruvate dehydrogenase (lipoamide) alpha 1 and beta,
which encode both subunits of the rate limiting enzyme linking glycolysis and the
TCA cycle and carnitine synthase.
Table 53: IGT/6-NASH Ys. IGT/6-DM Biological Process Up-Regulated Ontologies
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Go List Name C) I- w « w c..
Electron Transport GO:0006118 557 6.34 19 3.00 3. I7E-05
Generation of Precursor Metabolites And Energy GO:0006091 973 11.07 26 2.35 8. I2E-05
ATP Synthesis Coupled Electron Transport GO:0042773 64 0.73 6 8.24 9.26E-05
Acetyl-CoA Metabolism GO:0006084 69 0.79 6 7.64 1041 E-04
Glucose Metabolism GO:0006006 170 1.93 9 4.65 1.63E-04
Mitochondrial Electron Transport, NADH - Ubiquinone GO:0006120 52 0.59 5 8045 3. I8E-04
Fatty Acid Oxidation GO:0019395 33 0.38 4 10.65 5.27E-04
ATP Synthesis Coupled Electron Transport (Eukaryota) GO:0042775 59 0.67 5 7045 5.73E-04
Fatty Acid Beta-Oxidation GO:0006635 21 0.24 3 12.55 1.68E-03
Hexose Metabolism GO:0019318 243 2.77 9 3.25 2.09E-03
Monosaccharide Metabolism GO:0005996 247 2.81 9 3.20 2.33E-03
Positive Regulation of Angiogenesis GO:0045766 10 0.11 2 17.57 5A8E-03
Oxidative Phosphorylation GO:0006119 147 1.67 6 3.59 7.04E-03
Glycerol-3-Phosphate Metabolism GO:0006072 13 0.15 2 13.52 9.29E-03
Glucose Catabolism GO:0006007 112 1.27 5 3.92 9.39E-03
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Table 54: IGT/6-NASH vs IGT/6-DM Biological Process Down-Regulated Ontologies
III
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Acute-Phase Response GO:0006953 34 0.27 8 29.98 2.18E-10
Complement Activation GO:0006956 44 0.35 5 14.48 2.51 E-05
Regulation of Inflammatory Response GO:0050727 II 0.09 3 34.74 7.61 E-05
Positive Regulation of Secretion GO:0051047 12 0.09 3 31.85 1.0 IE-04
Response to Other Organism GO:0051707 747 5.86 17 2.90 1.24E-04
Response to Stress GO:0006950 1711 13.43 29 2.16 1.43E-04
Complement Activation, Classical Pathway GO:0006958 36 0.28 4 14.16 1.83E-04
Response to Biotic Stimulus GO:0009607 1277 10.02 23 2.29 2.86E-04
Innate Immune Response GO:0045087 73 0.57 5 8.73 2.87E-04
Response to Pest, Pathogen or Parasite GO:00096 13 731 5.74 16 2.79 2.96E-04
Regulation of Protein Secretion GO:0050708 17 0.13 3 22.48 3.03E-04
Defense Response GO:0006952 1216 9.54 22 2.30 3.60E-04
DNA Alkylation GO:0006305 45 0.35 4 11.32 4.37E-04
DNA Methylation GO:0006306 45 0.35 4 11.32 4.37E-04
Cytolysis GO:0019835 21 0.16 3 18.20 5.79E-04
DNA Modification GO:0006304 52 0.41 4 9.80 7.61 E-04
Platelet Activation GO:0030168 23 0.18 3 16.62 7.61 E-04
Immune Response GO:0006955 1128 8.85 20 2.26 8.26E-04
Immune Cell Chemotaxis GO:0030595 24 0.19 3 15.92 8.65E-04
Negative Regulation of Immune Response GO:0050777 24 0.19 3 15.92 8.65E-04
Immune Cell Migration GO:0050900 24 0.19 3 15.92 8.65E-04
Response to Bacteria GO:00096 I7 60 0.47 4 8.49 1.30E-03
Negative Regulation of Organismal Physiological Process GO:0051241 29 0.23 3 13.18 1.52E-03
Biopolymer Methylation GO:0043414 68 0.53 4 7.49 2.07E-03
Positive Regulation of Cytokine Production GO:0001819 35 0.27 3 10.92 2.62E-03
Regulation of Secretion GO:0051046 39 0.31 3 9.80 3.58E-03
Blood Coagulation GO:0007596 130 1.02 5 4.90 3.79E-03
Complement Activation, Alternative Pathway GO:0006957 12 0.09 2 21.23 3.86E-03
Coagulation GO:0050817 134 1.05 5 4.75 4.31 E-03
Response to Stimulus GO:0050896 3037 23.84 38 1.59 4.36E-03
Regulation of Translational Initiation GO:0006446 84 0.66 4 6.07 4.45E-03
Hemostasis GO:0007599 140 1.10 5 4.55 5.18E-03
Wound Healing GO:0042060 146 1.15 5 4.36 6. I7E-03
Protein Secretion GO:0009306 49 0.38 3 7.80 6.81 E-03
Neutral Amino Acid Transport GO:OO I5804 16 0.13 2 15.92 6.87E-03
Regulation of Gene Expression. Epigenetic GO:0040029 96 0.75 4 5.31 7.12E-03
Epidermal Growth Factor Receptor Signaling Pathway GO:0007173 51 0.40 3 7.49 7.61 E-03
Positive Regulation of Phosphorylation GO:0042327 18 0.14 2 14.16 8.67E-03
Positive Regulation of Phosphate Metabolism GO:0045937 18 0.14 2 14.16 8.67E-03
Regulation of Body Fluids GO:0050878 159 1.25 5 4.01 8.76E-03
Humoral Immune Response GO:0006959 225 1.77 6 3.40 9.21 E-03
Regulation of Cytokine Production GO:0001817 55 0.43 3 6.95 9.36E-03
Humoral Defense Mechanism (Sensu Vertebrata) GO:0016064 163 1.28 5 3.91 9.68E-03
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Table 55: IGT/6-DM vs Control Biological Process Down-Regulated Ontologies
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Electron Transport GO:0006118 557 7.4 20 2.7 8.23E-05
Biosynthesis GO:0009058 2004 26.7 46 1.7 3.80E-04
Generation of Precursor Metabolites And Energy GO:0006091 973 12.9 27 2.1 3.83E-04
Cellular Biosynthesis GO:0044249 1735 23.1 41 1.8 4.34E-04
Mitochondrial Electron Transport, NADH to GO:0006120 52 0.7 5 7.2 6.44E-04
Ubiquinone
ATP Synthesis Coupled Electron Transport (Sensu GO:0042775 59 0.8 5 6.4 1.15E-03
Eukaryota)
Protein Targeting to Mitochondrion GO:0006626 37 0.5 4 8.1 1.46E-03
ATP Synthesis Coupled Electron Transport GO:0042773 64 0.9 5 5.9 1.66E-03
Protein Localization GO:0008104 1300 17.3 31 1.8 1.74E-03
Protein Biosynthesis GO:00064 12 1027 13.7 26 1.9 1.76E-03
Establishment of Protein Localization GO:0045 184 1273 16.9 30 1.8 2.41 E-03
Purine Nucleoside Monophosphate Metabolism GO:0009126 21 0.3 3 10.7 2.62E-03
Purine Nucleoside Monophosphate Biosynthesis GO:0009127 21 0.3 3 10.7 2.62E-03
Purine Ribonucleoside Monophosphate Metabolism GO:0009167 21 0.3 3 10.7 2.62E-03
Purine Ribonucleoside Monophosphate Biosynthesis GO:0009168 21 0.3 3 10.7 2.62E-03
Response to Unfolded Protein GO:0006986 103 1.4 6 4.4 2.64E-03
Protein Transport GO:0015031 1226 16.3 29 1.8 2.67E-03
Translational Initiation GO:00064 I3 139 1.8 7 3.8 2.74E-03
Intracellular Protein Transport GO:0006886 805 10.7 21 2.0 3.26E-03
Oxidative Phosphorylation GO:0006119 147 2.0 7 3.6 3.73E-03
Peptide Metabolism GO:00065 18 24 0.3 3 9.4 3.87E-03
Protein Export From Nucleus GO:00066 I I 25 0.3 3 9.0 4.35E-03
Regulation of Translational Initiation GO:0006446 84 1.1 5 4.5 5.39E-03
Purine Ribonucleotide Biosynthesis GO:0009152 124 1.6 6 3.6 6.53E-03
Macromolecule Biosynthesis GO:0009059 1140 15.2 26 1.7 6.70E-03
Mitotic Spindle Organization And Biogenesis GO:0007052 30 0.4 3 7.5 7.31 E-03
Positive Regulation of Angiogenesis GO:0045766 10 0.1 2 15.0 7.42E-03
Nucleobase. Nucleoside, Nucleotide And Nucleic Acid GO:0015931 128 1.7 6 3.5 7.59E-03
Transport
DNA Fragmentation During Apoptosis GO:0006309 II 0.1 2 13.7 8.99E-03
Purine Nucleotide Biosynthesis GO:0006164 133 1.8 6 3.4 9.07E-03
Purine Ribonucleotide Metabolism GO:0009150 134 1.8 6 3.4 9.40E-03
Protein Folding GO:0006457 409 5.4 12 2.2 9.68E-03
In addition, IGT/6-NASH mICe show enrichment of the fatty acid oxidation
(GO:OO19395) and fatty acid ~-oxidation (GO:0006635) nodes. These include the
genes carnitine palmito.vltransferase 1a (which encodes the rate limiting enzyme that
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controls the entry of fatty acids into the mitochondria) and hydroxyacyl-Coenzyme A
dehydrogenase beta subunit (also known as 3-ketoacyl-Coenzyme A thiolase and enoyl-
Coenzyme A hydratase) which encodes the trifunctional enzyme that performs 3 of the
4 reactions in mitochondrial fatty acid ~-oxidation.
3.3.6.3 Cellular Component Ontology Classification
309 fully annotated ontology terms were tested. The results are presented in Table S6
to Table 61.
Table 56: IGT/6-NASH vs Control Cellular Component Up-Regulated Ontologies
III
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Go List Name ~ I- w « w a.
Lytic Vacuole GO:0000323 222 5.27 17 3.23 2.79E-05
Lysosome GO:0005764 222 5.27 17 3.23 2.79E-05
Chylomicron GO:0042627 II 0.26 4 15.32 9. I6E-05
Vacuole GO:0005773 260 6.17 17 2.75 1.93E-04
Sodium:Potassium-Exchanging ATPase Complex GO:0005890 22 0.52 4 7.66 1.65E-03
Integral to Membrane GO:0016021 5937 140.93 170 1.21 8.78E-03
Intrinsic to Membrane GO:0031224 5957 141.40 170 1.20 9.83E-03
Table 57: IGT/6-NASH vs Control Cellular Component Down-Regulated Ontologies
III
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Nuclear Heterochromatin GO:0005720 27 0.16 3 18.26 5.90E-04
Heterochromatin GO:0000792 31 0.19 3 15.91 8.91 E-04
Nuclear Chromatin GO:0000790 32 0.19 3 15.41 9.79E-04
Chromatin GO:0000785 220 1.34 6 4.48 2.47E-03
Nucleosome GO:0000786 55 0.33 3 8.97 4.67E-03
Eukaryotic Translation Initiation Factor 3 Complex GO:0005852 20 0.12 2 16.44 6.54E-03
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Table 58: IGT/6-NASH vs IGT/6-DM Cellular Component Up-Regulated Ontologies
Go List Name
Mitochondrion
Cytoplasm
Microsome
Vesicular Fraction
GO:0005739
GO:0005737
GO:0005792
GO:0042598
1162
6180
170
178
"a>t -;
a> ~Q. ....,
>< v
W «
13.22 40
70.33 112
1.93 7
2.03 7
....,
c
a>
E
..c
v
'i:
c
w
3.02
1.59
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3.46
1.71 E-09
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3.56E-03
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Table 59: IGT/6-NASH vs IGT/6-DM Cellular Component Down-Regulated Ontologies
III
a> ....,
.c c
0
"
a>
s- a> E a>Q. ....,
-; ..c ~~ v-; a> ~ v ~0 ...., Q. ...., 'i:0 >< v C IGo List Name l' I- w « w Q.
Extracellular Space GO:00056 I5 692 5.43 19 3.50 3.97E-06
Clathrin Coat of Coated Pit GO:0030132 19 0.15 3 20.12 4.27E-04
Membrane Attack Complex GO:0005579 6 0.05 2 42.47 9.05E-04
Nuclear Heterochromatin GO:0005720 27 0.21 3 14.16 1.23E-03
Coated Pit GO:0005905 107 0.84 5 5.95 1.63E-03
Clathrin Adaptor Complex GO:0030131 30 0.24 3 12.74 1.68E-03
Endocytic Vesicle GO:0030139 30 0.24 3 12.74 1.68E-03
Heterochromatin GO:0000792 31 0.24 3 12.33 1.84E-03
Nuclear Chromatin GO:0000790 32 0.25 3 11.94 2.02E-03
Extracellular Region GO:0005576 1778 13.96 26 1.86 2.40E-03
Membrane Coat Adaptor Complex GO:0030119 40 0.31 3 9.55 3.85E-03
C1athrin Coat GO:0030118 93 0.73 4 5.48 6.37E-03
Clathrin Vesicle Coat GO:0030125 93 0.73 4 5.48 6.37E-03
Table 60: IGT/6-DM vs Control Cellular Component Up-Regulated Ontologies
III
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Lytic Vacuole GO:0000323 222 5.2 20 3.9 3.38E-07
Lysosome GO:0005764 222 5.2 20 3.9 3.38E-07
Vacuole GO:0005773 260 6.0 20 3.3 3.93E-06
Coated Pit GO:0005905 107 2.5 9 3.6 9.13E-04
Extracellular Space GO:0005615 692 16.1 30 1.9 1.05E-03
Integral to Membrane GO:0016021 5937 137.9 174 1.3 1.53E-03
Membrane GO:0016020 7869 182.8 224 1.2 1.57E-03
Intrinsic to Membrane GO:0031224 5957 138.4 174 1.3 1.76E-03
Extracellular Region GO:0005576 1778 41.3 59 1.4 5.04E-03
180
Table 61: IGT/6-DM vs Control Cellular Component Down-Regulated Ontologies
III
Q) ~
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Go List Name C' I- w « w a..
Mitochondrion GO:0005739 1162 15.5 40 2.6 1.07E-07
Mitochondrial Envelope GO:0005740 269 3.6 IS 4.2 4.38E-06
Eukaryotic 43S Pre-initiation Complex GO:OO I6282 59 0.8 7 8.9 1.37E-05
Mitochondrial Membrane GO:0031966 242 3.2 13 4.0 2.74E-05
Cytoplasm GO:0005737 6180 82.2 121 1.5 3.26E-05
Organelle Envelope GO:0031967 541 7.2 19 2.6 1.62E-04
Envelope GO:0031975 545 7.3 19 2.6 1.77E-04
Ribosome GO:0005840 327 4.4 13 3.0 5.33E-04
Mitochondrial Inner Membrane GO:0005743 189 2.5 9 3.6 1.07E-03
Proton-Transporting ATP Synthase Complex, GO:0045263 18 0.2 3 12.5 1.65E-03
Coupling Factor F(O)
Eukaryotic Translation Initiation Factor 3 Complex GO:0005852 20 0.3 3 I 1.3 2.27E-03
Mitochondrial Intermembrane Space GO:0005758 21 0.3 3 10.7 2.62E-03
Organelle Inner Membrane GO:0019866 274 3.6 10 2.7 4.09E-03
Ribonucleoprotein Complex GO:0030529 675 9.0 18 2.0 4.90E-03
Proton-Transporting ATP Synthase Complex GO:0045259 28 0.4 3 8.1 6.0 IE-03
Mitochondrial Outer Membrane GO:000574I 56 0.7 4 5.4 6.64E-03
Outer Membrane GO:0019867 130 1.7 6 3.5 8.16E-03
Organelle Outer Membrane GO:0031968 62 0.8 4 4.8 9.47E-03
3.3.7 Metabolic Pathway Analysis
The biological processes highlighted by gene ontology analysis (section 3.3.6.2) were
used as a basis from which to study changes in gene expression in pathologically
important metabolic pathways. KEGG and GeneMAPP 2.0 software were used to
superimpose the gene expression data onto established biochemical pathways in order
to determine if the observed changes were indicative of a consistent increase or
decrease in metabolic capacity.
Figure 42 is a custom made representation of the changes in gene expression between
IGT/6-NASH and control animals in the key NAFLD pathogenic pathways. IGT/6-
181
NASH mice were found to have increased expression ofgenes effecting the conversion
of glucose to pyruvate by glycolysis, the conversion of pyruvate to citrate and
subsequent fatty acid and triglyceride synthesis. IGT/6-NASH mice also showed a
significant reduction in expression of apolipoproteins necessary for lipid export as
VLDL. The expression of genes that mediated w-oxidation (a major source of reactive
oxygen species and tissue oxidative stress) were increased although this did not reach
statistical significance in this comparison.
Comparison of IGT/6-NASH to littermates that did not develop steatohepatitis
(Figure 43) demonstrated that the major differences in gene expression between the
two groups influence fatty acid disposal capacity. Mice with NAFLD had significantly
increased expression of genes that mediate mitochondrial ~-oxidation and microsomal
w-oxidation (both sources of reactive oxygen species) and reduced expression of genes
necessary for hepatic lipid export as VLDL.
In contrast to animals with NAFLD, IGT/6-DM mice showed increased expression of
genes that contributed to hepatic lipid export and reduced expression of genes that
mediate fatty acid oxidation and increase tissue oxidative stress. The expression of
genes that mediated glycolysis and fatty acid synthesis were slightly elev~, consistent
with the increased circulating glucose load although this did not reach statistical
significance.
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Figure 42: Metabolic Pathways Showing Genes Differentially Expressed in IGT/6-
NASH vs. Control Mice
Expression data for differentially expressed genes between IGT/6-NASH and control mice was
superimposed onto the metabolic pathways for glycolysis, Kreb's TeA cycle, fatty acid
synthesis, triglyceride synthesis, fatty acid ~-oxidation, fatty acid w-oxidation and VLDL
synthesis. NAFLD mice have increased expression of genes that convert glucose into fatty
acids and triglycerides and that mediate fatty acid uptake into the liver but reduced expression
of genes necessary for VLDL production and lipid excretion. An increase in w-oxidation is also
noted although this did not reach statistical significance.
The expression fold-change is shown as a log2 value (positive indicates increased expression
and negative indicates reduced expression). Genes significantly up-regulated by > 1.5 fold are
shown in dark red, those < 1.5 fold are coloured light red. Genes significantly down regulated
by > 1.5 fold are shown in dark blue and those < 1.5 fold are shown in light blue.
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Figure 43: Metabolic Pathways Showing Genes Differentially Expressed in IGT/6-
NASH vs. IGT/6-DM Mice
Expression data for differentially expressed genes between IGT/6-NASH and IGT/6-DM mice
was superimposed onto the metabolic pathways for glycolysis, Kreb's TeA cycle, fatty acid
synthesis, triglyceride synthesis, fatty acid ~-oxidation, fatty acid w-oxidation and VLDL
synthesis. NAFLD mice have significantly increased expression of genes that mediate fatty acid
~-oxidation and fatty acid w-oxidation (leading to production of reactive oxygen species) and
reduced expression of genes necessary for VLDL production and lipid excretion.
The expression fold-change is shown as a log2 value (positive indicates increased expression
and negative indicates reduced expression). Genes significantly up-regulated by > I.S fold are
shown in dark red, those < I.S fold are coloured light red. Genes significantly down regulated
by > I.S fold are shown in dark blue and those < I.S fold are shown in light blue.
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Figure 44: Metabolic Pathways Showing Genes Differentially Expressed in IGT/6-
OM vs. Control Mice
Expression data for differentially expressed genes between IGT/6-DM and control mice was
superimposed onto the metabolic pathways for glycolysis, Kreb's TeA cycle, fatty acid
synthesis, triglyceride synthesis, fatty acid ~-oxidation, fatty acid w-oxidation and VLDL
synthesis. IGT/6-DM mice do not show a significant increase in expression of genes that
mediate fatty acid synthesis or uptake but do exhibit increased expression of genes related to
VLDL secretion. A reduction in fatty acid ~-oxidation and w-oxidation is also noted.
The expression fold-change is shown as a log2 value (positive indicates increased expression
and negative indicates reduced expression). Genes significantly up-regulated by > 1.5 fold are
shown in dark red, those < 1.5 fold are coloured light red. Genes significantly down regulated
by > 1.5 fold are shown in dark blue and those < 1.5 fold are shown in light blue.
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3.3.8 Validation by rtPCR
A subset of genes was selected for validation by rtPCR. Relative gene expressIon
compared to control animals was determined using the ~~CT calculation as described
in the methods section. These included 6 genes that had passed the initial non-specific
filtering stage of the microarray analysis and one gene (peroxisome proliferator activated
receptor alpha, Ppara) that had not passed into statistical testing but which was deemed
to be of sufficient interest to warrant examination. The results for the seven genes
tested are shown in Figure 4S and the fold change values are shown along side those
from the microarray experiment in Table 62.
Table 62: Comparison of Fold-Change Values for Microarray & rtPCR Results
Gene Microarray* rtPCR*
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Ceacaml 2.00 0.037 1041 NS 0.39 0.00 1.63 0.0038 1.39 0.0036 0.85 NS
Fadsl 1.07 NS 1.66 0.006 1.54 0.01 1.79 9.75E-7 1.88 3.76E-7 1.05 NS
Srebfl 2.35 0.001 1.91 0.006 0.81 NS 1.73 0.0076 1047 0.0007 0.85 0.037
Fgf21 1.04 NS 2.69 0.012 2.60 0.009 2.77 NS 7.80 0.0096 2.82 0.0297
CD36 1.68 NS 3.03 0.019 1.87 NS 2.33 NS 3.23 0.033 1.39 NS
Vnnl 0.25 NS 2.3 NS 9.51 0.021 0.22 NS 2.22 NS 10.09 0.0015
Ppara - - - - - - 1.63 0.0330 1.30 0.0006 0.80 NS
* Values in this table are true fold-change values, not log transformed values.
Inspection of Table 62 shows that there was generally a high level of consistency
between the levels ofgene expression detected by microarray and rtPCR both in terms
of magnitude of change and significance of test results. One anomaly, in the IGT/6-
DM vs. control comparison for Fads] was observed where rtPCR detected a significant
increase in Fads] expression whilst the array had not.
Expression ofPpara was found to be significantly increased in both IGT/6 groups over
control and but not significantly different between the two IGT/6 sub-groups.
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Figure 45: Results of Microarray Validation by rtPCR
Anti-logged fold change values relative to the control group ±SEM. Two-tailed p-values are
shown for each comparison. Significance was accepted at p<O.OS.
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3.4 Discussion
'1n all chaos there is a cosmos, in all disorder a secret order. "
Cacl]ung(1875-1961)
As previously mentioned, hepatic regulation of glucose and lipid homeostasis is
controlled by a complex system of hormones, hormonally regulated signalling
pathways and transcription factors79. The complexity of these pathways and the
volume of data generated by microarray studies have meant that, to increase clarity,
some interpretation of the data has already been presented alongside the results of high
level analysis. To some extent this is inevitable as high level microarray analysis is by its
nature a discursive process.
The full interpretation of the analysis is described in section 3.4.2 below. The data will
be contrasted with the results of previous studies examining gene expression in
NAFLD (3.4.5) and finally, the roles of specific genes that have been highlighted in
this study will be discussed (3.4.6). Throughout this process, the gene expression
changes observed in IGT16 will be correlated with the current literature describing the
pathogenesis ofNAFLD.
3.4.1 Conduct of the Study
3.4.1.1 Quality Control Analysis
The validity of any analysis rests upon the quality of the data. This is especially true of
microarray studies where flaws or small discrepancies between microarray chips may be
amplified during analysis. The results of Bioconductor quality control analysis
presented in section 3.3.1 confirm that the processing of samples and the
hybridisationlscanning of chips were performed to an appropriate standard. Similacly,
the application of the GC-RMA algorithm225 during pre-processing effectively
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normalised the data, facilitating inter-chip compansons (section 3.3.2). Recent
published data also confirms that selection of an RMA based algorithm is appropriate
in this setting and that sample amplification according to the Affymetrix GeneChip
Eucaryotic Small Sample Target Labelling Assay version II (Affymetrix Inc, USA) does
not bias results216, 244.
3.4.1.2 Statistical Analysis
High-throughput techniques such as mlCroarray, although widely adopted by the
biological science community, remain the subject of considerable bio-statistical
research and debate. A full discussion of the theories behind the statistical methods
used in the analysis is outside the scope of this thesis however tests were chosen in line
with current best practice in microarray analysis216•
The power of high-throughput microarray techniques carries with it the burden of
simultaneously testing many thousands of hypotheses. For example, a Mouse 430v2
microarray chip contains 45,101 probe-sets and so a simple comparison involves
testing 45,101 null hypotheses. With a p-value of 0.05 this would mean that up to
2,255 probe-sets may be considered significant by chance alone. Traditionally, the
'family-wise error rate' (the rate at which a set of comparisons would be expected to
produce one or more type I errors or false positives) is controlled using the Bonferroni
correction. A balance must be struck between the need to control type 1 error and loss
of power to detect true differences (type 2 error). When testing very large numbers of
hypotheses, Bonferroni correction reduces the power of studies so drastically as to be
unworkable.
In biological studies a more pragmatic approach is frequently adopted; a proportion of
false positives are accepted in order that type 2 error is not unduly inflated216• This led
Benjamini and Hochberg to propose the concept of a 'false discovery rate' (FDR)245.
This differs from the p-value in that, the p-value (or false positive rate) is the rate that
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truly null features are called significant whilst the FDR is the rate that features called
significant are truly null240• A variety of methods to estimate and control the FDR have
been proposed however there is no consensus as to which method is most
appropriate216• Further, existing techniques fail to effectively address the effect of
biological interaction between genes. As changes in the expression of one gene may
modulate the expression of many others, it is debateable whether statistical tests are
truly independent216.
The present study has sought to adopt a robust approach to controlling type 1 error
that also preserved discriminatory power and could adapt to future bio-statistical
advances. Due to the high costs of microarray analysis, a frequent problem that is
encountered is that a great many hypotheses are simultaneously tested using a relatively
small number of replicates in each group. This can affect the power of the analysis to
detect genuine differences. In this study, the primary statistical tool used to detect
differential expression (limma) employs an empirical Bayes approach227• This effects
shrinkage of the estimated sample variances towards a pooled estimate - information
can thus be 'borrowed' across genes to provide a more stable inference216, 227. This
maximises statistical power and is particularly effective when, as in this case, the
number ofarrays being studied is relatively smaIl227•
To minimise the impact of multiple testing on the identification of significant genes,
expression data was filtered prior to analysis, reducing the number ofhypotheses tested
by approximately 90%. Returning to the example given above, this reduced the mean
number of false positive genes expected in a comparison to less than 250. In parallel to
limma analysis, the data were also analysed using the SAM algorithm to generate a q-
value (the lowest false discovery rate at which the gene is considered to be
significant) 228, 240. In view of the evolving nature of FDR control methodology, rather
than selecting and enforcing an arbitrary q-value threshold for the data that further
restricts the pool of genes identified and which may be rapidly superseded by another
technique, both p- and q-values are presented.
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To further ensure that true, biologically significant, differences were identified, the
pool of significant probe-sets was analysed by gene ontology to detect those nodes with
significant enrichment (i.e. nodes containing significantly more significant probe-sets
than would be expected by chance). Such 'gene-class testing' is a widely accepted tool
that relies on the assumption that genes with similar functions or within similar
pathways will behave in a similar fashion216• Thus, if genes belong to a group where
several members show similar expression profiles, it is more likely that the observed
change is valid. This technique also aids in determining the biological effects of
differential gene expression. Data were also tested by principal components analysis to
identify those genes with the greatest changes in expression. Finally, a selection ofgenes
was independently validated using a separate methodology, rtPCR.
The combination of analytical methods used thus ensured that each probe-set and
gene was tested for both statistical and biological significance. In interpreting the
results, the behaviour of genes and probe-sets was considered over all the analyses
described. Thus, the relevance of those genes that were consistently highlighted was
prioritised and false discovery effectively controlled.
3.4.2 Metabolic Changes Promoting Steatosis in IGT/6-NASH Mice
The patterns of gene expression identified both by gene ontology analysis (section
3.3.6) and metabolic pathway exploration (section 3.3.7) demonstrate that the
development of NASH on a background of insulin resistance in the IGT/6 line is
associated with changes involving each of the four metabolic check-points summarised
in the Introduction (i.e. hepatic fatty acid uptake, de novo fatty acid synthesis,
esterification & VLDL secretion and fatty acid oxidation; Figure 2 on page 30, *1-4).
Whilst the effects of any post-translational regulation on gene-product function or
activity can not be directly assessed using microarray technology, the observed changes
are consistent with a permissive metabolic environment for hepatic lipid accumulation
191
and the development of steatosis. Further, the mlCroarray data suggests that the
IGT/6-NASH phenotype is the result of a number of small changes in activity of
several different pathways that, whilst individually insufficient to produce the disease
phenotype, combine to promote steatosis and steatohepatitis. This is in-keeping with
the concept of clinical NAFLD being a complex trait rather than a monogenic disease.
Relevant metabolic pathways are summarised in Figure 46.
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Figure 46: Overview of Relevant Carbohydrate & Lipid Metabolic Pathways
Conversion of glucose to pyruvate may be performed by glycolysis or the pentose phosphate
pathway. The latter is the main source of NADPH metabolic reducing power. Within
mitochondria pyruvate is metabolised by pyruvate dehydrogenase to release acetyl CoA and
oxaloacetate that then enter the TCA cycle. Citrate formed in this reaction is transferred to
the cytoplasm by the citrate synthase/citrate lyase shuttle where acetyl CoA is released and
converted into fatty acids and triglycerides. Modified from 83.
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3.4.2.1 Regulation of Carbohydrate & Lipid Metabolism
The maintenance of homeostasis via regulation of hepatic carbohydrate and lipid
metabolism by insulin and glucose is mediated through two transcription factors:
Sterol regulatory element binding protein-1 (Srebf1, encodes SREBP-l a and the liver
predominant alternative splicing isoform SREBP-lc) and Carbohydrate response
element binding protein (ChREBP) (Table 3). Insulin promotes lipid metabolism via
SREBP-l which induces expression of>30 genes that effect the uptake and synthesis of
fatty acids, triglycerides, cholesterol and phospholipids (SREBP-lc preferentially
effects fatty acid and triglyceride synthesis)80. SREBP-l also has limited activity to
promote glycolysis and, by inhibiting Pck1 (PEPCK) expression, inhibits
gluconeogenesis79. In keeping with previous observations that the lipogenic actions of
insulin are not compromised in insulin resistant states79, expression of Srebf1 was
significantly increased over control in both IGT/6 phenotypic groups. The Srebf1
promoter sequence contains response elements for LXR, SREBP-l, NF-Y and Sp1246
and can also be activated via phosphatidyl inositol 3-kinase and protein kinase C_1247.
Whilst post-translational modification may affect passage to the nucleus, activity of
SREBP-lc closely correlates to expression, suggesting it is primarily regulated at the
transcription leveF48 and so the observed 1.9-2.3 fold increases in gene expression in
IGT/6 mice are likely to truly reflect biological change.
No significant changes in the levels of expression of ChREBP were observed in this
study. However, ChREBP activation is primarily controlled by post-translational
phosphorylation or dephosphorylation and so changes would not necessarily be
detected at the transcriptome level. Expression of the gene whose product is
responsible for ChREBP activation, Protein phosphatase 2A (Ppp2r1a), was
consistently increased in IGT/6-NASH mice by rv 1.5 fold. No consistently significant
change was seen in the IGT/6-DM group. Increased expression of genes within the
pentose phosphate pathway was also observed in IGT/6 mice and recently published
193
work demonstrates that xylulose-5-phosphate generated by this pathway controls
Ppp2r1a activation249 . This suggests that both the transcription factors regulating
glycolysis and lipid biosynthesis are likely to be active in the IGT/6 model ofNAFLD.
The up-regulated target genes that are controlled by SREBP-I and ChREBP include
effectors in all the major pathways involved in carbohydrate and lipid metabolism.
3.4.2.2 Glycolysis
Increased expreSSIon by >1.5 fold of glucose-6-phosphate lsomerase 1,
phosphofructokinase, fructose-bisphosphate aldolase A and pyruvate kinase suggests an
increased capacity to convert glucose into pyruvate in IGT/6-NASH mice (Figure 42).
Whilst a similar trend was observed in the IGT/6-DM group, it was of a smaller
magnitude and did not reach statistical significance.
3.4.2.3 Pentose Phosphate Pathway
The pentose phosphate pathway takes glucose-6-phosphate from the glycolytic
pathway and generates NADPH within the cell (Figure 46). It is the principal source
of the metabolic reducing power required to fuel lipid and steroid reductive
biosynthesis83• Genes from both the oxidative and non-oxidative stages of the pathway
were significantly up-regulated In IGT/6 mICe (1.5-2.2 fold) including
phosphogluconate dehydrogenase, hexose-6-phosphate dehydrogenase and ribose 5-
phosphate isomerase A. As discussed above, xylulose-5-phosphate, a product of the non-
oxidative stage of this process, promotes ChREBP activation, further enhancing the
lipogenic drive within the liver249•
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3.4.2.4 Kreb's Tricarboxylic Acid (TCA) Cycle
The observed increase in expression of dihydrolipoamide S-acetyltransferase (the E2
component of the mitochondrial pyruvate dehydrogenase complex) indicates an
increase in capacity for pyruvate conversion to acetyl-coenzyme A (acetyl-CoA).
Within Kreb's cycle, expression of the citrate synthase gene was increased. Expression
of the cytoplasmic partner enzyme, ATP-citrate lyase, was also increased (Figure 42).
Together these perform an important metabolic translation, allowing the synthesis of
citrate within mitochondria by the TCA cycle and its subsequent transport to the
cytoplasm and re-conversion to acetyl-CoA (Figure 46), potentially making it available
for fatty acid biosynthesis.
3.4.2.5 Fatty Acid Synthesis
On the basis of the changes in gene expression so far described one can conclude that
the substrates necessary for fatty acid synthesis (Acetyl CoA and NADPH, Figure 46)
are potentially available at increased levels within the cytoplasm of IGT/6-NASH
hepatocytes.
As one would predict from the reported effects ofSrebf] over-expression in transgenic
mice l41 . 142, the increased expression of Srebf] in IGT/6 is associated with increased
expression of many genes in the fatty acid synthetic pathway. Acetyl-CoA carboxylase,
which converts cytoplasmic Acetyl-CoA into Malonyl-CoA for fatty acid synthesis was
found to be increased in IGT/6-NASH mice over control animals (Figure 42). The
expression ofFatty acid synthase was approximately two-fold increased in IGT/6 mice
(this did not reach statistical significance by limma and so was not included in gene
ontology analysis although it did reach significance in SAM analysis). In addition,
Srebf] regulated ELOVL family member 6 which mediates elongation of C 16
(Palmitic acid) fatty acid chains and Fatty acid desaturases ] & 2 (Fads] & Fads2)
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showed significantly increased expression in IGT/6-NASH mice. Suggesting that the
liver's capacity to take-up fatty acids from the circulation was also increased, expression
ofScavenger receptor B-1 (Scarb1) was increased in IGT/6 mice (interestingly, more so
in the IGT/6-DM group) whilst expression of CD36 (Fatty acid translocase) was
significantly increased in IGT/6-NASH mice. These findings are in agreement with
published isotope tracer studies in patients with NAFLD showing hepatic fat is
derived from a combination of adipose tissue stores, de novo hepatic synthesis and the
dierl1•
3.4.2.6 Triacylglycerol (Triglyceride) Synthesis
Genes that mediate conversion of fatty acids to triacylglycerol for storage or export to
adipose tissue including aldehyde dehydrogenase 1, glycerol-3-phosphate acyltransferase,
1-acylglycerol-3-phosphate O-acyltransferase 3, phosphatidic acid phosphatase 2 and
diacylglycerol O-acyltransferase 1 were also over-expressed in IGT/6 livers compared
with control. In general, this effect was greater in those IGT/6 animals with NAFLD
than the IGT/6-DM group (Figure 43) and IGT/6-NASH mice also had significantly
higher glycerol kinase levels than IGT/6-DM mice.
3.4.2.7 Changes Affecting HepatiC Lipid Export & Trafficking
The results of the microarray experiment are consistent with an increase in glycolysis
and synthesis of fatty acids and triglycerides within the liver. Hepatic lipid export is
mainly via secretion of very low density lipoprotein (VLDL) particles into the
circulation. VLDL is composed of Apolipoprotein B-IOO, triglyceride or cholesterol
esters and phospholipids83. As shown in Figure 42, alterations in expression of genes
that mediated hepatic lipid export differentiate IGT/6 mice from control. The
microarray data is consistent with the conclusion that hepatic VLDL export is affected
1%
to varying degrees in the two IGT/6 phenotypic groups studied and is supported by
the lower circulating triglyceride levels observed in IGT/6 animals (Table 23).
Srebfl, Hepatocyte nuclearfactor-4a (Hnf4a or MODY1) and Peroxisome proliftrator
activated receptor-alpha (Ppara) all regulate Mttp activity at the transcription leveF50.
251. Changes in expression of Microsomal triglyceride transfer protein (Mttp) , the
enzyme that assembles VLDL particles252, did not reach statistical significance.
Expression of Hepatocyte nuclear factor-4a (Hnf4a or MODYl), a promoter of Mttp
expression, was found to be significantly reduced relative to control in both IGT/6
groups and Srebfl (an inhibitor ofMttp expression) was up-regulated in both groups.
In contrast, as measured by rt-PCR, expression ofPpara was significantly elevated in all
IGT/6 mice (Figure 45). The net effect of these changes may be that, as is observed in
the ob/ob mouse253, there is relative preservation ofMttp activity in these animals.
3.4.2.8 Apolipoprotein B (ApoB)
Apolipoprotein B is a 512kd protein involved in the transport of triglycerides and
cholesterol from the liver to peripheral tissues for storage. Control of hepatic ApoB
expression is regulated by the combined actions of several transcription factors; to date
three have been identified (Hnf4a, Hnfl and Cebp)254-256. As the main apolipoprotein
constituent of VLDL, VLDL secretion is dependent on the availability of
Apolipoprotein B87. ApoB expression of was found to be significantly reduced in the
IGT/6-NASH group with mRNA levels at one third of those seen in control. This was
in agreement with the reports of reduced ApoB expression in human NASH studies87
and contrasted to the IGT/6-DM group where a significant 2.7 fold increase in ApoB
expression was observed. These differences were also highlighted by principal
components analysis (Table 43). Suggesting a possible explanation for the differences
in ApoB expression and consequent lipid accumulation between IGT/6 sub-groups,
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levels of Cebpb mRNA, shown to enhance intestinal ApoB expression257, were 3 fold
increased in IGT/6-DM mice but not significantly increased in the IGT/6-NASH
group.
3.4.2.9 Bile Acid Metabolism
An alternative route for hepatic disposal of lipid is by the conversion of cholesterol to
bile acids. Consistent with an increase in hepatic lipid load, compared to control,
increased expression in the level of gene expression within the bile acid synthetic
pathway was seen in both IGT/6-NASH and IGT/6-DM mice. However, expression
of the rate limiting enzyme, Cytochrome P450 tal (Cyp7al), was only significantly
elevated in IGT/6-DM mice, where it was 2.7 fold greater than control, and 1.6 fold
greater than in IGT/6-NASH, although the latter did not reach statistical significance.
These data would be consistent with the interpretation that sufficient export of
hepatic triglyceride occurs in the IGT/6-DM mice to mitigate against the observed
trend towards increased fatty acid and triglyceride synthesis. In contrast, those mice
that do develop NAFLD have both greater expression of genes performing de novo
fatty acid synthesis and fatty acid uptake and have significantly reduced VLDL export
capacity. This is also reflected in the trend towards lower circulating levels of
triglyceride in IGT/6-NASH mice than IGT/6-DM mice (Table 24). Consequently,
whilst all IGT/6 mice have impaired glucose tolerance and insulin resistance, mice in
the IGT/6-NASH group accumulate triglyceride within the hepatic parenchyma
leading to steatosis.
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3.4.3 Changes Promoting Steatohepatitis in IGT/6-NASH Mice
The spontaneous transition from steatosis to steatohepatitis observed in the IGT/6
line may be explained by a combination of changes, both in the potential to generate
free radicals and other reactive oxygen species within the hepatocyte, and in the
balance between fatty acid synthesis and oxidative destruction.
3.4.3.1 Fatty Acid Oxidation
In mammalian liver, fatty acid oxidation occurs in three organelles; ~-oxidation takes
place in the mitochondria and peroxisomes and cytochrome P450-4A mediated w-
oxidation takes place in the microsomes88, 258 (discussed in section 1.5.2 on page 17).
The IGT/6-NASH phenotype is associated with an increase in the expression ofgenes
that facilitate fatty acid oxidation. IGT/6 mice show significantly greater expression of
Ppara, the main regulator of fatty acid catabolism, than control animals. The activity
of carnitine palmitoyltransferase lA (Cptla) is the rate-limiting step in the carnitine
dependent enzymatic transfer of fatty acids into mitochondria for mitochondrial
trifunctional protein (MtpbIHadhb) mediated ~-oxidation. In comparison to IGT/6-
DM mice (where an 80% reduction in Cyp4alO and a 35% reduction in Mtpb
expression were observed compared to control, Figure 44 on page 185), expression of
Cptla and Mtpb were both significantly increased in the IGT/6-NASH group (Figure
43 on page 184). IGT/6-NASH mice exhibited evidence that microsomal w-oxidation
was highly activated in response to the expanded hepatic lipid load with expression of
Cyp4alO increased almost 4 fold over control animals (ns) and more than 18 fold over
IGT/6 mice that did not exhibit fat accumulation. Supporting the strength of these
effects, several of the same changes in gene expression were also flagged by principal
components analysis (3.3.5). Together, these changes are consistent with a shift
towards lipid disposal via mitochondrial ~-oxidation (Cptl and MtpbIHadhb), extra-
199
mitochondrial peroxisomal ~-oxidation (Pexl1a) and microsomal w-oxidation
pathways (increased Cyp4a10 and Cyp2b9) leading to increased free-radical
production and hepatic oxidative stress. The observed increase in w-oxidation in
IGT/6-NASH mice is of particular interest since w-oxidation leads to production of
reactive oxygen species and dicarboxylic acid which is both cytotoxic and, in addition,
inhibits mitochondrial ~-oxidation.Dicarboxylic acid therefore prevents the products
ofboth peroxisomal and microsomal oxidation from being completely metabolised258 •
3.4.3.2 Peroxisome Proliferator Activated Receptor-Alpha (Ppara) Activity
In addition to hormonally regulated transcription factors such as Srebf1, much of the
metabolic control over fatty acid and cholesterol metabolism is mediated by nuclear
receptors that detect the substrates, intermediaries or end-products of metabolic
pathways. Such receptors include PPARrx, Hnf4a, LXR, FXR and possibly RXR89. The
control of fatty acid oxidation is primarily regulated by the ligand-activated
transcription factor PPARrx which serves as an intracellular lipid detector. Upon
activation, PPARrx complexes with RXR and binds to DNA PPAR response elements
(PPRE) so triggering target gene transcription and stimulating lipid catabolism89• The
expression of Ppara (which encodes PPARrx) was significantly increased in all IGT/6
mice compared to control animals however the response of animals from the two
IGT/6 phenotypic groups was markedly different.
The differences in response between IGT/6-DM and IGT/6-NASH mice to increased
Ppara expression may be a function of differing ligand availability and as such would
not be detected at the transc;iption level. It is generally accepted that some fatty acids
are more potent PPARrx agonists than others (e.g. polyunsaturated fatty acids such as
Eicosapentaenoic acid, C20:5n3, are strong PPARrx agonists whilst monounsaturated
fats such as Oleic acid, C18:1n9, are not) and that changes in the concentration and
type of fatty acids within the hepatocyte lipid pool are thus able to regulate PPARrx
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activity259. In keeping with the previous studies260, the enhanced expression of Elovl6
and Fadsl & 2 and reduced expression ofElovl3 in IGT/6-NASH mice was associated
with increased Srebf1 expression (Figure 42 on page 183). These changes may then
increase the proportion of effective PPARa ligands (unsaturated fatty acids) in the
intracellular lipid pool and promote PPARa activity to favour increased fatty acid
oxidation in IGT/6-NASH mice. Future work to characterise changes in the activity
of fatty acid metabolic pathways and the composition of the lipid pool in IGT/6 mice
is therefore a priority.
In addition to stimulating fatty acid oxidation, PPARa is also able to suppress fatty
acid synthesis at the transcription level. An interesting anomaly that is shared by both
the IGT/6 line and the ob/ob mouse is the failure to suppress Srebfl mediated fatty
acid synthesis despite increased Ppara levels and increased w-oxidation activity116, 119.
261. In the IGT/6-NASH mouse, expression of genes mediating fatty acid synthesis
remained high despite the potentially suppressive effect of PPARa (Figure 42). The
possibility that a simultaneous mixed PPARa and LXR/SREBP-lc response may
contribute to the IGT/6-NASH phenotype is supported by studies showing that co-
administration of PPARa and LXR agonists to CS7BL/6 mice can generate hepatic
triglyceride accumulation associated with a small reduction in circulating triglyceride
levels and simultaneously, a significant increase in ~-oxidation262.
The IGT/6 data suggest a loss of the normal coordinated reciprocal regulation that
characterises the changes in metabolism between the fasted and fed state263. This may
be indicative of an interaction between transcription factors and their co-factors to
favour both a steatotic and an oxidative/inflammatory environment. The concept of
transcription factor interference is already established within the literature. In vitro
and in vivo studies have demonstrated that direct competition to dimerise with the
available RXR pool can modulate the transcription promoter activity of both PPARa
and LXR, thus affecting the expression of genes containing PPRE and LXRE
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sequences such as mediators of fatty acid oxidation or Srebfl respectively (Figure
47)263, 264. This effect is enhanced in the presence of the appropriate ligands263, 264.
Further, in addition to the effect of competing with PPARrt for RXR ligands, LXRcd~
can dimerise with PPARrt and directly block its binding to PPRE sites, preventing
down stream activation of transcription264.
FATTY ACIDS INSULIN
OXYSTEROLS
L
Competition
PPARa +; RXR 4 .. RXR + LXR P!3K1AktNFY
Sp1
+
Fatty Acid Oxidation 0 + +Srebf-1~
Fatty Acid Synthesis
Figure 47: Competition for RXR ligand by PPARa & LXR Helps Modulate PPARa
& Srebf-I (SREBP-I c) Activity
Transcription factors PPARa and both LXR isoforms compete to dimerise with the available
RXR pool. Binding of their respective ligands (fatty acids and oxysterols) increases affinity for
RXR and thus alters the balance to favour specific gene transcription.
Both LXR isoforms (LXRrt and LXR~) are cellular oxysterol responsive transcription
factors but they exhibit substantially different effects on lipid metabolism265, 266.
Knockout studies have shown that the LXRa (Nr1h3) isoform is the main effector of
LXR mediated metabolic regulation in hepatic tissue with little contribution from the
LXR~ (Nr1h2) isoform267, 268. Srebf1 induction is LXRrt rather than LXR~ dependent
and loss ofLXRrt activity prevents hepatic triglyceride accumulation265. Further, LX~
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activity has been shown to reduce expression of key genes that mediate fatty acid and
triglyceride synthesis266 whilst promoting cellular cholesterol efflux265• In the current
study, whilst LXRa expression was not significantly altered, expression ofLXR~ was
1.S fold greater in IGT/6-DM mice than in IGT/6-NASH animals. In light of the
preceding discussion, this increase in LXR~ expression may directly block PPARa
signalling and, by increasing competition for the available RXR pool, reduce LXRa
activity (and further downgrade PPARa activity) in IGT/6-DM mice. These affects
would be consistent with the observation that, unlike IGT/ -NASH mice, despite
increased expression of Ppara, IGT/6-DM mice do not induce fatty acid oxidation.
Reports also indicate that LXR~ has anti-inflammatory properties and is able to
suppress the macrophage response to lipopolysaccharide or TNFa stimulated injury by
reducing expression of a range of pro-inflammatory mediators and other proteins
including IL-l~, IL-6, MMP-9 and tissue factor268• This suggests that, in addition to
reducing tissue damage and lipid peroxidation, the increased expression ofLXR~ seen
in IGT/6-DM mice may also reduce the subsequent innate immune response that
would otherwise exacerbate tissue damage.
3.4.4 Response to Oxidative Stress
The synthesis of reactive oxygen species (ROS) by fatty acid metabolism and the
mitochondrial respiratory chain is increased in patients with NAFLD269. The changes
in gene expression observed in IGT/6-NASH mice are consistent with increased
generation of ROS and dicarboxylic acid within hepatocytes. These ROS are able to
induce lipid peroxidation of the expanded lipid stores, compromise mitochondrial
integrity and promote apoptotic cell death269. Consistent with an increase in oxidative
stress in IGT/6-NASH mice is the observed up-regulation by apprOXimately two-fold
over both control and IGT/6-DM animals ofglutathione-S-transferase (Mgst3), which
mediates the safe disposal of the products of lipid peroxidation by conjugation with
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glutathione270• Expression of several mediators of apoptosis were increased in IGT/6
mice including Caspases 7 & 9 which also showed significantly higher expression in
IGT/6-NASH than IGT/6-DM animals.
3.4.4.1 Vanin-I (Vnn I)
Principal components analysis demonstrated that expression of Vanin-l (Vnnl) was a
major differentiator between those animals that developed NAFLD and those that did
not. The Vnnl promoter contains functional antioxidant response element-like
(ARE) sequences and so expression is increased in the presence ofoxidative stress27 l, 272.
Expression of Vnnl is also increased by PPAR~ agonists273 however it is not established
whether this is a primary or secondary effect. Compared to IGT/6-DM mice,
expression of Vnnl was found to be approximately 9-10 fold increased in IGT/ 6-
NASH animals (Table 43). Vnnl encodes an epithelial pantetheinase ectoenzyme that
hydrolyses pantetheine to produce pantothenic acid (vitamin BS) and cysteamine, an
anti-oxidant sulfhydryl compound272, 274. Vnnl knockout mice have greatly reduced
hepatic cysteamine/cystamine levels275 but are relatively protected from oxidative stress
induced damage272 and inflammation induced by a range of insults276• When tissue
cysteamine levels are artificially reconstituted this protective effect is lost. This
counter-intuitive effect appears to be due to cysteamine mediated inhibition of y-
glutamylcysteine synthase, the rate limiting enzyme in the synthesis of glutathione
which acts as the main cellular redox buffer272• Thus, increased Vnnl expression leads
to depletion of hepatic reduced-glutathione, compromise of the hepatic defence
against oxidative stress and a greater inflammatory/apoptotic response272. 276. As such
the increased expression observed in IGT/6-NASH mice may favour the progression
from steatosis to steatohepatitis.
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This observation is ofparticular interest since, to date, much of the focus in the NASH
literature has been on factors that promote tissue damage and inflammation whilst
compromise of those elements that protect the liver has been largely ignored. It is also
tempting to speculate whether the effect of functional polymorphisms in this and
related genes may be significant determinants of the outcome in adverse drug reactions
(for example, contributing to the variability in response observed in clinical practice to
relatively small, inadvertent, paracetamol overdose).
3.4.5 Comparison with Previous Microarray Studies
In Section 2 it was demonstrated that the IGT/6 phenotype compares favourably with
the clinical manifestations of NAFLD and represents a better overall approximation
than existing models. Comparisons may be made at the transcriptome level to identify
commonality between IGT/6 and both clinical NAFLD and existing models.
Microarray technology has been used to examine the transcriptome level changes that
occur in patients with steatosis21S, steatohepatitis212, 213 and NAFLD related
cirrhosis211 . Gene expression in the Pten hepatic knockout model and the Ob mouse
(with and without leptin administration) has also been assessed by microarray. These
studies, already summarised in 3.1.2, have contributed to our understanding of the
pathogenesis of NAFLD and will be used as comparators for the expression profile of
the IGT/6 line.
Broadly the same metabolic pathways are involved in IGT/6 pathogenesis as were
highlighted by these studies, suggesting a commonality of pathogenesis. Detailed
comparison between these studies and the IGT/6 data was complicated as few studies
have been reported in accordance with the guidelines established by the Microarray
Gene Expression Data Society (MIAME)277 and none have placed their data into
publicly accessible repositories to allow re-analysis. Gene level comparisons are
therefore limited to the data provided within each publication.
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3.4.5.1 Human Studies
1. Simple Steatosis
Chiappini et al studied differential gene expressIon In liver tissue from cadaveric
transplant donors21s • Normal tissue or tissue with simple steatosis was selected however
details about insulin resistance or diabetes were not reported. The analysis used
commercial full genome scale arrays and identified 110 differentially expressed genes
(100 over-expressed and 10 under-expressed). The genes identified clustered into
functional groups within metabolic, transcription regulation, apoptosis/cell cycle,
stress/inflammation and cellular adhesion categories.
Twenty of the 110 genes associated with steatosis were also flagged in the IGT/6 study.
Interestingly, not all were associated with the development ofNAFLD in IGT/6, some
being equally related to the IGT/6-DM phenotype. Due to the patient population
used (cadaveric transplant donors), although viral hepatitis status and body weight
were determined, it was not possible to ascertain how many of the donors had evidence
of diabetes or impaired glucose tolerance. Thus, the discrepancy is particularly
interesting and allows us to expand on the conclusions drawn by the authors and
suggest that changes in some of the genes highlighted in their study may be related to
an associated insulin resistant state rather than steatosis per se. Genes that were
associated with steatosis in both studies included: Agpat3 (triglyceride synthesis), ApoE
(reverse lipoprotein transport), Cdc42epl, Ndujb7 and Tollip (positive regulation of
inflammatory response to lipopolysaccharide). Genes associated with either IGT/6
sub-group included Abhd2, Aktl (signalling), Aldh4al, C2, Camk2b, Eif4g1, Flot2,
Igf2, Igfbp4, Naglu, Pexl6, Plxnbl Ptprj', Scarbl (hepatic lipid uptake) and Sdcl.
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II. Steatohepatitis
Younossi et al have presented two papers in which they describe the hepatic gene
expression profiles of morbidly obese patients with varying degrees of NAFLD
undergoing bariatric surgery212. 213. In both studies the same population was sampled
and analysis performed using the same custom made microarray chips produced from
5,200 cDNA clones thought likely to be associated with NAFLD pathogenesis. These
studies therefore are based upon an a priori assumption regarding the genes and
pathways that were involved in NAFLD (the authors do not provide full details of
which genes were represented on the arrays). The smaller first study, identified 34
differentially expressed genes between obese NAFLD patients and either obese or non-
obese controls213. The second study identified 22 genes but used only the obese control
population. These studies identified relatively few genes related to carbohydrate or
lipid metabolism as being involved in NAFLD pathogenesis212. 213. Of the 34 genes
identified from the restricted dataset analysed in those papers, overlap with IGT/6
data was limited to two genes, serine dehydratase and acyl-CoA dehydrogenase. It is
perhaps pertinent that the overlap between the Younossi studies and the other
published studies is equally limited.
III. NAFLD Related Cirrhosis
The first large scale microarray study to examine human NAFLD (Sreekumar et aI,
2003) compared hepatic gene expression in tissue from patients with cirrhosis due to
NASH with healthy tissue and tissue from patients with HCV or PBC related
cirrhosis211 . Reflecting the limitations of microarray technology at that time,
Affymetrix Hu6800 arrays sampled expression of just 6,412 genes. Only sixteen genes
were identified as differentially expressed including genes that mediate ROS
scavenging, lipid metabolism, glucose metabolism and fatty acid oxidation. It is
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interesting to note that, unlike the other studies, the majority of genes identified were
under-expressed in the NASH-cirrhosis population.
3.4.5.2 Mouse Models
L Leptin & the Db/Db Mouse
Two of the earliest microarray studies examined the transcription level changes that
occurred in the leptin deficiency and the subsequent effects of leptin administration
using the ob/ob mouse (section 2.1.1.1)209,210. The results share much in common with
changes observed in the IGT16 study. Both studies demonstrate altered expression of
genes involved in metabolic pathways including carbohydrate and lipid metabolism,
lipoprotein metabolism, fatty acid synthesis, triacylglycerol synthesis, fatty acid
oxidation and the respiratory chain.
Increased expression of genes that contribute to the conversion of carbohydrates to
fatty acids such as Pdhal (pyruvate metabolism) and Fatty acid synthase (fatty acid
synthesis) were found. In addition, expression of Cd36 (hepatic fatty acid uptake) was
also increased. Expression of many of these genes was further increased by
administration ofleptin (indicating their roles in the normal physiological response to
obesity). Genes mediating fatty acid mitochondrial ~-oxidation (Mtpb/Hadhb) were
over expressed in Ob mice whilst the administration of leptin appeared to enhance
microsomal w-oxidation by increasing Cyp4alO expression. Genes that are involved in
the disposal of reactive oxygen species are also over-expressed in both IGT16-NASH
and Ob mice including Cytochrome C oxidase (electron transport chain) and
Mgst3/Gst (glutathione metabolism). Administration of leptin to Ob mice was also
associated with increased expression of coagulation factor X an effect also observed in
IGT/6-NASH mice.
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II. Hepatic Pten (phosphatase and tensin homolog) Knockout Mice
Earlier this year a study was published examining gene expression in a new model of
NAFLD generated by deletion of the phosphatase and tensin homolog (Pten) gene
(section 2.1.1.5)214. Hepatocyte-specific deletion of this gene leads (in the absence of
obesity, diabetes, insulin resistance or dyslipidaemia) to hepatic triglyceride
accumulation and steatohepatitis which progresses to fibrosis and tumour
development 145, 146. This study highlighted similar groups of genes to those seen in the
ob/ob mouse but by virtue of the improvements in microarray technology, was able to
identify several genes that had not previously be associated with NAFLD.
Comparison with the Pten knockout mouse demonstrated multiple similarities
associated with lipid accumulation and inflammatory response. Expression of Cd36
(hepatic lipid uptake), Elovl6 (fatty acid synthesis/elongation) and MgatS were all
increased whilst ApoB (hepatic lipid export) expression was reduced. Several other
flagged genes were also identified as differentially expressed in both of the IGT/6
categories relative to control, suggesting that they may reflect insulin resistance. These
included Sgk and Cebpb. Differentially expressed genes that may reflect tissue damage,
oxidative stress or inflammatory response included Vnn1 (response to oxidative stress)
and Pdk (pyruvate metabolism). Highlighted in principal components analysis,
expression ofMt1 (metallothionein 1) was significantly increased in IGT/6 mice (more
so in those without NAFLD). Similarly, whilst Mt2 was also increased in IGT/6-DM
mice, expression was not significantly increased in IGT/6-NASH mice.
III. High Fat Fed Inbred Strains ofMice
Based on the differences in sensitivity to dietary induced NAFLD observed between
inbred strains that are reported in Section 4, members of the BAIR consortium
performed microarray experiments comparing diet induced changes in gene expression
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in sensitive (129S6/SvEv) and resistant (BALB/c) strains of mice. I am a co-author ofa
manuscript, currently in preparation, that describes this work (Toye et aI, manuscript
in preparation, 2006). The inbred strain study used the same Affymetrix microarray
platform as was used in the IGT/6 study, making cross study comparison more
straightforward. Of2,S96 probe-sets identified as differentially expressed between high
fat fed BALB/c and 129S6/SvEv mice, 325 (12.5%), equating to 253 genes, were also
found to be differentially expressed in the IGT/6 study.
Reflecting changes in fatty acid metabolism, genes identified by both studies include
Pdhal (pyruvate metabolism), Cs (transfer of acyl-CoA out of mitochondria) and
Fatty acid synthase (fatty acid synthesis), Cd36 (hepatic lipid uptake), Elovl3 (fatty acid
synthesis/elongation). Oxidation of fatty acids was also affected, altered expression of
MtpblHadbh and Cptla (fatty acid ~-oxidation) and Cyp4alO (fatty acid w-oxidation)
potentially contributing to cellular oxidative stress. Cellular oxidative stress response
was also reflected in changes in expression ofglutathione-S-transferase (Mgst3), Mtl &
2 and Vnnl.
The biological process ontologies that were enriched when the common differentially
expressed genes were analysed are shown in Table 63. These highlight the
derangements of carbohydrate and lipid metabolism that occur in these models and
appear to be central to NAFLD pathogenesis.
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Table 63: Biological Process Ontologies of Genes Differentially Expressed in IGT/6
& High fat Fed I29S6/SvEv Mice
GO List Name III
Cl) ...,
.c c
0 "'C Cl)~ Cl) E Cl)A. ~
ni .c ~v~ ni Cl) ~ v ni
0 ..., c. ~ .~ >0 >< v C IC) ... w <t w A.
Glucose Metabolism GO:0006006 198 1.81 10 5.53 1.72E-05
Glucose Catabolism GO:0006007 130 1.19 8 6.74 2.93E-05
Hexose Metabolism GO:0019318 276 2.52 II 4.36 5.87E-05
Hexose Catabolism GO:0019320 144 1.32 8 6.08 6.06E-05
Monosaccharide Metabolism GO:0005996 281 2.57 II 4.29 6.89E-05
Monosaccharide Catabolism GO:0046365 147 1.34 8 5.96 7.00E-05
Alcohol Catabolism GO:0046 I64 151 1.38 8 5.80 8.45E-05
Lipid Metabolism GO:0006629 1067 9.74 23 2.36 0.000191
Main Pathways Of Carbohydrate Metabolism GO:0006092 217 1.98 9 4.54 0.000201
Lipid Transport GO:0006869 131 1.20 7 5.85 0.00022
Generation Of Precursor Metabolites And Energy GO:0006091 1011 9.23 22 2.38 0.000228
Carbohydrate Metabolism GO:0005975 818 7.47 19 2.54 0.000267
Acute-Phase Response GO:0006953 35 0.32 4 12.5 0.00029
Carbohydrate Catabolism GO:0016052 183 1.67 8 4.79 0.000315
Cellular Carbohydrate Catabolism GO:0044275 183 1.67 8 4.79 0.000315
Glycerol-3-Phosphate Metabolism GO:0006072 15 0.14 3 21.9 0.000319
Catabolism GO:0009056 1085 9.91 22 2.22 0.000583
Cellular Carbohydrate Metabolism GO:0044262 605 5.53 15 2.71 0.000584
Glycerol Metabolism GO:0006071 20 0.18 3 16.4 0.000773
Alcohol Metabolism GO:0006066 498 4.55 13 2.86 0.000827
Polyol Metabolism GO:0019751 22 0.20 3 14.9 0.00103
Response To Pathogenic Bacteria GO:0009618 24 0.22 3 13.6 0.001335
Cellular Catabolism GO:0044248 963 8.79 19 2.16 0.001793
mRNA Catabolism GO:0006402 61 0.56 4 7.18 0.002399
Energy Derivation By Oxidation of Organic GO:0015980 311 2.84 9 3.17 0.002528
Compounds
Glycolysis GO:0006096 107 0.98 5 5.12 0.003126
Response To Unfolded Protein GO:0006986 109 1.00 5 5.02 0.003385
Response To Protein Stimulus GO:0051789 109 1.00 5 5.02 0.003385
Response To Pathogen GO:0042828 35 0.32 3 9.39 0.004007
Acetyl-CoA Metabolism GO:0006084 72 0.66 4 6.08 0.004369
Transition Metal Ion Homeostasis GO:00469 I6 42 0.38 3 7.82 0.006704
Regulation Of DNA Binding GO:0051101 15 0.14 2 14.6 0.008092
RNA Catabolism GO:0006401 89 0.81 4 4.92 0.009183
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3.4.6 Genes of Interest in NAFLD Pathogenesis Identified in this Study
Whilst IGT/6 has been shown to share similarities to both existing models and the
human disease in terms of the biological pathways that are affected, this study has also
identified a number of genes outside these pathways that may be pertinent to the
pathogenesis of NAFLD. The roles played by some genes, such as Vanin-l, have
already been discussed. The effects ofsome of the others are discussed below.
3.4.6.1 Carcinoembryonic Antigen-Cell Adhesion Molecule-I (Ceacam I)
The concentration of circulating insulin is determined by the rate of secretion from
the pancreatic ~-cells and by the rate of insulin clearance, which predominantly occurs
by receptor-mediated endocytosis in the liver278. Elevated insulin secretion occurs to
compensate for target tissue insulin resistance; paradoxically, a chronic elevation of
circulating insulin (e.g. due to failure of insulin clearance) leads to secondary peripheral
insulin resistance278.
CEACAMI is a transmembrane glycoprotein that is activated by the insulin receptor
tyrosine kinase. Transcription of Ceacaml is controlled by insulin, CEBP, HNF-l, -4
& -5 and cAMp279. CEACAM family members play important roles in regulation of
apoptosis, tumour development, as receptors for pathogenic bacteria and viruses and as
modulators of the immune response280. CEACAMI regulates hepatic insulin
clearance; expression of a phosphorylation defective (dominant negative) Ceacaml
isoform causes hyperinsulinaemia, visceral adiposity and impaired glucose tolerance278,
281. In addition, once phosphorylated and endocytosed, CEACAMI directly interacts
with fatty acid synthase to post-transcriptionally reduce its activity - an effect which is
blunted by chronic insulin resistance282.
The array experiment demonstrated that expreSSIon of Ceacaml was significantly
greater in IGT/6 mice than controls and that, between IGT/6 groups, expression was
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highest in those mICe that did not develop steatohepatitis. This observation was
validated by rtPCR (3.3.8). These findings could be consistent with reduced Ceacaml
mediated suppression of fatty acid synthesis in IGT/6-NASH mice, contributing to a
net hepatic accumulation of lipid. Similarly, a fractional increase in CEACAMI
mediated inhibition ofFAS in IGT/6-DM animals may partially explain why they do
not become steatotic.
3.4.6.2 Metallothionein I & 2 (Mt I & Mt2)
Metallothionein is a highly conserved cysteine-rich zinc-binding protein whose
expression is induced by zinc or oxidative stress. In the current study, expression of
Mtl was significantly increased in IGT/6 mice over that seen in controls; IGT/6-DM
animals (13-fold increase) had higher levels than IGT/6-NASH animals (S-fold
increase). Expression ofMt2 was only significantly increased in IGT/6-DM animals.
Studies have demonstrated that increased expression of metallothionein reduces
hepatotoxicity induced by various agents including paracetamoF83, carbon
tetrachloride284 and ethanoF85. It has previously been demonstrated that
metallothionein expression is suppressed in the Ob mouse and that leptin
administration increases expression, reducing sensitivity to cellular oxidative stress286.
The role of gut derived bacterial lipopolysaccharide (LPS) and endotoxin, in the
pathogenesis ofalcohol-related and non-alcoholic steatohepatitis has been suggested by
several investigators12o, 287. Recent studies also indicate that metallothionein plays a
protective role against a LPS induced inflammatory response288 and that its actions
reduce endothelial damage and inflammation related intravascular coagulation289.
Thus, the lower levels of Mtl and Mt2 expression seen in IGT/6-NASH mice may
contribute to their progression to steatohepatitis as, relative to IGT/6-DM, they are
vulnerable to oxidative stress.
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3.4.7 Conclusion
The microarray analysis of the IGT/6 line demonstrates increased expression of genes
that mediate catabolism of glucose, de novo fatty acid synthesis and conversion to
triglycerides. Those animals that develop NASH appear to have compromised hepatic
VLDL export associated with compensatory increases in ~-oxidation and particularly
w-oxidation which will generate oxidative stress and lipid peroxidation. Thus, IGT/6-
NASH animals accumulate lipid within the hepatic parenchyma and progress to
steatohepatitis.
The character of insulin resistance and NAFLD as complex disease traits is further
established by these data which demonstrate how multiple small changes in gene
expression in complementary pathways combine to promote the disease phenotype.
The conclusions of this study are consistent with the current literature describing the
pathogenesis ofNAFLD, indeed many of the same pathways are affected in IGT/6 as
have been shown to be affected in both the human disease and other models. In
addition, these studies have led us to identify several genes (and gene products) that
appear to be important in the pathogenesis of NAFLD and its progression from
steatosis to steatohepatitis. It may be that some of these shed light on the true nature of
an intrinsic 'second hit' that allows disease progression.
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SECTION 4:
4.1 Background
DIFFERENTIAL RESPONSE OF INBRED MOUSE
STRAINS TO HIGH FAT DIET
4.1.1 Aetiological Relevance of Diet to NAFLD
Changes in diet, towards a high fat and high calorific intake, are a major contributing
factor to the worldwide epidemic ofobesity, type 2 diabetes and NAFLD (section 1.4).
It has been recognised by the scientific community for some time that the rise of
obesity as a medical problem has coincided with a shift towards eating larger portions
ofhigh fat foods290. More recently, the effects of increasing portion size and a sustained
high fat, high calorie diet have gained greater media attention. This has led to the
production of films such as Morgan Spurlock's "Super-Size Me" (2004), depicting the
effects of consuming solely fast-food for a period of 30 days. Underlining the topicality
of this research, at the time of writing, the BBC is reporting political concern
(http://news.bbc.co.uk/l/hi/uk_politics/4941878.stm) over the health implications
of sale of a "Bigger Big Mac'"''' by the McDonald's Restaurant chain that contains
apprOXimately 30% more calories and saturated fat than their normal product.
4.1.2 The Effect of Genetic Background on Disease Susceptibility
The impact that adopting a high fat diet has upon phenotype varies markedly
according to genetic background. This is exemplified by racial differences in the
penetrance of diabetes and obesity and lead to the concept of a 'thrifty genotype' being
proposed291 • The development of obesity and elements of the metabolic syndrome,
including NAFLD, are the product of a complex interaction between genetic factors
and environment62. Thus, genetic effects may be influenced by metabolic rate, exercise,
food intake and culture60.
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Subtle genetic variations between inbred strains of mice can affect the expression of
many complex traits24. The capacity for different genetic backgrounds to significantly
influence the phenotypic response of mice has been established in studies examining
dietary modification292, 293, naturally occurring mutations206, 207 and targeted induced
mutations208. In the preceding sections a model of NAFLD was sought by randomly
inducing subtle mutations whilst maintaining a stable genetic background and
standard environment. The background strain was found to exert a modifier effect on
the IGT/6 phenotype. This was exemplified by the observations that only male
animals were found to exhibit the impaired glucose tolerance phenotype and that the
C57BL/6 background appeared to be more permissive to impaired glucose tolerance
than either C3H or 129S6/SvEv (section 2.5.3.2). Whilst the effects of sustained
consumption of an elevated fat content diet (HFD) on inbred mouse strains are
reported elsewhere294, much of this literature is primarily concerned with changes in
insulin sensitivity, glucose tolerance and obesity rather than hepatic fat accumulation
and steatohepatitis. The only comprehensive study describing changes in liver
histology is part of the Mouse Phenome Database (http//:www.jax.org/phenome)295.
However, this study reports the effects of a relatively short, 8 week, period of exposure
to an 'atherogenic' 15% fat diet that may be insufficient to generate steatohepatitis.
4.1.3 Aims & Objectives
The aIm of this study was to determine how modifiers within standard genetic
backgrounds affect the response of inbred strains ofmice to prolonged consumption of
a high fat diet. Specifically, to determine whether inbred strains of mice differ in their
capacity to develop or resist dietary induced NAFLD and the associated features of the
metabolic syndrome. Strains were sought which exhibited a genetically determined
increased sensitivity to dietary induced NAFLD or a genetically determined resistance
to dietary induced NAFLD.
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4.2 Methods
This research was initially carried out as part of a collaborative effort with Drs D.
Gaugier and A. Toye of the BAIR ('Biological Atlas of Insulin Resistance') consortium.
The animals studied in the preliminary histology experiments were part this wider
study into the effects of a very high fat diet on insulin resistance, only histological data
is presented. To further investigate the effects of high fat diet and to determine
whether these histological findings could be replicated in a second cohort of mice, the
experiment was repeated outside this collaboration using animals housed at MRC
Harwell.
4.2.1 Conduct of the Study
4.2.1.1 Animal Husbandry & Selection of Strains for Testing
All research using live animals was approved by the local ethics committee and was
carried out under Home Office supervision in accordance with the Animal (Scientific
Procedures) Act 1986 taking care to minimise any distress caused to the animal.
To determine how different strains of mouse differ in their sensitivity to dietary
induced steatosis and steatohepatitis, mice from 4 inbred strains were selected for
study. The four strains selected for study were: C57BL/6], BALB/c, C3H and
129S6/Sv. Animals were housed under standard conditions (12 hour light/dark cycle,
temperature 21 + 2°C, humidity 55 + 10%). From weaning, all animals were given
access to a standard commercial diet and drinking water ad libitum. This diet was
maintained until the animals were randomised into the study at 6 weeks of age. Full
details of the collaborative elements of this work and the independent studies are
provided below.
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4.2.1.2 BAIR Collaborative Studies
The animals for this study were sourced and housed at the]ohn Radcliff Infirmary,
Oxford, UK. The specific animals studied were from lines that had been maintained at
this facility for some time by inbreeding and so may be considered sub-strains
(C57BL/6]Oxjr, BALB/cOxjr, C3H/Oxjr and 129S6/SvEvOxjr) due to the potential
for genetic drift.
---------+
I Age 6 weeks I
Randomise<!
to study group
C3H
BALBfc
129S6fSv
C57BU6J
Figure 48: Time Line for the BAIR HFD Study
All animals were fed the standard (control) chow from weaning to age 6 weeks. At 6 weeks
animals were randomised to either remain on the standard diet or to receive the HFD for the
rest of the study. Animals were culled at 5 months. In addition, cohorts of BALB/c and
I 29S6/Sv mice were aged to 7 months.
From the age of 6 weeks, male mice were randomised to receive either a nutritionally
replete, pelleted, very high fat diet (approximately 67.8 kcal% from fat; 40% fat by
weight as 32% lard & 8% corn oil, SDS, UK) or to remain on a standard pelleted chow
containing "'5 % fat (B&K Universal Ltd., UK). Details of the composition of the
diets are provided in Table 64. As can be seen in Figure 48, mice from all strains were
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culled at age 5 months (an extra time point at age 7 months was later generated for
some strains). Post mortem liver tissue was fixed in 10% formalin, processed into
paraffin wax and sections stained with Haematoxylin & Eosin. All sections were jointly
examined with a histopathologist (Dr R. Goldin) by light microscopy using the
NIDDK scoring system for NAFLD previously described in section 2.3.7.
4.2.1.3 Independent MRC Harwell Studies
The animals used in this study were sourced and housed at MRC Harwell. Procedures
were performed under the authority of Home Office licence 30/2161 'Genetics of
Diabetes & the Metabolic Syndrome'. As with the BAIR collaborative study, the
inbred lines studied had been maintained by inbreeding at MRC Harwell for up to 50
years and so may be considered sub-strains (C57BL/6], BALB/cAnNCd, C3H/HeH
and 129S6/Sv(NIMR)) due to the potential for genetic drift.
I Age 6 weeks I
Randomised
to stooy grovp
C57SLl6J
___1_29_S_G/_SV__-,1~ Start Diet
1
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---S-A-L-S-/c--- / / IAge 3 Monlt\s I IAge 5 Months I IAge 9 Months I
------- S'~ Animals
.,
' IPGTT IPGTT Sacrificed
C3H
Figure 49: Time Line for the MRC Harwell HFD Study
All animals were fed the standard (control) chow from weaning to age 6 weeks. At 6 weeks
animals were randomised to either remain on the standard diet or to receive the HFD for the
rest of the study. Animals were weighed regularly throughout the study, had IPGTTs
performed at age 3 and 5 months and were culled at age 9 months.
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The nutritionally replete pelleted high fat diet used in this study was of a less extreme
fat content than that previously used (45 kcal% from fat; 24% fat by weight as 21 %
lard & 3% soybean oil, Research Diets Inc, USA) but still represented a significantly
higher fat content than the standard control chow which contained", 4 % fat by
weight (SDS, UK). Details of the composition ofboth diets are provided in Table 64.
Mice had IPGTTs performed 6 and 14 weeks after randomisation (age 3 and 5
months) as described in section 2.3.5 and were weighed regularly during the
experiment to monitor changes in body weight. Animals were culled at age 36 weeks (9
months), liver was collected and preserved in 10% formalin, processed into paraffin
wax and sections stained with Haematoxylin & Eosin. All sections were jointly
examined with a histopathologist (Dr R Goldin) by light microscopy. Snap frozen
tissue was also collected and stored at -80°C as a resource for future studies.
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Table 64: Details of Control & High Fat Diets Used in this Study
Nutrients BAIR- BAIR- MRC- MRC-
Standard Diet High Fat Diet Standard Diet High Fat Diet
Diet Supplier (#) BK (BKOOI E) SDS (829146) SDS (No3 Breeding) RD (DI2451)
Crude Fat % 4.73 37.97 4.20 24.00
Crude Protein % 18.68 19.11 22.45 24.00
Crude Fibre % 3.48 3.30 4.42 5.82
Ash % 5.38 1.55 8.05
NFE % 59.73 28.06 50.40 46.18
Metabolisable Energy kcal/g (MJ/kg) 335 (14.00) 5.07 (21.20) 2.72 (12.22) 4.73 (19.78)
Energy from Fat %kcal -12% 67.8% 11.5% 45.0%
Fatty Acids
Monounsaturated % 39.80 33.00 45.20
Myristoleic (C 14: I) % 0.01 0.01 0.10
Palmitoleic (C 16: I) % 0.02 0.09 0.78
Oleic (CI8:1) % 10.97 1.01 9.21
Polyunsaturated % 21.30 46.20 18.50
Linoleic (C 18:2) % 2.04 5.69 1.26 3.33
Linolenic (C 18:3) % 0.18 0.18 0.17 0.43
Arachidonic (C20:4) % 0.12 0.35
Saturated % 38.90 20.80 36.30
Lauric (C 12:0) % 0.02 0.05
Myristic (C 14:0) % 0.49 0.17 0.19
Palmitic (C 16:0) % 7.17 037 5.03
Stearic (C 18:0) % 3.07 0.11 2.87
Amino Acids
Arginine % 0.61 1.42 0.71
Lysine % 1.10 1.22 1.34 1.56
Methionine % 0.33 0.48 0.37 0.60
Cystine % 0.37 0.35 0.50
Tryptophan % 0.17 0.27 0.25
Histidine % 0.44 0.55 0.54
Threonine % 0.66 0.88 0.85
Isoleucine % 0.97 0.98 0.89
Leucine % 1.47 1.87 1.87
Phenylalanine % 0.80 1.23 1.00
Valine % 1.16 1.15 1.10
Tyrosine % 0.80 0.87 1.08
Glycine % 0.76 1.85 0.35
Aspartic Acid % 1.09 1.40 1.43
Glutamic Acid % 3.15 4.39 4.50
Proline % 1.32 1.56 2.09
Serine % 0.72 1.01 1.18
Alanine % 0.27 0.60
Vitamins
Vitamin A iu/kg 14609.40 3771.10 22213.06 4661.20
Vitamin D iu/kg 1504.10 942.78 2948.01 1165.30
Vitamin E iu/kg 101.90 70.71 111.02 58.30
Vitamin BI (Thiamine) mg/kg 13.50 5.63 28.39 6.99
Vitamin B2 (Riboflavin) mg/kg 11.80 5.92 10.28 6.99
Vitamin B6 (Pyridoxine) mg/kg 14.40 6.56 18.87 8.16
Vitamin BI2 mcg/kg 31.50 23.57 19.23 11.65
Vitamin K (Menadione) mg/kg 16.00 0.68 4.14 0.58
Folic Acid mg/kg 2.80 1.86 2.99 2.33
Nicotinic Acid mg/kg 71.30 28.03 85.74 34.96
Pantothenate mg/kg 25.50 13.84 40.79 18.64
Choline mg/kg 1390.20 16404.37 1422.37 2330.59
Inositol mg/kg 1714.00 1839.97
Biotin mcg/kg 357.50 188.56 316.66 233.00
Minerals
Sodium % 0.22 0.12 0.24 0.12
Potassium % 0.69 0.49 0.81 0.70
Chloride % 0.44 0.64 0.36 0.19
Magnesium % 0.18 0.06 0.29 0.06
Calcium % 0.73 0.46 1.24 0.70
Total Phosphate % 0.70 0.21 0.83 0.35
Iron mg/kg 87.00 43.70 163.44 52.44
Copper mg/kg 18.30 6.79 20.53 6.99
Manganese mg/kg 86.90 10.25 102.71 68.75
Zinc mg/kg 92.50 57.08 48.67 33.79
Cobalt mcg/kg 456.80 604.44
Iodine mcg/kg 1840.80 194.68 867.77 233.06
Selenium mcg/kg 391.80 138.59 388.94 186.45
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4.3 Results
4.3.1 Liver Histology
As the cohort sizes for the original collaborative studies were larger, these histology
results are presented in the tables below. Overall, there was good agreement between
the results of the two studies, any differences noted when the second cohort of animals
was tested at MRC Harwell are also reported.
4.3.1.1 C57BU6
Livers from 7 high fat fed mice and 10 control mice were examined (Table 65).
C57BL/6 mice were shown to develop moderate/severe steatosis when fed a high fat
diet but no evidence of inflammation or ballooning was observed by 5 months ofage.
Table 65: Histology for BAIR C57BL/6 Mice Fed Standard or High Fat Diet
Strain Age Control Diet --~ .[thror I NotesS F I B
------------
- --~ ---~-- ,._._._--
C57BL/6 5 months I 0 0 0 Normal
0 0 0 000 0 0 "
0 0 0 0 3 0 0 0 Steatosis in HFD group
0 0 0 0 3 0 0 0 "
0 0 0 0 I 3 0 0 0 "
0 0 0 0 3 0 0 0 "
0 0 0 0 I 0 0 0 "
0 0 0 0
0 0 0 0
0 0 0 0
The MRC cohort of animals also exhibited lone steatosis with no histological features
ofsteatohepatitis at age 9 months.
222
4.3.1.2 C3H
Livers from 6 high fat diet fed mice and 10 control mice were examined (Table 66).
C3H mice were found to develop only a mild steatosis when fed a very high fat diet for
5 months although some hepatocyte ballooning was seen in 2 out of 6 samples,
consistent with early steatohepatitis.
Table 66: Histology for BAIR C3H Mice Fed Standard or High Fat Diet
Strain Age Control Diet High Fat Diet l Notes
I
S F I B S F I B I
C3H 5 months 0 0 0 0 I 0 0 0 Zone 3, mixed steatosis
0 0 0 0 I 0 I I "
0 0 0 0 I 0 0 0 "
0 0 0 0 I 0 0 I "
0 0 0 0 0 I 0 0 No fatty liver disease
0 0 0 0 0 0 0 0 Normal
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
The second cohort of animals studied at MRC Harwell exhibited a similar phenotype.
By age 9 months, the high fat diet induced steatosis was more marked (steatosis scores
of 2 most frequently observed) than that seen in the BAIR cohort and two-thirds of
animals exhibited features ofa mild steatohepatitis.
4.3.1.3 BALB/c
Livers from 5 high fat diet fed mice and 5 standard diet fed animals were examined
from animals culled at 5 months of age (Table 67). No evidence of NAFLD was
observed in either group. To determine if BALBlc mice were resistant to dietary
induced steatosis after prolonged exposure further samples were collected from mice
fed HFD to approximately 7 months. These also showed no evidence of steatosis
suggesting that the BALBIc line is resistant to dietary induced NAFLD. These
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findings were replicated in the second cohort of mice studied at MRC Harwell where
again no high fat diet induced steatosis could be identified at age 9 months.
Table 67: Histology for BAIR BALB/c Mice Fed Standard or High Fat Diet
Strain Age Control Diet ! High Fat Diet I Notes
S F I B ,S F I B
~----~. .. ._-~~ I ~o NAFLD seen ,. __ .... -_ ...-BALB/c 5 months 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 i "
:
0 0 0 0 0 0 0 0 "
0 0 0 0 0 0 0 0 "
"
••__....,....".··........4
BALB/c 7 months 0 0 0 0
0 0 0 0 "
0 0 0 0 "I
0 0 0 0 "
0 0 0 0 "
0 0 0 0 "
-
._---
4.3.1.4 129S6/SvEv
10 high fat fed mice and 8 standard chow fed mice were culled at 5 months of age
(Table 68). All high fat fed animals had evidence of moderate/severe steatosis with
inflammation and ballooning seen in some mice. Two animals fed standard chow were
also found to have evidence of mild spontaneous steatosis. A further cohort of mice
was aged to 7 months to see if the NAFLD would progress in this line. Out of 8 high
fat fed animals, 7 were found to have severe mixed microvesicular and macrovesicular
steatosis associated with widespread hepatocyte ballooning degeneration and a necro-
inflammatory infiltrate. Several of the chow fed 129S6/SvEv animals had developed a
mild steatosis with some ballooning degeneration seen.
The MRC Harwell cohort of 129S6/Sv(NIMR) mice yielded similar results after 9
months high fat diet when the experiment was repeated although the inflammatory
infiltrate was more severe in the original study (necro-inflammatory scores of 1 rather
than 1-3 in the initial study).
Table 68: Histology for BAIR I 29S6/SvEv Mice Fed Standard or High Fat Diet
Strain Age Control Diet High Fat Diet Notes
S F I B S F I B
I29SvEv 5 months 0 0 0 0 3 0 0 I Zone 3, microvesicular steatosis
0 0 0 0 2 0 0 0 "
0 0 0 0 3 0 0 0 "
0 0 0 0 2 0 I 0 "
0 0 0 0 3 0 0 0 "
I 0 0 0 3 0 I I "
0 0 0 0 3 0 0 0 "
I 0 0 0 I 0 0 0 "
I 0 0 0 "
3 0 I 2 "
I29SvEv 7 months I 0 0 0 2 0 0 0 Severe, mixed steatosis & NASH
I 0 0 I 2 0 2 2 "
I 0 0 I 2 0 I I "
0 0 0 0 3 0 I 2 "
0 0 0 0 2 0 0 I "
I 0 0 I 3 0 3 2 "
0 0 0 0 2 0 I I "
I 0 0 0 3 0 I 2 "
0 0 0 0
Figure 50 shows representative images from a 129S6/SvEvOxjr mouse fed high fat diet
and culled at age 7 n1onths. These images highlight the extent of the steatosis observed
and also the widespread ballooning hepatocyte degeneration that was found.
Figure 50: Liver Histology Images from High Fat Fed I 29S6/SvEv Mice
A lOx objective image of H&E stained liver tissue from a high fat fed I29S6/SvEv mouse culled
at age 7 months showing widespread macrovesicular steatosis.
B 30 x objective image from a high fat fed I29S6/SvEv mouse culled at age 7 months showing
macrovesicular steatosis and multiple cells with ballooning hepatocyte degeneration.
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4.3.2 Glucose Tolerance
In the MRC Harwell study, glucose tolerance data was collected on control and HFD
fed mice 6 and 14 weeks after randomisation (age 3 and 5 months). Due to the small
study group sizes (n = 5-12 in each arm) this study was only powered to detect
relatively large changes in glucose tolerance. By age 3 months (6 weeks after
randomisation) no significant difference in glucose tolerance was detected amongst the
4 strains of the chow fed mice (ANOVA p=0.223). There were significant differences
in glucose tolerance between the HFD fed mice (ANOVA p<O.OOl). Of the HFD fed
animals, C3H mice had significantly higher t=120 minute glucose levels than any
other strain (Figure 51A) indicating significant glucose intolerance compared to chow
fed littermates (mean blood glucose 13.91 vs. 9.99 mmolll, p=O.Ol).
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Figure 51: Effect of HFD on Glucose Tolerance of Inbred Strains of Mice
Graphs show t= 120 minute glucose tolerance test results taken 6 (A) and 14 (B) weeks after
mice were randomised to control or HFD (n = 5-12 in each study group).
By age 5 months (14 weeks after randomisation), the HFD fed mice showed a trend
towards greater t= 120 minute blood glucose levels than chow fed littermates although
this did not reach statistical significance. HFD fed BALBIc mice showed the smallest
change in t= 120 minute blood sugar levels over chow fed littermates.
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Table 69: Effect of Diet on Body Weight by Strain
Strain Weight at Mean Weight at 3 Months (SEM) Mean Weight at 5 Months (SEM) Mean Weight at 7 Months (SEM)
Start (SEM)
Diet Control Control HFD p-value* Control HFD p-value* Control HFD p-value*
C57BU6J 22.56 (0.32) 26.48 (0.62) 26.90 (0.32) 0.560 28.99 (0.42) 32.18 (0.83) 0.003 29.64 (0.78) 35.21 (1.16) 0.003
BALB/c 23.41 (0.36) 25.05 (1.68) 23.45 (0.37) 0.443 27.12 (0.54) 27.80 (0.63) 0.453 27.56 (0.65) 31.73 (0.88) 0.008
129S6/Sv(NIMR) 24.42 (0.33) 21.06 (0.94) 26.41 (0.71) 0.004 29.52 (0.31) 31.03 (1.05) 0.194 30.92 (0.72) 36.48 (2.12) 0.03
C3H 25.32 (0.30) 30.29 (0.69) 39.08 (0.74) 0.012 35.39 (1.49) 43.96 (0.58) <0.001 36.58 (3.30) 49.1 1 (0.60) 0.012
* n = 5-12 mice per study group.
4.3.3 Body Weight
Body weight data are presented in Table 69 and Figure 52. With the exception of
BALBIc mice (which initially lost weight on HFD), throughout the study high fat diet
fed mice were found to have greater mean body weights than control diet fed
littermates. Of the control diet fed animals, C3H mice maintained the highest body
weights of any strain. C3H animals gained weight most rapidly on the HFD. At age 3
months (6 weeks after randomisation), high fat fed C3H mice were significantly
heavier than control diet fed littermates (39.1 vs. 30.3g, p<O.OOl). 129S6ISv(NIMR)
mice had the lowest body weight in the control chow group but had a significantly
increased body weight on the HFD (26.4 vs. 21.1g, p=O.04). High fat fed C57BL/6
and BALB/c mice did not have increased body weight over control at this time point
(Figure 52A).
Over the subsequent months BALBIc mice appeared to be least sensitive to dietary
induced obesity, gaining an average of only 4g more than control fed animals. In
contrast, C3H mice were the most sensitive, gaining 12.5g more than controls. High
fat fed C57BL/6] and 129S6ISv(NIMR) animals both gained an average of 5.6g more
than chow fed littermates (Table 69). The BALB/c strain did not achieve a significant
increase in body weight over control until age 7 months (22 weeks after
randomisation) .
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Figure 52: Effect of HFD on Body Weight of Inbred Strains of Mice
Body weight at 3 (A), 5 (8) and 7 (C) months of age are shown for each strain and diet.
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4.4 Discussion
The current work demonstrates that there are significant differences in the response to
HFD among the four inbred strains of mice studied. The results obtained from the
two cohorts of animals housed in different facilities correlated well. In terms of
changes in hepatic histology, 129S6/Sv mice and C3H mice developed features
consistent with steatohepatitis whilst C57BL/6J mice developed only simple steatosis
and BALB/c mice were completely resistant to the development of NAFLD. These
changes were paralleled by changes in body weight and glucose tolerance with the
greatest increases being seen in C3H, 129 and C57BL/6 respectively whilst BALB/c
gained least weight and maintained the best glucose tolerance during the course of the
study.
As reviewed in section 2.1.1.4 on page 43 and in the background to this section (4.1.2),
to date, several studies have demonstrated that a high fat diet is able to induce steatosis
in selected inbred strains of mice. In agreement with many of these studies135. 136, the
data presented here demonstrates that C57BL/6J mice develop diet induced steatosis
but do not progress to steatohepatitis, even after 9 months consuming 45% of their
calorific intake from fat. Given the previous publications describing how susceptible
the C57BL/6line is to obesity and diabetes, it is perhaps surprising that these mice did
not exhibit a more severe glucose intolerant or increased body weight phenotype in the
current study. This may be partially explained by reports that C57BL/6J mice exhibit a
heterogeneous metabolic adaptation to prolonged HFD feeding with only 50%
developing the classic obese/diabetic phenotype and up to 20% retaining a lean
phenotype296•
C3H and especially 129S6/Sv animals are shown to be highly sensitive to dietary
induced NAFLD - both serving as potential models for this disease. Whilst both
strains exhibit histological features of spontaneous steatohepatitis associated with
significant weight gain and impaired glucose tolerance, exposure to the very high fat
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diet used in the BAIR study appeared to precipitate a more florid steatohepatitis in
129S6/Sv mice than exposure to the 45%kcal fat diet used at MRC Harwell. In
contrast, the histological steatohepatitis observed in the C3H animals was more severe
in the MRC Harwell study. C3H animals were only examined at the 5 month point in
the collaborative studies with the BAIR consortium when, as the 129S6/Sv mice were
shown to have a more florid steatohepatitis, they were not selected for extended high
fat feeding. It may be that by 7 months they would have progressed to a similarly florid
steatohepatitis to that seen in the MRC study. Whilst the 'BAIR-High Fat Diet'
derived a greater proportion of its calories from fat than the 'MRC-High Fat Diet'
(67.8% vs. 45.0% respectively), both diets were broadly similar in composition in terms
of the proportion ofsaturated and mono- or poly-unsaturated fats contained (Table 64
on page 221). The BAIR diet did however contain considerably more choline than
either the 'MRC-High Fat Diet' (16,404 vs. 2,330 mg/kg respectively) or any of the
control chows. It is not clear whether the differences in choline content made any real
contribution to the differences in the severity of NASH in 129 and C3H mice in the
two arms of the study. Whilst, a choline deficient diet is associated with histological
steatosis1S1, there is no data reporting adverse effects of supra-normal doses of choline
on hepatic lipid metabolism297• An alternative explanation is that the differences may
be due to genetic drift producing subtle differences between the sub-strains of animals
housed at the two facilities. In this respect, the 129 strain is considered to be
particularly heterogeneous, making the presence ofgenetic differences likeli98, 299. This
may also explain why other investigators have not been able to demonstrate a
spontaneous mild NAFLD in chow fed 129 mice as described in the present study13s.
A novel observation in this study is that the BALBIc strain is resistant to dietary
induced obesity, impaired glucose tolerance and NAFLD. Thus, BALB/c provides a
useful comparator for the dietary NAFLD models. This is of significance as better
understanding of the mechanisms of effective physiological compensation that allow
BALBIc to avoid NAFLD are likely to inform future research into novel therapeutic
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targets. I am a co-author of the manuscript, currently in preparation, that describes the
comparative phenotypic, gene expression and MRI spectroscopy analysis of the
129S6/SvEvOxjr and BALB/cOxjr strains (Toye et aI, in preparation, 2006).
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SECTION 5:
5.1 Background
GENETIC MODIFIERS OF HEPATIC FIBROSIS
5.1.1 Factors determining Progression of Hepatic Fibrosis
The development of hepatic fibrosis following chronic liver injury, irrespective of
aetiology, is a complex genetic trait that may be influenced by the interaction between
host genetic factors, the pathogen and other coincidental environmental influences. In
man these effects are best described and understood in chronic hepatitis C (HCV)
where large cross-sectional studies have been used to determine the natural history of
the disease.
Cross-sectional studies in European patients with chronic HCV infection have
determined a number of host factors that influence the rate of disease progression to
cirrhosis12, 300. The median time from infection to cirrhosis in these studies was 30-35
years (Figure 53).
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Figure 53: Natural History of Chronic Hepatitis C Infection
The median time from infection to cirrhosis is 30-35 years l2, 300. Subsequently, disease
progresses to hepatic decompensation (4-9.5% per annum) or Hepatocellular carcinoma (1.4-
5% per annum). Annual transition form cirrhosis to death or transplant is 2-6%301-304.
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Male gender, greater age at tlme of infection and higher alcohol consumptIOn
(>50g/day) have consistently been highlighted as determinants of accelerated fibrosis
progression 12.13. However, these factors only account for a small fraction (17-29%) of
the inter-patient variability that is observed in clinical practice lO. 12. As discussed in the
Introduction, patient cohort studies have also identified a number of additional
genetic and environmental cofactors that influence the rate of hepatic fibrogenesis
(Table 1, page 19). These include steatosis42 and carriage ofpro-thrombotic mutations
including Factor V Leiden (FvL)9.1O.30S.306.
5.1.2 Procoagulant States and Accelerated Liver Fibrosis in Man
Observations that carbon tetrachloride induced liver injury was associated with hepatic
deposition of fibrin and fibrinogen307 and that the presence of thrombi within the
hepatic micro-vasculature were associated with cirrhosis308, 309 led to epidemiological
studies examining whether prothrombotic risk factors were associated with accelerated
hepatic fibrosis. Using a cohort of Greek patients with hepatitis B and hepatitis C,
Papatheodoridis et al demonstrated that patients with advanced fibrosis (Ishak31O stage
4-6) were significantly more likely to have deficiency of protein C, antithrombin III
and plasminogen30s. This association was reinforced when the HENCORE
collaboration published data demonstrating that that heterozygote carriage of the
Factor V Leiden mutation was associated with an odds ratio of 3.28 for rapid
progression to cirrhosis in a European Caucasian HCV population lO• Subsequently,
this observation was repeated in a separate patient population9 and protein C
deficiency, increased expression of factor VIII and hyperhomocysteinaemia were also
linked to advanced HCV fibrosis306.
Whilst there is considerable epidemiological data supporting this association, the role
played by pro-thrombotic mutations in determining the rate of hepatic fibrosis has not
yet been confirmed in a controlled laboratory environment.
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5.1.3 The Factor V Leiden Mutation
The Factor V gene maps to chromosome lq23 in man and is composed of 25 exons
encoding a 6 domain, 2224 amino acid precursor protein311 • FV has little intrinsic
procoagulant activity until activated by thrombin or FXa mediated proteolytic
cleavage at three arginine residues (Arg709, Argl018 and Arg1545). Cleavage and
removal of the B domain leaves the active two-chain peptide (FVa), see Figure 54311 •
FVa is an essential cofactor within the final common pathway of the coagulation
cascade. Factor V and Factor X form the prothrombinase complex that converts
prothrombin to thrombin (Figure 55). Thrombin catalyses the conversion of
fibrinogen to fibrin allowing clot formation and activates both positive and negative
feedback loops to regulate its own activation. The latter, negative regulation is
mediated by activation of Protein C (APC) which then inactivates Factor V by
cleavage at the Arg506 primary cleavage site312, 313.
Thrombin 1FXa APCr----.,;~.....;;,;.;.~..;..;,,;,..-__l Precursor FV ...------------,
Arg709/1018/1545 Arg506
Procoagulant
FYa
APC
....••...•...••.•.~
Arg506
Partial
Procoagulant ~.T~.r5:l!1.~j!1.~.I:~?_. Anticoagulant
FVainl Arg709/101811545 FVac
APC + PS
•...•.........•....•••.••••~
Arg306
00:(0Q..: o
+ ,C')
0'0)o..:~
.... _.~t .
Inactive
FVi
Thrombin / FXa
~ .....••.•• _ .
Arg1545
Figure 54: Activation of Factor V by Proteolytic Cleavage
Factor V has both pro-coagulant and anti-coagulant activity. Cleavage at Arg709, Arg 1018 and
Arg 1545 activates FV to its procoagulant form. This activity is terminated by cleavage at the
Arg506 primary cleavage site and at two secondary sites (Arg306 and Arg679). Anticoagulant
FV activity is activated by cleavage at the Arg506 site and terminated by cleavage at Arg709,
ArglOl8 and Arg1545. (Modified from 311. APC, Activated Protein C; PS, Protein S).
235
HK
PK
XII~
INTRINSIC PATHWAY
Xlia -.@
XI ~ Xl8
EXTRINSIC PATHWAY
VASCULAR
INJURY
~
IX ~
"
VII -.@IX. Vila
..~ ~rn w(i)'- ~~ Vila"'0
X
'" "
X8 X
w
~ Fvl
ZXiii~ e<t>'- ~~ Va'" --------------------
Iro
~o
o
Ir
lL
PROTHROMBIN
(n)
THROMBIN
(lIa)
__TM_--1~~0
Figure 55: Thrombin, Factor V Leiden and the Coagulation Cascade
The Intrinsic and Extrinsic coagulation cascades unite to form a final common pathway
mediated by the activity of factors II (Thrombin), V and X which enables fibrin clot formation.
Thrombin is able to regulate its own generation both via positive feed-back activation of other
factors within the cascade (red arrows) and negative feed-back via activated protein C (APC,
dotted arrow). The FvL mutation renders factor V resistant to APC degradation. Synthesis of
the Vitamin K dependent clotting factors (II, VII, IX and X) is inhibited by warfarin. (TF, Tissue
factor; TM, Thrombomodulin)
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The common FvL mutation (affecting 2-7% of the Caucasian population) causes an
amino acid change from Arginine to Glutamine in codon 506. This abolishes the
primary APC cleavage site, leaves pro-coagulant FVa activity unchecked and hence
confers a procoagulant tendency. The presence of the FvL allele increases the risk of
venous thrombosis 5-7 fold in heterozygotes and 80 fold in homozygotes311 .
Transgenic mice with a phenotype identical to human FvL have been generated using
site directed mutagenesis and are maintained on a congenic C57BL/6 background
(Strain B6.129S2-F5tm2Dgi/J, Jackson Laboratory, USA)314. The ~R504Qmutation
carried by these mice is homologous to the human mutation.
5.1.4 Aims & Objectives
The aim of these studies was to examIne the capacity of increased or decreased
thrombin generation and coagulation status to affect hepatic fibrogenesis. Three areas
were to be studied:
1. The biological impact of carriage of the FvL mutation (as an exemplar of pro-
thrombotic tendency) on the progression of chemically induced hepatic
fibrosis was determined.
2. The effect of anticoagulation with warfarin on the progression of hepatic
fibrosis in C57BL/6 and FvL mutant mice was determined.
3. The effect of direct thrombin inhibition by Ximelagatran (Astra-Zenica, UK)
on the progression of hepatic fibrosis in C57BL/6 and FvL mutant mice was
determined.
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5.2 Methods
5.2.1 Establishment of a Breeding Colony of Factor V Leiden Mutant Mice
All research using live animals was approved by the local ethics committee and was
carried out in accordance with the Animal (Scientific Procedures) Act 1986.
Procedures were performed under the authority of animal licence 70/SS62 "Factors
Affecting the Development of Liver Fibrosis". Throughout the experiment care was
taken to minimise any distress caused to the animals. Animals were housed under
standard conditions (12 hour light/dark cycle, temperature 21 + 2°C, humidity SS +
10%) in a specific pathogen free facility and provided with a standard diet and access to
drinking water ad libitum.
Three pairs ofFvL mutant mice (congenic strain B6.129S2-FStm2Dgi/J maintained on a
CS7BL/6J background) were purchased from the Jackson Laboratory, USA and a
breeding colony established to provide animals for this study. All animals used in this
study were generated by intercrossing mutant animals and so were obligate
homozygote mutants.
5.2.2 Confirmation of Carriage of the FvL Mutation
Homozygous carriage of the FvL mutation was confirmed by genotyping the original
founder animals, a random sample of their offspring and wildtype CS7BL/6 control
mice using a polymerase chain reaction (PCR) technique.
The ~RS04Qmutation in exon 10 is separated by only 400 base pairs from a loxP site
introduced into intron 10 as part of the original targeting vector. Two primers,
oIMR1482 (S'-CCTCTGGACTCTGACTGCAG-3') and oIMR1483 (S'-
TATTCTGGACTACAAGAGTGAG-3'), flank the 139 base pair insertion
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containing the loxP site and amplify fragments of 400 base pairs from wild type and
540 base pairs from FvL mutant mice314•
As previously described in section 2.3.10, DNA was extracted from tail tip biopsies
and/or tissue from ear punches using a commercially available kit (DNeasy, Qiagen,
USA). The DNA was then quantified and checked for purity by measuring light
absorbance at 260/280nm (with background correction at 320nm) in a Beckman DU-
600 spectrophotometer (Beckman-Coulter Inc., USA). DNA was diluted to a
standard working concentration of5ng/p.1.
Primers were synthesized to order by Sigma Genosys, UK. PCR reactIons were
prepared using GeneAmp PCR reagents and AmpliTaq Gold DNA Polymerase
(Applied Biosystems Inc, USA). Optimization of the PCR reaction was performed
using a range of temperatures and magnesium concentrations. The following PCR
reagent mixture was determined to provide optimum amplification (Table 70). The
'RH55' PCR cycle was programmed as described in Table 8 on page 66.
Table 70: Optimised Reagent Mixture for olMRI482 and olMRI483 primers.
Reagent
DNA (5nghll)
dNTP (lOx, 1.25mM)
MgCI2 (25mM)
PCR Buffer* (lOx)
AmpliTaq Gold (5 U/IJI)
Primers olMR 1482 & olMR 1483 (2IJM)
Nuclease-free Water
Total Volume
Volume per Reaction (1-11)
3.0
2.5
2.5
2.5
0.1
0.05 each
14.3
25.0
Final Concentration
0.6 ng/lJl
0.125 mM
2.5 mM
Ix
0.02 U/IJI
0.004 IJM
* lOx PCR Buffer contains 100 mM Tris-HCI, pH 8.3; 500 mM KCI; 15 mM MgCI2; 0.1 % w/v Gelatin.
Electrophoresis ofPCR products was performed on a 2% Agarose gel (100mllx TAE
buffer to 2g Agarose and 4p.l Ethidium bromide). A 100 base pair DNA ladder was
loaded into the first and last well of the gel to measure DNA fragment sizes. Five
microlitres of the PCR product and 1p.l ofxylene orange loading dye were loaded into
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each well. The gel was run at a constant potential difference of 100 volts (maximum
amps) for 45 minutes at room temperature after which the migration of the PCR
product was determined using ultraviolet light and a photograph of the gel taken. The
fragment sizes were determined by comparison to the DNA ladder to determine the
genotype of the animals.
5.2.3 Carbon Tetrachloride & Warfarin Exposure
Male and female homozygote FvL mutant mice derived from the breeding colony and
C57BL/6 control animals purchased from designated supplier (Harlan, UK) aged
between 6-8 weeks were used in this study. Animals were housed under standard
conditions (12 hour light/dark cycle, temperature 21 + 2°C, humidity 55 + 10%) and
provided with a standard diet and access to drinking water ad libitum.
Mice were treated with carbon tetrachloride (CC14) diluted in a corn oil vehicle and
administered by intraperitoneal injection on alternate week days. The dose of CC14
administered was increased weekly in a stepwise fashion. A maximum dose of 1 ml
CC14 per kg body weight was reached after 3 weeks (Figure 56A). Subgroups of
C57BL/6 and FvL mice were anticoagulated by the addition of warfarin to the
drinking water. A warfarin dose of 1 !lg/ml was chosen as pilot studies have indicated
that this apprOXimately doubles the whole blood clotting time but minimises
spontaneous adverse events (Dr M. Thursz, personal communication).
As summarised in Figure 56B, animals from each experimental group were culled at
the start of the experiment and after two and four weeks (n~ 10 mice per group at each
time point) by intraperitoneal injection of O.lml Pentoject (Pentobarbitone Sodium
Ph.Eur. 200mg/ml, Animal Care Ltd., UK) followed by cervical dislocation. Liver
tissue was collected and preserved in 10% formalin for histological examination or
snap frozen in liquid nitrogen and stored at -80°C as a resource for subsequent RNA
and protein analysis.
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Figure 56: Design of Carbon Tetrachloride Exposure Experiment
A The dose of carbon tetrachloride was increased from O.125ml/kg body weight to a
maximum of I ml/kg over a three week period and then maintained at the maximal dose
throughout the rest of the study.
B Schematic representation of animal study showing the two strains of mice and the two
treatment groups that were analysed. Mice from each group were culled 2 and 4 weeks after
the study commenced. (n~ I0 mice per group at each time point).
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5.2.4 Carbon Tetrachloride & Ximelagatran Exposure
The influence of anticoagulation on fibrogenesis was confirmed in a second study. In
light of the effects of warfarin on the progression of hepatic fibrosis, I hypothesised
that the direct thrombin inhibitor Ximelagatran (Astra-Zenica, UK) would reduce the
development ofcarbon tetrachloride induced hepatic fibrosis. The experimental design
was similar to that described in section 5.2.3 except that the dose of carbon
tetrachloride was not increased in the 4th week but instead was maintained at O.smg/kg
until the end of the experiment. Only male animals were used. Ximelagatran was
administered as a specially prepared mouse chow (estimated dose 300mM / kg body
weight per day; a kind gift from Astra-Zenica) instead of warfarin. Blood levels of the
active metabolite, Melagatran, were checked in a cohort of animals after 2 weeks
treatment to confirm drug dosing was sufficient.
5.2.5 Histology
Tissue collected at each time point was fixed in 10% formal saline, processed into
paraffin wax and sections were stained with both Haematoxylin & Eosin and the
Chromotrope Aniline Blue (CAB) trichrome315 by experienced technicians at St
Mary's Hospital cellular pathology department.
All sections were jointly examined by light microscopy with a histopathologist (Dr R.
Goldin) blinded to the nature of the specimen. The extent of hepatic fibrosis observed
in each sample was assessed and a semi-quantitative score was used to record key
features in a manner analogous to the scoring of diagnostic specimens in patients with
chronic Hepatitis C. Unlike hepatitis C, where the fibrosis extends from the portal
veins, carbon tetrachloride is known to induce fibrosis extending from the central
veins316, 317. The (Ishak) Modified Histological Activity Index310 fibrosis score was
therefore adapted to accommodate these differences in the pattern of fibrosis
deposition (see Table 71).
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Table 71: Semi-Quantitative Histological Score for Liver Fibrosis
Score
o
2
3
4
5
6
Description
No fibrosis
Fibrous expansion (spurs) around some central veins
Fibrous expansion around >50% central veins
Fibrous expansion around most central veins plus some CV-to-CV bridging
Fibrous expansion around most central veins plus marked (>50%) CV-to-CV bridging
Marked bridging fibrosis plus some nodules
Cirrhosis (>50% nodularity)
5.2.6 Digital Image Analysis
Digital image analysis (DIA) allows semi-automated quantification of fibrous tissue
deposition within histological sections without the need to determine morphological
distribution.
Tissue collected at each time point was fixed in 10% formal saline, sections cut and
stained using the collagen specific stain Pico-Sirius Red318. 319. An average of 12 fields
(lOx objective) distributed throughout each section were randomly selected and digital
images captured using a Zeiss AxioVeft 200M microscope. Images were analysed using
AxioVision (Carl Zeiss, Germany) and AnalySIS (Soft Imaging System Inc, USA)
software. The mean percentage area of fibrosis for each section was calculated to
generate a measure offibrous tissue deposition.
5.2.7 Immunohistochemical Analysis
Expression of alpha-Smooth Muscle Actin (aSMA) is a sensitive marker of hepatic
stellate cell activation to a fibroblast-like phenotype therefore aSMA levels were
measured as an indicator of HSC activation. Formalin fixed tissue from a subset of the
male animals culled at the 4 week time point was immunohistochemically stained for
aSMA by technicians in St Mary's hospital histopathology department. The primary
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antibody was a mouse IgG2a isotype monoclonal antibody raised against a synthetic
decapeptide that has the same sequence as the NH2-terminal of alpha-Smooth Muscle
Actin (Clone lA4, Dako Inc, USA)320. This was then detected using a horse radish
peroxidise conjugated goat anti-mouse secondary antibody.
5.2.8 Total RNA Extraction from Liver Tissue
The effects of coagulation status were most marked in male animals culled at the 4
week time point and so this group was selected for further detailed analysis of stellate
cell activation, collagen deposition and gene induction.
Total RNA was extracted from snap frozen liver tissue (n =4-7 mice per group) using
an RNeasy Mini kit (Qiagen, USA). Care was taken throughout the procedure to
avoid any contamination of the samples. The method, as previously described in
section 3.2.2, followed the manufacturer's protocol. Extraction included a 15 minute
digestion with DNAse (Qiagen, USA) to ensure that the extracted total RNA was not
contaminated with genomic DNA.
The amount and quality of RNA extracted was assessed by measuring light absorbance
at 260/280nm in a Beckman DU-600 spectrophotometer (Beckman-Coulter Inc.,
USA) and assessing the rRNA 28s/18s concentration ratio using an Agilent 2100
Bioanalyser (Agilent Technologies, USA).
5.2.9 Reverse transcription for cDNA Synthesis
Based on the results of the Agilent 2100 Bioanalyser, total RNA was diluted to a
concentration of 0.15!lg/!l1 with nuclease free water (Ambion, USA). For each sample,
1.5!lg total RNA with a 28s/18s concentration ratio of 1.8-2.1 and no evidence of
DNA contamination or degradation was then reverse transcribed to cDNA using a
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commercially available kit (RETROscript, Ambion, USA). The method was as
described by the manufacturer, full details of the reagents are given in Appendix A.
Reactions were prepared in 200~ nuclease free PCR tubes. Briefly, 2fLi SOfLM random
sequence oligonucleotide decamers (first strand primers) were added to l.SfLg total
RNA in IOfLl nuclease free water and the mixture heated to 80°C for 3 minutes in a
DNA Engine tetrad thermal cycler (BioRad Inc., USA) to denature the RNA template
and remove any secondary structure which could impede the activity of the reverse
transcriptase. Reaction tubes were spun briefly and placed on ice. The remaining
reagents were then added (2fLllOx RT Buffer, 4fL12.5mM dNTP mixture, 10 units/lfLl
RNase inhibitor, 100 units/lfLl MMLV-RT) to a total volume of20fLi and the mixture
incubated at 43°C for 1 hour. The reverse transcriptase was then denatured by heating
to 92°C for 10 minutes. Samples were stored at -20°C until used in the rtPCR
reaction.
S.2.IO Quantification of Relative Gene Expression by rt-PCR
Quantitative peR analysis was performed using TaqMan Gene Expression Assay
reagents and primers (Applied Biosystems Inc, USA). Primers specific for Pro-collagen
type I and key mediators of tissue remodelling and collagen degradation, Tissue
Inhibitor ofMetalloproteinases 1,2 and 3 (TIMP-l, 2 and 3), were studied. Data were
normalised to the endogenous house-keeping gene Hypoxanthine Guanine
Phosphoribosyl Transferase (Hprtl). All primers were selected so that they amplified a
region that crossed an exon-exon boundary and so were robust to genomic DNA
contamination. Details of the primers are summarised in Table 73, further details of
the reagents and TaqMan Assay and validation are provided in Appendix A.
Three technical replicates of each sample were performed. Singleplex reactions were
performed. Twenty five nanograms of template eDNA were added to each PCR
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reaction and rate of template amplification was measured under standard conditions
using an iCycler Thermal Cycler (BioRad Inc, USA).
Table 72: TaqMan rt-PCR Cycling Conditions
Reaction Step Temp °C Time
Amperase UNG Activation 50°C 2 minutes
Initial activation step 95°C 10 minutes
Cycle (x45) Denature 95°C 15 seconds
Anneal/Extend 60°C 60 seconds
Data were normalised to Hprtl expression and analysed by the Comparative ~~CT
method239 to determine the fold change difference in expression between sample
groups relative to non-warfarin treated C57BL/6 control animals.
The efficiency of all the inventoried T aqMan Gene Expression assays used has been
determined over a six log range of dilutions by the manufacturer. They have
demonstrated that all assays have efficiencies approaching 100% (+ 10%) and so
routine validation of assay efficiency before using the ~~CT method of relative fold
change calculation is not necessary (ABI Technical Note #00113186, 2004
'Amplification Efficiency ofTaqMan Gene Expression Assays').
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Table 73: Fluorescently Labelled TaqMan Probes for FvL rtPCR
Gene Symbol Primer 10 Exons Context Sequence Label
Hypoxanthine guanine phosphoribosyl transferase I Hprtl Mm00446968 m I 6/7 AGGTTGCAAGCTTGCTGGTGAAAAG FAM
Pro-collagen type Ia Colla2 Mm00483888 m I 1/2 TAGCAACATGCCAATATTTGCAATC FAM
Tissue Inhibitor of Metalloprotinase-I TIMP-I Mm00441818 ml 1/2 CTGCAACTCGGACCTGGTCATAAGG FAM
Tissue Inhibitor of Metalloprotinase-2 TIMP-2 Mm00441825 m I 4/5 AGTGCAAGATCACTCGCTGTCCCAT FAM
Tissue Inhibitor of Metalloprotinase-3 TIMP-3 Mm00441826 ml 1/2 AACTCCGACATCGTGATCCGGGCCA FAM
• All primers cross an exon-exon boundary and so would not detect genomic DNA if contamination had occurred.
• Context sequence refers to the 25 base nucleotide sequence surrounding the probe i.e. including the targeted exons (data provided by Applied
Biosystems Inc., USA).
• All of the inventoried TaqMan Gene Expression assays used have efficiencies approaching 100% (± 10%) over a 6 log range of dilutions as determined
by the manufacturer.
5.2.1 I Comparative Western Blot Analysis of Alpha-Smooth Muscle Actin
(aSMA) Protein Expression
Protein was extracted from snap frozen liver tissue of male mice culled at the 4 week
time point (n = 4-7 mice per group). 50 ml ofLysis Buffer was prepared. Two hundred
milligrams of frozen liver tissue from each sample was homogenised in ",6x wIv lysis
buffer and left on ice to digest for 1 hour. The homogenate was centrifuged at 3,000
rpm for 15 minutes at 4°C any precipitate was discarded and the centrifugate solution
centrifuged again at 14,000 rpm for a further 1 hour at 4°C. The precipitate was
discarded and the protein solution retained. Protein concentration in the extract
solution was quantified using a commercial assay (DC Protein Assay, Bio-Rad
Laboratories, USA) by comparing optical absorbance at 750nm to bovine serum
albumin (BSA) standards ofknown concentration.
For each of the four study groups, pools containing 50flg protein were made up using
the available extracts. One microlitre of lOx ~-Mercaptoethanol was added to each
pool and the pooled samples were loaded onto a 4-12% NuPage Bis-Tris gel
(Invitrogen, USA) in an XCell Sure Lock Mini-Cell (Invitrogen, USA). A standard
graduated protein ladder was also loaded onto the gel (SeeBlue Plus2, Invitrogen,
USA). NuPage MOPS SDS Running Buffer was added to the cell and the gel was run
at a constant potential difference of 200 volts (maximum current) for 1 hour at room
temperature. The gel was removed and assembled into an XCell Blot Module and a
Western blot performed onto a nitrocellulose membrane (constant 30 volt potential
difference for 1 hour). The protein was then stained using a primary mouse
monoclonal antibody to aSMA (Clone 1A4, Dako Inc, USA)320 or a control mouse
monoclonal antibody to Actin. Chromogenic detection of bound antibody was
performed (Western Breeze, Invitrogen, USA). Consistent transfer ofprotein from gel
to membrane was confirmed by back-staining the gel. Images were captured using an
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HP4100C scanner (Hewlett Packard Inc., USA) and comparative quantification of
the aSMA protein band at 43kDa was performed using Image-J software321 •
5.2.12 Hydroxyproline
Collagen helices deposited within the liver during fibrogenesis are stabilised by
hydroxyproline. This amino acid is almost exclusively confined to collagenous
connective tissue and so may be used as a surrogate to quantify collagen deposition322•
The hydroxyproline content of snap frozen liver tissue from male mice culled at the 4
week time point (n = 4-7 mice per group) was determined using a colorimetric
technique323• 50mg of tissue was hydrolysed in 1.5ml of 6M HCl at 115°C for 18
hours. Samples were centrifuged at 8000g for 10 minutes. The pellet was discarded and
the centrifugate neutralised by addition of an equal volume of 6M NaOH. Samples
were tested in triplicate in a 96 well plate format. 40[l1 of the neutralised solution was
added to 5[l1 7% Chloramine T solution, 20[l1 Acetate/Citrate buffer (57g Sodium
acetate, 37.5g trisodium citrate, 5.5g citric acid, 385ml isopropanol to 1 litre with
dH20) and 150[l1 Ehrlich's solution (2g p-dimethylamino-benzaldehyde, 3ml
perchloric acid and 9ml isopropanol). The samples were incubated at 60°C for 35
minutes. Appropriate experimental blanks were also performed to allow absorbance
background correction. Absorbance was measured at 560nm and compared to
standards of known hydroxyproline concentration. Hydroxyproline content ([lg) was
calculated per gram ofliver tissue.
5.2.13 Malondialdehyde Assay as a Marker of Oxidative Stress
CCL induces tissue damage predominantly by the release of free radicals and reactive
oxygen species as it is metabolised by cytochrome P450324• Malondialdehyde (MDA)
and 4-hydroxyalkenals are end products derived from peroxidation of polyunsaturated
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fatty acids and related esters and therefore tissue oxidative stress is reflected by the
MDA content32S• To determine if warfarin interacts with CC14 metabolism and thus
limits its injurious effect, hepatic MDA content was measured. Liver tissue was
collected from cohorts of warfarin treated and non-warfarin treated mice culled 24
hours after their last CC14 exposure (n = 5 per group). A commercially available
colorimetric assay kit was used to measure tissue MDA content (Lipid Peroxidation
Assay Kit #437634, Calbiochem Inc., USA). Details of reagents are provided in
AppendixA.
For each sample, 100 mg of liver tissue was homogenised on ice in Tris-HCl, pH 7.4
with 5mM butylated hydroxytoluene. The total protein concentration of the
homogenate was measured using Bradford Reagent (Sigma, UK) in a 96-well format.
For each sample, 250[11 of Bradford reagent was added to 5[11 of tissue homogenate.
The solution was mixed gently on a shaker for IS minutes and then absorbance at
595nm measured in a spectrophotometer. Protein concentration was determined by
comparison to the absorbance spectra of known concentrations of Bovine Serum
Albumin (Sigma, UK) diluted in the same Tris-HCl based buffer as the protein
homogenate.
The chromophore for MDA detection was prepared by adding one volume of ferric
iron/methanol solution to three volumes of reagent Rl. 650[-tl of the Rl/ferric iron
mixture and 150[1112 N HCl were added to 200[11 of each sample homogenate (total
volume Iml). The sample was then incubated in a water bath at 45°C for 1 hour.
'Sample-Blank' (650[-tl 75% Acetonitrile/25% Water instead of Rl/ferric iron
mixture) and 'Reagent-Blank' (200[11 water instead of homogenised tissue) reactions
were also processed to allow absorbance background correction. A standard curve was
generated by processing serial dilutions of 20[1M 1,1,3,3-T etramethoxypropane
(TMOP), see Table 74.
2S0
Table 74: Dilutions of TMOP to Generate Standard Curve for MDA Assay
Target Concentration of Standard (f-LM)
Volume of 20f-LM Standard to Add (f-LI)
Volume of Buffer to Add (f-LI)
o
o
200
0.5
25
175
1.0
50
150
2.0
100
100
3.0
150
50
4.0
200
o
After cooling on ice, the samples were spun at 15,OOOg for 10 minutes to remove any
debris and the absorbance measured at 586nm in a spectrophotometer. Results are
shown as rtmoles MDA/mgprotein.
5.2.14 Statistical Analysis
Data were collated in Microsoft Excel (Microsoft Inc, USA) and statistical analysis
performed using SPSSv12 (SPSS, USA). Normally distributed continuous variables
were compared by Student's t-test or ANOVA; results are represented as mean
(+SEM). Ordinal and non-normally distributed variables were tested using the non-
parametric Mann-Whitney U or Kruskall-Wallis tests. Quantitative data are expressed
as mean + standard error of the mean (SEM) unless otherwise stated. Statistical
significance was accepted at p<O.05.
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5.3 Results
5.3.1 Animal Husbandry
Carriage of the homozygote FvL mutation was confirmed as described above (section
5.2.2) for all founder mutant animals. Early mortality was limited to warfarin treated
animals where death could be ascribed to haemorrhage soon after intraperitoneal
injection.
5.3.2 Histopathology & Digital Image Analysis
Representative histological images are shown in Figure 57. Histopathology and digital
image analysis (DIA) scores are presented in Table 75 with inter-group analysis
summarised in Table 76. Animals culled at the start of the experiment had no evidence
ofspontaneous hepatic fibrosis (histology score = 0).
Table 75: Effect of Carbon Tetrachloride Exposure on Histology & Digital Image
Analysis Scores for each Study Group
Histology Score (maximum 6) Mean Percentage Area Fibrosis (DIA)
s..
>.Q. ell 2 Weeks 4 Weeks 2 Weeks 4 Weeks
." :::s
."
:::s 0 c~ s.. ell Mean (SEM) n Mean (SEM) n Mean (SEM) n Mean (SEM) nV)C) C)
C57BU6 M 3.00 (0.45) 6 4.00 (0.26) 6 1.76 (0.2) 6 2.76 (0.09) 6
F 2.00 (0.32) 5 3.14 (0.14) 7 1.40 (0.29) 5 2.38 (0.37) 7
FvL M 4.11 (0.20) 9 4.86 (0.26) 7 3.18 (0.28) 9 4.47 (0.40) 7
F 2.78 (0.15) 9 4.15 (0.15) 13 2.97 (0.32) 9 4.14 (0.21 ) 13
C57BU6 + M 2.60 (0.4) 5 1.75 (0.25) 4 1.43 (0.11 ) 5 1.84 (0.27) 4
Warfarin F 2.40 (0.25) 5 2.88 (0.29) 8 1.89 (0.27) 5 2.11 (0.14) 8
FvL + M 3.83 (0.48) 6 4.57 (0.2) 7 2.68 (0.27) 6 3.82 (0.18) 6
Warfarin
F 3.40 (0.4) 5 4.17 (0.31 ) 6 2.92 (0.33) 5 3.70 (0.35) 6
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Figure 57: Representative Histological Images
Liver tissue sections were stained with CAB trichrome to delineate fibrosis which stains blue.
A, 8 & C Warfarin treated (A) and non-warfarin treated (8) C57BU6 mice after 2 weeks
CCI4 exposure. FvL mutant tissue (C) showing evidence of bridging fibrosis and early nodule
formation after 2 weeks CCI4 exposure. Original magnification x300.
0, E & F Tissue from a warfarin treated C57BU6 mouse (0) with evidence of fibrous spur
formation but no nodule formation. Tissue from a non-warfarin treated C57BU6 mouse (E)
with evidence of bridging fibrosis. FvL mutant tissue (F) showing nodule formation approaching
established cirrhosis Original magnification x 150.
G, H & I High magnification images of CAB Trichrome stained liver tissue from a warfarin
treated C57BU6 mouse (G), a non-warfarin treated C57BU6 animal (H) and an FvL mutant
mouse (I). Original magnification x300.
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After 2 weeks of CCl4 exposure, FvL mice exhibited bridging fibrosis and occasional
nodule formation (Figure 57C). In contrast, C57BL/6 control mice showed more
mild fibrosis with evidence of fibrous expansion of peri-venous areas and minimal
bridging (Figure 57B). The histological scores are summarised graphically in Figure
58A & C and in Figure 59. Warfarin treatment did not significantly reduce fibrosis in
either strain at this stage (C57BL/6 shown in Figure 57A). Measurement of mean
percentage area fibrosis by digital analysis (presented in Table 75 and Figure 58B & D)
supports these observations. Further, inspection of Figure 58B & D shows that mean
fibrosis area was increased by 80% in male FvL mutants compared to C57BL/6
controls (p=0.002) and more than doubled in female mice (p=0.007).
Figure 60 and Figure 59 summarises the four week data for male and female mice.
Non-warfarin treated C57BL/6 control mice culled at 4 weeks exhibited greater
hepatic fibrosis than those culled at 2 weeks however progression was much more
pronounced in FvL mutant mice. After 4 weeks CCl4 exposure, FvL mutant mice had
developed extensive bridging fibrosis with nodule formation and in some cases
established cirrhosis (Figure 57F & I). As can be seen in Table 75 and Table 76, this
equates to a 60% increase in mean fibrosis area over C57BL/6 controls for FvL males,
p=0.003 and a 74% increase for females, p<O.OOl. Table 75 also shows that FvL and
the non-warfarin treated C57BL/6 male mice have significantly higher mean histology
scores than female littermates (C57BL/6 ~+SEM 0.86+0.28, p=0.012; FvL
0.71 +0.28, p=0.023). Warfarin administration reversed this gender effect. Warfarin
treated male C57BL/6 mice showed only moderate fibrous expansion around the
central veins (Figure 57D & 2G) with a mean reduction in histological score of2.25 +
0.38 (SEM) compared with control (p=0.007).
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Figure 58: Extent of Hepatic Fibrosis after 2 Weeks Carbon tetrachloride
Exposure
Histological score (A & C) and Mean Percentage Area Fibrosis as measured by digital image
analysis (8 & D) for Male and Female mice respectively. Data are represented as mean ± SEM.
Carriage of the FvL mutation significantly increased histological score and mean percentage
area fibrosis in all C57BU6 mice. Warfarin treatment did not significantly alter these
parameters. Data shown as mean ± SEM.
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Table 76: Comparative Differences in Mean Percentage Area Fibrosis and Mean Histology Score Following 2 or 4 Weeks CCI4 Exposure
Study Variable MALE FEMALE
Group Mean Difference Relative to C57BLl6 Mean Difference Relative to C57BLl6
2 Weeks 4 Weeks 2 Weeks 4 Weeks
Mean (SEM) P Mean (SEM) P Mean (SEM) P Mean (SEM) P
FvL % Area Fibrosis* 1.42 (0.38) 0.002 1.71 (0.45) 0.003 1.57 (0.48) 0.007 1.76 (0.39) 0.000
Histology. Scoret 1.1 I (0.44) 0.031 0.86 (0.37) 0.044 0.78 (0.30) 0.034 1.01 (0.24) 0.001
C57BLl6 + % Area Fibrosis* -0.33 (0.24) 0.207 -0.92 (0.24) 0.005 0.49 (0.39) 0.252 -0.27 (0.37) 0.480
Warfarin Histology Scoret -0.40 (0.61) 0.492 -2.25 (0.38) 0.007 0.40 (0.40) 0.339 -0.27 (0.34) 0.429
Mean Difference Relative to FvL Mean Difference Relative to FvL
FvL + % Area Fibrosis* 0.50 (0.41) 0.238 0.65 (0.47) 0.196 0.05 (0.5) 0.921 0.44 (0.39) 0.275
Warfarin Histology Scoret 0.28 (0.46) 0.746 0.29 (0.33) 0.424 -0.62 (0.43) 0.101 -0.0 I (0.3 I) 0.918
* P-values derived from Student's t-test.
t P-values derived from the non-parametric Mann Whitney U test.
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Figure 59: Pie Charts Showing the Effect of Genotype & Warfarin on the
Distribution of Histology Scores by Study Group and Gender
Confirming the differences demonstrated in Table 76, warfarin treatment at 4 weeks has a
strong effect: all warfarin treated C57BU6 mice have scores of 2 or less whist the majority of
untreated C57BU6 mice score at least 4 and untreated FvL mice score at least 5. However,
taking the mean value of histological scores may mask true differences. This is exemplified by
the male 2 week data for C57BU6 mice where, although the mean fibrosis score was not
significantly different, the majority of warfarin treated C57BU6 mice have a histology score of
2 whilst the majority of untreated animals have a score of 3. Similarly, in this figure it can be
seen that at 4 weeks warfarin treatment of male FvL mice prevented progression beyond score
5 and increased the proportion of mice with a fibrosis score of 4.
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Figure 60: Extent of Hepatic Fibrosis after 4 Weeks Carbon tetrachloride
Exposure
Histological score (A & C) and Mean Percentage Area Fibrosis as measured by digital image
analysis (8 & D) for Male and Female mice respectively. Data are represented as mean ± SEM,
Carriage of the FvL mutation significantly increased histological score and mean percentage
area fibrosis in all C57BU6 mice. Warfarin treatment significantly reduced these parameters
but the effect was confined to male animals. The reduction in liver fibrosis seen in warfarin
treated FvL mice did not reach statistical significance. Data shown as mean ± SEM.
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From Table 75, DIA demonstrated that mean fibrosis area was 33% reduced in male
warfarin treated C57BL/6 mice (p=0.005). There was no significant difference in
fibrosis area between warfarin treated C57BL/6 mice at 2 and 4 weeks (i1 0.44%+0.27,
p=0.171) although control animals had a 1.0%+0.22 increase (p=O.Ol). At 4 weeks,
the effects ofwarfarin were less marked in females with no significant differences from
control detected. FvL mice treated with warfarin showed levels of fibrosis similar to
FvL mice which had not been anticoagulated (Table 75), suggesting that the
antifibrotic effect of warfarin was less marked in FvL animals. Inspection of Figure 59
does suggest that a weak effect of warfarin treatment may be present in male FvL
animals however it is clear that the strongest effect is seen in the C57BL/6 cohort.
5.3.3 Tissue Hydroxyproline Content
Exploratory analysis demonstrated that hydroxyproline data was not normally
distributed and so was unsuitable for parametric analysis. The non-parametric Mann-
Whitney U test was used to test for significance. This, combined with the relatively
small study group sizes (n=4-7 mice per group) may have affected the power of the
study. However, as is demonstrated in Figure 61, carriage of the FvL mutation in males
was associated with a significant 49% increase in tissue hydroxyproline content over
control (FvL 215.6 + 27.4[1g/g liver tissue vs. C57BL/6 146.6 + 23.7[1g/g, p=0.043).
Warfarin treatment of C57BL/6 mice was associated with a 32% reduction in
hydroxyproline content although this did not reach statistical significance (C57BL/6
+ Warfarin 98.4 + 18.3[1g/g, p=0.243). Consistent with the histological studies
reported in section 5.3.2, warfarin did not have a significant effect on hydroxyproline
content in FvL mice (306.9 + 44.9, p=0.278). Comparison of hydroxyproline levels
between either FvL or warfarin treated FvL mice and warfarin treated C57BL/6 mice
indicates that coagulation status has a highly significant effect on tissue hydroxyproline
content (p=0.003 & p=0.008 respectively).
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Figure 61: Liver Hydroxyproline Content after 4 Weeks Carbon tetrachloride
Exposure
Liver hydroxyproline content is expressed as IJg of hydroxyproline per gram of liver tissue.
Statistical significance was sought using the Mann-Whitney U test. Data shown as mean ± SEM.
(n = 4 - 7 mice per group).
5.3.4 Hepatic Gene Expression
Expression of genes that reflect hepatic fibrogenic activity and tissue matriX
remodelling were measured using quantitative rt-PCR. Data are presented in Figure 62
as fold change relative to the C57BL/6 control group and SEM range. Pro-collagen
type 1 expression was significantly increased by 32% in mice carrying the FvL mutation
(1.32, 1.02-1.67, p=0.027) and reduced by 40% (0.6, 0.45-0.82, p=O.OO1) in C57BL/6
animals treated with warfarin. TIMP-1 expression was elevated in FvL mice (1.25,0.9-
1.75) and reduced in warfarin treated C57BL/6 mice (0.75, 0.47-1.22) however these
did not reach statistical significance. Expression of TIMP-2 (C57BL/6 + Warfarin
0.84, 0.61-1.15; FvL 1.1, 0.94-1.26) and TIMP-3 also not significantly affected
(C57BL/6 + Warfarin 0.8, 0.59-1.1; FvL 1.2,1.0-1.45).
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Figure 62: Differential Gene Expression between Study Groups Relative to
C57BU6
Pro-collagen type I and TIMPs-l, 2 & 3 were analysed by quantitative rt-PCR (n = 4-7 mice per
group). Normalised fold change values relative to C57BU6 are shown +/-SEM. Pro-collagen
type I expression was significantly reduced in C57BU6 mice treated with warfarin and
increased in FvL mutant mice. Differences in expression for TIMPs-l, 2 & 3 were not
statistically significant.
5.3.5 Relative Quantification of alpha-Smooth Muscle Actin Expression
Western blot analysis demonstrated that the level of aSMA expression in male FvL
mice after 4 weeks CC14 exposure was approximately twice that of CS7BL/6 controls
(Figure 63). Treatment with warfarin reduced aSMA expreSSIon in both FvL and
CS7BL/6 animals by 12-30% respectively. As illustrated In Figure 64,
immunohistochemical staining of a subset of tissue samples supported these
observations. An increase in the number of aSMA positive cells was seen in FvL mice
whilst a reduction was seen in warfarin treated CS7BL/6 animals. These findings are
consistent with increased stellate cell activation in response to CC14 exposure In
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animals that carry the FvL homozygote mutation and reduced activation In those
concomitantly treated with warfarin.
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Figure 63: Western Blot of alpha-SMA Protein Expression after 4 Weeks Carbon
tetrachloride Exposure
A Image of Western blot stained with primary antibodies to aSMA and skeletal Actin
(control). The relative staining density (area under the curve) of each aSMA band was
measured using Image Jsoftware and is shown in panel B. After 4 weeks of CCI4 exposure, FvL
mutant mice have greater aSMA expression, and hence hepatic stellate cell activation, than
C57BU6 mice. Anticoagulation was shown to reduce aSMA expression. (n = 4-7 mice per
group). Pooled samples were used and so further statistical analysis was not appropriate.
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Figure 64: Immunohistochemical Staining of Liver Tissue for alpha-SMA
For illustrative purposes, a subset of tissue samples from male animals culled at the 4 week
time point were immunohistochemically stained for aSMA. Relative to C57BU6 control mice
(8), these demonstrated reduced numbers of aSMA positive cells in warfarin treated C57BU6
mice (A) and increased numbers of aSMA positive cells in FvL mutant animals (C).
5.3.6 Lipid Peroxidation Malondialdehyde (MDA) Assay
No significant difference in hepatic MDA content was observed between warfarin
treated and untreated C57BL/6 mice 24 hours after exposure to CCl4 (mean MDA
concentration + SEM: warfarin treated animals 0.24 + 0.03~moles/mg; control mice
0.26 + 0.02~0Ies/n1g). We therefore conclude that effects of anticoagulation were
not an artefact due to a reduction in the injurious capacity of CCk.
5.3.7 Effects of Ximelagatran on Histological Fibrosis Score
Ximelagatran treated mice had a mean plasma melagatran concentration ofO.94~mol/1
(range 0.33-2.01~mol!I).The active drug was confirmed to be undetectable in animals
from the untreated groups.
In contrast to warfarin, a significant reduction in mean fibrosis score was detected in
Ximelagatran treated C57BL/6 mice compared to untreated littermates after only two
weeks (2.40 + 0.245 vs. 3.40 + 0.245, p=0.015). FvL mice treated with Ximelagatran
also showed a reduction in liver fibrosis (3.4 + 0.24 vs. 4.11 + 0.20, p=0.026).
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Figure 65: Pie Charts Showing the Effect of Ximelagatran on Fibrosis Histology
Scores by Study Group and Gender at 2 and 4 Weeks
After 2 weeks, Ximelagatran treatment had limited fibrosis progression in C57BU6 mice to a
maximum score of 3 with the majority of mice only scoring 2. For FvL mice, the majority of
treated animals had not progressed beyond a score of 3 (the same profile as untreated
C57BU6 mice) whilst 89% of untreated FvL mice scored 4 or above. The effect was even more
marked by 4 weeks, when a greater proportion of treated C57BU6 animals scored 3 or less
(78%) whilst 62.5% of untreated littermates scored 4. Similarly, in the FvL group -86% of
Ximelagatran treated mice scored 3 whilst 67% of untreated littermates had fibrosis scores of
at least 4.
Due to problems with the breeding colony, insufficient FvL animals were available to
provide a full FvL control group at the 4 week time point. The available data are
shown. Taking the average of histological scores may mask changes in the distribution
of disease severity. Comparison of the raw histology scores for each study group
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(Figure 65) with the mean values shown in Figure 66 and Figure 67 suggests that the
effect of Ximelagatran treatment in individual animals may be greater than the mean
histological scores at first suggest. For example, at 4 weeks, 77.8% of C57BL/6 mice
treated with Ximelagatran had fibrosis scores of 2-3 whereas the majority of untreated
littermates had scores of 4. Similarly, 85.8% of Ximelagatran treated FvL mice had
scores of2-3 whilst the majority ofuntreated FvL mice had fibrosis scores of4-5.
Comparison of the two and four week data demonstrates that Ximelagatran treatment
was able to slow the progression of fibrosis in C57BL/6 mice. Further, mirroring the
effect of anticoagulation with warfarin in C57BL/6 mice (section 5.3.2), the mean
fibrosis score for Ximelagatran treated FvL mice at 4 weeks was lower than that at 2
weeks, suggesting that progression of fibrosis may actually have halted (Figure 66 and
Figure 67). This is also demonstrated in Figure 65 where ",43% of Ximelagatran
treated FvL mice have histological scores of 2 at 4 weeks whilst none scored less than 3
at 2 weeks.
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Figure 66: Mean Histology Scores after 2 Weeks Ximelagatran Treatment
Ximelagatran significantly reduced fibrosis in both genotypes. Ximelagatran treatment reduced
the mean fibrosis score of FvL mice to the same as for untreated C57BU6 animals. One-tailed
p-values are shown.
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Figure 67: Mean Histology Scores after 4 Weeks Ximelagatran Treatment
Ximelagatran significantly reduced mean fibrosis scores in FvL mice. A similar effect was seen
in C57BU6 animals although this did not reach statistical significance. One-tailed p-values are
shown.
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5.4 Discussion
The development of hepatic fibrosis following chronic liver injury, irrespective of
aetiology, is a complex genetic trait that may be influenced by the interaction between
host genetic factors, the pathogen and other coincidental environmental influences.
Studies in man are complicated by the inability to limit environmental and genetic
variability which may mask true associations or exaggerate the significance of others.
Recently, epidemiological evidence from the study of large patient cohorts has
suggested that prothrombotic status and specifically carriage of the Factor V Leiden
mutation is associated with an accelerated hepatic fibrosis phenotype in individuals
with chronic hepatitis C infection9, 10,305,306. I sought to examine this association using
a genetically homogeneous study population in a controlled environment that was free
from extraneous environmental influences and confounders.
5.4.1 Effect of the FvL Mutation on Progression of Liver Fibrosis
The data presented above demonstrates that, for a given duration and dose of a carbon
tetracWoride exposure, animals from a congenic strain of FvL mutant mice exhibit
significantly more extensive hepatic fibrosis than non-mutant C57BL/6 controls
(Figure 58 and Figure 60). These findings are in agreement with the original
epidemiological observations in HCy9, 10,305.306.
The effect ofFvL mutation carriage, as measured by histological score and digital image
analysis, was apparent in subjects of either gender after two weeks CC14 exposure and
became more marked at the four week time point. Quantification of hydroxyproline,
the amino acid that stabilises collagen helices deposited during fibrogenesis, was used as
a surrogate marker of hepatic collagen deposition322• Demonstrably greater tissue
hydroxyproline content was found in FvL mutant mice, corroborating the initial
histological findings. Further, increased induction of aSMA expression in mutant
267
animals over C57BL/6 as measured by Western blot (Figure 63) and
immunohistochemistry (Figure 64) indicated that the maIn effector of hepatic
fibrogenesis, the hepatic stellate celF, was differentially activated in the presence of a
prothrombotic state.
Expression of Pro-collagen type 1, a key component of collagen accumulation, was
significantly increased in FvL mice. Whilst the expression of TIMP-1, TIMP-2 and
TIMP-3 were also increased, these did not reach statistical significance (Figure 62).
Although this could have been due to relatively small sizes of the study groups, these
findings may suggest that prothrombotic status predominantly promotes stellate cell
mediated de novo collagen synthesis rather than altering the equilibrium between
metalloprotinases and their inhibitors.
The presented data indicates that, for a given duration of CCl4 exposure, male animals
had higher histological fibrosis scores than female littermates. A similar effect of
gender on the rate of fibrosis has been observed in human HCV cohorts where males
progress more rapidly12, 13. Currently the reason for this well accepted discrepancy is
not known. Recently presented data suggests that oestrogen can act as an in vivo
antioxidant, inhibiting HSC profibrotic TGF~ expression and possibly also reducing
PDGF-induced cell proliferation326,327 which may partially explain the effect.
The association between prothrombotic status and progression of tissue fibrosis is also
pertinent to fibrogenesis in other organ systems. Corroborative data has been reported
by investigators studying pulmonary fibrosis where prothrombotic status, and
specifically carriage of the FvL mutation, have been shown to lead to more rapid
development of pulmonary fibrosis in mice after Bleomycin inhalation328. Reports
describing enhanced fibrin induced collagen accumulation leading to the development
of fibrotic skin lesions in tissue plasminogen activator deficient mice have also been
published329.
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5.4.2 Effect of Anti-coagulation on Progression of Liver Fibrosis
A novel finding in this study was the observation that anticoagulation retards hepatic
fibrosis in male mice. This was demonstrated using both warfarin, a coumarin anti-
coagulant that reduces production of clotting factors II, VII, IX and X, and
Ximelagatran, a direct thrombin inhibitor. To the best of my knowledge, this study
represents the first reported therapeutic use of anticoagulation to slow hepatic
fibrogenesis.
The effect with warfarin was most evident at the 4 week time point (Figure 60) and
was more marked in C57BL/6 animals than in FvL mutant mice. At 4 weeks,
anticoagulated male C57BL/6 mice were found to have a mean histological score lower
than those observed in control mice at 2 weeks whist fibrosis had progressed
significantly in their non-warfarin treated littermates. These findings would be
consistent with the interpretation that histological fibrosis had regressed in the
warfarin treated group. A small reduction in fibrosis was observed in warfarin treated
male FvL mice however this did not reach statistical significance. The reduced efficacy
of anticoagulation in the FvL mutant animals may be explained in terms of a balance
between pro-fibrotic and anti-fibrotic processes. The dose of warfarin that could be
tolerated in this intraperitoneal injection based model was sufficient to overcome the
pro-fibrotic drive generated by CCl4 in C57BL/6 mice but not the pro-fibrotic drive
induced by the higher levels of thrombin production in homozygote FvL mutant mice.
In contrast to warfarin, the efficacy of the direct thrombin inhibitor, Ximelagatran,
was evident at an earlier time point and was present in both C57BL/6 and FvL mice.
By two weeks, treatment with Ximelagatran had completely removed the profibrotic
drive exhibited by FvL mice, giving treated FvL mice the same mean histological score
(Figure 66) and histological profile as untreated C57BL/6 animals (Figure 65). Figure
67 also demonstrates that, by 4 weeks, the anti-fibrotic effect of Ximelagatran had
waned slightly in C57BL/6 mice but remained very pronounced in FvL animals.
Indeed, Ximelagatran treated FvL mice had lower mean fibrosis scores than any other
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group at 4 weeks and scores were lower than most of those seen at 2 weeks. As was
noted for warfarin treated CS7BL/6 mice, these data may be indicative of a degree of
regression rather than progression ofhepatic fibrosis. The differences in the strength of
effect ofXimelagatran between CS7BL/6 and FvL mice at the 4 week time point may
reflect the relative contribution that thrombin production makes to fibrotic drive in
these animals. The greater background thrombin production in FvL mice making a
greater contribution to fibrotic drive, hence when thrombin activity is effectively
inhibited by Ximelagatran there is a greater reduction in tissue fibrosis than that seen
in CS7BL/6 animals.
Whilst the effect of anticoagulation on fibrogenesis was hypothesised, the significant
differences in response to anticoagulation between the genders were an unexpected
finding. The bleeding times in warfarin treated males did not differ from females.
Previous reports describing the association between FvL mutation carriage and
accelerated hepatic fibrosis with H CV infection found the effect was most
pronounced in menlO. A full explanation for this effect is more difficult however
recently published data suggests that female sex hormones are able to modulate PAR-l
expreSSIon in certain tissues330 and so may blunt this pathway's effect on HSC
activation. Further, in human subjects carrying the FvL mutation, increased
occurrence of thromboembolic events is seen in males. Taken together these findings
suggest that males are more sensitive to APC resistance and the generation of
thrombin331 and that the effects of coagulation status may therefore be of greater
significance in males. It was for this reason that detailed study of fibrogenesis and HSC
activity was confined to male animals. As is discussed further below, this difference
may also suggest the mechanism by which increased thrombin production affects
fibrogenesis.
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5.4.3 General Applicability of these Data to Human Disease
As is the case in all studies that use animal models, one can debate whether
observations made are applicable to human disease. The carbon tetrachloride model
used in these studies is well established in fibrosis research where it has been widely
adopted over many years332 with findings based on its use subsequently being replicated
in humans. Indeed, it was this model that was first used to establish the role of stellate
cells in hepatic fibrogenesis333-335. Key features of this model are a gradual and discreet
progression of pathological changes and although variability is to be expected in any
biological system, a high level of reproducibility332. The distribution of hepatic fibrosis
observed with CCl4 toxicity resembles that seen in alcoholic liver disease more closely
than that of hepatitis C and so the histological scoring system used in this study was
adapted to account for these differences.
Like other haloalkanes, CCl4 requires activation by cytochrome P4SO mixed function
oxidases (CYP2El, 2Bl and 2B2) to the trichloromethyl free radical (CCb*) before it
can induce lipid peroxidation and tissue damage324. Whilst warfarin is primarily
metabolised by different mixed function oxidases (CYP2C9, lA2 and 3A4)336,
interference between these metabolic pathways could theoretically increase or reduce
CCl4 toxicity, artefactually influencing fibrosis progression. Malondialdehyde (MDA)
and 4-hydroxyalkenals are end products derived from peroxidation of polyunsaturated
fatty acids and related esters and therefore tissue oxidative stress is reflected by the
MDA content325. No significant difference in the MDA levels were detected between
warfarin treated and un-treated mice. This confirmed that the effect of warfarin was
not due to a metabolic interaction and so one can conclude that the carbon
tetrachloride model is appropriate for the conduct of these studies.
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5.4.4 Biological Mechanisms
5.4.4.1 Hypercoagulation in Liver Disease
The role of the coagulation cascade in hepatic fibrogenesis may not be limited to viral
hepatitis. Patient cohort studies indicate that NAFLD is an independent risk factor for
increased necroinflammatory activity and hence more extensive hepatic fibrosis in
HeV infection42,43. The mechanism of this effect remains an area of active research
however patients with the NAFLD associated metabolic syndrome have been shown
to exhibit increased levels of coagulation proteins, reduced fibrinolysis capacity,
disregulation of platelet function and a fibrin structure that is inherently resistant to
degradation337.
The mechanism of initiation of coagulation cascade activity in inflammatory liver
disease requires further study. Expression of tissue factor, a key effector of the
coagulation cascade that results in thrombin synthesis, is increased in patients with
viral hepatitis338, obesity and the metabolic syndrome (NAFLD)339 and in ob/ob
mice34o. In contrast, the expression of tissue factor pathway inhibitor (Tfpi) is
reduced340. Until recently it was thought that the reaction between tissue factor and
factor VII (Figure 55) occurred only when the vessel wall was injured, exposing tissue
factor to the circulation. Recent data demonstrates that there is a separate pool of
active, thrombogenic tissue factor circulating in the blood associated with monocytes
and microparticles341, 342. The size of this pool has been shown to expand in the
presence of hyperglycaemia and hyperinsulinaemia as well as a range of other
inflammatory conditions including viral hepatitis339, 343 and thus also favours a pro-
thrombotic state.
Based on current literature, two hypotheses may be proposed that explain how activity
of the coagulation cascade (in terms ofboth pro-coagulant and anti-coagulant effect) as
observed in this study may be translated into changes in the rate of hepatic fibrosis
progressIon.
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1. Parenchymal Extinction: Micro-Thrombi within the Intra-Hepatic Vasculature
Causing Tissue Ischaemia and Fibrosis
Large thrombi occluding the hepatic vein are generally accepted as a cause of hepatic
fibrosis in Budd-Chiari syndrome344. Wanless et al observed that the extent and
distribution of micro-thrombi within branches of the hepatic vein and portal vein
(Figure 68) correlated with progression of hepatic fibrosis in a number of pathologies
including HCV, HBV and alcoholic liver disease. They proposed that occlusive
thrombi, initiated by intimal injury due to adjacent hepatic necroinflammation, form
within branches of the hepatic vein and portal vein, disrupt the flow of blood within
the liver and cause tissue ischaemia and cell death308, 309. The resulting parenchymal
extinction] defined as the irreversible loss of contiguous hepatocytes from a region, and
replacement by fibrous tissue was considered a critical event in the genesis of fibrous
septa and hence cirrhosis.
Portal Triad:
Portal venule,
Hepatic arteriole,
Bile ductule.
Acinus
Figure 68: Structure of a Hepatic Acinus
The hepatic acinus is defined as the unit of tissue supplied by a terminal portal venule and
drained by two or more terminal hepatic venules. Hepatocytes nearest the portal venule (zone
I) are the best oxygenated and those furthest away (zone 3) are the least oxygenated.
2 3
This hypothesis also attempts to distinguish between fibrosis, the accumulation of
collagen within tissue, and discreet fibrous septa, a consequence of parenchymal
extinction345. Micro-thrombi have been described within the livers of patients with
cardiac cirrhosis309, viral hepatitis, primary biliary cirrhosis308 and N ASH346.
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Figure 69: Natural History of Parenchymal Extinction & Fibrous Septa Formation
A Normal liver with patent portal (burgundy) and hepatic veins (blue). B Inflammatory injury
causes venous thrombosis (black). The consequent hepatocyte ischaemia and death leads to
parenchymal extinction (orange). C Extinction allows tissue to collapse so that adjacent portal
tracts and hepatic veins are approximated. D Regions of extinction are replaced by fibrous
septa. The obliterated venules are no longer evident. Modified from345.
In the presence of the pro-coagulant FvL mutation, the incidence of thrombosis and
hence hepatic vascular occlusion leading to parenchymal extinction would be
increased. Previous reports that FvL mice have increased deposition of fibrin in
multiple tissues and develop spontaneous focal hepatic fibrosis, add weight to this
hypothesis314 however no micro-infarcts or evidence of parenchymal extinction were
noted during this study. Studies in a rabbit model of fibrosing steatohepatitis induced
by a combination of diethylstilbestrol injections (a synthetic oestrogen that is
associated with an increased risk of thrombosis) and a high cholesterol diet have
reported evidence of parenchymal extinction347. Further, concomitant administration
of dipyridamole (a pyrimidopyridine derivative with antiplatelet and vasodilator
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properties) was found to reduce hepatic fibrosis347. The exact in VlVO actIons of
dipyridamole remain incompletely understood however the anti-fibrotic effect may be
due to a reduction in intra-hepatic thrombosis, a reduction in oxidative stress or the
prevention of platelet degranulation and release of PDGF, a potent stellate cell
mitogen. This same agent has also been shown to reduce CCl4 induced hepatic fibrosis
in rats348. Another agent, pentoxifylline (a drug that has recently come to the fore in
the treatment of alcoholic hepatitis349), has been used in the treatment of peripheral
vascular disease for some time where studies show that it reduces blood viscosity and
thrombosis formation35o. Thus, the data presented in this thesis may also suggest that,
in addition to the its anti-TNFa properties349, a secondary mode of therapeutic action
may be via an anti-thrombotic effect.
2. Direct Stellate CellActivation: Thrombin Mediated HSC Activation via PAR-l
The alternative hypothesis centres on thrombin's wide range of biological activity
beyond the coagulation cascade and so does not require the development of intra-
hepatic thrombosis to explain the increase in tissue fibrosis.
Thrombin is a serine protease and is able to signal to variety ofcell types via a family of
G-protein coupled protease activated receptors (PAR). Four PAR receptors have been
described (PAR-I, -2, -3, -4). PAR-I and PAR-3 are considered to have high affinity
for thrombin activation whilst PAR-4 has a reduced affinity and PAR-2 is resistant to
thrombin activation351 . Fibroblasts and stellate cells from both humans and rodents
have been shown to express PAR-I, rodents also expressed PAR-4 although this was
not tested in the human studies352, 353. Cleavage of the amino-terminal extracellular
domain of the PAR receptor unmasks a new N-terminus tethered ligand that effects
transmembrane signalling. In vitro studies using selective PAR-I and PAR-4 agonists
demonstrate that these are able to induce stellate cell activation352.
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Figure 70: PAR-I Mediated Actions of Thrombin in Stellate Cell Activation
Inflammation within the hepatic parenchyma increases expression of Tissue Factor, a key
initiator of the coagulation cascade, and the thrombin receptor, PAR-I. Inflammation thus
primes both the generation of thrombin and its down-stream signalling activity. In the presence
of the FvL mutation, the normal Thrombin/Thrombomodulin negative feedback loop via
Activated Protein C (APC) that limits thrombin production is ineffective. This allows thrombin
generation to proceed unchecked in a hepatic environment that is already sensitised for PAR-I
mediated stellate cell activation both directly and via platelet released PDGF. (TM,
thrombomodulin).
276
Acting via PAR-l, thrombin is chemotactic for monocytes and mitogenic for smooth
muscle cells, fibroblasts and hepatic stellate cells (Figure 70). Activation of stellate cells
in this way leads to secretion of extracellular matrix proteins, tissue remodelling and
fibrogenesis352, 353. Several studies have established that hepatic PAR-l expression is
increased during acute and chronic hepatitis353 and in liver injury caused by bile duct
ligation 352. The observations suggest that substrate (PAR-l) availability ceases to be a
rate limiting factor at sites of inflammation. Therefore, increased thrombin
production, due to failure of the Thrombin/Thrombomodulin negative feedback loop
via Activated Protein C (APC), as occurs in carriage of the FvL mutation, could lead to
increased PAR-l signalling (Figure 70). This model for the role of thrombin and FvL
in the genesis of hepatic fibrosis is supported by bile duct ligation studies that
demonstrate fibrosis is ameliorated by administration ofa PAR-l antagonist352• Similar
results have been reported with low molecular weight heparin in models of liver
damage354• PAR-l knockout mice and animals exposed to aerosolized heparin and
urokinase have also been shown to develop less pulmonary fibrosis after bleomycin
inhalation355. 356. Pursuing a similar hypothesis, a Japanese group has also reported
reduced mortality in a study of warfarin treatment in patients with idiopathic
pulmonary fibrosis357•
Platelets in mice express PAR-3 and PAR-4 whilst in humans PAR-l and PAR-4
expression has been demonstrated358 • Thus, in addition to direct PAR mediated
stellate cell activation, thrombin can also stimulate platelet degranulation and the
release of platelet derived growth factor (PDGF), another potent stellate cell activator,
via the PAR receptor (Figure 70Y. Further, activation of PAR-l has been shown to
facilitate the av~6 integrin-dependent post-translational activation of latent TGF~, a
key mediator of fibrogenesis359• Published data therefore places thrombin-mediated
PAR signalling as an effector of direct stellate cell activation, indirect stellate cell
activation via PDGF release and post-translational TGF~ activation.
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The data presented here indicates that stellate cell activation (as determined by ctSMA
expression) and fibrosis was increased in FvL mice and reduced in CS7BL/6 animals
treated with warfarin. No evidence of significant vena-occlusion or parenchymal
extinction was found despite close examination during histological scoring.
The two mechanisms described are complementary rather than mutually exclusive.
Both are biologically plausible and support a role for the coagulation system in the
control of tissue repair and remodelling. However, whilst the role of direct PAR-I
activation is supported by an expanding literature and offers greater mechanistic
insights into stellate cell biology, the parenchymal extinction theory remains to a large
extent an explanation espoused by only a single research group345.
Clinical studies show that both warfarin and Ximelagatran are effective at reducing
thrombosis formation. Whilst, the data presented here demonstrates both are able to
ameliorate hepatic fibrosis in CS7BL/6 mice, the effect of the thrombin specific
inhibitor Ximelagatran was evident at an earlier stage (2 vs. 4 weeks with warfarin) and
was also present in the FvL group (Figure 66). These differences would be consistent
with the explanation that Ximelagatran's activity extends beyond simply an anti-
coagulant effect. In that direct thrombin inhibition more successfully limits
fibrogenesis, the second hypothesis, PAR mediated stellate cell activation, is therefore
favoured as the explanation for the data presented.
5.4.4.2 Hypocoagulation in Liver Disease
In clinical practice, the progression of liver disease to cirrhosis is associated with
hepatic synthetic compromise and reduced production of coagulation factors, as
reflected in the prolongation of the prothrombin time. In light of the data presented
here, this raises the prospect of an equilibrium forming between pro-fibrotic and anti-
fibrotic drive which begs the question: why does disease progression not level out? A
possible explanation for this lies in the liver's role in the synthesis of not only pro-
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thrombotic clotting factors but also naturally occurring anticoagulants (e.g. protein C,
anti-thrombin and tissue factor pathway inhibitor (TFPI)). Additionally, the liver
synthesises thrombomodulin which is necessary for the activation of protein C by
thrombin (Figure 70). Anticoagulant factor synthesis and activity are not measured in
normal clinical clotting assays.
In an elegant experiment using blood from cirrhotic patients and healthy controls,
Tripodi et al highlighted how current clinical assays such as prothrombin time and
activated partial thromboplastic time fail to reflect all the physiological mechanisms
that control thrombin formation. As expected, the measurement of the endogenous
thrombin potential (ETP) without the addition of thrombomodulin showed that
cirrhotic patients had reduced thrombin synthesis over healthy controls - reflecting
the reduction in the synthesis of procoagulant factors. However, when the test was
repeated with the addition of thrombomodulin, no difference in the levels of thrombin
synthesis could be detected360. These data indicate that, as the synthetic function of the
liver is compromised by progressive fibrosis, the synthesis of pro-coagulant and anti-
coagulant factors diminishes proportionally. Indeed the same authors suggested that
the reduction in protein C synthesis may actually be greater than that of
prothrombin360. This maintains the capacity for thrombin synthesis, and hence
profibrotic dive, in status quo. Whilst there remains debate about the relative
contribution to any observed bleeding tendency in cirrhosis made by changes in
fibrinolysis activity361. 362 and platelet function, which may affect fibrin clot formation,
these later changes would not compromise direct thrombin mediated PAR-I
activation ofstellate cells as described above.
5.4.5 Conclusion
The results generated by this study provide strong support for the hypothesis that
carriage of the FvL mutation promotes hepatic stellate cell activation and enhances
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hepatic fibrogenesis. Furthermore, anticoagulation with either agent diminishes
stellate cell activation and fibrogenesis in male mice. These effects are likely to me
mediated via changes in PAR receptor activation status. Although existing data does
not support the routine use of therapeutic anticoagulation as an antifibrotic therapy, it
is evident that activity of the coagulation cascade has a profound influence on tissue
fibrogenesis. This may have significant clinical implications and potentially offers the
prospect of novel therapeutic approaches.
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SECTION 6: GENERAL CONCLUSIONS
In the present study, the pathogenesis of progressive liver disease has been investigated
using mouse models. In particular, new models ofNAFLD have been generated using
both genetic and environmental manipulation. Phenotype driven random mutagenesis
screens of F1 animals following paternal END exposure have generated models of
simple steatosis (GENA/263) and steatohepatitis (IGT/6). Both models exhibit many
of the features associated with the metabolic syndrome. Similarly, dietary manipulation
using a chronic high saturated and mono-unsaturated fat intake has allowed
identification of mouse models of sensitivity (129S6/Sv and C3H) and resistance
(BALB/c) to dietary induced steatohepatitis. Transcriptome level analysis of IGT/6
mice has been performed to characterise hepatic gene expression in the presence of
insulin resistance and steatohepatitis. Finally, the role played by thrombin and
coagulation status in the development ofhepatic fibrosis has been studied.
As described in Sections 2 and 4, it is possible to promote NAFLD in inbred strains of
mice by either genetic or dietary manipulation, confirming that NAFLD is a complex
disease trait. The IGT/6 line was subjected to extensive phenotypic and transcriptome
level analysis during this study. This revealed that, like the human disease it simulates,
the IGT/6 model is likely to be polygenic and that modifiers within the background
strain and dietary influences can affect the severity of the disease phenotype and
penetrance. Similarly, the differences in response to dietary challenge between
129S6/Sv and BALB/c mice also reflect the influence of modifier genes within their
backgrounds. Both genetic and environmental approaches have thus successfully
identified disease models that replicate the complexity of the human disease.
The IGT/6 phenotype accurately reflects the clinical features associated with
steatohepatitis in man (i.e. increased body weight, impaired glucose tolerance, insulin
resistance, histological steatohepatitis and biochemical transaminitis; described in
section 1.3 on page 21). As described in section 3.4.5.1 on page 206, comparison of
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currently published human and murine NAFLD microarray studies with the results of
the IGT/6 analysis suggest a commonality of pathogenesis. Microarray analysis of the
IGT/6 line, whilst limited to the transcriptome level, offers considerable insight into
the metabolic pathways that are likely to be involved in the genesis of steatohepatitis.
Thus, in the face of high circulating glucose and insulin loads, increased glycolysis,
hepatic de novo fatty acid synthesis and fatty acid uptake from the circulation occur.
Simultaneously, those animals that progress to NASH appear to exhibit reduced
VLDL lipid export and to preferentially dispose of lipid by fatty acid oxidation (w-
oxidation > ~-oxidation), generating oxidative stress. Further, the microarray analysis
indicates that, underlying these changes is a complex web of interaction between
transcription factors including PPARa, SREBP-l, ChREBP, LXRa/~ and RXR.
Failure of the normal cross-regulatory mechanisms permits an expanding intracellular
lipid pool to be exposed to reactive oxygen species and free-radicals, allowing lipid
peroxidation, cellular damage and promoting an inflammatory response. The
observation that expression ofLXR~ was increased only in those IGT/6 mice that did
not develop NASH may suggest that the relative expression of the LXRa and LXR~
isoforms are pivotal to this effect. In contrast to LXRa, knockout studies have
demonstrated that LXR~ has minimal capacity to induce Srebf1 expression and may
directly interfere with fatty acid synthesis26s, 266. LXR~ may serve as a 'decoy',
consuming some of the available RXR pool, reducing LXRa and PPARa activity
(3.4.3.2 on page 200). In addition, LXR~ may confer anti-inflammatory and anti-
thrombotic effects on tissues268•
The results of the current microarray study on IGT/6 animals also highlight the
potential influence of several modifier genes (e.g. Ceacam-l and Vanin-l) which may
affect the rate ofde novo fatty acid synthesis282 or tissue sensitivity to oxidative stress272,
276. Changes in gene activity and genetic polymorphisms affecting the function of the
encoded proteins may contribute to the variability in the accumulation ofsteatosis and
the progression to steatohepatitis observed in man. Investigation in patient cohorts to
282
determine what contribution they make to the human disease process would seem
appropriate.
The results of these studies are consistent with the evolving nature of the 'two-hit'
hypothesis which has already been adapted to incorporate advances in our
understanding of NAFLD pathogenesis62. Thus, IGT/6 reflects the NAFLD
phenotype at the gross histological, biochemical and cellular biology level to model the
true complexity of the pathogenic process and fulfils the criteria for a model of
steatohepatitis that were established in section 2.2 on page 52.
The metabolic syndrome and by extension, NAFLD, is considered a pro-thrombotic
state by many investigators33?, 363, 364. This pro-thrombotic state has been suggested to
contribute to the increased frequency of thromboembolic events in obese subjects365
and the progression of atherothrombotic and cardiovascular disease in metabolic
syndrome patients33? Further evidence for the prothrombotic effect of insulin
resistance and NAFLD was provided in the current study. Microarray analysis of the
IGT/6 line demonstrated increased hepatic expression of coagulation factors VII and
X. These key components of the extrinsic coagulation cascade interact with tissue
factor leading to thrombin activation (Figure 55 on page 236). These same factors have
been shown to correlate with increased central body fat deposition and biochemical
markers of steatosis in humans366• Similarly, the BAIR microarray analysis comparing
the effects of high fat diet on 129S6/Sv and BALB/c animals demonstrated increased
expression of PAR-l in animals with NASH (Toye et aI, manuscript in preparation).
Taken together with the data presented in Section 5, which demonstrates how
coagulation status may affect hepatic fibrogenesis (and specifically how a pro-
thrombotic state induced by unopposed factor X activity may contribute to accelerated
progression of hepatic fibrosis), these findings suggest a mechanism which may
contribute to the transition from steatohepatitis to fibrosis and ultimately cirrhosis.
As mentioned in the Introduction (section 1.5.2 on page 35), the generation ofcellular
oxidative stress is central to the progression ofNAFLD and leads to lipid peroxidation,
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cellular damage and the induction of an inflammatory response9S. 100. 367. 368. The
induction of genes responsible for mitochondrial and extra-mitochondrial fatty acid
oxidation (w-oxidation > ~-oxidation), potentially leading to the production of
reactive oxygen species and other toxic intermediaries, was demonstrated in the IGT/6
model of NASH. Further, an increase in Vanin-1 expression was observed in IGT/6
mice with NASH, possibly contributing to their sensitivity to oxidative damage.
Oxidative stress is also a common pathogenic process in a range of progressive liver
diseases, including viral hepatitis369. 370, and both alcoholic371 and non-alcoholic
steatohepatitis. In the current study, interference with the synthesis of components of
the coagulation cascade (II, VII, IX and X) by warfarin or direct inhibition of
thrombin's protease activity by Ximelagatran372 is shown to ameliorate fibrosis caused
by carbon tetrachloride induced tissue oxidative stress. These findings suggest a direct
clinical application in the control of progressive hepatic fibrosis in general and, in
particular, steatohepatitis. This is discussed further in section 6.1.1 below
6.1 Translational Studies
Whilst the work described in this thesis relates solely to the study of liver disease in
animal models, a number of the findings are likely to be pertinent to the pathogenesis
of progressive liver disease in man. Thus, the findings in this thesis warrant
translational study in patient populations to determine general applicability in the
clinical setting. Studies may include determining the effect of anti-thrombotic therapy
on liver fibrogenesis and the role ofgenes highlighted by the IGT/6 microarray analysis
in human NAFLD.
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6.1.1 Pilot clinical trial of Anticoagulation as an Anti-fibrotic in Chronic
Hepatitis C
The data presented in Section 5, together with the human epidemiological evidence
that a pro-thrombotic state is associated with accelerated liver fibrosis in HCVIo. 305. 306
(5.1.2 page 234) and the work by other groups exploring the role of PAR-1
activation352 (described in section 5.4.4.1 on page 272), provides compelling evidence
for the influence of thrombotic state over hepatic fibrogenesis. The use of
anticoagulation to ameliorate liver fibrosis, as described in section 5.4.2, raises the
prospect of novel therapeutic approaches that affect the thrombin / PAR-1 / stellate
cell axis to down-grade the fibrotic response provoked by chronic liver injury. Whilst
clinical studies in idiopathic pulmonary fibrosis have already shown benefit357, the
existing data is insufficient to support the routine use of therapeutic anticoagulation as
an antifibrotic therapy in liver disease. Clearly such treatment would be
contraindicated in advanced liver disease when haemorrhage related morbidity and
mortality are already high.
To assess the efficacy and safety of an anti-thrombogenic, anti-fibrotic approach in the
early stages of chronic liver disease, ethical approval has been obtained and a phase IIII
clinical trail initiated at hospitals allied to Imperial College London
(www.clinicaltrials.gov.#NCT00180674).This small pilot study (20 patients) has an
open label, randomised, cross-over design (Figure 71) and aims to determine whether a
short period of anti-coagulation (8 weeks) can effect a reduction in surrogate markers
of liver fibrosis in patients with early chronic hepatitis C (modified Ishak liver fibrosis
score of 2-4) who have not responded to conventional, interferon-alpha/ribavarin
based therapy.
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Figure 71: Outline of Anticoagulation Clinical Trial
The study has an open-label, cross-over design. During the period of anticoagulation the blood
clotting (INR value) will be checked regularly to ensure that it stays within a safe but effective
range (INR 2.5 - 3.5). Patients will have serum fibrosis markers, micro-bubble ultrasound and
magnetic resonance spectroscopy (MRS) performed at enrolment, after 8 weeks and after 16
weeks. Patients who consent (as part of the clinical management of HeV infection) will
undergo a liver biopsy at the end of the first 8 week study period.
Patient safety is of paramount importance. Thus, to mInImIse the risks of
haemorrhage, patients must not have any other contra-indications for anti-coagulation
and exclusion criteria specifically include clinical evidence (including ultrasound) or
history indicating the presence of portal hypertension or coagulopathy. Patients must
have had a recent upper GI endoscopy to exclude the presence of varices or
hypertensive gastropathy before entry into the study. Each patient will be
anticoagulated with warfarin (as Ximelagatran is no longer available for clinical use)
for an 8 week period. Liver fibrosis indices will be serially measured during the study
using serum fibrosis markers, micro-bubble ultrasound hepatic transit times and
magnetic resonance spectroscopy (Figure 71). This trial will complete the translational
circuit from epidemiological study of patient cohorts to hypothesis generation/testing
in animal models and finally back to clinical study. If successful, it is hoped that the
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data generated will provide an impetus towards the identification of novel agents that
may combine clinical efficacy with a better safety profile for more general adoption.
6.2 Future Studies using the New in vivo Models Identified
The models of NAFLD that have been identified during the course of this thesis
remain tools that may be used for future study of NAFLD, either in basic research or
therapeutics development. These will allow further exploration of the changes in
transcription factor activity and related metabolic pathways that contribute to
steatosis, cellular oxidative stress and steatohepatitis. Although the causative END
induced mutation(s) in IGT/6 have not as yet been identified, the use of 12 week
glucose tolerance data to discriminate mutant from non-mutant animals has proved
effective and allows littermates to be used as a control population. Similarly, whilst the
late onset of the phenotype in chow fed animals may limit the practicality of this
model of general adoption, it strengthens the likelihood that the processes underlying
the development of NAFLD in this line do truly reflect those associated with clinical
disease (itself a disease of later life). The addition of dietary stressors (high fat diet) to
the genetic predisposition of the IGT/6 line can hasten the onset of the disease
phenotype and increase the utility of this modeL
As NAFLD and the metabolic syndrome confer a pro-coagulant state337, 364, the
introduction of the FvL mutation onto one of the novel models of steatohepatitis
identified by this study may amplify the pro-fibrotic profile of the metabolic syndrome
and permit a more florid fibrosing steatohepatitis to develop. In addition, studies
addressing the contribution of Vanin-1 and related proteins to variation in individual
sensitivity to xenobiotic induced liver injury may be undertaken in these and other
mouse models.
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6.3 Closing Remarks
This thesis describes the identification and characterisation of novel mouse models of
steatosis, steatohepatitis and liver fibrosis. These are the result of genetic and
environmental manipulation of inbred strains of mice. Demonstrating the power of
END chemical mutagenesis l71 , 172, a model generated without any bias introduced by a
priori assumptions regarding the specific genes involved in disease pathogenesis
(IGT/6) appears to simulate the human NAFLD phenotype more closely than most
currently available murine models. Characterisation of global hepatic gene expression
within this model demonstrates how derangements within a complex web of
transcription regulators and their cofactors may combine to produce the disease
phenotype and has implicated genes such as Vanin-l and Ceacam-l as potential
modifiers ofdisease progression.
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SECTION 7: APPENDICIES
7.1 APPENDIX A: Reagents & Proprietary Technology
7.1.1 'RETROscript' Reverse Transcription Kit (Ambian, USA #171 0)
This kit is manufactured by Ambion Inc, USA. Much of the content of this kit is
proprietary technology and so full details ofall the constituents are not available.
Component
Control Template RNA (mouse liver RNA 0.5 mg/ml)
lOX RT Buffer
• 500 mM Tris-HCI, pH 8.3
• 750 mM KCI
• 30 mM MgCl2
• 50 mM DTT
lOX PCR Buffer
• 100 mM Tris-HCI. pH 8.3
• 500 mM KCI
• 15 mM MgCI2
Deoxynucleotide trisphosphate (dNTP) mix (2.5 mM each dNTP)
Random Decamers (50 IJM)
Oligo(dT) Primers (50 IJM)
MMLV-RT (100 units/IJI)
RNase Inhibitor (10 units/IJI)
Control PCR Primers forward and reverse primers at 5 IJM each
High Resolution Gel Loading Solution (5X)
Nuclease-free Water
Amount
50 IJI
200 IJI
400 IJI
300 IJI
80 IJI
80 IJI
40 IJI
40 IJI
50 IJI
1.0 ml
3.5 ml
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7.1.2 'RNeasy Mini' RNA Extraction Kit (Qiagen #74104)
The RNeasy Mini kit is manufactured by Qiagen, USA. Much of the content of this
kit is proprietary and so details of the constituents of the buffers are not available. The
table below lists the available details.
Component
RNeasy mini spin columns
Collection tubes (1.5 ml)
Collection tubes (2 ml)
Buffer RLT (contains guanidine thiocyanate)
Buffer RWI
Buffer RPE
RNase-free water
Amount
50
50
50
45 ml
45 ml
II ml
10 ml
7.1.3 TaqMan Gene Expression Assays (Applied Biosystems Inc.)
TaqMan Gene Expression assays are built on proprietary technology (Applied
Biosystems Inc., USA) the information presented here is based on the ABI TaqMan
Gene Expression Assay Protocol (#4333458 Revision C).
Each assay contains two unlabelled PCR primers (both at a 900nM final
concentration) and a TaqMan MGB (minor groove binder) 6-FAM labelled probe
(final concentration 250nM). All components are quality tested and formulated into a
20x mixture that is optimised to run under standard thermal cycling conditions. All
murine assays have been designed to avoid areas with known inter-strain
polymorphisms that may affect the affinity of the primers. Each probe contains a 6-
FAM reporter dye linked to the 5' end of the probe, a minor groove binder (which
increases the melting temperature of the probe without increasing its length) and a
non-fluorescent quencher on the 3' end. During PCR the probe anneals to its
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complementary sequence between the forward and reverse pnmer sites. DNA
polymerase cleaves only those probes that are bound to their target sequence and so
releases the reporter dye from the probe/quencher construct and allows a fluorescent
signal to be detected.
The efficiency of all the inventoried T aqMan Gene Expression assays used has been
determined over a six log range of dilutions by ABI. They have demonstrated that all
assays have efficiencies approaching 100% (+ 10%) and so further validation of their
efficiency before using the ~~CT method of relative fold change calculation are not
necessary (ABI Technical Note #00113186 'Amplification Efficiency of TaqMan
Gene Expression Assays' 2004). The gapdhcontrol primer used in multiplex reactions
(3.2.6.2 on page 143) was specifically designed for this purpose.
7.1.4 Malondialdehyde Assay (Calbiochem #437634)
Much of the content of this kit is proprietary technology and so details of all the
constituents are not available. Available information is details below.
Component
RI Reagent
• N-methyl-2-phenylindole
• Acetonitrile
Ferric Iron in Methanol
M DA Standard
• I, I ,3,3-Tetramethoxypropane (TMOP) in Tris-HCI
Amount
3 x 18 ml
I x 30 ml
I x I ml
Condensation of one molecule of MDA with two molecules of the chromogenic
reagent R1 produces a stable chromophore with a maximal absorbance at 586 nm.
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7.1.5 Protein Extraction Lysis Buffer for Western Blot
A stock of lysis buffer A was prepared and stored at 4°C until used.
Lysis Buffer A (remains stable at 4°C for 3 months)
Component Amount
50mM HEPES pH 7.4 25ml
10% Triton X-IOO 50ml
50mM Sodium pyrophosphate 250ml
EDTA 10mi
Water 40ml
Total Volume 375ml
Just prior to use the following components were added to a 5°111 aliquot on ice.
Add the following to S0!ll of Lysis Buffer A (use immediately)
Component
10mM Sodium f10ride
10mM Sodium orthovanadate
2mM Benzamideine
10V-g/ml Leupeptin
10V-g/ml Iprotinin
10V-g/ml AEBSF
7.1.6 Tris-Acetate-EDTA (TAE) Buffer
Component
Tris Base
Glacial Acetic Acid
0.5M EDTA
Deionised (MiIIiQ) water.
Amount
242g
57.1 ml
100 ml
To I litre
Amount
5ml
2.5ml
5ml
50V-1
50V-1
50V-1
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7.2 APPENDIX B: Microarray Analysis Bioconductor Scripts
# LOAD BIOCONDUCTOR LIBRARIES
# =====================================================
> library(simpleaffy)
> library(genefilter)
> library(geneplotter)
> library(multtest)
> library (affy)
> library (limma)
> library (gcrma)
> library(xtable)
> library(mouse4302)
> library(mouse4302cdf)
> library (GO)
> library(annotate)
> library(annaffy)
> library(affycoretools)
#
# 2. READ IN EXPERIMENT DESCRIPTION FILE
# =====================================================
#
> myexp <- read. phenoData (" Sample InfoR. txt", header=TRUE,
row.names=l)
#
# 3. READ IN CEL FILES
#
#
> raw <-
ReadAffy(filenames=rownames(pData(myexp) ),phenoData=myexp,verbose=TR
UE)
#
# +++++++++++++ ALTERNATIVE METHOD TO READ IN FILES ++++++++++
#
# This from 'affycoretools' package. Also saves some QC images.
# If you use this go to Step 7.
#
> esetGCRMA<-affystart(filenames=rownames(pData(myexp)),
phenoData=myexp, pca=FALSE, express=c("gcrma"))
#
# Or this to do Principal Components Analysis
#
> esetGCRMA<-affystart(filenames=rownames(pData(myexp)),
phenoData=myexp, pca=TRUE, groups=c(1,1,1,1,2,2,2,3,3,3,3,3),
groupnames=c("DM", "CONTROL", "NAFLD"), express=c("gcrma"))
#
# For a ScreePlot
#
> plotPCA(esetGCRMA, groups=c(1,1,1,1,2,2,2,3,3,3,3,3),
groupnames=c("DM", "CONTROL", "NAFLD"), screeplot=TRUE, addtext
=c(1,2,3,4,S,6,7,8,9,lO,11,12), x.coord = NULL, y.coord = NULL,
squarepca = FALSE)
#
#
#
#
296
a. Box & Whisker plots (inc. save)
=====================================================
=====================================================
5. CHECKS/QC ON RAW DATA AT PROBE PAIR LEVEL
****LINE DOES NOT WORK****hist(raw)
c. Chip Image
par(mfrow=c(2,3)) #array images arranged in 2 rows and three
columns
b.Histogram
boxplot(raw, las=3, cex.axis=O.5, pch="-", col=2)
title ("Boxplots of Raw Affyrnetrix CEL-level Data")
show(raw)
pData(raw)
head (exprs (raw) )
slotNames(qc.data)
# 4. CHECK DATA READ CORRECTLY
#
#
>
>
>
>
#
#
#
#
#
#
>
>
#
#
#
#
>
#
#
#
#
>
> for (i in l:ncol(exprs(raw)))
#
# You mi g h t try II for (i in 1: N) II
#
# d. RNA Degradation
# -----------------------------------------------------
#
> myrnadeg <- AffyRNAdeg(raw)
> plotAffyRNAdeg(myrnadeg)
#
# e. M v A Pairs for PM probes (log ratios 'M' vs log intensities 'A')
# -----------------------------------------------------
#
> mva.pairs(pm(raw) [,c(1,4,7)])
#
# Plots against pseudomedian reference chip
#
> MAplot (raw)
#
#
# f. Use Simpleaffy to do QC
# ----------------------------------------------------
> ampli. eset<-call. exprs (raw, "mas 5 ")
> qc.data<-qc(raw,ampli.eset)
#
> slotNames(qc.data)
#
> qc.data@percent.present
#
> plot (qc.data)
#
# Use this for the 3':Midpoint ratio instead of 3':5'
> plot (qc.data,usemid=T)
#
297
# 6 NORMALISATION OF DATA
# =====================================================
# a. Apply RMA algorithm (NB output is 10g2 transformed)
# -----------------------------------------------------
#
> esetRMA <- rma(raw, normalize=TRUE, background=TRUE, bgversion=2)
#
# b. Apply GC-RMA algorithm (NB output is 10g2 transformed)
# -----------------------------------------------------
#
> esetGCRMA <- gcrma(raw)
#
# +++++++++++NOTE: COULD START HERE, THIS USES LESS MEMORY++++++++++
#
> esetGCRMA <- justGCRMA (filenames = rownames(pData(myexp)),
phenoData = myexp, verbose = TRUE)
#
# 7. CHECKS/QC ON NORMALISED DATA
# =====================================================
# a. Box-and-Whisker plots (for RMA)
# -----------------------------------------------------
> boxplot(as.data.frame (exprs (esetRMA) ), las=3, cex.axis=O.5,
pch=".",col=6)
> title ("Boxplots of RMA Processed Data")
#
# b. Box-and-Whisker plots (for GC-RMA)
# -----------------------------------------------------
> boxplot(as.data.frame(exprs(esetGCRMA)), las=3, cex.axis=O.5,
pch=".",col=4)
> title ("Boxplots of GC-RMA Processed Data")
#
# c. Check output
# -----------------------------------------------------
#
> head(exprs(esetGCRMA))
#
# d. To show Actual Numeric Data for plots
# -----------------------------------------------------
> boxplot(as.data.frame(exprs(esetRMA)), las=3, cex.axis=O.5,
pch=".",col=6, plot=FALSE)
#
> boxplot(as.data.frame(exprs(esetGCRMA)), las=3, cex.axis=O.5,
pch=".",col=4,plot=FALSE)
TO SELECT FILES 1-3 FOR PLOTS USE:
TO SELECT SPECIFIC FILES FOR PLOTS USE:
++++++++++++++++++++ NOTE +++++++++++++++++++++++++++
Sel<-1:3
mva.pairs(exprs(esetGCRMA[,Sel] ),Log.it=FALSE)
# pairwise plots
# pairwise M vs. A plots
pairs (esetGCRMA, pch=".")
mva.pairs(esetGCRMA, cex=O.l)
#
# e. M vs A Plots
#
#
#
>
>
#
#
#
#
#
>
>
#
#
#
#
298
#
> Sel<-c (1, 4, 7)
> mva.pairs(exprs(esetGCRMA[,Sel]),Log.it=FALSE)
#
# May need to add ,Log.it=FALSE (NOT SURE THIS WORKS!)
#
#
# 8. DATA FILTERING
# =====================================================
# The genefilter package is used. Functions include: kOverA, ttest,
Anova, coxfilter,gapFilter.
#
# a. Build filter requirements
# -----------------------------------------------------
# To filter and remove genes where less than 3 samples have expression
values greater than 2 A 6.
#
> f1 <- kOverA(3,6)
> f2 <- function(x) (IQR(x) > 0.4)
> f3 <- Anova(esetGCRMA$Sample Group)
#
# b. Build filter with filterfun
# ----------------------------------------------------
> ff<-filterfun(f1,f2)
#
# c. Apply the filter to the eset with Genefilter
# ----------------------------------------------------
#
> wh<-genefilter(esetGCRMA, ff)
> mySubSet<-esetGCRMA[wh,]
#
# How many genes left?
#
> mySubSet
#
#
# 9. FOLD CHANGE CALCULATIONS
# =====================================================
#
> DM_CONTROL.fc.log2 <- rowMeans (exprs (esetGCRMA) [,1:4]) -
rowMeans(exprs(esetGCRMA) [,5:7])
> DM_NAFLD.fc.log2 <- rowMeans (exprs (esetGCRMA) [,1:4]) -
rowMeans (exprs (esetGCRMA) [,8: 12] )
> NAFLD_CONTROL.fc.log2 <- rowMeans (exprs (esetGCRMA) [,8:12]) -
rowMeans(exprs(esetGCRMA) [,5:7])
#
#
# 10. LINEAR MODELLING WITH LIMMA
# =====================================================
# a. Specify a design matrix for the experiment
# -----------------------------------------------------
#
> design <- model.matrix(- -1+factor(c(1,1,1,1,2,2,2,3,3,3,3,3)))
> colnames(design) <- c("DM", "CONTROL", "NAFLD")
#
#
#
#
#
#
# b. Fit linear model to RMA data
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# -----------------------------------------------------
#
# If you have filtered change 'esetGCRMA' to 'mySubSet' so it looks
like this:
#
> fit <- lmFit(mySubSet, design)
#
# Output a copy of the data. This contains the mean normalised values
for each study group.
#
> MeanTab<-as.data.frame.MArrayLM(fit)
> write. table (MeanTab, file="MeanValue. txt")
#
# c. To make pair wise comparisons between the three groups: Define a
Contrasts Matrix
# -----------------------------------------------------
#
> contrastNames<-c ("DM_CONTROL", "NAFLD_CONTROL", "NAFLD_DM")
> contrast.matrix <- makeContrasts(DM-CONTROL, NAFLD-CONTROL, NAFLD-
DM, levels=design)
> fit2 <- contrasts.fit(fit, contrast.matrix)
#
# d. Empirical Bayes Statistics
# ----------------------------------------------------
> fi t2 <- eBayes (fi t2)
#
# To annotate the list *
> xx <- as.list(mouse4302GENENAME)
> fi t2$genes<-xx
#
# You can now export a data table that summarises all the mean
expression levels and t-test or ANOVA type p-values.
#
> MeanTab2<-as.data.frame.MArrayLM(fit2)
> write.table(MeanTab2,file="Unadjusted_eBayes(ANOVA) All GCRMA Filter
ed. txt")
#
# e. Volcano Plots
# ----------------------------------------------------
#
# This will give a p<O.05, 1.5 fold change
# See help on 'par' for more infomation
#
#
> volcanoplot(fit2,coef=3,abline(v=c(-O.586,O.585),h=-
4.32,untf=FALSE,lty=2,col="red"),fg
=gray(O.5),col.axis=gray(O.5),cex.lab=O.9,cex.axis=O.9,main="Volcano
Plot for NAFLD-DM Comparison")
#
# f. Venn Diagrams
# ---------------------------------------------------
#
# To do a Venn Diagram
#
> rslt<-decideTests (fit2, adjust.method="none")
> vc<-vennCounts2 (rsl t, method="both")
> vennDiagram(vc,cex=O.8)
> vennSelect (mySubSet, fit2, design, rslt,method="both")
#
#
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# 11. DISPLAY TABLES OF DIFFERENTIALLY EXPRESSED GENES
# ====================================================
> topTable(fit2,coef=l,n=10) #1 hope this is DM-CONTROL, the n=10
limits the genes
> topTable(fit2,coef=2) #1 hope this is NAFLD-CONTROL
> topTable(fit2,coef=3) #1 hope this is NAFLD-DM
#
# topTable contains a a default multadjust
#
> numGenes <- nrow(esetGCRMA@exprs)
>
> TableDM CONT <-
topTable(fit2,coef=l,number=numGenes,adjust.method="none")
> write.table(TableDM_CONT,file="UnadjustedP DM_CONT.xls",sep="\t",quo
te=FALSE,col.names=NA)
#
#
> TableNAFLD CONTROL <-
topTable(fit2,coef=2,number=numGenes,adjust.method="none")
> write.table (TableNAFLD_CONTROL, file="UnadjustedP_NAFLD_CONTROL.xls",
sep="\t",quote=FALSE,col.names=NA)
#
#
> TableNAFLD-DM <-
topTable(fit2,coef=3,number=numGenes,adjust.method="none")
> write. table (TableNAFLD-DM, file="Unadj ustedP_NAFLD-
DM.xls",sep="\t",quote=FALSE,col.names=NA)
#
#
# 12. EXPORT ANNOTATED TABLES
# ===================================================
#
# Gives an annotated table with fold change, p-value, etc.
#
> limma2annaffy(mySubSet, fit2, design, contrast.matrix,
annotation(mySubSet), pfilt=O.05, adjust="none", html=FALSE,
text=TRUE, FC=TRUE, addname=" XXX")
#
#
#
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7.3 APPENDIX C: Microarray Analysis Results Table
The table contained in this section lists the changes in gene expression for each of the
1,892 probe-sets that were identified as differentially expressed in the IGT16
microarray study. The probe-set ID, corresponding gene symbol and gene name 1 brief
description are shown to assist in interpretation. In addition, the EntrezGene database
ID (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene) is also provided to
facilitate future study of gene function and the comparison of this data with other
studies that may not be based on the Affymetrix platform.
The table shows the magnitude of fold-change and statistical significance of any
difference detected for each probe-set and comparison made. A p-value < 0.05 was
considered significant. The q-value, a measure of positive false discovery rate, as
calculated using SAM software228, is also shown for each gene in each comparison. The
q-value represents the proportion of genes that would falsely be considered
differentially expressed if a given change in expression was considered significant (i.e.
the lowest false discovery rate at which the gene is considered to be significant)228, 240.
Note
All fold-chage values are expressed as log2 values. Up-regulated genes have positive
values and down-regulated genes have negative values. A 1.5-fold change is therefore
represented in the table as Log2(1.5) = 0.586 and a two-fold change is represented as
Log2(2) = 1.
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene 10 t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I460688_U!t AM07659 106840 expressed sequence AA407659 1.38 0.19 0.15 0.42 2.42 0.03 0.09 0.7 1.07 0.305 0.44 0.28
1419327_at AMI5817 94184 expressed sequence AA41 5817 1.79 0.095 0.07 1.87 2.28 0.04 0.09 2.27 0.43 0.671 0.44 0.4
I438021_at AA571391 245945 expressed sequence AA571391 3.28 0.006 0.05 0.99 1.6 0.132 0.17 0.46 -1.99 0.067 0.41 -0.53
I45608 I_a_at Aacs 78894 acetoacetyl-CoA synthetase 0.22 0.83 0.26 0.07 2.52 0.025 0.10 0.81 2.5 0.026 0.22 0.74
I434935_at Aakl 269774 AP2 associated kinase I 1.71 0.111 0.12 0.51 2.29 0.039 0.11 0.65 0.55 0.593 0.55 0.14
I428756_at Aasdhppt 67618 aminoadipate-semialdehyde dehydrogenase- -4.16 0.001 0.07 -1.04 -2.2 0.046 0.33 -0.52 2.34 0.035 0.22 0.51
phosphopantetheinyl transferase
1451731_at Abca3 27410 ATP-binding cassette. sub-family A3 (ABC I) 3.22 0.006 0.05 1.44 2.43 0.03 0.10 1.03 -1.03 0.322 0.48 -0.4
1418838_at Abcdl 11666 ATP-binding cassette. sub-family D I (ALD) 2.38 0.033 0.07 0.66 2.13 0.052 0.13 0.56 -0.39 0.703 0.68 -0.09
14201 57_s_at Abdl 224742 ATP-binding cassette. sub-family FI (GCN20) 2.36 0.034 0.05 0.51 2.07 0.058 0.15 0.43 -0.43 0.677 0.68 -0.08
I452236_at Abdl 224742 ATP-binding cassette. sub-family FI (GCN20) 3.26 0.006 0.05 0.87 2.02 0.063 0.13 0.51 -1.5 0.156 0.62 -0.35
1419393_at Abcg5 27409 ATP-binding cassette. sub-family G5 (WHITE) 3.25 0.006 0.05 1.24 1.96 0.071 0.11 0.71 -1.56 0.142 0.55 -0.52
I420656_at Abcg8 67470 ATP-binding cassette. sub-family G8 (WHITE) 3.64 0.003 0.05 1.31 2 0.066 0.11 0.69 -1.96 0.071 0.44 -0.62
1418148_at Abhdl 57742 abhydrolase domain containing I 1.63 0.127 0.08 1.26 2.8 0.015 0.09 2.07 1.19 0.254 0.22 0.81
1441945_s_at Abhdl4a 68644 abhydrolase domain containing 14A -2.34 0.035 0.24 -0.88 -0.21 0.834 0.39 -0.08 2.43 0.03 0.20 0.8
I435653_at Abhd2 54608 abhydrolase domain containing 2 5 0 0.05 1.15 5.26 0 0.07 1.16 0.03 0.973 0.63 0.01
1434185_at Acaca 107476 acetyl-Coenzyme A carboxylase alpha 1.5 0.156 0.12 0.74 2.61 0.021 0.09 1.23 1.14 0.276 0.32 0.49
1419261_at Acad8 66948 acyl-Coenzyme A dehydrogenase member 8 -1.03 0.321 0.38 -0.24 0.97 0.349 0.27 0.22 2.23 0.043 0.22 0.46
I435630_s_at Acat2 110460 acetyl-Coenzyme A acetyltransferase 2 2.17 0.048 0.08 0.65 1.65 0.122 0.13 0.47 -0.68 0.508 0.68 -0.18
I428236_at Acbd5 74159 acyl-Coenzyme A binding domain containing 5 -2.74 0.016 0.15 -0.77 -0.83 0.421 0.39 -0.22 2.22 0.044 0.27 0.55
1439459_x_at Acly 104112 ATP citrate lyase 1.33 0.207 0.17 0.4 2.25 0.042 0.11 0.64 0.93 0.366 0.41 0.25
1451 666_at Acly 104112 ATP citrate lyase 1.76 0.102 0.07 0.94 2.35 0.034 0.10 1.21 0.56 0.583 0.50 0.27
I449065_at Acotl 26897 acyl-CoA thioesterase I -2.5 0.026 0.15 -1.38 0.24 0.815 0.30 0.13 3.11 0.008 0.20 1.51
1422997_s_at Acotl 171210 acyl-CoA thioesterase 1/2 -4.3 0.001 0.07 -1.56 -1.11 0.286 0.39 -0.38 3.69 0.003 0.20 1.17
I439478_at Acot2 171210 acyl-CoA thioesterase 2 0.98 0.343 0.14 0.42 2.16 0.05 0.11 0.88 1.23 0.24 0.38 0.46
I42271 6_a_at Acpl 11431 acid phosphatase I. soluble -2.64 0.02 0.15 -0.92 -1.97 0.069 0.32 -0.66 0.85 0.408 0.48 0.26
425559_a_at Acsm3 20216 acyl-CoA synthetase medium-chain member 3 -2.53 0.024 0.15 -1.02 -2.36 0.034 0.31 -0.91 0.32 0.754 0.60 0.11
428585_at Aetnl 109711 actin in. alpha I 3.81 0.002 0.05 0.96 3.74 0.002 0.07 0.9 -0.27 0.788 0.68 -0.06
426403_at Actrl b 226977 ARP I actin-related protein I homolog B (yeast) -2.15 0.05 0.27 -0.54 -0.52 0.612 0.39 -0.12 1.88 0.082 0.27 0.41
428502_at Actr6 67019 ARP6 actin-related protein 6 homolog (yeast) -2.58 0.022 0.24 -0.58 -0.8 0.438 0.39 -0.17 2.07 0.059 0.27 0.41
433725_at Acvrl b 11479 activin A receptor. type IB 2.93 0.011 0.05 0.65 2.1 0.055 0.13 0.44 -1.05 0.314 0.66 -0.2
421022_x_at Acypl 66204 acylphosphatase I, erythrocyte (common) type -4.32 0.001 0.07 -1.19 -2.2 0.046 0.32 -0.58 2.53 0.025 0.20 0.61
450095_a_at Acypl 66204 acylphosphatase I, erythrocyte (common) type -4.57 0 0.07 -0.94 -2.13 0.052 0.33 -0.42 2.88 0.013 0.20 0.52
41 8586_at Adcy9 11515 adenylate cyclase 9 1.06 0.308 0.18 0.29 2.45 0.029 0.10 0.64 1.46 0.167 0.38 0.35
450054_at Addl 11518 adducin I (alpha) 2.36 0.034 0.05 0.73 1.97 0.069 0.13 0.59 -0.54 0.597 0.68 -0.15
424392_at Adhfel 76187 alcohol dehydrogenase. iron containing. I -0.66 0.521 0.40 -0.21 -2.76 0.016 0.31 -0.83 -2.26 0.041 0.14 -0.62
424393_s_at Adhfel 76187 alcohol dehydrogenase, iron containing. I 0.32 0.753 0.26 0.09 -1.98 0.068 0.33 -0.51 -2.52 0.025 0.17 -0.59
437864_at Adipor2 68465 adiponectin receptor 2 2.16 0.049 0.09 0.53 -0.28 0.786 0.39 -0.06 -2.76 0.016 0.14 -0.59
435495_at Adoral 11539 adenosine A I receptor 3.07 0.009 0.05 0.89 3.41 0.004 0.07 0.94 0.21 0.838 0.63 0.05
41 9263_a_at Adrml 56436 adhesion regulating molecule I 2.23 0.043 0.05 0.55 -0.97 0.347 0.39 -0.23 -3.6 0.003 0.10 -0.78
449383_at Adssll 11565 adenylosuccinate synthetase like I 3.33 0.005 0.05 1.06 1.95 0.073 0.15 0.59 -1.67 0.117 0.55 -0.47
434080_at Aebp2 11569 AE binding protein 2 1.48 0.162 0.14 0.37 3.26 0.006 0.09 0.78 1.87 0.084 0.30 0.41
420619_a_at Aes 14797 amino-terminal enhancer of split 1.45 0.171 0.07 0.68 -1.09 0.294 0.39 -0.49 -2.84 0.014 0.14 -1.18
427561_a_at Afm 280662 afamin 1.68 0.116 0.11 0.63 2.31 0.038 0.10 0.83 0.6 0.561 0.50 0.2
433819_s_at Agpat3 28169 l-acylglycerol-3-phosphate O-acyltransferase 3 0.56 0.583 0.26 0.15 2.73 0.017 0.10 0.69 2.33 0.036 0.22 0.54
42683 I_at Ahcyll 229709 S-adenosylhomocysteine hydrolase-like 1 -0.88 0.395 0.35 -0.35 -2.59 0.022 0.31 -0.99 -1.82 0.091 0.46 -0.64
452217_at Ahnak 66395 AHNAK nucleoprotein (desmoyokin) 1.27 0.227 0.14 0.45 3.07 0.009 0.07 1.03 1.9 0.079 0.27 0.59
435975 at All 15600 102442 exoressed seauence All 15600 -1.63 0.126 0.27 -0.37 1.64 0.124 0.17 0.35 3.64 0.003 0.20 0.72
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6·NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t·stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I458442_at All 32709 101494 expressed sequence All 32709 1.9 0.079 0.05 2.31 3.43 0.004 0.07 4 1.57 0.139 0.27 1.68
1440327 at AI 195470 107131 expressed sequence AI I95470
-2.77 0.016 0.14 -0.65 -3.35 0.005 0.30 -0.76 -0.5 0.627 0.68 -0.1
1439127_at AI314180 230249 expressed sequence AI314180
-0.83 0.422 0.33 -0.38 -2.4 0.031 0.32 -1.06 -1.67 0.117 0.46 -0.68
I449614_s_at AI314976 106821 expressed sequence AI314976
-2.85 0.013 0.08 -0.88 -0.09 0.933 0.39 -0.03 3.16 0.007 0.20 0.86
I459666_at AI413908 102495 expressed sequence AI41 3908 1.24 0.237 0.15 0.3 2.9 0.012 0.10 0.67 1.75 0.102 0.32 0.37
I423876_at AI450540 226252 expressed sequence AI450540 1.85 0.086 0.11 0.44 4.01 0.001 0.07 0.91 2.26 0.041 0.22 0.47
1435417_at AI464131 329828 expressed sequence AI464 I31 2.38 0.033 0.05 0.68 1.61 0.13 0.20 0.44 -0.96 0.355 0.66 -0.24
I455320_at AI480535 104840 expressed sequence AI480535 2.23 0.043 0.05 0.56 2.2 0.046 0.13 0.52 -0.15 0.881 0.68 -0.03
1417255_at AI661311 106633 expressed sequence AI661311 2.35 0.035 0.07 0.62 0.85 0.408 0.29 0.22 -1.75 0.104 0.50 -0.41
I435207_at A1835735 330938 expressed sequence AI835735 1.17 0.262 0.18 0.35 2.17 0.049 0.11 0.62 1.03 0.322 0.41 0.27
I435589_at AI842788 240514 expressed sequence AI842788 1.42 0.178 0.14 0.45 2.46 0.028 0.10 0.74 1.06 0.309 0.44 0.29
I438007_at AI851790 268354 expressed sequence AI851790 2.99 0.01 0.05 1.33 1.5 0.157 0.17 0.64 -1.77 0.099 0.46 -0.7
I437393_at AI875142 103885 expressed sequence AI875142 0.78 0.449 0.25 0.25 2.45 0.028 0.10 0.77 1.78 0.097 0.27 0.51
1420679_a_at Aigl 66253 androgen-induced I 3.42 0.004 0.05 1.13 1.39 0.186 0.13 0.44 -2.37 0.033 0.32 -0.69
I44845 I_at Ak2 11637 adenylate kinase 2 0.03 0.977 0.26 0.01 2.27 0.04 0.11 0.57 2.44 0.029 0.22 0.56
1450387_s_at Ak311 11639 adenylate kinase 3 alpha-like I 1.28 0.222 0.17 0.39 2.65 0.02 0.09 0.76 1.42 0.178 0.36 0.38
I434764_at Akapll 219181 A kinase (PRKA) anchor protein II 2.69 0.018 0.05 0.63 2.47 0.028 0.11 0.55 -0.38 0.711 0.68 -0.08
I455454_at Akrlcl9 432720 aldo-keto reductase family I, member C 19 -2.59 0.022 0.18 -1.01 -1.69 0.113 0.32 -0.63 1.11 0.287 0.44 0.38
1455100_at Akrldl 208665 aldo-keto reductase family I, member D I -3.15 0.007 0.15 -0.76 -3.01 0.01 0.30 -0.69 0.31 0.764 0.62 0.06
141 7826_at Akrlel 56043 aldo-keto reductase family I, member EI -1.39 0.186 0.27 -0.95 1.37 0.194 0.17 0.89 3.07 0.009 0.07 1.85
1416657_at Aktl 11651 thymoma viral proto-oncogene I 2.29 0.039 0.07 0.66 0.73 0.48 0.29 0.2 -1.81 0.092 0.53 -0.46
I455070_at ALI 18268 404593 expressed sequence AL I 18268 -0.25 0.807 0.40 -0.07 1.75 0.103 0.15 0.5 2.19 0.047 0.22 0.58
I426300_at Alcam 11658 activated leukocyte cell adhesion molecule 3.36 0.005 0.05 0.99 1.44 0.174 0.20 0.4 -2.26 0.041 0.20 -0.58
42630'_at Alcam 11658 activated leukocyte cell adhesion molecule 3.29 0.006 0.05 0.92 3.37 0.005 0.09 0.9 -0.08 0.94 0.68 -0.02
437466_at Alcam 11658 activated leukocyte cell adhesion molecule 4.31 0.001 0.05 1.38 4.56 0 0.07 1.4 0.06 0.955 0.63 0.02
437467_at Alcam 11658 activated leukocyte cell adhesion molecule 2.23 0.044 0.05 0.78 3.84 0.002 0.07 1.28 1.64 0.124 0.30 0.5
451 260_at Aldhlbl 72535 aldehyde dehydrogenase I family, member BI 3.2 0.007 0.05 1.06 2.55 0.024 0.10 0.81 -0.86 0.403 0.67 -0.25
452375_at Aldh4al 212647 aldehyde dehydrogenase 4 family, member A I 3.92 0.002 0.05 0.91 0.12 0.904 0.30 0.03 -4.33 0.001 0.05 -0.88
448104_at Aldh6a I 104776 aldehyde dehydrogenase family 6, subfamily A I -2.46 0.028 0.24 -0.67 -1.05 0.313 0.39 -0.27 1.66 0.121 0.32 0.4
427336_at Aldh8al 237320 aldehyde dehydrogenase 8 family, member A I 2.25 0.042 0.05 0.68 1.47 0.164 0.22 0.42 -0.96 0.355 0.66 -0.25
436689_a_at Aldh9al 56752 aldehyde dehydrogenase 9, subfamily A I -2.46 0.Q28 0.26 -0.49 0.42 0.685 0.30 0.08 3.25 0.006 0.20 0.56
41 692I_x_at Aldoa 11674 aldolase I, A isoform 2.22 0.044 0.08 0.58 1.98 0.068 0.11 0.5 -0.36 0.722 0.68 -0.08
434799_x_at Aldoa 11674 aldolase I, A isoform 1.74 0.105 0.10 0.41 2.68 0.019 0.10 0.6 0.94 0.365 0.48 0.19
45 I461_a_at Aldoc 11676 aldolase 3, C isoform 2.55 0.024 0.05 0.83 1.28 0.222 0.22 0.4 -1.51 0.155 0.62 -0.43
438941_x_at Ampd2 109674 adenosine monophosphate deaminase 2 -3.47 0.004 0.09 -0.82 -0.34 0.741 0.39 -0.08 3.58 0.003 0.20 0.75
435177_a_at Anapc5 59008 anaphase-promoting complex subunit 5 2.4 0.031 0.05 0.65 1.36 0.197 0.22 0.35 -1.26 0.23 0.65 -0.3
4521 24_at Ank3 11735 ankyrin 3, epithelial 1.78 0.098 0.10 0.68 3.97 0.001 0.07 1.45 2.3 0.038 0.20 0.77
41 7685_at Ankfyl 11736 ankyrin repeat and FYVE domain containing I 2.39 0.032 0.07 0.69 2.48 0.027 0.10 0.69 -0.02 0.983 0.68 -0.01
448008_at Ankhdl 108857 ankyrin repeat and KH domain containing I 0.36 0.723 0.26 0.16 -2.32 0.037 0.32 -I -2.94 0.011 0.11 -1.17
460559_at Ankrd25 235041 ankyrin repeat domain 25 0.91 0.377 0.23 0.25 2.18 0.048 0.11 0.57 1.33 0.206 0.36 0.32
450407_a_at Anp32a 11737 acidic nuclear phosphoprotein 32A -2.02 0.064 0.27 -0.53 2.12 0.053 0.10 0.53 4.61 0 0.07 1.07
4241 76_a_at Anxa4 11746 annexin A4 2.73 0.017 0.05 1.51 2.57 0.023 0.09 1.35 -0.31 0.761 0.68 -0.15
457658_x_at Anxa4 11746 annexin A4 2.75 0.016 0.05 1.17 2.21 0.045 0.10 0.9 -0.72 0.486 0.66 -0.27
416279_at Aplbl 11764 adaptor protein complex AP-I, beta I subunit 2.71 0.017 0.05 0.62 2.06 0.059 0.13 0.45 -0.84 0.416 0.68 -0.17
452292_at Ap2bl 71770 adaptor-related protein complex 2 beta I 4.65 0 0.05 1.45 2.94 0.011 0.09 0.87 -2.1 0.056 0.15 -0.57
450894_a_at Ap2ml 11773 adaptor protein complex AP-2, mu 1 2.51 0.026 0.05 0.65 0.38 0.708 0.30 0.09 -2.44 0.029 0.36 -0.55
450915_at Ap3bl 11774 adaptor-related protein complex 3 beta I 2.2 0.046 0.05 0.55 -0.01 0.989 0.39 0 -2.52 0.025 0.32 -0.55
422593 at Ap3s1 11777 adaptor-related protein complex 3 Sl2ma I -2.61 0.021 0.18 -0.61 0.09 0.926 0.30 0.02 3.08 0.009 0.20 0.63
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I452342_at Apbb2 11787 amyloid beta (A4) precursor protein-binding 3.19 0.007 0.05 I 2.09 0.057 0.13 0.62 -1.36 0.195 0.63 -0.37
I435543_at Ape 11789 adenomatosis polyposis coli
-0.59 0.568 0.40 -0.14 3.62 0.003 0.07 0.85 4.61 0 0.07 0.99
1419059_at Apes 20219 serum amyloid P-component 2.94 0.011 0.05 1.74 2.03 0.062 0.10 1.15 -1.14 0.275 0.53 -0.59
1437715_x_at Apex 1 11792 apurinidapyrimidinic endonuclease I 2.52 0.025 0.05 0.7 3.27 0.006 0.09 0.87 0.69 0.502 0.50 0.17
1421887_a_at Aplp2 11804 amyloid beta (A4) precursor-like protein 2 2.73 0.017 0.05 0.71 2.36 0.034 0.10 0.59 -0.54 0.599 0.68 -0.12
1421889_a_at Aplp2 11804 amyloid beta (A4) precursor-like protein 2 2.58 0.022 0.05 0.87 1.93 0.075 0.13 0.62 -0.83 0.418 0.66 -0.25
1423739_x_at Aplp2 11804 amyloid beta (A4) precursor-like protein 2 2.01 0.065 0.11 0.43 2.55 0.023 0.10 0.52 0.49 0.63 0.58 0.09
1417761_at Apoa4 11808 apolipoprotein A-IV 0.66 0.521 0.22 0.55 2.45 0.029 0.09 1.94 1.91 0.077 0.20 1.39
I436504_x_at Apoa4 11808 apolipoprotein A-IV 0.75 0.467 0.20 0.52 2.62 0.021 0.09 1.75 2 0.067 0.20 1.23
I455593_at Apob 238055 apolipoprotein B 1.69 0.113 0.14 0.35 3.24 0.006 0.09 0.64 1.6 0.133 0.32 0.29
I457554_at Apob 238055 apolipoprotein B 2.71 0.018 0.05 1.45 -3.1 0.008 0.27 -1.6 -6.46 0 0.00 -3.05
1418069_at Apoc2 11813 apolipoprotein C-II 0.49 0.634 0.26 0.15 2.52 0.025 0.10 0.74 2.19 0.046 0.22 0.59
1419096_at Apom 55938 apolipoprotein M -0.62 0.548 0.40 -0.18 -3.23 0.006 0.30 -0.9 -2.81 0.014 0.17 -0.72
I420621_a_at App 11820 amyloid beta (A4) precursor protein 2.19 0.047 0.07 0.99 1.32 0.209 0.13 0.57 -1.06 0.308 0.65 -0.42
I427442_a_at App 11820 amyloid beta (A4) precursor protein 3.38 0.005 0.05 1.03 3.37 0.005 0.D7 0.99 -0.17 0.866 0.68 -0.05
I423973_a_at ArB 11842 ADP-ribosylation factor 3 3.02 0.009 0.05 0.83 1.72 0.108 0.15 0.45 -1.57 0.14 0.60 -0.38
1437331_a_at ArB 11842 ADP-ribosylation factor 3 2.75 0.016 0.05 0.66 2.13 0.052 0.13 0.49 -0.81 0.431 0.67 -0.17
1439367_x_at Arf4 11843 ADP-ribosylation factor 4 -2.51 0.026 0.15 -0.77 -1.86 0.085 0.33 -0.54 0.84 0.418 0.50 0.22
I426534_a_at Arfgap3 66251 ADP-ribosylation factor GTPase activating protein 3 -2.7 0.018 0.11 -1.33 -1.84 0.088 0.33 -0.87 1.07 0.304 0.38 0.46
1428369_s_at Arhgap21 71435 Rho GTPase activating protein 21 -1.15 0.269 0.37 -0.24 1.62 0.129 0.17 0.32 3.07 0.009 0.20 0.56
I450896_at Arhgap5 11855 Rho GTPase activating protein 5 -4.03 0.001 0.07 -1.79 -1.83 0.089 0.32 -0.78 2.6 0.022 0.20 1.01
I450897_at Arhgap5 11855 Rho GTPase activating protein 5 -2.18 0.048 0.25 -0.74 -0.98 0.342 0.39 -0.32 1.41 0.181 0.36 0.42
1451 I68_a_at Arhgdia 192662 Rho GDP dissociation inhibitor (GDI) alpha 3.14 0.008 0.05 1.06 1.57 0.139 0.17 0.51 -1.86 0.085 0.46 -0.55
1421 I64_a_at Arhgefl 16801 Rho guanine nucleotide exchange factor I 2.6 0.022 0.05 0.68 1.41 0.182 0.22 0.35 -1.42 0.178 0.63 -0.33
1418553_at Arhgefl8 102098 rholrac guanine nucleotide exchange factor 18 2.36 0.034 0.D7 0.57 2.62 0.021 0.10 0.6 0.17 0.87 0.63 0.04
I454802_x_at Arih2 23807 ariadne homolog 2 (Drosophila) 2.72 0.017 0.05 0.6 2.54 0.024 0.10 0.54 -0.33 0.743 0.68 -0.06
1428137_at ArilOc 67166 ADP-ribosylation factor-like 10C -3.41 0.004 0.08 -1.19 -1.79 0.096 0.33 -0.6 1.94 0.074 0.27 0.59
1431429_a_at Arl4 11861 ADP-ribosylation factor-like 4 -2.62 0.021 0.24 -0.7 -I 0.335 0.39 -0.26 1.9 0.079 0.27 0.45
I435092_at Arl4 11861 ADP-ribosylation factor-like 4 -2.7 0.018 0.17 -0.99 -1.25 0.233 0.39 -0.44 1.71 0.11 0.22 0.55
I435594_at Arl6ip2 56298 ADP-ribosylation factor-like 6 ip 2 -0.47 0.645 0.40 -0.11 2.26 0.041 0.11 0.49 3 0.01 0.20 0.59
456739_x_at Armcx2 67416 armadillo repeat containing, X-linked 2 -2.11 0.054 0.26 -0.59 0.55 0.593 0.30 0.15 3 0.01 0.20 0.73
428112_at Armet 74840 arginine-rich, mutated in early stage tumors -2.41 0.031 0.17 -1.1 I -2.17 0.049 0.32 -0.95 0.38 0.707 0.58 0.16
437042_at Arnt 11863 aryl hydrocarbon receptor nuclear translocator 0.74 0.471 0.25 0.18 2.54 0.024 0.10 0.58 1.92 0.076 0.30 0.41
460444_at Arrbl 109689 arrestin, beta I 2.15 0.05 0.05 1.34 1.52 0.152 0.13 0.9 -0.8 0.439 0.66 -0.44
426239_s_at Arrb2 216869 arrestin, beta 2 2.31 0.037 0.05 0.82 0.87 0.398 0.27 0.3 -1.69 0.115 0.55 -0.52
454617_at Arrdc3 105171 arrestin domain containing 3 -0.26 0.799 0.40 -0.11 1.81 0.092 0.13 0.74 2.27 0.04 0.20 0.85
460346_at Arsa 11883 arylsulfatase A 2.87 0.013 0.05 1.05 2.71 0.017 0.09 0.94 -0.32 0.754 0.68 -0.1
435010_at Asb7 117589 ankyrin repeat and sacs containing protein 7 2.39 0.032 0.05 0.65 1.31 0.211 0.22 0.34 -1.3 0.217 0.65 -0.31
4271 56_s_at Ascc2 75452 activating signal cointegrator I subunit 2 1.99 0.067 0.09 0.41 2.73 0.017 0.10 0.54 0.7 0.493 0.53 0.13
460552_at Ascc311 320632 activating signal cointegrator I subunit 3-like I 2.71 0.017 0.05 0.65 1.63 0.126 0.20 0.37 -1.31 0.212 0.64 -0.28
41 9747_at Asgr2 11890 asialoglycoprotein receptor 2 2.9 0.012 0.05 1.09 0.56 0.583 0.30 0.2 -2.69 0.018 0.17 -0.89
424395_at Asrgll 66514 asparaginase like I 1.18 0.257 0.15 0.36 2.66 0.019 0.10 0.78 1.55 0.144 0.32 0.42
424396_a_at Asrgll 66514 asparaginase like I 3.41 0.004 0.05 0.97 4.95 0 0.07 1.35 1.51 0.154 0.32 0.38
41 6239_at Assl 11898 argininosuccinate synthetase I 0.95 0.361 0.15 0.37 -1.63 0.127 0.35 -0.6 -2.85 0.013 0.15 -0.97
43456 I_at Asxll 228790 additional sex combs like I (Drosophila) 2.04 0.061 0.07 0.66 2.16 0.049 0.11 0.67 0.03 0.976 0.63 0.01
435077_at Asxll 228790 additional sex combs like I (Drosophila) 2.81 0.014 0.05 1.28 1.84 0.087 0.11 0.8 -1.19 0.256 0.65 -0.47
437343_x_at Atad3a 108888 ATPase family, AAA domain containing 3A 3.22 0.006 0.05 1.11 4.45 0.001 0.07 1.47 1.18 0.257 0.41 0.36
438178 x at Atad3a 108888 ATPase familv. AAA domain containinl! 3A 1.97 0.07 0.11 0.52 3.43 0.004 0.07 0.86 1.5 0.158 0.32 0.34
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I456541_x_at Atad3a 108888 ATPase family. AAA domain containing 3A 1.79 0.096 0.14 0.45 3.61 0.003 0.07 0.86 1.89 0.081 0.27 0.41
1449709_s_at Atel 11907 arginine-tRNA-protein transferase I
-1.82 0.091 0.27 -0.46 0.13 0.895 0.30 0.03 2.22 0.044 0.22 0.5
I426583_at Atf2 11909 activating transcription factor 2
-2.8 0.015 0.17 -0.83 -2.52 0.025 0.32 -0.71 0.44 0.668 0.58 0.11
I438992_x_at Atf4 11911 activating transcription factor 4
-1.22 0.243 0.33 -0.3 -2.4 0.032 0.32 -0.57 -1.22 0.245 0.65 -0.27
1425927_a_at Atf5 107503 activating transcription factor 5 2.37 0.033 0.08 0.71 3.14 0.008 0.07 0.9 0.72 0.486 0.50 0.19
1428612_at Atg7 74244 autophagy-related 7 (yeast)
-2.27 0.04 0.24 -0.83 -1.1 0.292 0.39 -0.38 1.39 0.188 0.32 0.45
I442367_at Atpllc 320940 Atpase. class VI. type I IC 1.01 0.33 0.20 0.33 -0.93 0.369 0.39 -0.29 -2.16 0.049 0.32 -0.62
1417475_at Atpl3al 170759 ATPase type 13A I 3.49 0.004 0.05 0.79 2.38 0.033 0.11 0.52 -1.39 0.188 0.64 -0.28
I423653_at Atplal 11928 ATPase. Na+/K+ transporting. alpha I 1.29 0.219 0.17 0.37 2.5 0.026 0.09 0.68 1.25 0.233 0.41 0.31
I41 8453_a_at Atplbl 11931 ATPase. Na+/K+ transporting. beta I 3.07 0.009 0.05 0.82 1.2 0.25 0.22 0.31 -2.18 0.047 0.44 -0.51
I423890_x_at Atplbl 11931 ATPase. Na+/K+ transporting. beta I 3.71 0.002 0.05 0.97 3.64 0.003 0.07 0.91 -0.27 0.793 0.68 -0.06
I439036_a_at Atplbl 11931 ATPase. Na+/K+ transporting. beta I 2.12 0.053 0.07 0.63 2.69 0.018 0.09 0.76 0.51 0.62 0.58 0.13
1451 I52_a_at Atplbl 11931 ATPase. Na+/K+ transporting. beta I 4.28 0.001 0.05 1.02 4.27 0.001 0.07 0.97 -0.23 0.823 0.68 -0.05
I428936_at Atp2bl 67972 ATPase. Ca++ transporting 2.41 0.031 0.05 0.77 2.14 0.052 0.11 0.65 -0.42 0.682 0.68 -0.12
I434386_at Atp2cl 235574 ATPase. Ca++-sequestering 1.94 0.074 0.10 0.48 2.77 0.016 0.09 0.65 0.81 0.433 0.50 0.18
I433562_s_at Atp5f1 11950 ATP synthase. H+ transporting. mitochondrial -2.67 0.019 0.24 -0.58 -1.16 0.265 0.39 -0.24 1.77 0.099 0.30 0.34
1416269_at Atp5j2 57423 ATP synthase. H+ transporting. mitochondrial -2.49 0.026 0.25 -0.59 -1.08 0.301 0.39 -0.24 1.67 0.119 0.30 0.35
I448203_at Atp51 27425 ATP synthase. H+ transporting. mitochondrial -2.57 0.023 0.22 -0.68 -1.03 0.319 0.39 -0.26 1.8 0.094 0.27 0.42
14371 64_x_at Atp50 28080 ATP synthase. H+ transporting. mitochondrial -3.46 0.004 0.14 -0.71 -0.81 0.429 0.39 -0.16 3.06 0.009 0.20 0.55
437688_x_at Atp6ap2 70495 ATPase. H+ transporting accessory protein 2 2.3 0.038 0.08 0.52 3.45 0.004 0.07 0.75 1.14 0.275 0.44 0.23
439456J_at Atp6ap2 70495 ATPase. H+ transporting accessory protein 2 1.97 0.07 0.11 0.43 2.93 0.011 0.09 0.61 0.94 0.362 0.48 0.18
41 5932_x_at Atp9a 11981 ATPase. class II, type 9A 3.66 0.003 0.05 1.06 3.49 0.004 0.07 0.97 -0.36 0.726 0.68 -0.09
427604_a_at Atp9a 11981 ATPase. class II. type 9A 2.54 0.024 0.05 0.81 2.54 0.024 0.10 0.78 -0.13 0.896 0.68 -0.04
420946_at Atrx 22589 alpha thalassemia/mental retardation syndrome 2.52 0.025 0.07 0.67 -2.37 0.033 0.32 -0.6 -5.44 0 0.04 -1.27
420947_at Atrx 22589 alpha thalassemia/mental retardation syndrome 1.25 0.233 0.17 0.32 -2.7 0.018 0.32 -0.66 -4.36 0.001 0.05 -0.97
45005 I_at Atrx 22589 alpha thalassemia/mental retardation syndrome 0.83 0.418 0.17 0.34 -2.85 0.013 0.30 -1.12 -4.06 0.001 0.05 -1.46
435019_at Atxn713 217218 ataxin 7-like 3 2.86 0.013 0.05 0.7 3.05 0.009 0.09 0.72 0.07 0.947 0.63 0.01
437073_x_at AV025504 105633 expressed sequence AV025504 -2.63 0.02 0.15 -I -0.64 0.531 0.39 -0.23 2.29 0.039 0.22 0.77
449568_at AV071179 83379 expressed sequence AV071 I79 3.02 0.01 0.05 0.87 3.41 0.004 0.07 0.94 0.28 0.785 0.62 0.07
423197_a_at AWOl 1752 104570 expressed sequence AWO 11752 1.23 0.239 0.17 0.35 2.55 0.023 0.09 0.7 1.38 0.191 0.38 0.35
447946_at AW046396 329173 expressed sequence AW046396 2.75 0.016 0.05 0.81 2.05 0.06 0.11 0.58 -0.89 0.388 0.67 -0.23
451 261_s_at AW049765 106766 expressed sequence AW049765 3.12 0.008 0.05 0.81 1.06 0.307 0.25 0.26 -2.39 0.032 0.38 -0.55
438035_at AW061290 381110 expressed sequence AW061290 -3.79 0.002 0.08 -1.52 -1.86 0.085 0.32 -0.71 2.3 0.038 0.22 0.81
I438036_x_at AW061290 381110 expressed sequence AW061290 -3.32 0.005 0.08 -1.49 -1.4 0.184 0.34 -0.6 2.25 0.042 0.22 0.89
435326_at AWl 12037 98667 expressed sequence AWl 12037 2.32 0.037 0.07 0.59 2.9 0.012 0.09 0.7 0.52 0.614 0.58 0.11
454923_at AW214353 107036 expressed sequence AW214353 1.14 0.274 0.18 0.25 2.25 0.042 0.11 0.48 1.15 0.271 0.44 0.22
433854_at AW547186 209497 expressed sequence AW547 I86 1.75 0.103 0.12 0.58 2.61 0.021 0.09 0.82 0.85 0.408 0.48 0.25
454741_s_at AW547186 209497 expressed sequence AW547 I86 2.8 0.015 0.05 1.17 3.5 0.004 0.07 1.39 0.62 0.543 0.48 0.23
456295_at B230114PI7Rik 402735 RIKEN eDNA B230114PI7 gene -2.78 0.015 0.15 -1.09 1.32 0.21 0.22 0.49 4.59 0 0.07 1.58
433832_at B230369L08Rik 223697 RIKEN eDNA B230369L08 gene -1.05 0.313 0.36 -0.25 1.03 0.322 0.27 0.23 2.31 0.037 0.22 0.48
436841_at B230380D07Rik 235461 RIKEN cDNA B230380D07 gene 0.59 0.568 0.26 0.23 2.37 0.033 0.10 0.9 1.91 0.077 0.27 0.67
454842_a_at B3galnt2 97884 UDP- beta 1.3-galactosaminyltransferase -2.25 0.041 0.18 -0.79 -1.51 0.155 0.36 -0.5 0.93 0.37 0.46 0.29
460509_at B3galtl 26877 UDP-beta IJ-galactosyltransferase 2.27 0.04 0.05 1.34 1.45 0.17 0.17 0.82 -1.01 0.332 0.58 -0.52
418014_a_at B4galtl 14595 UDP-Gal 3.21 0.007 0.05 0.89 2.33 0.036 0.10 0.62 -1.12 0.284 0.66 -0.27
434374_at B930006L02Rik 319604 RIKEN eDNA B930006L02 gene 1.94 0.074 0.09 0.59 -0.54 0.596 0.39 -0.16 -2.8 0.015 0.16 -0.75
434375_at B930006L02Rik 319604 RIKEN cDNA B930006L02 gene -1.02 0.326 0.26 -1.13 -2.25 0.042 0.30 -2.39 -1.29 0.219 0.60 -1.26
1419001_at Baat 12012 bile acid-Coenzyme A -3.59 0.003 0.08 -1.14 -2.9 0.012 0.31 -0.88 0.92 0.373 0.46 0.26
1437846 x at Bace2 56175 beta-site APP-c1eavinl! enzyme 2 -2.29 0.038 0.23 -0.92 -3.09 0.008 0.27 -1.19 -0.76 0.462 0.67 -0.27
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I438645_x_at Bace2 56175 beta-site APP-c1eaving enzyme 2
-1.86 0.085 0.26 -0.83 -2.99 0.01 0.27 -1.27 -1.14 0.274 0.65 -0.45
144931 I_at Bach I 12013 BTB and CNC homology I 3.62 0.003 0.05 1.09 -0.21 0.839 0.39 -0.06 -4.35 0.001 0.05 -1.14
1421082_s_at Banfl 23825 barrier to autointegration factor 1
-1.49 0.16 0.28 -0.35 0.74 0.47 0.30 0.17 2.5 0.026 0.22 0.52
I422799_at Bat2 53761 HLA-B associated transcript 2 2.28 0.04 0.05 0.75 1.13 0.277 0.24 0.36 -1.36 0./95 0.63 -0.39
I429433_at Bat2d 226562 BAT2 domain containing I 1.92 0.076 0.07 0.5 3.5 0.004 0.09 0.88 1.62 0.128 0.32 0.37
I438663_at Bat2d 226562 BAT2 domain containing I 0.9 0.382 0.20 0.46 2.92 0.012 0.07 1.41 2.15 0.051 0.22 0.95
141 5732_at Bat5 193742 HLA-B associated transcript 5 2.55 0.024 0.05 0.71 1.46 0.168 0.20 0.39 -1.31 0.211 0.65 -0.32
I438433_at BB081391 434204 expressed sequence BB081391 2.63 0.02 0.05 0.84 -0.04 0.965 0.39 -0.01 -3.05 0.009 0.11 -0.86
1417688_at BC004044 80752 cDNA sequence BC004044 3.89 0.002 0.05 0.93 2.92 0.012 0.09 0.66 -1.26 0.231 0.65 -0.26
I425328_at BC008163 230789 cDNA sequence BC008163 0.64 0.534 0.26 0.16 2.33 0.036 0.11 0.54 1.81 0.093 0.30 0.39
1425751_at BCOl4805 236149 cDNA sequence BCOl4805 3 0.01 0.05 1.72 1.79 0.096 O. " 0.99 -1.46 0.167 0.58 -0.74I425752_at BCOl4805 236149 cDNA sequence BCO 14805 2.41 0.031 0.05 1.58 2.73 0.017 0.07 1.71 0.23 0.822 0.63 0.13
I426232_at BC024479 235184 cDNA sequence BC024479 1.99 0.067 0.09 0.56 2.32 0.037 0.11 0.62 0.26 0.802 0.62 0.06
I43700 I_at BC031361 56637 cD NA sequence BC03 I361 3.16 0.007 0.05 0.74 3.86 0.002 0.07 0.87 0.61 0.555 0.55 0.13
1437267_x_at BC035291 208043 cDNA sequence BC03529I
-3.21 0.007 0.11 -0.9 -1.6 0.133 0.34 -0.43 1.91 0.Q78 0.27 0.47
1435427_x_at BC037112 231128 cDNA sequence BC037112
-1.98 0.069 0.27 -0.73 -3.24 0.006 0.30 -1.14 -1.28 0.221 0.58 -0.41
1455306_at BC037112 231128 cDNA sequence BC037112 3.03 0.009 0.05 0.89 3.53 0.003 0.07 I 0.4 0.699 0.60 0.1
I455307_at BC037112 231128 cDNA sequence BC037112
-1.66 0.121 0.27 -0.75 -3.99 0.001 0.09 -1.72 -2.46 0.028 0.16 -0.97
I434835_at BC037674 2/8914 cDNA sequence BC037674
-2.8 0.015 0.17 -0.86 -0.64 0.531 0.39 -0.19 2.49 0.027 0.20 0.67
I435397_at BC038156 270135 cDNA sequence BC038156
-2.42 0.03 0.24 -0.98 -0.47 0.648 0.39 -0.18 2.25 0.042 0.22 0.8
1455 I55_at BC040823 241846 cDNA sequence BC040823 0.94 0.365 0.22 0.29 2.41 0.031 0.10 0.72 1.55 0.143 0.30 0.43
I436355_at BC044804 328035 Fatty acid desaturase (Fads6) 3.84 0.002 0.05 0.85 2.72 0.017 0.10 0.58 -1.41 0.181 0.64 -0.28
I437262_x_at Bcas2 68183 breast carcinoma amplified sequence 2 -3.08 0.009 0.07 -1.86 -1.93 0.Q75 0.32 -1.1 I 1.4 0.183 0.32 0.74
I429539_at Bel2113 94044 BCl2-like 13 (apoptosis facilitator) 3.07 0.009 0.05 0.87 2.5 0.026 0.10 0.68 -0.77 0.454 0.68 -0.19
I428845_at Bclafl 72567 BCl2-associated transcription factor I 1.73 0.106 0.12 0.45 -0.23 0.823 0.39 -0.06 -2.22 0.044 0.22 -0.51
I436023_at Belafl 72567 BCl2-associated transcription factor I 1.81 0.093 0.07 0.75 -1.06 0.308 0.39 -0.42 -3.22 0.007 0.09 -1.17
I429438_at Bcor 71458 Bel6 interacting corepressor 1.74 0.105 0.10 0.42 2.67 0.019 0.10 0.61 0.93 0.371 0.48 0.19
I426959_at Bdh 71911 3-hydroxybutyrate dehydrogenase 0.89 0.39 0.22 0.32 2.66 0.019 0.09 0.91 1.89 0.081 0.27 0.59
141 6866_at Betl 12068 blocked early in transport I homolog -2.62 0.021 0.23 -0.71 -1.51 0.154 0.37 -0.39 1.34 0.203 0.32 0.32
I426372_a_at Betll 54399 blocked early in transport I homolog -2.97 0.011 0.12 -0.67 -3.6 0.003 0.30 -0.78 -0.54 0.595 0.68 -0.11
I435484_at BF642829 503859 expressed sequence BF642829 -1.25 0.234 0.31 -0.46 1.13 0.28 0.24 0.39 2.64 0.02 0.20 0.85
1416405_at Bgn 12111 biglycan 3.05 0.009 0.05 0.68 0.64 0.535 0.30 0.14 -2.78 0.015 0.17 -0.55
I448323_a_at Bgn 12111 biglycan 3.4 0.005 0.05 0.91 1.43 0.176 0.17 0.37 -2.31 0.037 0.38 -0.54
I450732_a_at Bicd2 76895 bicaudal D homolog 2 (Drosophila) -2.24 0.042 0.23 -0.56 -0.65 0.526 0.39 -0.15 1.84 0.087 0.30 0.4
1421 392_a_at Bird 11796 baculoviral lAP repeat-containing 3 1.05 0.312 0.22 0.24 2.64 0.02 0.10 0.59 1.68 0.116 0.30 0.34
I456088_at Birc4 11798 BaculovirallAP repeat-containing 4 (Birc4), -0.37 0.714 0.40 -0.13 -3.9 0.002 0.24 -1.29 -3.82 0.002 0.05 -1.16
I438961_s_at Blmh 104184 bleomycin hydrolase 2.22 0.044 0.05 0.76 0.8 0.438 0.30 0.26 -1.66 0.12 0.58 -0.5
141 6923_a_at Bnip31 12177 BCl2ladenovirus EIB -3.23 0.006 0.15 -0.64 -1.55 0.144 0.35 -0.29 1.99 0.068 0.27 0.34
I434544_at Bola2 66162 bolA-like 2 (E. coli) -0.51 0.616 0.40 -0.14 1.76 0.101 0.17 0.45 2.5 0.026 0.22 0.59
144921 I_at Bpntl 23827 bisphosphate 3'-nucleotidase I -2.35 0.035 0.24 -0.55 -1.33 0.207 0.39 -0.3 1.23 0.241 0.41 0.25
I43877 I_at Brdl 223770 bromodomain containing I 1.79 0.096 0.09 0.43 -0.28 0.782 0.39 -0.06 -2.35 0.035 0.38 -0.49
1437210_a_at Brd2 14312 bromodomain containing 2 2.32 0.036 0.07 0.58 1.08 0.298 0.25 0.26 -1.47 0.166 0.63 -0.32
I424922_a_at Brd4 57261 bromodomain containing 4 3.24 0.006 0.05 0.87 2.45 0.029 0.11 0.63 -1.03 0.322 0.66 -0.24
145071 I_at Brd4 57261 bromodomain containing 4 3.65 0.003 0.05 1.04 3.68 0.003 0.07 I -0.15 0.881 0.68 -0.04
1453651_a_at Brp441 55951 brain protein 44-like -2.19 0.046 0.25 -0.59 -0.27 0.788 0.39 -0.07 2.2 0.046 0.27 0.52
I437345_a_at Bsel2 14705 Bernardinelli-Seip congenital lipodystrophy 2 homolog 1.89 0.08 0.09 0.48 2.23 0.043 0.11 0.54 0.28 0.784 0.62 0.06
(human)
1435248 a at Btafl 107182 BTAF I RNA Dolymerase II -2.71 0.017 0.15 -0.57 -1.06 0.308 0.39 -0.21 1.94 0.074 0.30 0.36
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I42727 I_at Btbd 15 235132 BTB (POZ) domain containing 15 1.53 0.15 0.11 0.53 2.6 0.021 0.10 0.86 1.09 0.293 0.41 0.33
1423839_a_at Btf3 218490 basic transcription factor 3
-3.29 0.006 0.12 -0.88 -2.4 0.032 0.32 -0.61 1.14 0.275 0.44 0.27
I426083_a_at Btgl 12226 B-cell translocation gene I, anti-proliferative
-2.32 0.037 0.26 -0.67 -0.41 0.688 0.39 -0.11 2.2 0.046 0.22 0.56
I437455_a_at Btgl 12226 B-cell translocation gene I, anti-proliferative
-3.7 0.003 0.08 -1.17 -1.22 0.243 0.39 -0.37 2.88 0.013 0.20 0.8
I450846_at Bzwl 66882 basic leucine zipper and W2 domains I
-0.21 0.839 0.40 -0.06 -3.1 0.008 0.31 -0.81 -3.14 0.008 0.14 -0.75
I428490_at Clgaltl 94192 core I UDP-galactose
-2.62 0.021 0.15 -0.95 -1.3 0.217 0.37 -0.45 1.57 0.14 0.32 0.5
1417009_at Clr 50909 complement component I, r subcomponent 1.86 0.084 0.12 0.46 -0.27 0.79 0.39 -0.06 -2.42 0.03 0.27 -0.53
1416051_at C2 12263 complement component 2 (within H-2S) 2.86 0.013 0.05 0.79 1.49 0.158 0.20 0.4 -1.62 0.127 0.55 -0.4
I457664_x_at C2 12263 complement component 2 (within H-2S) 2.81 0.014 0.05 0.73 1.17 0.262 0.24 0.29 -1.92 0.076 0.48 -0.44
I435485_at C230096C 1ORik 230866 RIKEN cDNA C230096C10 gene 2.55 0.024 0.07 0.66 1.71 0.11 0.13 0.42 -1.04 0.316 0.66 -0.24
1436194_at C330008K 14Rik 77619 RIKEN cDNA C330008KI4 gene 4.57 0 0.05 3.58 3.57 0.003 0.Q7 2.67 -1.32 0.21 0.41 -0.91
1434171_at C3300 II K17Rik 238692 RIKEN cDNA C3300 II K17 gene -3.12 0.008 0.07 -2.17 -2.7 0.018 0.29 -1.8 0.61 0.55 0.53 0.37
I439764_s_at C330012H03Rik 319765 RIKEN cDNA C3300 12H03 gene 1.77 0.1 0.08 1.27 2.24 0.042 0.07 1.54 0.43 0.673 0.55 0.27
I439783_at C330018D20Rik 77422 RIKEN cDNA C330018D20 gene
-3.86 0.002 0.10 -0.8 -3.14 0.007 0.31 -0.62 0.97 0.347 0.46 0.18
1427131_s_at C330018J07Rik 69110 RIKEN cDNA C3300 18J07 gene -2.28 0.039 0.15 -0.77 -2.13 0.052 0.32 -0.69 0.27 0.788 0.62 0.08
1434217_at C330019G07Rik 215476 RIKEN cDNA C3300 19G07 gene 3.25 0.006 0.05 0.76 3.08 0.008 0.09 0.69 -0.35 0.732 0.68 -0.07
435550_at C4300 14K I IRik 320003 RIKEN cDNA C430014KII gene 4.54 0.001 0.05 1.01 4.05 0.001 0.07 0.86 -0.76 0.46 0.68 -0.15
455339_at C430014M02Rik 338355 RIKEN cDNA C430014M02 gene 2.18 0.048 0.Q7 0.7 1.57 0.139 0.15 0.48 -0.76 0.458 0.68 -0.22
448028_at C530046L02Rik 224617 RIKEN cDNA C530046L02 gene 1.1 0.291 0.17 0.34 2.58 0.023 0.09 0.75 1.55 0.143 0.36 0.42
449308_at C6 12274 complement component 6 -0.31 0.763 0.40 -0.08 -3.3 0.005 0.30 -0.78 -3.24 0.006 0.11 -0.71
435691_at C630028N24Rik 235386 RIKEN cDNA C630028N24 gene -0.05 0.961 0.40 -0.01 2.81 0.014 0.10 0.68 3.11 0.008 0.20 0.69
442349_at C630028N24Rik 235386 RIKEN cDNA C630028N24 gene 0.39 0.701 0.22 0.23 -2.2 0.046 0.32 -1.24 -2.84 0.014 0.11 -1.47
455383_at C730043017 330126 hypothetical protein C7300430 17 2.39 0.032 0.07 0.78 1.66 0.119 0.13 0.52 -0.91 0.38 0.66 -0.26
4361 62_at C730048C 13Rik 319800 RIKEN cDNA C730048C 13 gene -2.2 0.046 0.22 -0.71 -2.22 0.044 0.32 -0.68 0.08 0.934 0.63 0.02
4461 47_at C79248 96982 expressed sequence C79248 2.19 0.046 0.05 1.03 3.27 0.006 0.07 1.47 1.06 0.306 0.32 0.44
436489_x_at C85492 215494 expressed sequence C85492 2.45 0.029 0.07 0.68 4.44 0.001 0.07 1.18 2.04 0.061 0.27 0.5
427472_a_at C8b 110382 complement component 8, beta subunit 1.3 0.216 0.17 0.35 -0.79 0.442 0.39 -0.2 -2.34 0.035 0.30 -0.55
422477_at Cables I 63955 Cdk5 and Abl enzyme substrate 1 3.67 0.003 0.05 1.79 2.66 0.019 0.09 1.24 -1.28 0.222 0.63 -0.55
424768_at Caldl 109624 caldesmon I 1.49 0.158 0.15 0.44 -0.52 0.613 0.39 -0.15 -2.26 0.041 0.17 -0.59
454611_a_at Calml 12313 calmodulin I -2.58 0.023 0.15 -0.78 -0.83 0.419 0.39 -0.24 2.03 0.063 0.27 0.54
I426710_at Calm3 12315 calmodulin 3 2.54 0.024 0.05 0.8 2.58 0.022 0.10 0.78 -0.08 0.941 0.68 -0.02
I424474_a_at Camkk2 207565 calcium/calmodulin-dependent protein kinase kinase 2, 2.33 0.036 0.05 0.63 1.94 0.073 0.15 0.5 -0.53 0.602 0.68 -0.13
beta I
429044_at Camsaplll 67886 calmodulin regulated spectrin-associated protein I-like I 1.65 0.122 0.12 0.38 2.99 0.01 0.09 0.65 1.38 0.191 0.38 0.28
41 6265_at CapnlO 23830 calpain 10 2.4 0.032 0.07 0.66 0.85 0.41 0.27 0.22 -1.8 0.094 0.48 -0.43
425916_at Capn8 170725 calpain 8 -3.19 0.007 0.12 -1.15 -5.08 0 0.00 -1.74 -1.89 0.081 0.41 -0.6
439455_x_at Capzal 12340 capping protein (actin filament) muscle Z-line -2.7 0.018 0.23 -0.67 -1.84 0.088 0.33 -0.43 1.08 0.3 0.44 0.23
423058_at Capza2 12343 capping protein (actin filament) muscle Z-line -1.09 0.293 0.31 -0.34 -2.24 0.042 0.32 -0.66 -1.19 0.253 0.65 -0.32
427482_a_at Car8 12319 carbonic anhydrase 8 -3.06 0.009 0.15 -0.82 -1.8 0.094 0.33 -0.46 1.53 0.15 0.36 0.36
41 9743_s_at Carmi 59035 coactivator-associated arginine methyltransferase I 2.18 0.048 0.07 0.68 1.52 0.152 0.20 0.45 -0.83 0.421 0.66 -0.23
452394_at Cars 27267 cysteinyl-tRNA synthetase 2.21 0.045 0.Q7 0.9 1.19 0.253 0.20 0.47 -1.21 0.246 0.63 -0.44
434099_at Casp7 12369 Caspase 7 2.47 0.027 0.05 0.65 4.9 0 0.07 1.23 2.52 0.025 0.22 0.58
434100_x_at Casp7 12369 Caspase 7 2.27 0.04 0.07 0.57 5.35 0 0.07 1.29 3.24 0.006 0.20 0.72
437537_at Casp9 12371 caspase 9 2.69 0.018 0.05 0.78 2.3 0.038 0.11 0.64 -0.56 0.588 0.68 -0.14
437448_s_at Catns 12388 catenin src 2.29 0.039 0.05 0.73 1.39 0.187 0.20 0.43 -1.09 0.295 0.66 -0.31
460 I96_at Cbrl 12408 carbonyl reductase 1 0.57 0.575 0.26 0.13 2.18 0.047 0.13 0.49 1.72 0.108 0.32 0.35
452678_a_at Ccbll 70266 cysteine conjugate-beta lyase I 2.42 0.03 0.05 0.73 0.61 0.549 0.30 0.18 -2.09 0.057 0.41 -0.55
419803 s at Ccdcl2 72654 coiled-coil domain containinl! 12 1.37 0.194 0.15 0.41 2.19 0.047 0.10 0.63 0.83 0.423 0.50 0.22
~
00
Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene 10 t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1416488_at Ccng2 12452 cyclin G2
-4.15 0.001 0.07 -1.09 -2.16 0.049 0.33 -0.55 2.36 0.034 0.22 0.55
1416427 at Ccni 12453 cyclin I
-0.64 0.533 0.40 -0.24 -2.6 0.022 0.31 -0.93 -2.1 0.055 0.36 -0.69
I448334_a_at Ccni 12453 cyclin I
-3.78 0.002 0.08 -1.02 -1.82 0.092 0.33 -0.47 2.33 0.036 0.22 0.55
I448335_s_at Ccni 12453 cyclin I 2.32 0.036 0.09 0.57 -0.23 0.825 0.39 -0.05 -2.89 0.012 0.14 -0.62
14321 95_s_at Ccnl2 56036 cyclin L2 2.24 0.042 0.07 0.76 0.93 0.368 0.25 0.3 -1.54 0.147 0.58 -0.46
1420127_s_at Ccpgl 72278 cell cycle progression I 3.26 0.006 0.05 0.83 4.43 0.001 0.07 1.07 1.12 0.284 0.41 0.25
1448715y_at Ccrn41 12457 CCR4 carbon catabolite repression 4-like 2.24 0.043 0.08 0.61 1.39 0.187 0.20 0.36 -1.03 0.32 0.66 -0.25
I433534_a_at Cct2 12461 chaperonin subunit 2 (beta)
-2.66 0.019 0.22 -0.76 -1.56 0.141 0.35 -0.43 1.33 0.206 0.36 0.33
I455988_a_at Cct6a 12466 chaperon in subunit 6a (zeta)
-2.65 0.019 0.24 -0.53 -0.88 0.395 0.39 -0.17 2.06 0.059 0.27 0.36
I448919_at Cd302 66205 CD302 antigen 2.11 0.055 0.07 0.6 -0.05 0.958 0.39 -0.01 -2.46 0.028 0.36 -0.62
1423 I66_at Cd36 12491 CD36 antigen 1.18 0.26 0.12 0.79 2.65 0.019 0.09 1.69 1.55 0.145 0.27 0.91
I450883_a_at Cd36 12491 CD36 antigen 1.17 0.261 0.11 0.8 2.44 0.029 0.09 1.59 1.32 0.209 0.32 0.79
1450884_at Cd36 12491 CD36 antigen 0.95 0.358 0.14 0.6 2.53 0.025 0.09 1.52 1.67 0.118 0.27 0.92
1449507_a_at Cd47 16423 CD47 antigen 2.2 0.046 0.08 0.76 1.67 0.118 0.15 0.55 -0.68 0.508 0.68 -0.21
14491 93_at Cd51 11801 CD5 antigen-like 1.72 0.109 0.08 1.14 -0.32 0.754 0.39 -0.2 -2.3 0.038 0.22 -1.34
1416066_at Cd9 12527 CD9 antigen 1.63 0.126 0.10 0.82 2.96 0.011 0.07 1.42 1.36 0.195 0.27 0.6
1436197_at Cdc42bpg 240505 CDC42 binding protein kinase gamma 2.26 0.041 0.05 0.68 3.57 0.003 0.07 1.02 1.31 0.213 0.41 0.34
1416511_a_at Cdc42ep4 56699 CDC42 effector protein (Rho GTPase binding) 0.68 0.509 0.22 0.27 2.31 0.038 0.10 0.88 1.74 0.105 0.30 0.61
1448261_at Cdhl 12550 cadherin I -2.47 0.028 0.11 -1.79 -1.5 I 0.153 0.32 -1.05 1.16 0.266 0.38 0.74
I452832_s_at Cds2 110911 CDP-diacylglycerol synthase (phosphatidate 2.49 0.027 0.05 0.75 2.55 0.024 0.10 0.74 -0.06 0.955 0.68 -0.02
cytidylyltransferase) 2
I425675_s_at Ceacaml 26365 CEA-related cell adhesion molecule I 3.55 0.003 0.05 0.93 -1.61 0.13 0.35 -0.4 -5.79 0 0.00 -1.33
I450494_x_at Ceacaml 26365 CEA-related cell adhesion molecule I 2.55 0.024 0.05 1.05 1.18 0.259 0.24 0.46 -1.62 0.129 0.50 -0.58
4221 23_s_at Ceacaml/2 26365 CEA-related cell adhesion molecule 1/2 2.32 0.037 0.05 1.05 1.22 0.243 0.22 0.53 -1.31 0.212 0.63 -0.52
46068 I_at Ceacam2 26367 CEA-related cell adhesion molecule 2 3.95 0.002 0.05 0.85 2.98 0.01 0.09 0.61 -1.25 0.232 0.65 -0.23
418901_at Cebpb 12608 CCMT/enhancer binding protein beta 2.26 0.041 0.05 1.02 1.24 0.236 0.22 0.53 -1.22 0.244 0.63 -0.48
427844_a_at Cebpb 12608 CCMT/enhancer binding protein beta 2.55 0.024 0.05 1.62 1.81 0.093 0.13 1.09 -0.94 0.365 0.65 -0.52
441 864_x_at Cenpa 12615 centromere autoantigen A -1.15 0.271 0.31 -0.71 -2.59 0.022 0.22 -1.53 -1.5 I 0.153 0.50 -0.82
45229 I_at Centdl 212285 centaurin, delta I 2.31 0.037 0.05 0.74 3.22 0.006 0.09 0.99 0.87 0.398 0.48 0.25
44908 I_at Ces3 104158 carboxylesterase 3 -1.19 0.253 0.35 -0.35 0.87 0.401 0.25 0.24 2.3 0.038 0.22 0.59
448052_at Cgnll 68178 cingulin-like I 1.17 0.262 0.17 0.37 -1.05 0.312 0.39 -0.32 -2.48 0.027 0.27 -0.69
452309_at Cgnll 68178 cingulin-Iike I 1.88 0.081 0.09 0.55 2.51 0.025 0.10 0.7 0.59 0.565 0.55 0.15
41 6938_at Chchdl 66121 coiled-coil-helix-coiled-coil-helix domain -2.62 0.021 0.23 -0.6 -1.98 0.069 0.33 -0.43 0.83 0.422 0.50 0.17
445843_at Chd2 244059 chromodomain helicase DNA binding protein 2 2.96 0.011 0.05 0.84 3.44 0.004 0.07 0.93 0.37 0.715 0.60 0.09
436343_at Chd4 107932 chromodomain helicase DNA binding protein 4 3.82 0.002 0.05 1.18 -0.4 0.697 0.39 -0.12 -4.78 0 0.04 -1.3
I457672_at Chd9 109151 chromodomain helicase DNA binding protein 9 -1.07 0.303 0.33 -0.4 0.98 0.344 0.27 0.35 2.29 0.039 0.20 0.76
1434529y_at Chfr 231600 checkpoint with forkhead and ring finger -2.29 0.039 0.15 -0.7 -0.48 0.637 0.39 -0.14 2.08 0.057 0.27 0.56
1426146_a_at Chptl 212862 choline phosphotransferase I -3.49 0.004 0.12 -0.91 -1.71 0.111 0.33 -0.42 2.12 0.054 0.27 0.48
I435446_a_at Chptl 212862 choline phosphotransferase I -1.88 0.082 0.27 -0.5 -2.57 0.023 0.32 -0.65 -0.66 0.52 0.68 -0.15
1455901_at Chptl 212862 choline phosphotransferase I -4.41 0.001 0.07 -1.78 -3.23 0.006 0.22 -1.25 1.5 0.156 0.32 0.53
1417091_at Chuk 12675 conserved helix-loop-helix ubiquitous kinase -2.92 0.012 0.15 -0.75 -1.3 0.214 0.38 -0.32 1.91 0.078 0.27 0.43
1428210_s_at Chuk 12675 conserved helix-loop-helix ubiquitous kinase -3.13 0.008 0.11 -1.12 -1.38 0.191 0.34 -0.47 2.06 0.059 0.27 0.65
1455019_x_at Ckap4 216197 cytoskeleton-associated protein 4 2.54 0.024 0.05 0.99 1.06 0.309 0.22 0.39 -1.74 0.105 0.53 -0.6
1423792_a_at Cklfsf6 67213 chemokine-like factor super family 6 -2.86 0.013 0.11 -0.95 -1.22 0.242 0.39 -0.39 1.92 0.076 0.27 0.56
141 6698_a_at Cksl b 54124 CDC28 protein kinase Ib -4.02 0.001 0.08 -0.99 -3.81 0.002 0.27 -0.89 0.42 0.68 0.60 0.09
I452702_at Clcn7 26373 chloride channel 7 2.24 0.042 0.07 0.6 1.77 0.1 0.17 0.45 -0.63 0.54 0.68 -0.15
I420345_at Cldnl4 56173 claud in 14 2.28 0.039 0.07 0.87 1.96 0.071 0.10 0.72 -0.46 0.65 0.68 -0.16
1417231 at Cldn2 12738 claudin 2 1.85 0.086 0.09 0.67 2.18 0.047 0.10 0.75 0.27 0.794 0.62 0.08
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Probe Symbol Entrez Description IGTI6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene 10 t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1419477_at Clec2d 93694 C-type lectin domain family 2, member d
-2.5 0.026 0.15 -0.71 -1.24 0.238 0.39 -0.33 1.51 0.155 0.36 0.37
I424673_at Clec2h 94071 C-type lectin domain family 2, member h
-2.31 0.Q38 0.12 -1.95 -2.16 0.049 0.32 -1.75 0.27 0.791 0.60 0.2
I42532I_a_at Clmn 94040 calmin
-0.9 0.382 0.37 -0.41 1.55 0.144 0.09 0.68 2.72 0.017 0.20 1.09
1417551_at Cln3 12752 ceroid lipofuscinosis, neuronal 3, juvenile 2.57 0.023 0.05 0.79 3.07 0.009 0.09 0.9 0.42 0.683 0.60 0.11
1423 I81_s_at Clnsla 12729 chloride channel, nucleotide-sensitive, IA
-1.73 0.107 0.27 -0.44 -2.7 0.018 0.31 -0.66 -0.97 0.35 0.66 -0.22
I428043_a_at Cmah 12763 cytidine monophospho-N-acetylneuraminic acid -0.29 0.777 0.40 -0.14 -2.26 0.041 0.32 -1.02 -2.13 0.053 0.36 -0.88
hydroxylase
I437850_a_at Cnbpl 12785 cellular nucleic acid binding protein I
-3.57 0.003 0.08 -0.87 -2.42 0.03 0.32 -0.56 1.43 0.176 0.38 0.3
I448263_a_at Cndp2 66054 CNDP dipeptidase 2 (metallopeptidase M20) 2.22 0.045 0.07 0.65 1.97 0.07 0.11 0.55 -0.38 0.711 0.68 -0.1
I459783_s_at Cno 117197 cappuccino
-4 0.001 0.08 -0.89 -3.1 0.008 0.30 -0.66 1.19 0.256 0.41 0.23
I433882_at CnotlO 78893 CCR.4-NOT transcription complex, subunit 10 2.42 0.03 0.05 0.91 2.07 0.058 0.13 0.74 -0.5 0.623 0.68 -0.17
I436645_a_at Cnot4 53621 CCR4-NOT transcription complex, subunit 4 1.93 0.075 0.10 0.54 3.1 0.008 0.09 0.83 1.17 0.261 0.41 0.29
1426327_s_at Cntf III Zfp91 109910 ciliary neurotrophic factor 3.36 0.005 0.05 0.85 -1.04 0.317 0.39 -0.25 -4.95 0 0.04 -1.1
141 6740_at Col5al 12831 procollagen, type V, alpha I 1.92 0.076 0.08 0.55 3.32 0.005 0.09 0.9 1.42 0.177 0.38 0.36
I454642_a_at Commd3 12238 COMM domain containing 3 -2.99 0.01 0.12 -0.79 -1.75 0.102 0.34 -0.44 1.5 0.157 0.36 0.35
1419017_at Corin 53419 corin 0.45 0.658 0.24 0.25 2.9 0.012 0.09 1.5 2.64 0.02 0.20 1.26
14371 46_x_at Coro7 78885 coronin 7 2.7 0.018 0.05 0.86 2 0.067 0.11 0.61 -0.91 0.38 0.67 -0.25
I437524_x_at Coro7 78885 coronin 7 2.93 0.011 0.05 0.95 1.5 0.157 0.17 0.46 -1.7 0.112 0.58 -0.48
1437811_x_at Codl 72042 coactosin-like I (Dictyostelium) 1.6 0.132 0.11 0.76 2.3 0.038 0.09 1.04 0.68 0.51 0.50 0.28
I437982_x_at Coxl5 226139 COX 15 homolog, cytochrome c oxidase -2.91 0.012 0.12 -1.04 -0.94 0.366 0.39 -0.32 2.29 0.039 0.22 0.72
141 5933_a_at Cox5a 12858 cytochrome c oxidase, subunit Va -2.15 0.05 0.26 -0.45 -0.32 0.751 0.39 -0.06 2.1 0.055 0.27 0.38
1416565_at Cox6bl 110323 cytochrome c oxidase, subunit Vlb polypeptide -0.88 0.396 0.38 -0.2 1.06 0.308 0.27 0.24 2.15 0.05 0.27 0.44
I43449 I_a_at Cox6c 12864 cytochrome c oxidase, subunit Vic -3.74 0.002 0.11 -0.71 -0.58 0.573 0.39 -0.1 3.63 0.003 0.20 0.6
41 7496_at Cp 12870 ceruloplasmin 4.21 0.001 0.05 1.38 3.38 0.005 0.07 1.06 - 1.11 0.287 0.65 -0.32
455393_at Cp 12870 ceruloplasmin 2.55 0.024 0.07 0.77 1.99 0.068 0.10 0.57 -0.75 0.469 0.68 -0.2
456048_at Cpeb3 --- cytoplasmic polyadenylation element binding 2.71 0.017 0.05 0.83 0.96 0.353 0.27 0.28 -2.04 0.061 0.44 -0.55
427459_at Cpn2 71756 carboxypeptidase N, polypeptide 2 3.38 0.005 0.05 0.84 2.35 0.035 0.11 0.56 -1.29 0.22 0.63 -0.28
430520_at Cpne8 66871 copine VIII 2.43 0.03 0.05 0.96 0.75 0.464 0.30 0.28 -1.95 0.073 0.38 -0.67
424469_a_at Cpsf4 54188 cleavage and polyadenylation specific factor 4 2.32 0.037 0.05 0.85 2.43 0.03 0.11 0.85 0.01 0.995 0.63 0
434866_x_at Cptla 12894 carnitine palmitoyltransferase Ia, liver -1.35 0.198 0.28 -0.46 0.63 0.538 0.30 0.21 2.23 0.043 0.22 0.67
4381 56_x_at Cptla 12894 carnitine palmitoyltransferase 1a, liver
- 1.57 0.139 0.27 -0.56 0.52 0.609 0.30 0.18 2.36 0.034 0.22 0.74
434633_at Crebbp 12914 CREB binding protein 2.44 0.029 0.05 0.67 2.88 0.013 0.09 0.76 0.35 0.728 0.60 0.09
416614_at Cril 58521 CREBBP/EP300 inhibitory protein I 0.55 0.589 0.26 0.14 -2.31 0.038 0.32 -0.55 -3.14 0.008 0.09 -0.69
41 6201_at Crk 12928 v-crk sarcoma virus CT 10 oncogene homolog -0.19 0.853 0.40 -0.07 -2.48 0.027 0.32 -0.84 -2.49 0.027 0.20 -0.77
450966_at Crot 74114 carnitine O-octanoyltransferase -2.74 0.017 0.15 -0.74 -2.03 0.062 0.33 -0.53 0.9 0.384 0.48 0.21
422577_at Cs 12974 citrate synthase 0.98 0.346 0.22 0.3 2.19 0.047 0.11 0.63 1.27 0.224 0.36 0.34
450667_a_at Cs 12974 citrate synthase 0.08 0.938 0.26 0.02 2.1 0.056 0.13 0.47 2.19 0.047 0.27 0.45
435800_a_at Csda 56449 cold shock domain protein A - 1.5 0.157 0.29 -0.42 0.51 0.617 0.30 0.14 2.27 0.041 0.22 0.56
451012_a_at Csda 56449 cold shock domain protein A 1.14 0.274 0.18 0.37 - 1.1 0.291 0.39 -0.34 -2.5 0.026 0.20 -0.7
455660_at Csf2rbl 12983 colony stimulating factor 2 receptor, beta I 2.71 0.017 0.05 1.33 2 0.067 0.09 0.93 -0.92 0.375 0.66 -0.39
437690_x_at Csnkld 104318 casein kinase I, delta 2.34 0.035 0.05 0.7 1.99 0.067 0.11 0.57 -0.5 0.624 0.68 -0.13
423370_a_at Csnklg2 103236 casein kinase I, gamma 2 2.01 0.065 0.08 0.52 2.37 0.033 0.11 0.58 0.29 0.777 0.62 0.07
419038_a_at Csnk2al 12995 casein kinase II, alpha I polypeptide 2.2 0.045 0.07 0.62 -0.73 0.481 0.39 -0.2 -3.3 0.006 0.09 -0.82
459476_s_at Csrp2bp 228714 cysteine and glycine-rich protein binding 2.56 0.023 0.07 0.61 3.32 0.005 0.07 0.76 0.7 0.496 0.53 0.15
448597_at Cstfl 67337 cleavage stimulation factor, subunit I 2.93 0.011 0.05 0.73 2.35 0.034 0.11 0.56 -0.77 0.454 0.68 -0.17
449042_at Ctd 13018 CCCTC-binding factor 2.27 0.04 0.07 0.59 -0.76 0.46 0.39 -0.19 -3.41 0.004 0.10 -0.78
452055_at Ctdspl 227292 CTD small phosphatase I 2.96 0.011 0.05 0.63 1.52 0.152 0.20 0.31 - 1.71 0.11 0.58 -0.32
451075 s at Ctdso2 52468 CTD small ohosohatase 2 2.38 0.032 0.05 0.64 2.73 0.017 0.10 0.7 0.25 0.804 0.63 0.06
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1417490_at Ctsb 13030 cathepsin B 2.59 0.022 0.07 0.58 1.45 0.17 0.17 0.31 -1.37 0.192 0.64 -0.27
1417491_at Ctsb 13030 cathepsin B 2.8 0.015 0.05 1.16 1.9 0.079 0.10 0.75 -1.12 0.282 0.65 -0.41
I41 7492_at Ctsb 13030 cathepsin B 3.06 0.009 0.05 1.18 1.88 0.082 0.10 0.7 -1.43 0.174 0.63 -0.49
141 6382_at Ctsc 13032 cathepsin C 2.63 0.02 0.05 1.19 1.67 0.118 0.10 0.72 -1.17 0.261 0.65 -0.46
1448118_a_at Ctsd 13033 cathepsin D 2.62 0.021 0.05 0.64 2.2 0.046 0.11 0.51 -0.59 0.562 0.68 -013
1423917_a_at Cttn 13043 cortactin 2.49 0.027 0.07 0.56 2 0.066 0.13 0.43 -0.65 0.524 0.68 -0.13
I426408_at Cugbpl 13046 CUG triplet repeat, RNA binding protein I 1.14 0.274 0.17 0.32 3.52 0.004 0.07 0.93 2.53 0.024 0.22 0.61
1451971_at Cul4a 99375 cullin 4A -2.05 0.06 0.27 -0.49 0.47 0.643 0.30 0.11 2.85 0.013 0.20 0.6
I422484_at Cycs 13063 cytochrome c, somatic -2.95 0.011 0.15 -0.64 -1.22 0.243 0.39 -0.25 2.03 0.063 0.27 0.39
1456071_a_at Cycs 13063 cytochrome c, somatic -2.81 0.014 0.17 -0.74 -1.16 0.268 0.39 -0.29 1.94 0.073 0.27 0.45
I459866_x_at Cyfipl 93790 cytoplasmic FMR I interacting protein I 2.18 0.047 0.08 0.5 2.38 0.032 0.11 0.52 0.11 0.912 0.63 0.Q2
1419430_at Cyp26a I 13082 cytochrome P450, family 26 2.02 0.064 0.05 1.17 -1.24 0.237 0.37 -0.68 -3.65 0.003 0.05 -1.85
I449479_at Cyp2b 13 13089 cytochrome P450, family 2 1.2 0.249 0.05 1.42 2.66 0.019 0.07 3 1.53 0.15 0.27 1.58
I425645_s_at Cyp2b20 13088 cytochrome P450, family 2 0.22 0.833 0.26 0.15 2.28 0.039 0.10 1.57 2.24 0.042 0.20 1.41
I41 9590_at Cyp2b9 13094 cytochrome P450. family 2 2.88 0.012 0.05 3.88 5.15 0 0.00 6.62 2.32 0.037 0.20 2.74
I45250'_at Cyp2c38 f 39 13097 cytochrome P450, family 2 1.06 0.308 0.18 0.52 3.92 0.002 0.07 1.85 3.06 0.009 0.20 1.33
1421 363_at Cyp2c39 13098 cytochrome P450, family 2 1.9 0.079 0.07 1.9 3.45 0.004 0.07 3.3 1.59 0.134 0.20 1.4
1418780_at Cyp39al 56050 cytochrome P450, family 39 -0.87 0.399 0.39 -0.33 1.2 0.249 0.17 0.44 2.3 0.038 0.22 0.77
1417709_at Cyp46a I 13116 cytochrome P450, family 46 2.08 0.057 0.05 1.3 2.53 0.Q25 0.09 1.51 0.38 0.71 0.53 0.21
I424853_s_at Cyp4al0 13117 cytochrome P450, family 4 -1.46 0.166 0.26 -2.25 1.31 0.213 0.15 1.92 3.09 0.008 0.07 4.17
1417070_at Cyp4v3 102294 cytochrome P450, family 4 -2.27 0.04 0.26 -0.61 -2.11 0.054 0.32 -0.55 0.29 0.78 0.62 0.07
I438743_at Cyp7al 13122 cytochrome P450, family 7 3.16 0.007 0.05 1.45 1.69 0.114 0.15 0.74 -1.76 0.101 0.44 -0.71
I449309_at Cyp8bl 13124 cytochrome P450, family 8 -2.61 0.021 0.23 -0.73 -0.54 0.596 0.39 -0.14 2.38 0.032 0.22 0.58
455384y_at D030056L22Rik 225995 RIKEN cDNA D030056L22 gene -3.1 0.008 0.15 -0.72 -0.25 0.807 0.39 -0.06 3.26 0.006 0.20 0.67
41 8439_at D IOErtd322e 67270 DNA segment. Chr 10 -2.64 0.02 0.22 -0.65 -0.39 0.704 0.39 -0.09 2.58 0.022 0.22 0.56
449446_at D IOErtd718e 52713 DNA segment. Chr 10 -0.54 0.598 0.40 -0.12 -2.35 0.035 0.32 -0.49 -1.94 0.074 0.44 -0.37
424780_a_at D 10Uciai 28193 DNA segment, Chr 10 -0.89 0.389 0.39 -0.24 2.45 0.028 0.10 0.62 3.68 0.003 0.20 0.86
433976_at DIOUcial 28193 DNA segment, Chr 10 -1.06 0.307 0.34 -0.31 1.27 0.226 0.24 0.35 2.59 0.022 0.22 0.66
426715_s_at DII Ertdl8e 52466 DNA segment, Chr II 2.1 0.055 0.05 0.62 0.2 0.845 0.30 0.06 -2.17 0.048 0.41 -0.56
453111_a_at D II Ertd333e 68066 DNA segment, Chr I I 2.39 0.032 0.05 0.75 -1.05 0.313 0.39 -0.31 -3.86 0.002 0.05 -1.06
455500_at D II Ertd75ge 268513 DNA segment, Chr II 3.04 0.009 0.05 1.04 2.01 0.065 0.09 0.66 -1.27 0.224 0.65 -0.38
449257_at DIIWsu9ge 28081 DNA segment, Chr II 1.9 0.079 0.10 0.5 2.68 0.018 0.10 0.68 0.76 0.463 0.50 0.18
451 748_a_at D I2Ertd77I e 52690 DNA segment. Chr 12 -2.74 0.016 0.18 -0.81 -0.34 0.738 0.39 -0.1 2.75 0.016 0.22 0.71
443327_at D 130043K22Rik 210108 RIKEN cDNA D 130043K22 gene 2.4 0.032 0.05 1.23 3.29 0.006 0.07 1.61 0.86 0.407 0.46 0.38
460689_at DI5Wsu75e 28075 DNA segment. Chr 15 2.48 0.027 0.05 0.61 2.04 0.061 0.13 0.48 -0.6 0.56 0.68 -0.13
460741_x_at Dl7Wsu92e 224647 DNA segment, Chr 17 -1.22 0.245 0.33 -0.39 1.36 0.197 0.20 0.42 2.86 0.013 0.20 0.82
433702_at DI9Wsul2e 226090 DNA segment, Chr 19 1.65 0.121 0.07 0.59 2.15 0.05 0.11 0.74 0.46 0.653 0.58 0.15
451 743_at D 19Wsul62e 226178 DNA segment, Chr 19 -1.55 0.144 0.28 -0.44 0.53 0.603 0.30 0.15 2.34 0.035 0.22 0.59
43622 I_at D IErtd471e 27877 DNA segment, Chr I 2.78 0.015 0.05 1.39 2.23 0.043 0.10 1.06 -0.74 0.471 0.68 -0.32
436293_x_at D IErtd47I e 27877 DNA segment. Chr I 1.56 0.141 0.11 0.61 2.28 0.039 0.10 0.85 0.7 0.493 0.50 0.24
433808_at D33000 IF17Rik 223658 RIKEN cDNA D33000 IF 17 gene 3.12 0.008 0.05 0.98 2.28 0.039 0.11 0.68 -1.07 0.302 0.66 -0.29
434452_x_at D3Ertdl94e 229317 DNA segment. Chr 3 -3.66 0.003 0.08 -1.37 -1.24 0.235 0.39 -0.44 2.81 0.014 0.20 0.92
4391 85_x_at D430028G21 Rik 228607 RIKEN cDNA D430028G21 gene -2.3 0.038 0.24 -0.72 -0.49 0.632 0.39 -0.15 2.08 0.057 0.27 0.58
417321_at D4Wsul32e 28027 DNA segment, Chr 4 -1.81 0.092 0.27 -0.45 0.51 0.618 0.30 0.12 2.62 0.021 0.20 0.57
417001_a_at D4Wsu53e 27981 DNA segment, Chr 4 -1.63 0.127 0.27 -0.49 -2.27 0.04 0.32 -0.65 -0.62 0.547 0.68 -0.16
43472I_at D5Ertd585e 71782 DNA segment. Chr 5 -0.24 0.813 0.40 -0.06 2.13 0.052 0.11 0.51 2.6 0.022 0.22 0.57
425222_x_at D630002G06 236293 hypothetical protein D630002G06 0.69 0.501 0.15 0.39 3.77 0.002 0.07 2.01 3.32 0.005 0.20 1.63
451635 at D630002G06 236293 hvoothetical orotein D630002G06 0.94 0.363 0.15 0.65 3.87 0.002 0.07 2.57 3.14 0.008 0.20 1.91
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6·NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t·stat p-value q-value Fold Ch. t·stat p.value q-value Fold Ch t-stat p-value q-value Fold Ch.
1434446 at D6300 14A 15Rik 319666 RIKEN cDNA D630014AI5 gene 1.24 0.234 0.18 0.36 4.12 0.001 0.07 1.13 3.07 0.009 0.20 0.77
14391 89_at D630023B 12Rik 329679 RIKEN cDNA D630023B 12 gene 1.3 0.217 0.14 0.53 2.34 0.035 0.10 0.92 1.07 0.302 0.41 0.39
1434886_at D630048PI9Rik 403187 RIKEN cDNA D630048P 19 gene 2.73 0.017 0.05 0.61 2.77 0.016 0.10 0.59 -0.1 0.922 0.68 -0.02
I447724y_at D630048PI9Rik 403187 RIKEN cDNA D630048P19 gene 2.62 0.021 0.07 0.61 2.83 0.014 0.09 0.63 0.09 0.927 0.63 0.02
I433589_at D6Wsul16e 28006 DNA segment, Chr 6 2.89 0.012 0.05 1.18 2.25 0.041 0.10 0.88 -0.83 0.42 0.66 -0.3
I456056_a_at D6Wsul16e 28006 DNA segment, Chr 6 2.68 0.018 0.07 0.62 2.9 0.012 0.09 0.64 0.11 0.916 0.63 0.02
1417953_at D6Wsul76e 27999 DNA segment, Chr 6 2.4 0.032 0.07 0.6 1.67 0.117 0.17 0.4 -0.91 0.379 0.66 -0.2
I448904_at D6Wsu 176e 27999 DNA segment, Chr 6 3.05 0.009 0.05 0.73 3.31 0.005 0.09 0.76 0.13 0.897 0.63 0.03
I424989_at D730049H07Rik 109305 RIKEN cDNA D730049H07 gene 1.8 0.094 0.11 0.51 2.19 0.047 0.11 0.6 0.33 0.746 0.60 0.08
144861 I_at D8Ertd594e 52357 DNA segment, Chr 8 2.83 0.014 0.05 0.66 3.38 0.005 0.09 0.75 0.46 0.65 0.58 0.09
I454935_at D930001122Rik 228859 RIKEN cDNA D930001122 gene
-1.43 0.175 0.28 -0.38 1.13 0.276 0.25 0.29 2.87 0.013 0.20 0.66
I426834_s_at D930015E06Rik 229473 RIKEN cDNA D9300 15E06 gene 2.66 0.019 0.05 0.71 2.71 0.018 0.10 0.69 -0.08 0.934 0.68 -0.02
I433558_at Dab2ip 69601 disabled homolog 2 interacting protein 1.38 0.19 0.15 0.29 4.29 0.001 0.07 0.88 3.1 0.008 0.20 0.58
I423872_a_at Dagl 13138 dystroglycan I 2.83 0.014 0.05 0.7 3.04 0.009 0.09 0.72 0.08 0.935 0.63 0.02
I426778_at Dagl 13138 dystroglycan I 4.03 0.001 0.05 0.91 3.23 0.006 0.09 0.7 -1.07 0.303 0.66 -0.21
1456131_x_at Dagl 13138 dystroglycan I 3.29 0.006 0.05 0.81 3.4 0.005 0.07 0.8 -0.04 0.97 0.68 -0.01
I423790_at Dap 223453 death-associated protein 2.34 0.035 0.08 0.67 0.97 0.348 0.24 0.27 -1.61 0.131 0.58 -0.4
1451453_at Dapk2 13143 death-associated kinase 2 0.23 0.822 0.26 0.1 2.59 0.022 0.09 1.11 2.56 0.023 0.20 1.01
I438093_x_at Dbi 13167 diazepam binding inhibitor
-2.29 0.039 0.26 -0.44 -0.56 0.587 0.39 -0.1 2.01 0.065 0.27 0.34
I460334_at Dbnl 13169 drebrin-like 2.42 0.03 0.07 0.72 0.93 0.367 0.27 0.27 -1.74 0.105 0.44 -0.45
I436532_at Dcamkl3 245038 doublecortin and CaM kinase-like 3 4.26 0.001 0.05 1.34 4.16 0.001 0.07 1.25 -0.32 0.757 0.68 -0.09
I435414_s_at Dctnl 13191 dynactin I 1.69 0.115 0.08 0.47 2.43 0.03 0.11 0.65 0.72 0.482 0.53 0.18
1458541_at Dctn4 67665 dynactin 4
-1.03 0.323 0.36 -0.29 1.69 0.114 0.17 0.46 3.01 0.01 0.20 0.75
455400_at Ddahl 69219 dimethylarginine dimethylaminohydrolase I 1.49 0.16 0.11 0.81 2.33 0.036 0.10 1.22 0.84 0.417 0.41 0.4
435376_at Ddhd2 72108 DDHD domain containing 2 0.87 0.399 0.20 0.25 2.42 0.03 0.11 0.66 1.65 0.123 0.32 0.41
426438_at Ddx3y 26900 DEAD (Asp-Glu-Ala-Asp) box polypeptide -2.28 0.04 0.26 -0.56 -1.1 0.289 0.39 -0.26 1.39 0.187 0.38 0.3
424598_at Ddx6 13209 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 3.7 0.003 0.05 0.82 -0.62 0.546 0.39 -0.13 -4.89 0 0.05 -0.95
449443_at Decrl 67460 2,4-dienoyl CoA reductase I, mitochondrial -0.84 0.414 0.38 -0.26 1.61 0.13 0.17 0.47 2.72 0.017 0.20 0.73
41 8295_s_at Dgatl 13350 diacylglycerol O-acyltransferase I 1.67 0.117 0.09 0.45 2.29 0.039 0.11 0.59 0.59 0.568 0.55 0.14
4521 69_a_at Dgkz 104418 diacylglycerol kinase zeta 1.94 0.074 0.10 0.56 2.48 0.027 0.09 0.69 0.5 0.625 0.58 0.13
418129_at Dhcr24 74754 24-dehydrocholesterol reductase 2.36 0.034 0.05 0.89 0.7 0.495 0.30 0.25 -1.93 0.075 0.44 -0.64
448619_at Dhcr7 13360 7-dehydrocholesterol reductase 4.39 0.001 0.05 1.39 2.32 0.037 0.10 0.7 -2.47 0.Q28 0.27 -0.69
426440_at Dhrs7 66375 dehydrogenase/reductase (SDR family) 7 1.45 0.171 0.11 0.61 2.27 0.04 0.10 0.92 0.83 0.422 0.46 0.31
416144_a_at Dhxl5 13204 DEAH (Asp-Glu-Ala-His) box polypeptide 15 -2.15 0.05 0.26 -0.54 -1.51 0.155 0.37 -0.36 0.81 0.432 0.50 0.18
438969_x_at Dhx30 72831 DEAH (Asp-Glu-Ala-His) box polypeptide 30 2.59 0.022 0.05 0.61 2.86 0.013 0.10 0.64 0.16 0.873 0.63 0.03
420427_a_at Dhx32 101437 DEAH (Asp-Glu-Ala-His) box polypeptide 32 2.44 0.029 0.05 0.62 -0.48 0.636 0.39 -0.12 -3.31 0.005 0.10 -0.74
428267_at Dhx40 67487 DEAH (Asp-Glu-Ala-His) box polypeptide 40 -2.53 0.Q25 0.12 -1.03 -0.97 0.351 0.39 -0.38 1.82 0.09 0.27 0.66
425617_at Dhx9 13211 DEAH (Asp-Glu-Ala-His) box polypeptide 9 2.44 0.029 0.05 0.78 3.56 0.003 0.07 1.09 1.1 0.292 0.44 0.31
451 770_s_at Dhx9 13211 DEAH (Asp-Glu-Ala-His) box polypeptide 9 1.66 0.12 0.11 0.42 4.22 0.001 0.07 1.01 2.7 0.018 0.22 0.59
427564_at Diap2 54004 diaphanous homolog 2 (Drosophila) 2.72 0.017 0.05 0.72 0.81 0.432 0.30 0.21 -2.22 0.044 0.20 -0.52
454654_at Dirc2 224132 disrupted in renal carcinoma 2 (human) -2.36 0.034 0.26 -0.66 -1.52 0.153 0.33 -0.41 1.04 0.317 0.46 0.26
426264_at Dlat 235339 dihydrolipoamide S-acetyltransferase 1.1 0.289 0.17 0.43 2.58 0.023 0.09 0.96 1.55 0.145 0.32 0.53
426265y_at Dlat 235339 dihydrolipoamide S-acetyltransferase 1.26 0.23 0.15 0.49 2.68 0.018 0.09 I 1.49 0.16 0.32 0.51
452005_at Dlat 235339 dihydrolipoamide S-acetyltransferase 0.12 0.909 0.26 0.03 2.79 0.015 0.09 0.78 2.91 0.012 0.20 0.75
448665_at Dmd 13405 dystrophin, muscular dystrophy -1.87 0.084 0.27 -0.54 0.29 0.775 0.30 0.08 2.44 0.029 0.22 0.62
459835_s_at Dnajal 15502 DnaJ (Hsp40) homolog, subfamily A. member I -3.72 0.002 0.07 -1.37 -2.43 0.03 0.31 -0.85 1.59 0.135 0.32 0.51
417191_at Dnajb9 27362 DnaJ (Hsp40) homolog, subfamily B, member 9 -6.83 0 0.04 -1.84 -4.84 0 0.09 -1.25 2.5 0.026 0.22 0.59
426905 a at DnaiclO 66861 Dnal IHsD40l homolol1. subfamilY C 1.97 0.07 0.10 0.67 2.9 0.012 0.09 0.94 0.92 0.374 0.41 0.27
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1417441_at Dnajcl2 30045 Dna) (Hsp40) homolog, subfamily C 1.99 0.068 0.07 1.17 -0.24 0.814 0.39 -0.13 -2.52 0.025 0.17 -1.3
I434038_at Dnajcl3 235567 Dna) (Hsp40) homolog, subfamily e 1.59 0.135 0.11 0.44 -0.44 0.664 0.39 -0.12 -2.29 0.039 0.38 -0.56
1437546 at Dnajcl4 74330 Dna) (Hsp40) homolog, subfamily e
-2.89 0.012 0.15 -0.84 0.62 0.548 0.30 0.17 3.97 0.002 0.20 1.01
I446928_at Dnajcl7 69408 Dna) (Hsp40) homolog, subfamily e
-3.91 0.002 0.08 -1.04 -2.84 0.014 0.31 -0.72 1.36 0.197 0.38 0.32
I448986_x_at Dnase2a 13423 deoxyribonuclease II alpha
-2.19 0.047 0.26 -0.99 -0.62 0.548 0.39 -0.27 1.82 0.091 0.27 0.72
1416648_at Dnchcl 13424 dynein, cytoplasmic. heavy chain I 2.71 0.017 0.05 0.62 3.71 0.002 0.07 0.81 0.95 0.358 0.46 0.19
I428086_at Dnmll 74006 dynamin I-like
-1.92 0.076 0.27 -0.63 0 0.999 0.30 0 2.19 0.047 0.20 0.63
I427033_at Dnmbp 71972 dynamin binding protein
-0.04 0.966 0.40 -0.01 1.94 0.074 0.15 0.43 2.16 0.049 0.22 0.44
1423066 at Dnmt3a 13435 DNA methyltransferase 3A 2.32 0.037 0.07 0.7 -0.47 0.649 0.39 -0.13 -3.15 0.007 0.11 -0.84
1438557_x_at Dnpep 13437 aspartyl aminopeptidase
-2.43 0.03 0.24 -0.71 -0.91 0.379 0.39 -0.26 1.77 0.099 0.27 0.46
I439452_x_at Dnpep 13437 aspartyl aminopeptidase
-2.37 0.034 0.26 -0.69 -0.96 0.356 0.39 -0.27 1.65 0.122 0.27 0.42
1449757_x_at Dntt 21673 deoxynucleotidyltransferase, terminal 1.95 0.072 0.05 1.97 2.42 0.031 0.09 2.34 0.41 0.688 0.53 0.36
I452220_at Dockl 330662 dedicator of eyro-kinesis I 3.22 0.006 0.05 0.88 1.77 0.1 0.15 0.46 -1.75 0.103 0.50 -0.42
1423116_at Dom3z 112403 DOM-3 homolog Z (c. elegans) 1.74 0.104 0.08 0.5 2.2 0.046 0.11 0.61 0.41 0.689 0.60 0.1
I459973_x_at Dpp4 13482 dipeptidylpeptidase 4
-2.49 0.026 0.26 -0.6 0.44 0.664 0.30 0.1 3.32 0.005 0.20 0.71
I433770_at Dpysl2 12934 dihydropyrimidinase-Iike 2 1.92 0.077 0.05 0.75 2.16 0.05 0.11 0.81 0.17 0.869 0.63 0.06
1416018_at Drl 13486 down-regulator of transcription I
-2.27 0.04 0.25 -0.59 -1.74 0.105 0.34 -0.43 0.69 0.499 0.53 0.16
1421 I56_a_at Dsc2 13506 desmocollin 2 2.49 0.026 0.05 0.75 3.25 0.006 0.09 0.94 0.7 0.496 0.53 0.19
1421 425_a_at Dscrlll 53901 Down syndrome critical region gene I-like I 1.27 0.224 0.08 0.79 4.11 0.001 0.07 2.45 3.03 0.009 0.20 1.66
I436038_a_at Dscr5 56176 Down syndrome critical region homolog 5 2.49 0.027 0.05 0.91 3.22 0.007 0.07 1.12 0.67 0.517 0.50 0.21
I460380_at Dsg2 135 I I desmoglein 2 1.7 0.112 0.05 0.79 -1.61 0.13 0.34 -0.72 -3.69 0.003 0.07 -1.5 I
I435493_at Dsp 109620 desmoplakin
-1.03 0.32 0.35 -0.33 1.3 0.215 0.20 0.4 2.59 0.022 0.22 0.73
I437301_a_at Dvll 13542 dishevelled, dsh homolog I (Drosophila) 3.19 0.007 0.05 0.74 2.94 0.011 0.09 0.65 -0.43 0.673 0.68 -0.09
I450978_at Dvll 13542 dishevelled, dsh homolog I (Drosophila) 3.56 0.003 0.05 1.15 2.34 0.036 0.11 0.72 -1.51 0.154 0.55 -0.43
I436337_at E030031 F02Rik 319689 RIKEN cDNA E030031 F02 gene -2.53 0.025 0.15 -0.66 -1.1 0.289 0.39 -0.28 1.68 0.117 0.32 0.38
1451 275_at E030041 M21 Rik 75089 RIKEN cDNA E030041M21 gene 2.43 0.03 0.07 0.63 2.81 0.014 0.09 0.7 0.29 0.778 0.62 0.07
145 I276_at E030041 M21 Rik 75089 RIKEN cDNA E030041M21 gene 1.87 0.084 0.12 0.5 2.25 0.042 0.10 0.58 0.33 0.75 0.62 0.08
I456585y_at EI30309D02Rik 231868 RIKEN cDNA E130309D02 gene 1.44 0.172 0.15 0.42 2.37 0.033 0.10 0.65 0.94 0.366 0.44 0.24
I460450_at E230022H04Rik 225339 RIKEN cDNA E230022H04 gene 2.97 0.01 0.05 0.67 2.48 0.027 0.11 0.54 -0.69 0.504 0.68 -0.14
1441970_at E4300 ION07Rik 399572 RIKEN cDNA E43001 ON07 gene -0.87 0.401 0.39 -0.25 1.26 0.23 0.22 0.34 2.36 0.034 0.22 0.59
1421 323_a_at E430034L04Rik 23881 RIKEN cDNA E430034L04 gene 2.47 0.028 0.05 0.72 0.84 0.413 0.27 0.23 -1.89 0.081 0.50 -0.48
14341 77_at Ecel 230857 endothelin converting enzyme I 2.92 0.012 0.05 1.01 2.53 0.025 0.10 0.84 -0.57 0.578 0.68 -0.17
I455741_a_at Ecel 230857 endothelin converting enzyme I 3.94 0.002 0.05 0.91 3.41 0.004 0.09 0.75 -0.77 0.453 0.68 -0.16
1423571_at Edgl 13609 sphingolipid G-protein-coupled receptor I 3.09 0.008 0.05 0.96 -2.02 0.064 0.33 -0.6 -5.71 0 0.00 -1.56
I438045_at Eeal 216238 early endosome antigen I -1.68 0.116 0.27 -0.58 0.25 0.804 0.30 0.08 2.19 0.047 0.22 0.66
I437478_s_at Efhd2 27984 EF hand domain containing 2 -0.99 0.342 0.27 -1.26 1.2 0.251 0.20 1.47 2.43 0.03 0.20 2.73
I424932_at Egfr 13649 epidermal growth factor receptor 0.39 0.705 0.26 0.19 -1.76 0.102 0.33 -0.83 -2.35 0.034 0.27 -1.02
I460420_a_at Egfr 13649 epidermal growth factor receptor -0.97 0.348 0.31 -0.37 -3.59 0.003 0.27 -1.3 -2.8 0.015 0.16 -0.93
I424343_a_at Eifl a 13664 eukaryotic translation initiation factor IA -2.69 0.018 0.18 -0.91 -2.74 0.016 0.31 -0.89 0.07 0.943 0.63 0.02
1434331_at Eiflcl 236511 eukaryotic translation initiation factor 2e, I 3.26 0.006 0.05 0.72 1.95 0.072 0.13 0.41 -1.59 0.134 0.63 -0.31
I448820_a_at Eif2s2 67204 eukaryotic translation initiation factor 2 -2.45 0.029 0.15 -0.63 -0.97 0.35 0.39 -0.24 1.73 0.107 0.32 0.39
I426394_at Eif3s I 78655 eukaryotic translation initiation factor 3 -4.01 0.001 0.08 -0.96 -2.27 0.04 0.32 -0.52 2.1 0.056 0.27 0.44
I426395_s_at Eif3s I 78655 eukaryotic translation initiation factor 3 -3.5 0.004 0.10 -1.29 -2.12 0.053 0.30 -0.75 1.68 0.116 0.30 0.54
I452052_s_at Eif3s I 78655 eukaryotic translation initiation factor 3 -3.02 0.009 0.15 -0.67 -1.84 0.088 0.33 -0.39 1.44 0.173 0.38 0.28
1416661_at Eif3s I0 13669 eukaryotic translation initiation factor 3 -0.17 0.87 0.40 -0.04 -2.44 0.029 0.32 -0.6 -2.47 0.028 0.17 -0.55
I439268_x_at Eif3s6 16341 eukaryotic translation initiation factor 3 -3.52 0.004 0.10 -0.85 -1.8 0.094 0.34 -0.42 2.05 0.061 0.27 0.43
I450934_at Eif4a2 13682 eukaryotic translation initiation factor 4A2 -3.87 0.002 0.11 -0.88 -2.06 0.06 0.32 -0.45 2.17 0.049 0.27 0.43
1417977 at Eif4e3 66892 eukarvotic translation initiation factor 4E3 0.88 0.396 0.23 0.32 -2.06 0.059 0.31 -0.71 -3.24 0.006 0.09 -1.03
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1431075_a_at Eif4enifl 74203 eukaryotic translation initiation factor 4E I 3.98 0.001 0.05 0.9 4.21 0.001 0.07 0.91 0.05 0.957 0.63 0.01
I427037_at Eif4g1 208643 eukaryotic translation initiation factor 4 1.17 0.263 0.15 0.46 -3.87 0.002 0.15 -1.46 -5.54 0 0.00 -1.92
I426833_at Eif4g3 230861 eukaryotic translation initiation factor 4 2.9 0.012 0.05 0.8 3.05 0.009 0.09 0.8 0.01 0.99 0.63 0
I434605_at Eif5b 226982 eukaryotic translation initiation factor 5B
-0.78 0.448 0.40 -0.27 -3.18 0.007 0.30 -1.06 -2.57 0.023 0.11 -0.78
I423693_at Elal 109901 elastase I, pancreatic
-2.91 0.012 0.12 -1.47 -2.53 0.025 0.17 -1.22 0.56 0.584 0.55 0.25
141 7540_at Elfl 13709 E74-like factor I
-0.71 0.491 0.40 -0.2 1.99 0.067 0.13 0.54 2.98 0.01 0.20 0.74
I428045_a_at EIf2 69257 E74-like factor 2 3 0.01 0.05 0.84 3.03 0.009 0.07 0.81 -0.11 0.912 0.68 -0.03
14271 62_a_at Elk4 13714 ELK4, member of ETS oncogene family 1.47 0.164 0.15 0.35 2.18 0.048 0.13 0.5 0.69 0.499 0.53 0.15
1450744_at EII2 192657 elongation factor RNA polymerase II 2 -2.42 0.03 0.20 -0.82 -1.37 0.193 0.35 -0.45 1.27 0.227 0.41 0.38
I4425 I4_a_at EII3 269344 elongation factor RNA polymerase II-like 3 0.77 0.456 0.18 0.28 2.65 0.019 0.10 0.93 2.02 0.064 0.27 0.65
I434489_at Elmo3 234683 engulfment and cell motility 3, ced-12 homolog 2.71 0.017 0.05 0.77 1.99 0.067 0.15 0.54 -0.92 0.376 0.67 -0.23
I420722_at Elovl3 12686 elongation of very long chain fatty acids -2.93 0.011 0.08 -2.46 -2.37 0.033 0.24 -1.9 0.75 0.464 0.46 0.56
1417403_at Elovl6 170439 elongation of long chain fatty acids 1.24 0.235 0.12 0.85 2.25 0.041 0.10 1.48 1.04 0.317 0.36 0.63
I433670_at Emp2 13731 epithelial membrane protein 2 1.76 0.101 0.09 0.64 2.29 0.039 0.10 0.8 0.49 0.633 0.58 0.16
1421097_at Endog 13804 endonuclease G 2.53 0.025 0.05 0.68 2.63 0.02 0.10 0.68 -0.01 0.988 0.68 0
I448649_at Enpep 13809 glutamyl aminopeptidase 1.08 0.298 0.20 0.34 2.34 0.035 0.10 0.7 1.31 0.211 0.36 0.36
1419276_at Enppl 18605 ectonucleotide pyrophosphatase Iphosphodiesterase I 0.98 0.344 0.18 0.41 -1.58 0.138 0.33 -0.63 -2.83 0.014 0.14 -1.04
14481 36_at Enpp2 18606 ectonucleotide pyrophosphatase 2 2.46 0.028 0.05 0.7 1.22 0.242 0.22 0.33 -1.47 0.164 0.63 -0.37
I439260_a_at Enpp3 209558 ectonucleotide pyrophosphatase 3 2.1 0.055 0.09 0.51 2.83 0.014 0.09 0.66 0.7 0.497 0.53 0.15
I428620_at Ensa 56205 endosulfine alpha 1.4 0.184 0.14 0.38 2.48 0.027 0.11 0.65 1.11 0.287 0.44 0.27
1418259_a_at Entpd2 12496 ectonucleoside triphosphate diphosphohydrolase 2 2.41 0.031 0.05 0.85 2.12 0.053 0.10 0.72 -0.43 0.674 0.68 -0.13
I41 8850_at Epcl 13831 enhancer of polycomb homolog I (Drosophila) 1.08 0.298 0.20 0.25 2.41 0.031 0.10 0.53 1.39 0.188 0.38 0.28
I427537_at Eppkl 223650 epiplakin I 3.19 0.007 0.05 1.02 3.22 0.006 0.07 0.98 -0.13 0.901 0.68 -0.04
1426713_s_at Eprs 107508 glutamyl-prolyl-tRNA synthetase 0.77 0.455 0.25 0.21 2.46 0.028 0.11 0.63 1.81 0.093 0.27 0.43
1428011_a_at Erbb2ip 59079 Erbb2 interacting protein -2.46 0.028 0.15 -0.64 -0.38 0.707 0.39 -0.1 2.38 0.032 0.22 0.55
1434606_at Erbb3 13867 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2.33 0.036 0.05 0.63 2.47 0.028 0.11 0.63 0.03 0.977 0.63 0.01
3 (avian)
I448497_at Ercc3 13872 excision repair cross-complementing rodent repair 3.06 0.009 0.05 0.83 2.28 0.039 0.11 0.59 -I 0.334 0.66 -0.24
deficiency, complementation group 3
1432249_a_at Ercc8 71991 excision repaiross-complementing rodent repair -3.11 0.008 0.08 -2.42 -2.57 0.023 0.00 -1.91 0.74 0.47 0.48 0.51
deficiency, complementation group 8
1430536_a_at Erh 13877 enhancer of rudimentary homolog (Drosophila) -2.28 0.039 0.26 -0.65 -1.62 0.129 0.36 -0.44 0.84 0.416 0.46 0.21
I425705_a_at Erollb 67475 ERO I-like beta (5. cerevisiae) -2.27 0.041 0.26 -0.76 -1.1 0.29 0.39 -0.35 1.38 0.19 0.30 0.41 ,
I46059 I_at Esrl 13982 estrogen receptor I (alpha) 2.93 0.011 0.05 1.37 2.65 0.02 0.09 1.18 -0.45 0.662 0.68 -0.18
1429712_at Etohil 13999 ethanol induced I -4.88 0 0.07 -1.64 -5.12 0 0.00 -1.64 -0.01 0.99 0.68 0
434703_at Extl3 54616 exostoses (multiple)-like 3 3.83 0.002 0.05 0.99 2.6 0.021 0.10 0.64 -1.53 0.149 0.63 -0.35
418992_at FlO 14058 coagulation factor X 1.89 0.081 0.09 0.67 2.22 0.044 0.11 0.75 0.27 0.792 0.62 0.08
41 8993_s_at FlO 14058 coagulation factor X 3.86 0.002 0.05 1.16 3.52 0.004 0.07 1.01 -0.57 0.579 0.68 -0.15
424595_at FII r 16456 FI I receptor 2.07 0.058 0.09 0.57 2.99 0.01 0.09 0.78 0.9 0.385 0.46 0.22
41932I_at F7 14068 coagulation factor VII 2.18 0.047 0.08 0.63 1.66 0.12 0.15 0.46 -0.68 0.511 0.68 -0.17
43409 I_at Faah 14073 fatty acid amide hydrolase 1.68 0.116 0.12 0.41 2.47 0.028 0.10 0.58 0.77 0.453 0.50 0.17
423680_at Fads I 76267 fatty acid desaturase I 0.44 0.665 0.26 0.11 3.23 0.006 0.09 0.73 3.01 0.01 0.20 0.63
419031_at Fads2 56473 fatty acid desaturase 2 1.51 0.155 0.07 0.57 2.48 0.027 0.10 0.89 0.99 0.341 0.46 0.33
443838]_at Fads2 56473 fatty acid desaturase 2 0.74 0.47 0.18 0.25 2.44 0.029 0.10 0.8 1.81 0.092 0.30 0.54
449325_at Fads2 56473 fatty acid desaturase 2 1.83 0.089 0.05 0.73 3.16 0.007 0.09 1.21 1.35 0.198 0.36 0.48
439406_x_at Fars I 69955 phenylalanine-tRNA synthetase I -5.27 0 0.04 -1.84 -3.53 0.004 0.27 -1.18 2.16 0.05 0.22 0.66
423828_at Fasn 14104 fatty acid synthase 1.93 0.075 0.07 1.07 2.02 0.064 0.11 1.07 0 0.998 0.68 0
417407 at Fbxl14 101358 F-box and leucine-rich reoeat orotein 14 1.33 0.206 0.17 0.26 -1.59 0.136 0.35 -0.3 -3.24 0.006 0.11 -0.56
V>
-.j...
Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I452860_at Fbxl17 50758 F-box and leucine-rich repeat protein 17 2.63 0.02 0.05 0.64 0.78 0.449 0.30 0.18 -2.14 0.051 0.44 -0.46
I452826_s_at Fbxl20 72194 F-box and leucine-rich repeat protein 20 1.42 0.179 0.12 0.47 2.29 0.038 0.10 0.73 0.88 0.392 0.48 0.26
1434108_at Fbxoll 225055 F-box protein I I
-3.31 0.005 0.10 -0.98 -1.29 0.218 0.39 -0.36 2.36 0.034 0.22 0.61
I426593_a_at Fbxo22 71999 F-box only protein 22
-3.24 0.006 0.10 -1.05 -1.67 0.119 0.34 -0.52 1.87 0.083 0.27 0.54
1418243_at Fcna 14133 ficolin A 0.51 0.618 0.26 0.25 -1.58 0.137 0.32 -0.74 -2.3 0.038 0.30 -0.99
I436454_x_at Fenl 14156 flap structure specific endonuclease I
-1.56 0.142 0.27 -0.52 -2.66 0.019 0.31 -0.85 -1.13 0.28 0.65 -0.33
I449555_a_at Fetub 59083 fetuin beta 2.18 0.047 0.05 0.71 0.55 0.589 0.30 0.17 -1.88 0.081 0.48 -0.54
1435467_at Fgd6 13998 FYVE. RhoGEF and PH domain containing 6 0.71 0.489 0.24 0.23 3.15 0.007 0.09 0.96 2.62 0.021 0.22 0.74
1422916_at Fgf21 56636 fibroblast growth factor 21 0.09 0.927 0.26 0.05 2.88 0.012 0.09 1.43 3.03 0.009 0.20 1.38
I447878_s_at Fgfrll 116701 fibroblast growth factor receptor-like I 1.21 0.248 0.15 OJ4 3.53 0.004 0.07 0.95 2.47 0.028 0.22 0.61
1451912_a_at Fgfrll 116701 fibroblast growth factor receptor-like I 2.12 0.053 0.05 0.67 3.12 0.008 0.09 0.95 0.98 0.344 0.46 0.27
I424599_at FglI 234199 fibrinogen-like protein 1 3.35 0.005 0.05 1.75 2.29 0.038 0.09 1.15 -1.31 0.212 0.63 -0.6
I43468 I_at Fiat 353170 CXORFI5
-3.24 0.006 0.15 -1.02 -1.42 0.177 0.36 -0.43 2.13 0.052 0.22 0.59
I452720_a_at Fiplll 66899 FIP I like I (S. cerevisiae) 2.08 0.057 0.08 0.51 0.08 0.937 0.30 0.02 -2.28 0.039 0.38 -0.49
141 6858_a_at Fkbp3 30795 FK506 binding protein 3
-4.01 0.001 0.08 -1.02 -1.86 0.084 0.34 -0.46 2.54 0.024 0.20 0.57
1448189_a_at Fliih 14248 flightless I homolog (Drosophila) 1.91 0.078 0.09 0.43 2.19 0.047 0.13 0.47 0.21 0.836 0.63 0.04
I448559_at Flotl 14251 f10tillin I 3.27 0.006 0.05 0.87 2.47 0.028 0.10 0.63 -1.04 OJI6 0.66 -0.24
I444052_at Flt4 14257 FMS-like tyrosine kinase 4 2.2 0.046 0.05 0.55 1.36 0.195 0.22 0.33 -1.02 0.325 0.66 -0.23
1420917_at Fnbp3 56194 formin binding protein 3 -0.15 0.884 0.40 -0.04 -2.13 0.052 0.32 -0.55 -2.15 0.05 0.38 -0.51
I450035_a_at Fnbp3 56194 formin binding protein 3 0.74 0.474 0.25 0.16 -2.92 0.012 0.31 -0.62 -4.01 0.001 0.07 -0.78
I443863_at Fndc3a 319448 fibronectin type III domain containing 3a 1.06 0.31 0.20 0.28 -1.82 0.091 0.33 -0.46 -3.18 0.007 0.14 -0.73
I434655_at Foxkl 17425 forkhead box KI OJ 0.766 0.26 0.09 2.33 0.036 0.11 0.63 2.19 0.047 0.27 0.54
1434831_a_at Foxo3 56484 forkhead box 03 1.61 0.13 0.12 0.45 2.18 0.047 0.11 0.58 0.54 0.598 0.55 0.13
I435222_at Foxpl 108655 forkhead box PI 2.71 0.017 0.05 1.19 2.58 0.022 0.10 1.08 -0.28 0.786 0.68 -0.11
141 7592_at Frapl 56717 FK506 binding protein 12-rapamycin protein I 2.18 0.047 0.07 0.53 2.96 0.011 0.09 0.68 0.73 0.477 0.53 0.16
I426594_at Frmd4b 232288 FERM domain containing 4B 0.73 0.481 0.26 0.25 2.55 0.023 0.09 0.83 1.96 0.072 0.22 0.58
1438169_a_at Frmd4b 232288 FERM domain containing 4B -0.15 0.885 0.40 -0.06 2.23 0.044 0.11 0.83 2.59 0.022 0.07 0.89
14521 23_s_at Frmd4b 232288 FERM domain containing 4B 1.02 0.328 0.20 0.4 2.73 0.017 0.09 1.02 1.81 0.092 0.22 0.63
I433679_at Fubp3 320267 far upstream element (FUSE) binding protein 3 -1.12 0.282 0.36 -0.28 1.53 0.148 0.20 0.37 2.95 0.011 0.20 0.65
1437337-,,_at Fuk 234730 fucokinase 2.02 0.064 0.11 0.46 2.96 0.011 0.09 0.65 0.92 0.372 0.46 0.19
I437986_x_at Fuk 234730 fucokinase 1.28 0.222 0.18 0.29 2.17 0.048 0.10 0.48 0.91 0.379 0.48 0.18
1421 374_a_at Fxydl 56188 FXYD domain-containing ion transport reg I -1.68 0.117 0.28 -0.42 0.84 0.417 0.27 0.2 2.82 0.014 0.20 0.62
1419301_at Fzd4 14366 frizzled homolog 4 (Drosophila) 1.75 0.102 0.05 0.61 2.68 0.019 0.10 0.88 0.92 0.376 0.48 0.28
I454725_at G430041 MO IRik 101214 RIKEN cDNA G430041MOI gene -3.29 0.006 0.09 -1.28 -2.3 0.038 0.31 -0.86 1.24 0.238 0.38 0.42
I455998_at G630041 M05Rik 320448 PREDICTED 2.79 0.015 0.05 0.83 0.15 0.886 0.30 0.04 -3.02 0.009 0.14 -0.79
1419428_a_at Gaa 14387 glucosidase. alpha. acid 2.65 0.019 0.05 0.78 2.56 0.023 0.10 0.72 -0.23 0.822 0.68 -0.06
1436849_x_at Gaa 14387 glucosidase. alpha. acid 2.82 0.014 0.05 0.73 2.35 0.034 0.11 0.58 -0.65 0.529 0.68 -0.15
1417693_a_at Gabl 14388 growth factor receptor bound protein 2- 1.78 0.098 0.10 0.42 2.38 0.033 0.11 0.54 0.57 0.58 0.55 0.12
141 7694_at Gabl 14388 growth factor receptor bound protein 2 1.92 0.077 0.05 0.74 2.21 0.045 0.11 0.82 0.23 0.824 0.63 0.08
1416418_at Gabarapll 57436 GABA(A) receptor-associated protein-like I -2.28 0.039 0.26 -0.58 0.2 0.845 0.30 0.05 2.81 0.014 0.20 0.63
I424748_at Galntll 231050 UDP-N-acetyl-alpha-D-galactosamine 2.7 0.018 0.05 1.09 2.09 0.056 0.11 0.8 -0.8 0.44 0.66 -0.28
I426756_at Galnt2 108148 UDP-N-acetyl-alpha-D-galactosamine -0.59 0.564 0.40 -0.18 2.43 0.03 0.11 0.7 3.32 0.005 0.20 0.87
1455915_at Galnt4 14426 UDP-N-acetyl-alpha-D-galactosamine -0.12 0.905 0.40 -0.03 1.91 0.Q78 0.15 0.49 2.22 0.044 0.22 0.53
I429455_at Gapvdl 66691 GTPase activating protein and VPS9 domains 1 2.16 0.049 0.07 0.75 1.23 0.239 0.22 0.41 -1.12 0.281 0.65 -0.34
1441911_x_at Gart 14450 phosphoribosylglycinamide formyltransferase -3.97 0.001 0.08 -0.99 -2.32 0.037 OJ2 -0.55 2 0.066 0.27 0.44
I434928_at Gas211 78926 growth arrest-specific 2 like I 4.01 0.001 0.05 1.04 2.18 0.048 0.10 0.54 -2.19 0.047 0.41 -0.5
141 7399_at Gas6 14456 growth arrest specific 6 2.44 0.029 0.05 1.71 2.61 0.021 0.07 1.74 0.06 0.953 0.63 0.04
1423569 at Gatm 67092 21ycine amidinotransferase (L-ar2inine 2.7 0.018 0.05 0.88 -OJ5 0.734 0.39 -0.11 -3.45 0.004 0.10 -0.99
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Probe Symbol Entrez Description I IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene 10 It-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1450099_a_at Gba 14466 glucosidase, beta, acid 2.29 0.039 0.07 0.65 1.41 0.18 0.22 0.39 -1.06 0.306 0.66 -0.27
1418392_a_at Gbp4 55932 guanylate nucleotide binding protein 4 2.29 0.039 0.07 0.98 1.29 0.217 0.11 0.53 -1.2 0.252 0.65 -0.45
1433713_at Gcn III 231659 GCN I general control of amino-acid synthesis 3.27 0.006 0.05 1.01 2.15 0.05 0.11 0.63 -1.38 0.189 0.63 -0.37
I435748_at Gda 14544 guanine deaminase 2.8 0.015 0.05 0.78 2.44 0.029 0.11 0.65 -0.54 0.6 0.68 -0.13
I452272_a_at Gfer 11692 growth factor, ervl-like (liver regeneration)
-2.43 0.03 0.24 -0.8 -0.03 0.974 0.39 -0.01 2.74 0.017 0.20 0.79
I45606 I_at Gimap8 243374 GTPase, IMAP family member 8 0.82 0.428 0.22 0.34 2.47 0.028 0.09 0.98 1.76 0.102 0.27 0.64
1423391_at Git2 26431 G protein-coupled receptor kinase-interactor 2 2.51 0.025 0.05 0.58 2.24 0.042 0.13 0.5 -0.42 0.684 0.68 -0.08
I428603_at Glcci I 170772 glucocorticoid induced transcript I
-2.58 0.023 0.22 -0.65 -1.62 0.127 0.36 -0.39 1.16 0.265 0.41 0.26
1417087_at Gigi 20340 golgi apparatus protein I 2.44 0.029 0.05 0.73 2.13 0.052 0.13 0.61 -0.46 0.65 0.68 -0.12
1448579 at Gigi 20340 golgi apparatus protein I 3.36 0.005 0.05 0.76 3.35 0.005 0.07 0.73 -0.19 0.854 0.68 -0.04
I448580_at Gigi 20340 golgi apparatus protein I 3.52 0.004 0.05 1.02 3.93 0.002 0.07 1.09 0.27 0.793 0.63 0.07
I460554_s_at Gigi 20340 golgi apparatus protein 1 3.07 0.009 0.05 0.86 2.97 0.011 0.09 0.8 -0.26 0.797 0.68 -0.06
1458719 at Glplr 14652 glucagon-like peptide I receptor 2.37 0.033 0.05 1.71 1.85 0.087 0.11 1.28 -0.68 0.506 0.64 -0.43
I433496_at Glt25d I 234407 glycosyltransferase 25 domain containing I 2.01 0.065 0.07 0.65 -0.69 0.504 0.39 -0.21 -3.03 0.009 0.14 -0.87
1418681_at Glt28d I 67574 glycosyltransferase 28 domain containing 1 -2.4 0.031 0.20 -0.64 -2.52 0.Q25 0.32 -0.64 -0.01 0.994 0.68 0
1424867_a_at Glyat 107146 glycine-N-acyltransferase -3.93 0.002 0.07 -1.23 -2.39 0.032 0.32 -0.71 1.88 0.082 0.27 0.52
I434056_a_at Gml37 230075 gene model 137, (NCBI) -3.73 0.002 0.09 -0.9 -1.7 0.112 0.34 -0.39 2.39 0.032 0.22 0.51
I44824 I_at Gm2a 14667 GM2 ganglioside activator protein 2.09 0.056 0.10 0.5 2.63 0.02 0.10 0.6 0.48 0.637 0.58 0.1
1416356_at Gmpr2 105446 guanosine monophosphate reductase 2 -1.55 0.144 0.28 -0.46 0.47 0.649 0.30 0.13 2.27 0.04 0.22 0.59
I422555_s_at Gnal3 14674 guanine nucleotide binding protein, alpha I3 1.76 0.101 0.12 0.43 3.56 0.003 0.07 0.84 1.87 0.083 0.30 0.41
I422556_at Gnal3 14674 guanine nucleotide binding protein, alpha 13 3.7 0.003 0.05 1.29 1.79 0.095 0.13 0.6 -2.26 0.041 0.32 -0.69
I433749_at Gnal3 14674 guanine nucleotide binding protein, alpha 13 1.44 0.173 0.12 0.35 2.21 0.045 0.13 0.51 0.77 0.454 0.53 0.16
I450656_at Gnal3 14674 guanine nucleotide binding protein, alpha 13 1.08 0.297 0.20 0.25 2.77 0.015 0.09 0.62 1.79 0.097 0.30 0.37
420385_at Gnal4 14675 guanine nucleotide binding protein, alpha 14 2.19 0.047 0.07 0.8 1.25 0.233 0.22 0.44 -1.13 0.278 0.64 -0.36
429559_at Gnaq 14682 guanine nucleotide binding protein 2.27 0.04 0.09 0.54 2.01 0.064 0.11 0.46 -0.39 0.7 0.68 -0.08
450623_at Gnb2 14693 guanine nucleotide binding protein, beta 2 2.69 0.018 0.05 0.73 2.61 0.021 0.10 0.67 -0.22 0.829 0.68 -0.05
448810_at Gne 50798 glucosamine 2.99 0.01 0.05 0.84 2.45 0.029 0.11 0.66 -0.74 0.471 0.68 -0.18
455583_at Gne 50798 glucosamine 2.66 0.019 0.05 0.72 2.45 0.029 0.11 0.63 -0.36 0.721 0.68 -0.09
436946_s_at Gng5 14707 guanine nucleotide binding protein (G protein) -2.64 0.Q2 0.24 -0.61 -1.25 0.234 0.39 -0.27 1.65 0.122 0.32 0.33
451 633_a_at Gngtl 14699 guanine nucleotide binding protein (G protein) 1.33 0.205 0.12 0.51 2.46 0.028 0.10 0.9 1.16 0.268 0.38 0.39
448625_at Golga2 99412 golgi autoantigen, golgin subfamily a, 2 1.36 0.195 0.17 0.35 2.96 0.011 0.09 0.73 1.67 0.118 0.32 0.38
41 7674_s_at Golga4 54214 golgi autoantigen, golgin subfamily a, 4 -2.43 0.03 0.23 -0.64 -0.42 0.678 0.39 -0.11 2.31 0.037 0.22 0.53
I450394_at Golph3 66629 golgi phosphoprotein 3 -2.81 0.014 0.15 -I -1.37 0.192 0.35 -0.47 1.7 0.112 0.30 0.53
41 9499_at Gpam 14732 glycerol-3-phosphate acyltransferase 1.47 0.165 0.14 0.46 2.4 0.031 0.11 0.72 0.94 0.362 0.44 0.26
430981_s_at Gpbpl 73274 GC-rich promoter binding protein I 0.51 0.62 0.26 0.14 -2.9 0.012 0.31 -0.79 -3.74 0.002 0.06 -0.93
141 7389_at Gpcl 14733 glypican I 1.4 0.184 0.09 0.85 2.47 0.Q28 0.09 1.43 1.09 0.296 0.41 0.58
1421088_at Gpc4 14735 glypican 4 2.02 0.064 0.08 0.49 2.78 0.015 0.10 0.64 0.73 0.475 0.53 0.16
1417434_at Gpd2 14571 glycerol phosphate dehydrogenase 2 0.57 0.575 0.26 0.2 2.39 0.032 0.11 0.8 1.95 0.073 0.22 0.6
1452741_s_at Gpd2 14571 glycerol phosphate dehydrogenase 2 0.42 0.682 0.26 0.11 3.14 0.008 0.09 0.77 2.94 0.011 0.20 0.66
1434814_x_at Gpil 14751 glucose phosphate isomerase 1 1.64 0.125 0.14 0.54 2.52 0.Q25 0.09 0.8 0.88 0.395 0.46 0.26
I423632_at Gprl46 80290 G protein-coupled receptor 146 2.17 0.048 0.05 0.98 1.33 0.206 0.20 0.57 -1.03 0.323 0.65 -0.41
I437436_s_at Gprk6 26385 G protein-coupled receptor kinase 6 2.9 0.012 0.05 0.77 1.17 0.261 0.22 0.3 -2.02 0.063 0.44 -0.47
I4 I8508_a_at Grb2 14784 growth factor receptor bound protein 2 2.4 0.031 0.05 0.89 0.34 0.743 0.30 0.12 -2.37 0.033 0.30 -0.78
I41 8492_at Grem2 23893 gremlin 2 homolog, cysteine knot superfamily 2.57 0.023 0.05 0.79 1.2? 0.218 0.17 0.38 -1.52 0.151 0.63 -0.41
1417423_at Gnna 66168 glutamate receptor, ionotropic, N-methyl D-asparate- 4.21 0.001 0.05 1.05 1.87 0.083 0.15 0.45 -2.75 0.016 0.17 -0.6
associated protein I
1436297_a_at Grina 66168 glutamate receptor, ionotropic, N-methyl D-asparate- 3.26 0.006 0.05 0.73 2.3 0.038 0.11 0.49 -1.2 0.25 0.65 -0.24
associated orotein I
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t·stat p-value q-value Fold Ch. t·stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I448 I48_at Grn 14824 granulin 4.34 0.001 0.05 1.12 1043 0.175 0.17 0.35 -3.38 0.005 0.11 -0.77
1452262_at Grpel2 17714 GrpE-like 2, mitochondrial 0.58 0.572 0.26 0.18 2.76 0.016 0.09 0.84 2.35 0.035 0.22 0.65
I437838_x_at Grsfl 231413 G-rich RNA sequence binding factor I
-2.19 0.047 0.26 -0.58 -1.04 0.317 0.39 -0.27 1.36 0.196 0.38 0.32
1437171y_at Gsn 227753 gelsolin 0045 0.657 0.26 0.19 2.51 0.026 0.09 I 2.22 0.045 0.22 0.81
I423436_at Gsta3 14859 glutathione S-transferase. alpha 3
-2.37 0.033 0.20 -0.74 -1.1 0.293 0.39 -0.33 1.51 0.154 0.36 0041
I452239_at Gt(ROSA)26Sor 14910 gene trap ROSA 26, Philippe Soriano -4.08 0.001 0.08 -1.16 -3.08 0.008 0.30 -0.84 1.29 0.22 0.36 0.32
I425628_a_at Gtf2i 14886 general transcription factor II I 2.56 0.023 0.05 0.59 2.71 0.017 0.10 0.59 0.04 0.971 0.63 0.01
I434320_at Gtf3c4 269252 general transcription factor IIIC, polypeptide 4 2.21 0.045 0.Q7 0.65 1.86 0.085 0.15 0.52 -0049 0.634 0.68 -0.13
1423 I42_a_at Gtpbp4 69237 GTP binding protein 4
-3.38 0.005 0.07 -104 -2.35 0.035 0.32 -0.93 1.29 0.218 0.38 0047
1423 I43_at Gtpbp4 69237 GTP binding protein 4
-1.08 0.297 0.27 -0.34 -3.64 0.003 0.30 -1.09 -2.73 0.017 0.20 -0.75
1424519_at Gtpbp7 212508 GTP binding protein 7 (putative)
-0.58 0.569 0040 -0.16 1.81 0.092 0.15 0048 2.64 0.02 0.22 0.64
I422704_at Gyk 14933 glycerol kinase -2.19 0.047 0.26 -0047 0.92 0.376 0.29 0.19 3049 0.004 0.20 0.65
I456032_x_at H2afz 51788 H2A histone family, member Z -3.63 0.003 0.09 -0.87 -2.58 0.022 0.32 -0.59 1.32 0.208 0041 0.28
1417314_at H2-Bf 14962 histocompatibility 2, complement component factor B 2.65 0.02 0.07 0.69 104 0.183 0.20 0.35 -1048 0.161 0.62 -0.34
1450170_x_at H2-DI 14964 histocompatibility 2, D region locus I 2041 0.031 0.05 2.18 2.04 0.061 0.10 1.76 -0.52 0.609 0.63 -0042
I452 I45_at H6pd 100198 hexose-6-phosphate dehydrogenase (glucose 1- 2.94 0.011 0.05 0.73 2.56 0.023 0.10 0.61 -0.56 0.582 0.68 -0.12
dehydrogenase)
14371 72_x_at Hadhb 231086 hydroxyacyl-Coenzyme A dehydrogenasel3-ketoacyl- -2041 0.031 0.25 -0.61 -0.24 0.818 0.39 -0.06 2049 0.027 0.22 0.55
Coenzyme A thiolase/enoyl-Coenzyme A hydratase
(trifunctional protein), beta subunit
I429958y_at Haghl 68977 hydroxyacylglutathione hydrolase-like 2.17 0.048 0.08 0.64 2.2 0.046 0.11 0.62 -0.08 0.937 0.68 -0.02
1419196 at Hampl 84506 hepcidin antimicrobial peptide I -2.23 0.043 0.15 -1.07 0.02 0.986 0.30 0.01 2.56 0.023 0.20 1.08
1419197_x_at Hampl 84506 hepcidin antimicrobial peptide I -2.15 0.05 0.15 -0.97 0.24 0.817 0.30 0.1 2.71 0.017 0.20 1.08
I436643_x_at Hamp2 66438 hepcidin antimicrobial peptide 2 1.17 0.263 0.15 0.67 3.3 0.006 0.07 1.8 2.26 0.041 0.22 1.14
1418654_at Hao3 56185 hydroxyacid oxidase (glycolate oxidase) 3 1.15 0.271 0.Q7 1.16 3.98 0.001 0.07 3.86 3.03 0.009 0.20 2.7
I435650_at Hapln4 330790 hyaluronan and proteoglycan link protein 4 4.34 0.001 0.05 1.36 3.67 0.003 0.Q7 1.1 -0.94 0.363 0.66 -0.26
1417024_at Hars 15115 histidyl-tRNA synthetase 3.31 0.005 0.05 0.86 2041 0.031 0.11 0.6 -1.14 0.273 0.65 -0.26
14241 54_a_at Hbldl 74316 HESB like domain containing I -1.11 0.288 0.34 -0.31 0.88 0.396 0.29 0.23 2.21 0.045 0.22 0.54
14361 52_a_at Hbxip 68576 hepatitis B virus x interacting protein -4.37 0.001 0.07 -1.21 -1.9 0.08 0.33 -0.5 2.92 0.012 0.20 0.71
I433736_at Hdcl 15161 host cell factor C I 2.18 0.048 0.08 0.58 1.87 0.084 0.13 0047 -0045 0.662 0.68 -0.1
I428692_at Hddc3 68695 HD domain containing 3 2.25 0.042 0.05 1.31 2.86 0.013 0.07 1.6 0.56 0.584 0.53 0.29
I41 5888_at Hdgf 15191 hepatoma-derived growth factor 2.77 0.015 0.05 0.69 -0041 0.685 0.39 -0.1 -3.61 0.003 0.10 -0.79
I434477_at Heca 380629 headcase homolog (Drosophila) -1.21 0.247 0.34 -0.3 0.73 00479 0.30 0.17 2.17 0.048 0.27 0047
I434478_at Heca 380629 headcase homolog (Drosophila) -0.15 0.882 0040 -0.04 2.71 0.017 0.10 0.65 3.12 0.008 0.20 0.68
I438596_at Hectd2 226098 HECT domain containing 2 -2.87 0.013 0.11 -1.65 -2 0.066 0.30 -1.1 1.09 0.295 0041 0.55
I434060_at Hercl 235439 hect domain and RCC I (CHC I)-like domain 0.02 0.983 0.26 0.01 2.3 0.038 0.11 0.55 2048 0.027 0.22 0.54
I435626_a_at Herpudl 64209 ubiquitin-like domain I -2.15 0.05 0.17 -0.87 -lAS 0.169 0.36 -0.56 0.87 00402 0046 0.31
I449024_a_at Hexa 15211 hexosaminidase A 2.17 0.049 0.07 0.67 2.06 0.059 0.11 0.61 -0.22 0.826 0.68 -0.06
1423 I95_at Hiatl 15247 hippocampus abundant gene transcript I -2.5 0.026 0.24 -0.84 -0.64 0.535 0.39 -0.2 2.15 0.05 0.27 0.63
1448183_a_at Hilla 15251 hypoxia inducible factor I, alpha subunit 0.76 00461 0.17 0044 -2.93 0.011 0.29 -1.63 -4.05 0.001 0.05 -2.08
141 6480_a_at Higl 56295 hypoxia induced gene I -3042 0.004 0.15 -0.79 -1.57 0.139 0.33 -0.35 2.19 0.047 0.27 0.44
I424540_at Hipkl 15257 homeodomain interacting protein kinase I 1.63 0.127 0.14 0.36 2.99 0.01 0.09 0.64 1.4 0.184 0.38 0.28
I428433_at Hipk2 15258 homeodomain interacting protein kinase 2 -1.78 0.098 0.27 -0.52 0047 0.644 0.30 0.13 2.54 0.024 0.22 0.65
1426819_at Hipk3 15259 homeodomain interacting protein kinase 3 -1.24 0.235 0.31 -0.31 0.96 0.356 0.27 0.23 2046 0.Q28 0.22 0.53
I436994_a_rtt Histl h Ic 50708 histone I, HI c -3.95 0.002 0.07 -1049 -2046 0.Q28 0.31 -0.89 1.81 0.093 0.30 0.6
1418072_at Histl h2bc 68024 histone I, H2bc -3.59 0.003 0.08 -0.85 -2.5 0.026 0.32 -0.56 1.37 0.194 0.38 0.28
I434736_at Hlf 217082 hepatic leukemia factor 1.19 0.254 0.17 0.34 2.36 0.034 0.10 0.65 1.21 0.248 0041 0.31
1436930 x at Hmbs 15288 hvdroxvmethvlbilane synthase -2.86 0.013 0.20 -0.69 -2.8 0.015 0.31 -0.65 0.22 0.831 0.63 0.05
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1421983_U1t Hnf4a 15378 hepatic nuclear factor 4, alpha
-1.15 0.269 0.34 -0.34 -2.37 0.033 0.32 -0.67 -1.27 0.226 0.63 -0.33
I427000_at Hnf4a 15378 hepatic nuclear factor 4, alpha
-3.14 0.007 0.08 -I -2.05 0.06 0.33 -0.63 1.35 0.2 0.38 0.38
141 7702_a_at Hnmt 140483 histamine N-methyltransferase
-1.92 0.076 0.27 -0.49 0.19 0.849 0.30 0.05 2.4 0.031 0.22 0.54
I430019_a_at Hnrpal 15382 heterogeneous nuclear ribonucleoprotein A I 1.08 0.297 0.17 0.37 3.42 0.004 0.07 1.13 2.49 0.026 0.20 0.75
I430020_x_at Hnrpal 1538 heterogeneous nuclear ribonucleoprotein A I 1.72 0.108 0.08 0.59 3.78 0.002 0.07 1.24 2.15 0.05 0.22 0.65
1436549_a_at Hnrpal 15382 heterogeneous nuclear ribonucleoprotein A I 0.56 0.588 0.26 0.17 3.78 0.002 0.07 1.09 3.48 0.004 0.20 0.92
1425142_a_at Hnrpd 11991 heterogeneous nuclear ribonucleoprotein D 2.64 0.02 0.05 0.56 2.2 0.045 0.13 0.45 -0.61 0.551 0.68 -0.11
I42425 I_a_at Hnrpdl 50926 heterogeneous nuclear ribonucleoprotein D 2.26 0.041 0.09 0.49 3.19 0.007 0.07 0.66 0.89 0.388 0.48 0.17
1449039_a_at Hnrpdl 50926 heterogeneous nuclear ribonucleoprotein -like 1.61 0.131 0.14 0.4 3.14 0.007 0.09 0.75 1.59 0.135 0.36 0.35
I448 I76_a_at Hnrpk 15387 heterogeneous nuclear ribonucleoprotein K -1.26 0.228 0.34 -0.27 1.94 0.073 0.15 0.4 3.55 0.003 0.20 0.67
1424101_at Hnrpl 15388 heterogeneous nuclear ribonucleoprotein L 2.53 0.025 0.05 0.66 1.27 0.226 0.24 0.32 -1.49 0.158 0.63 -0.34
I437526y_at Hnrpr 74326 heterogeneous nuclear ribonucleoprotein R -2.74 0.016 0.15 -1.03 -1.29 0.219 0.37 -0.46 1.71 0.109 0.27 0.57
1423051_at Hnrpu 51810 heterogeneous nuclear ribonucleoprotein U 1.78 0.097 0.09 0.47 2.42 0.03 0.11 0.61 0.6 0.557 0.55 0.14
1420 139_s_at Hrb2 52705 HIV-I Rev binding protein 2 -3.16 0.007 0.15 -0.78 -1.1 I 0.286 0.39 -0.26 2.39 0.032 0.22 0.52
I433843_at Hslbp3 58240 HS I binding protein 3 3.22 0.006 0.05 0.83 2.47 0.027 0.11 0.61 -0.97 0.348 0.66 -0.22
141 7293_at Hs6stl 50785 heparan sulfate 6-0-sulfotransferase I 4.32 0.001 0.05 1.57 2.28 0.039 0.11 0.79 -2.44 0.029 0.27 -0.78
I425589_at Hsd 17bl3 243168 hydroxysteroid (17-beta) dehydrogenase I3 2.44 0.029 0.05 2 3.01 0.01 0.07 2.36 0.49 0.629 0.46 0.36
1417871_at Hsdl7b7 15490 hydroxysteroid (17-beta) dehydrogenase 7 1.07 0.303 0.18 0.32 -2.21 0.045 0.33 -0.62 -3.63 0.003 0.05 -0.94
I449385_at Hsdl7b9 27400 hydroxysteroid (17-beta) dehydrogenase 9 2 0.065 0.08 0.57 2.91 0.012 0.09 0.79 0.88 0.392 0.48 0.22
142053 I_at Hsd3b5 15496 hydroxysteroid dehydrogenase-5 -1.6 0.132 0.08 -2.9 -2.26 0.041 0.30 -3.91 -0.63 0.536 0.67 -1.01
I426856_at Hsdl2 72479 hydroxysteroid dehydrogenase like 2 -2.29 0.039 0.25 -0.97 0.65 0.527 0.25 0.26 3.32 0.005 0.20 1.23
I423566_a_at Hspl05 15505 heat shock protein 105 -2.96 0.011 0.08 -2.02 -2.56 0.023 0.30 -1.67 0.58 0.572 0.48 0.35
I425993_a_at Hspl05 15505 heat shock protein 105 -2.72 0.017 0.11 -1.31 -2.26 0.041 0.32 -1.04 0.64 0.533 0.50 0.27
14271 26_at Hspalb 15511 heat shock protein IB -3.48 0.004 0.04 -2.19 -3.16 0.007 0.27 -1.9 0.52 0.611 0.53 0.29
1427127_x_at Hspalb 15511 heat shock protein IB -3.96 0.002 0.04 -2.03 -3.7 0.003 0.24 -1.81 0.49 0.635 0.55 0.22
1452318_a_at Hspalb 15511 heat shock protein IB -3.88 0.002 0.04 -2.28 -2.35 0.035 0.32 -1.32 1.86 0.084 0.22 0.96
I447824y_at Hspa5 14828 heat shock 70kD protein 5 -2.51 0.025 0.08 -0.96 -1.54 0.148 0.36 -0.56 1.19 0.255 0.41 0.4
I460495_s_at Htra2 64704 HtrA serine peptidase 2 IAI 0.183 0.14 0.42 2.57 0.023 0.10 0.73 1.2 0.251 0.41 0.31
I434282_at Ibtk 108837 inhibitor of tyrosine kinase 0.16 0.879 0.26 0.09 -3.09 0.008 0.30 -1.79 -3.54 0.003 0.05 -1.88
I424067_at leaml 15894 intercellular adhesion molecule 2.99 0.01 0.05 1.17 2.29 0.039 0.09 0.86 -0.91 0.377 0.66 -0.31
I426500_at lemt 57295 isoprenylcysteine carboxyl methyltransferase 1.61 0.131 0.12 0.41 3.11 0.008 0.09 0.76 1.56 0.143 0.36 0.35
14351 76_a_at Idb2 15902 inhibitor of DNA binding 2 -3.12 0.008 0.15 -0.86 -1.45 0.17 0.36 -0.38 1.97 0.07 0.27 0.48
I423804_a_at Idil 319554 isopentenyl-diphosphate delta isomerase -2.68 0.019 0.15 -0.67 -2.82 0.014 0.32 -0.67 -0.02 0.985 0.68 0
1417460_at Ifitm2 80876 interferon induced transmembrane protein 2 2.94 0.011 0.05 1.1 -0.1 0.921 0.39 -0.04 -3.46 0.004 0.06 -1.14
I423754_at Ifitm3 66141 interferon induced transmembrane protein 3 2.5 0.026 0.07 0.56 0.46 0.652 0.30 0.1 -2.34 0.035 0.38 -0.46
449026_at Ifnarl 15975 interferon (alpha and beta) receptor I 2.55 0.024 0.05 0.59 2.88 0.012 0.10 0.64 0.24 0.817 0.63 0.05
4481 67_at Ifngrl 15979 interferon gamma receptor I 1.54 0.147 0.15 0.42 2.19 0.046 0.10 0.58 0.64 0.535 0.55 0.15
4241 1I_at 19f2r 16004 insulin-like growth factor 2 receptor 1.69 0.114 O. II 0.53 3.19 0.007 0.07 0.96 1.55 0.144 0.36 0.43
424112_at 19f2r 16004 insulin-like growth factor 2 receptor 2.26 0.041 0.05 0.66 2.43 0.03 0.10 0.68 0.07 0.949 0.63 0.02
423062_at Igfbp3 16009 insulin-like growth factor binding protein 3 1.06 0.308 0.15 0.47 2.6 0.022 0.09 1.1 1.62 0.128 0.30 0.63
421 991_a_at Igfbp4 16010 insulin-like growth factor binding protein 4 2.55 0.024 0.05 0.92 0.16 0.876 0.30 0.05 -2.73 0.017 0.14 -0.86
427351_s_at Igh-4 16019 immunoglobulin heavy chain 4 (serum IgG I) 1.76 0.102 0.07 2.06 2.16 0.05 0.10 2.42 0.35 0.734 0.53 0.36
427455_x_at Igk-C /11lgk-V28 16071 immunoglobulin kappa chain, constant region 2.2 0.046 0.05 1.86 0.98 0.344 0.17 0.79 -1.44 0.173 0.48 -1.07
41 7376_a_at Igsf4a 54725 immunoglobulin superfamily, member 4A 2.78 0.015 0.05 0.79 4.59 0 0.07 1.24 1.83 0.089 0.27 0.45
41 7377_at Igsf4a 54725 immunoglobulin superfamily, member 4A 2.6 0.021 0.05 0.57 2.41 0.031 0.11 0.51 -0.34 0.742 0.68 -0.06
41 7378_at Igsf4a 54725 immunoglobulin superfamily, member 4A 2.16 0.05 0.07 0.54 2.61 0.021 0.10 0.63 0.39 0.704 0.60 0.09
460675_at Igsf8 140559 immunoglobulin superfamily, member 8 3.1 0.008 0.05 1.15 2.86 0.013 0.07 1.02 -0.42 0.682 0.68 -0.14
417141 at l2'tD 16145 interferon 2'amma induced GTPase 2.22 0.044 0.07 1.07 1.47 0.166 0.10 0.68 -0.93 0.369 0.66 -0.39
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Fold Ch./Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value
1451 I 13_a_at Ik 24010 IK cytokine
-2.2 0.046 0.26 -0.58 -1.18 0.258 0.39 -0.3 1.22 0.244 0.38 0.28
14271 64_at 1113ra I 16164 interleukin 13 receptor, alpha I 2.86 0.013 0.05 1.01 1.95 0.073 0.11 0.66 -1.14 0.273 0.65 -0.35
1452416_at 116ra 16194 interleukin 6 receptor, alpha 3.72 0.002 0.05 1.37 0.23 0.818 0.30 0.08 -3.98 0.001 0.05 -1.29
I437303_at 116st 16195 interleukin 6 signal transducer 2.2 0.046 0.05 1.05 0.29 0.776 0.30 0.13 -2.18 0.047 0.15 -0.92
I460669_at liB 16201 interleukin enhancer binding factor 3 3.81 0.002 0.05 1.17 3.83 0.002 0.07 1.12 -0.17 0.869 0.68 -0.05
1451217_a_at Immpll 66541 inner mitochondrial membrane peptidase-like
-2.51 0.026 0.24 -0.72 -2.05 0.061 0.32 -0.56 0.62 0.543 0.55 0.16
I433470_a_at Immt 76614 inner membrane protein, mitochondrial -2.15 0.05 0.26 -0.56 -1.31 0.213 0.39 -0.32 1.03 0.322 0.46 0.23
I436848_x_at Impal 55980 inositol (myo)-I (or 4)-monophosphatase I -2.44 0.029 0.20 -0.78 -0.73 0.481 0.39 -0.22 1.99 0.067 0.27 0.56
I437288_at Impadl 242291 inositol monophosphatase domain containing I -1.79 0.095 0.27 -0.41 0.27 0.794 0.30 0.06 2.33 0.036 0.22 0.47
I437290_at Impadl 242291 inositol monophosphatase domain containing I 0.06 0.954 0.26 0.02 -3.02 0.01 0.30 -0.8 -3.35 0.005 0.09 -0.82
141 6860_s_at Ingl 26356 inhibitor of growth family, member I
-2.66 0.019 0.23 -0.6 -0.85 0.409 0.39 -0.18 2.11 0.054 0.27 0.42
I433605_at Inpp5a 212111 inositol polyphosphate-5-phosphatase A 2.6 0.022 0.05 1.42 3.48 0.004 0.07 1.81 0.83 0.423 0.44 0.39
1447757J_at Inpp5f 101490 inositol polyphosphate-5-phosphatase F -1.69 0.113 0.27 -0.45 0.63 0.537 0.30 0.16 2.62 0.021 0.20 0.61
141 7980_a_at Insig2 72999 insulin induced gene 2
-2.65 0.02 0.15 -0.92 -1.27 0.224 0.39 -0.43 1.62 0.128 0.27 0.5
I454955_at Ipo7 233726 importin 7
-1.1 0.292 0.36 -0.27 1.3 0.216 0.22 0.3 2.66 0.019 0.20 0.57
1439481_at Ipo9 226432 importin 9 2.45 0.029 0.07 0.53 4.11 0.001 0.07 0.85 1.68 0.116 0.32 0.32
1441 645_s_at Ipo9 226432 importin 9 1.86 0.085 0.10 0.66 2.9 0.012 0.07 0.98 1.04 0.318 0.41 0.32
I434998_at Iqgapl 29875 IQ motif containing GTPase activo protein 1 2.19 0.047 0.05 0.71 2.16 0.05 0.11 0.67 -0.15 0.885 0.68 -0.04
I452327_at Iqsecl 232227 IQ motif and Sec7 domain I 5.14 0 0.05 1.55 4.18 0.001 0.07 1.21 -1.29 0.218 0.63 -0.34
I448668_a_at Irakl 16179 interleukin-I receptor-associated kinase I 2.18 0.048 0.08 0.49 0.26 0.802 0.30 0.05 -2.2 0.046 0.41 -0.43
I433634_at Irf2bp2 270110 interferon regulatory factor 2 binding protein 2 0.33 0.746 0.26 0.11 2.31 0.037 0.11 0.73 2.14 0.051 0.22 0.62
I423957_at Isg2011 68048 interferon stim exonuclease gene 20-like I 1.22 0.243 0.15 0.36 2.39 0.032 0.10 0.68 1.21 0.247 0.41 0.31
I42505 I_at Isoc! 66307 isochorismatase domain containing I 0.73 0.478 0.23 0.24 -1.25 0.233 0.39 -0.39 -2.19 0.047 0.38 -0.63
I452784_at Itgav 16410 integrin alpha V 1.88 0.082 0.08 0.5 3.33 0.005 0.09 0.85 1.49 0.159 0.36 0.35
1426918_at Itgbl 16412 integrin beta I (fibronectin receptor beta) 1.48 0.162 0.11 0.51 2.57 0.023 0.10 0.84 1.12 0.283 0.41 0.34
1417533_a_at Itgb5 16419 integrin beta 5 2.15 0.05 0.07 0.79 2.22 0.045 0.10 0.78 -0.03 0.973 0.68 -0.01
14561 33_x_at Itgb5 16419 integrin beta 5 2.31 0.037 0.08 0.55 2.24 0.043 0.11 0.51 -0.2 0.847 0.68 -0.04
14561 95_x_at Itgb5 16419 integrin beta 5 2.8 0.015 0.05 0.88 2.9 0.012 0.09 0.87 -0.04 0.972 0.68 -0.01
I449 I23_at Itih3 16426 inter-alpha trypsin inhibitor, heavy chain 3 2.52 0.025 0.07 0.72 1.25 0.232 0.22 0.34 -1.5 0.156 0.62 -0.38
1431808_a_at Itih4 16427 inter alpha-trypsin inhibitor, heavy chain 4 2.68 0.018 0.05 0.67 1.92 0.076 0.13 0.46 -0.96 0.355 0.66 -0.21
I435884_at Itsn I 16443 intersectin I (SH3 domain protein IA) -2.4 0.031 0.15 -1.12 -1.78 0.098 0.33 -0.79 0.8 0.437 0.44 0.33
1452338_s_at Itsn I 16443 intersectin I (SH3 domain protein IA) 1.91 0.078 0.09 0.78 -0.19 0.856 0.39 -0.07 -2.38 0.033 0.17 -0.85
1425718_a_at Ivns Iabp 117198 influenza virus NS IA binding protein -2.8 0.015 0.15 -0.98 -1.18 0.258 0.39 -0.39 1.9 0.079 0.27 0.58
I450084_s_at Ivns Iabp 117198 influenza virus NS IA binding protein -0.6 0.558 0.40 -0.14 1.57 0.139 0.20 0.34 2.4 0.032 0.22 0.48
I433804_at jakl 16451 janus kinase 1 4.01 0.001 0.05 1.27 -1.77 0.099 0.33 -0.54 -6.49 0 0.00 -1.8
1444157_a_at jarid Ic 20591 jumonji, AT rich interactive domain Ie (Rbp2) 1.96 0.07 0.08 0.55 3.12 0.008 0.09 0.83 1.16 0.266 0.44 0.28
I422698_s_at jarid2 16468 jumonji, AT rich interactive domain 2 2.76 0.016 0.05 0.62 2.81 0.014 0.10 0.6 -0.08 0.937 0.68 -0.02
I426873_s_at jup 16480 junction plakoglobin 2.51 0.025 0.05 0.86 -0.47 0.646 0.39 -0.15 -3.37 0.005 0.05 -1.02
I442554_s_at Kalrn 545156 kalirin, RhoGEF kinase 0.2 0.843 0.26 0.07 -1.85 0.087 0.33 -0.62 -2.24 0.042 0.27 -0.69
I452700_s_at Kbtbd7 211255 kelch repeat and BTB (POZ) domain 7 -2.2 0.046 0.26 -0.61 -1.1 0.292 0.39 -0.29 1.31 0.213 0.38 0.32
I452625_at Kctd2 70382 potassium channel tetramerisation domain 2 1.39 0.188 0.17 0.37 2.63 0.02 0.09 0.67 1.29 0.22 0.38 0.3
1460211_a_at Kdelrl 68137 ER protein retention receptor I 0.61 0.551 0.26 0.13 2.55 0.024 0.10 0.51 2.07 0.058 0.27 0.39
1417205_at Kdelr2 66913 ER protein retention receptor 2 2.87 0.013 0.05 0.95 2.34 0.035 0.11 0.74 -0.72 0.485 0.66 -0.21
1416833_at Kegl 64697 kidney expressed gene 1 -2.67 0.019 0.10 -0.87 -1.7 0.112 0.34 -0.53 1.19 0.256 0.41 0.34
I423995_at Kiflb 16561 kinesin family member IB 3.92 0.002 0.05 1.1 1.93 0.074 0.13 0.52 -2.36 0.034 0.36 -0.58
I455029_at Kif2la 16564 kinesin family member 21 A 0.69 0.504 0.24 0.22 3.07 0.009 0.09 0.93 2.56 0.023 0.22 0.71
1418427_at Kif5b 16573 kinesin family member 5B 2.36 0.034 0.05 0.77 1.66 0.12 0.17 0.52 -0.88 0.393 0.66 -0.25
1418429 at Kif5b 16573 kinesin familv member 5B -4.15 0.001 0.00 -2.7 -3.02 0.009 0.30 -1.88 1.44 0.174 0.32 0.82
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6·NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t·stat p.value q-value Fold Ch t-stat p-value q-value Fold Ch.
1418431_at Kif5b 16573 kinesin family member 5B 2.36 0.034 0.05 0.8 0.67 0.512 0.30 0.22 -1.95 0.072 0.44 -0.58
I426493_a_at Kifc2 16581 kinesin family member C2 2.82 0.014 0.05 0.54 1.18 0.258 0.24 0.22 -1.93 0.076 0.46 -0.32
I432543_a_at Klfl3 50794 Kruppel-like factor 13 2.29 0.038 0.05 0.84 1.7 0.113 0.15 0.59 -0.77 0.457 0.68 -0.24
I436763_a_at Klf9 16601 Kruppel-like factor 9
-1.05 0.314 0.30 -0.4 -2.21 0.045 0.32 -0.82 -1.22 0.244 0.64 -0.41
141 5991_a_at Klhdc3 71765 kelch domain containing 3 3.68 0.003 0.05 1.0 I 4.33 0.001 0.07 1./3 0.52 0.608 0.58 0.13
1454747_a_at Klhdc3 71765 kelch domain containing 3 3.52 0.004 0.05 0.92 4.46 0.001 0.07 1.12 0.85 0.411 0.50 0.2
I426978_at Klhl2 77113 kelch-like 2, Mayven (Drosophila)
-2.35 0.035 0.23 -0.86 -2.07 0.059 0.31 -0.72 0.42 0.68 0.60 0.14
I458351_s_at Klhl2 77113 kelch-like 2, Mayven (Drosophila)
-2.81 0.014 0.17 -0.95 -1.57 0.138 0.32 -0.51 1.48 0.161 0.36 0.44
141 7974_at Kpna4 16649 karyopherin (importin) alpha 4
-2.65 0.019 0.17 -0.69 -2.76 0.016 0.31 -0.69 0.01 0.99 0.63 0
1451967_x_at Kpnbl 16211 karyopherin (importin) beta I
-1.41 0.182 0.27 -0.43 0.89 0.392 0.29 0.26 2.56 0.023 0.22 0.68
I423691_x_at Krt2-8 16691 keratin complex 2. basic, gene 8 2.15 0.05 0.08 0.63 2.32 0.037 0.10 0.64 0.08 0.941 0.63 0.02
I455434_a_at Ktnl 16709 kinectin I 0.4 0.696 0.26 0.12 2.36 0.034 0.11 0.68 2.11 0.054 0.27 0.56
1416343_a_at Lamp2 16784 lysosomal membrane glycoprotein 2
-1.36 0.197 0.30 -0.35 -2.54 0.024 0.32 -0.63 -1.22 0.244 0.65 -0.28
I438365_x_at Laptm4b 114128 lysosomal-associated prot transmembrane 4B 1.25 0.232 0.15 0.32 2.57 0.023 0.11 0.63 1.37 0.193 0.38 0.31
I426025_s_at Laptm5 16792 lysosomal-associated protein transmembrane 5 2.42 0.03 0.05 1.2 0.63 0.541 0.22 0.3 -2.07 0.058 0.38 -0.9
I434597_at Larp5 217980 La ribonucleoprotein domain family, member 5 2.24 0.042 0.07 0.5 2.07 0.059 0.13 0.44 -0.3 0.767 0.68 -0.06
I448403_at Lars 107045 leucyl-tRNA synthetase 2.88 0.013 0.05 0.77 2.36 0.034 0.11 0.6 -0.7 0.493 0.68 -0.16
I452266_at Las II 76130 LAS I-like (S. cerevisiae) 2.22 0.044 0.08 0.71 2.48 0.027 0.10 0.76 0.17 0.871 0.63 0.05
1456309_x_at Laspl 16796 LIM and SH3 protein I 1.25 0.233 0.15 0.31 -1.08 0.299 0.39 -0.25 -2.6 0.022 0.30 -0.56
14601 73_at Lasp I 16796 LIM and SH3 protein I 1.6 0.132 0.12 0.4 -0.39 0.705 0.39 -0.09 -2.25 0.042 0.41 -0.49
1448550_at Lbp 16803 lipopolysaccharide binding protein 3.37 0.005 0.05 1.65 1.81 0.093 0.10 0.85 -1.86 0.084 0.44 -0.8
I428022_at Lcnl3 227627 lipocalin I3
-1.61 0.13 0.27 -1.68 -3.04 0.009 0.00 -3.02 -1.47 0.164 0.44 -1.34
1427747_a_at Lcn2 16819 lipocalin 2 4.15 0.001 0.05 5.84 2.2 0.046 0.07 2.96 -2.33 0.036 0.15 -2.88
I424378_at Ldlrapl 100017 LDL receptor adaptor protein I 3.28 0.006 0.05 0.67 1./4 0.276 0.25 0.22 -2.5 0.026 0.20 -0.45
1433891_at Lgr4 107515 leucine-rich repeat 1.08 0.301 0.20 0.26 2.45 0.029 0.10 0.56 1.44 0.173 0.38 0.3
1423141_at Lipl 16889 lysosomal acid lipase I 1.17 0.262 0.10 0.5 -0.83 0.423 0.39 -0.33 -2.23 0.043 0.36 -0.83
I450872_s_at Lipl 16889 lysosomal acid lipase I 2.35 0.034 0.07 0.6 2.37 0.034 0.10 0.57 -0.1 0.918 0.68 -0.02
1416303_at Litaf 56722 LPS-induced TN factor 2.37 0.034 0.07 0.89 1.53 0.15 0.11 0.55 -1.03 0.32 0.66 -0.34
1421 654_a_at Lmna 16905 laminA 3.28 0.006 0.05 0.83 3.09 0.008 0.09 0.74 -0.37 0.718 0.68 -0.08
I457670_s_at Lmna 16905 laminA 2.95 0.011 0.05 0.93 3.01 0.01 0.09 0.91 -0.09 0.932 0.68 -0.02
I438432_at Lnpep 240028 leucylfcystinyl aminopeptidase 4.27 0.001 0.05 1.15 0.94 0.363 0.27 0.24 -3.83 0.002 0.06 -0.91
I438932_at LOC381240 381240 RAS, guanyl releasing protein 2 (Rasgrp2) -2.42 0.03 0.26 -0.57 -3.44 0.004 0.30 -0.78 -0.99 0.342 0.66 -0.2
I456846_at LOC382639 382639 similar to RP58 protein 2.51 0.026 0.05 0.86 1.97 0.069 0.13 0.65 -0.71 0.492 0.68 -0.21
I450632_at LOC433749 433749 similar to aplysia ras-related homolog A2 -3.81 0.002 0.08 -1.03 -1.24 0.234 0.38 -0.32 2.98 0.01 0.20 0.71 !
14363 I6_at LOC434069 434069 hypothetical gene supported by AK079127 2.8 0.014 0.05 1.02 1.65 0.122 0.15 0.57 -1.4 0.185 0.63 -0.45
14371 76_at LOC43434I 434341 similar to nucleotide-binding oligomerization 3.81 0.002 0.05 1.18 3.3 0.005 0.07 0.98 -0.74 0.473 0.68 -0.2
1437014_x_at LOC545161 545161 similar to Peroxiredoxin I -2.39 0.032 0.26 -0.61 -0.72 0.483 0.39 -0.18 1.93 0.D75 0.30 0.43
1453207_at LOC554362 554362 hypothetical gene LOC554362 -2.81 0.014 0.22 -0.58 -0.75 0.464 0.39 -0.15 2.38 0.033 0.22 0.43
I42622 I_at Loh II cr2a 67776 loss of heterozygosity, II 2.23 0.044 0.08 0.64 1.91 0.078 0.15 0.53 -0.46 0.655 0.68 -0.12
I437235]_at Lpp 210126 preferred translocation partner in lipoma 0.26 0.796 0.26 0.07 2.5 0.026 0.10 0.66 2.42 0.031 0.22 0.59
1440167_s_at Lpp 210126 preferred translocation partner in lipoma 1.19 0.253 0.18 0.32 3.1 0.008 0.07 0.79 2.01 0.064 0.27 0.47
1417290_at Lrgl 76905 leucine-rich alpha-2-glycoprotein I 2.86 0.013 0.05 1.03 0.47 0.644 0.30 0.16 -2.74 0.016 0.17 -0.87
I448655_at Lrpl 16971 LDL receptor-related protein I 2.91 0.012 0.05 0.8 1.1 I 0.288 0.24 0.29 -2.11 0.054 0.44 -0.51
141 6836_at LrplO 65107 LDL receptor-related protein 10 3.22 0.006 0.05 0.85 1.61 0.131 0.13 0.41 -1.92 0.076 0.50 -0.44
I426696_at Lrpapl 16976 LDL receptor-related protein 2.04 0.061 0.05 1.01 2.19 0.046 0.10 1.03 0.06 0.949 0.63 0.03
1436609_a_at Lrpapl 16976 LDL receptor-related protein 2.48 0.027 0.05 1.13 3.38 0.005 0.07 1.47 0.85 0.408 0.46 0.34
1452148_at Lrpapl 16976 LDL receptor-related protein 2.52 0.025 0.05 1.23 2.11 0.054 0.11 0.98 -0.57 0.58 0.68 -0.24
1427125 s at Lrrc41 230654 leucine rich repeat containinJ! 41 2.35 0.034 0.05 0.74 2.84 0.014 0.10 0.85 0.41 0.687 0.60 0.11
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6·NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1437477_at Lrriip I 16978 leucine rich repeat interacting protein I 2.93 0.011 0.05 0.81 1.38 0.191 0.22 0.36 -1.83 0.089 0.46 -0.45
1451 985_at Lrrkl 233328 leucine-rich repeat kinase I 2.43 0.03 0.05 0.96 2.67 0.019 0.09 1.01 0.14 0.892 0.63 0.05
141 8656_at lsm5 66373 LSM5 homolog
-3.66 0.003 0.12 -0.8 -2.54 0.024 0.32 -0.53 1.4 0.184 0.36 0.27
1420013_s_at lss 16987 lanosterol synthase 2.26 0.041 0.05 0.9 0.87 0.402 0.27 0.33 -1.63 0.125 0.46 -0.57
I452708_a_at Luc71 66978 Luc7 homolog (S. cerevisiae)-Iike
-0.12 0.908 0.40 -0.03 -2.33 0.036 0.31 -0.6 -2.41 0.031 0.36 -0.57
I42325 I_at Luc712 192196 LUC7-like 2 (S. cerevisiae)
-2.63 0.02 0.20 -0.76 0.11 0.915 0.30 0.03 3.12 0.008 0.20 0.79
141 6469_at Luzpl 269593 leucine zipper protein 1 2.5 0.026 0.07 0.59 3.01 0.01 0.09 0.68 0.43 0.674 0.60 0.09
1417185_at Ly6a 110454 lymphocyte antigen 6 complex. locus A 2.71 0.018 0.05 1.97 0.5 0.626 0.30 0.35 -2.54 0.024 0.09 -1.62
I453304_s_at Ly6e 17069 lymphocyte antigen 6 complex, locus E 2.87 0.013 0.05 1.3 1.46 0.168 0.13 0.63 -1.68 0.115 0.48 -0.67
1434690 at Lycat 225010 Iysocardiolipin acyltransferase 2.25 0.042 0.07 0.61 2.27 0.04 0.11 0.59 -0.09 0.929 0.68 -0.02
I448244_at Lyplal 18777 Iysophospholipase I
-2.33 0.036 0.15 -0.89 -1.77 0.099 0.33 -0.64 0.73 0.481 0.50 0.24
I423704_at Lypla3 192654 Iysophospholipase 3 2.95 0.011 0.05 0.88 2.45 0.029 0.10 0.7 -0.69 0.5 0.68 -0.18
I460335_at Lysmd3 80289 putative peptidoglycan-binding domain -2.79 0.015 0.17 -0.61 -1.54 0.147 0.37 -0.32 1.5 0.158 0.36 0.29
I434674_at Lyst 17101 lysosomal trafficking regulator 2.11 0.054 0.09 0.61 2.57 0.023 0.10 0.71 0.4 0.697 0.58 0.1
I423547_at Lyzs 17105 lysozyme 0.9 0.381 0.20 0.63 -1.08 0.299 0.32 -0.72 -2.21 0.045 0.27 -1.36
I437473_at Maf 17132 v-maf AS42 oncogene homolog 2.38 0.033 0.05 0.92 0.97 0.35 0.25 0.36 -1.65 0.121 0.50 -0.56
I450062_a_at Magedl 94275 melanoma antigen, family D, I 2.46 0.028 0.07 0.66 1.38 0.19 0.22 0.35 -1.3 0.216 0.63 -0.31
I43546 I_at Magi3 99470 membrane associated guanylate kinase 2.22 0.045 0.09 0.55 2.19 0.046 0.10 0.52 -0.13 0.896 0.68 -0.03
I453263_at MaklO 78689 amino-acid N-acetyltransferase subunit 0.24 0.81 0.26 0.09 -4.46 0.001 0.15 -1.64 -5.13 0 0.00 -1.73
I427042_at Mal2 105853 mal, T-cell differentiation protein 2 -3.6 0.003 0.08 -1.42 -2.55 0.023 0.31 -0.97 1.31 0.211 0.30 0.46
1418188_a_at Malatl 72289 metastasis associated lung adenocarcinoma 1.88 0.082 0.07 0.95 -3.27 0.006 0.27 -1.57 -5.7 0 0.00 -2.52
418 I89_s_at Malatl 72289 metastasis associated lung adenocarcinoma 1.21 0.246 0.10 0.73 -3.04 0.009 0.29 -1.75 -4.69 0 0.00 -2.48
429060_at Malatl 72289 metastasis associated lung adenocarcinoma 0.82 0.428 0.22 0.3 -1.96 0.071 0.32 -0.69 -3.07 0.009 0.11 -I
452378_at Malatl 72289 metastasis associated lung adenocarcinoma 0.6 0.557 0.24 0.32 -2.93 0.011 0.27 -1.51 -3.88 0.002 0.05 -1.83
435203_at Man2a2 140481 mannosidase 2, alpha 2 2.83 0.014 0.05 1.36 3.25 0.006 0.07 1.49 0.32 0.754 0.58 0.14
423687_a_at Man2cl 73744 mannosidase, alpha. elass 2C, member I 2.96 0.011 0.05 0.76 3.07 0.009 0.09 0.75 -0.03 0.978 0.68 -0.01
41 5930_a_at Mapl1c3b 67443 microtubule-associated protein I chain 3 beta -2.01 0.065 0.27 -0.44 0.02 0.982 0.30 0 2.31 0.037 0.22 0.44
451 982_at Map2k4 26398 mitogen activated protein kinase kinase 4 1.48 0.163 0.15 0.34 2.6 0.021 0.10 0.58 1.15 0.27 0.44 0.24
459800_s_at Map3k4 26407 mitogen activated protein kinase kinase kinase 0.57 0.581 0.26 0.15 3.19 0.007 0.09 0.78 2.82 0.014 0.20 0.64
439830_at Map3k5 26408 mitogen activated protein kinase kinase kinase 1.39 0.187 0.14 0.38 2.45 0.028 0.11 0.64 1.09 0.295 0.44 0.26
422764_at Maprel 13589 microtubule-associated protein -2.22 0.044 0.26 -0.72 -1.12 0.281 0.39 -0.35 1.31 0.213 0.38 0.37
428819_at Maprel 13589 microtubule-associated protein 3.59 0.003 0.05 0.9 3.75 0.002 0.07 0.89 -0.01 0.995 0.68 0
426245_s_at Mapre2 212307 microtubule-associated protein 3.55 0.003 0.05 1.03 2.94 0.011 0.09 0.81 -0.84 0.418 0.66 -0.21
459871_x_at March2 224703 membrane-associated ring finger (C3HC4) 2 -3.58 0.003 0.11 -0.77 -2.09 0.056 0.33 -0.43 1.8 0.093 0.30 0.34
I436893_a_at March7 57438 membrane-associated ring finger (C3HC4) 7 1.18 0.26 0.18 0.29 2.72 0.017 0.10 0.65 1.62 0.129 0.30 0.36
1415922_s_at Marcksll 17357 MARCKS-like I 2.35 0.035 0.07 0.62 1.87 0.084 0.15 0.47 -0.64 0.531 0.68 -0.15
1435415J_at Marcksll 17357 MARCKS-like I 3.07 0.009 0.05 0.89 2.45 0.029 0.09 0.68 -0.83 0.424 0.67 -0.21
1426914_at Marveld2 218518 MARVEL domain containing 2 2.31 0.037 0.08 0.61 2.19 0.047 0.11 0.55 -0.25 0.807 0.68 -0.06
I438602_s_at Maspl 17174 mannan-binding lectin serine protease I 1.93 0.074 0.07 0.72 -0.74 0.469 0.39 -0.27 -3.01 0.01 0.11 -0.99
1451099_at Mbc2 23943 membrane bound C2 domain containing 2.64 0.02 0.07 0.66 1.78 0.098 0.15 0.42 -1.07 0.301 0.66 -0.23
I44864 I_at Mbtdl 103537 mbt domain containing I -0.2 0.846 0.40 -0.05 1.98 0.069 0.15 0.47 2.38 0.033 0.22 0.51
1437527_x_at Mel I 17210 myeloid cell leukemia sequence I 3.44 0.004 0.05 1.01 2.48 0.027 0.09 0.7 -1.21 0.248 0.65 -0.31
I456243_x_at Mell 17210 myeloid cell leukemia sequence I 2.67 0.019 0.05 0.75 1.41 0.18 0.17 0.38 -1.5 0.156 0.63 -0.37
141 6671_a_at Mcolnl 94178 mucolipin I 2.18 0.048 0.05 0.66 3.41 0.004 0.07 0.99 1.23 0.239 0.41 0.33
141 6672_s_at Mcolnl 94178 mucolipin I 1.26 0.228 0.15 0.29 2.92 0.012 0.10 0.64 1.74 0.104 0.32 0.35
14271 85_at Mef2a 17258 myocyte enhancer factor 2A 0.43 0.675 0.26 0.11 2.17 0.048 0.11 0.52 1.88 0.083 0.27 0.41
1427186_a_at Mef2a 17258 myocyte enhancer factor 2A -2.3 0.038 0.24 -0.52 -0.75 0.467 0.39 -0.16 1.8 0.095 0.30 0.36
1422869 at Mertk 17289 comer oroto-onCOl!ene tyrosine kinase 2.28 0.039 0.07 0.78 1.11 0.286 0.24 0.36 -1.39 0.187 0.63 -0.42
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Probe Symbol Entrez Description IGTI6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I436897_at Mfhasl 52065 fibrous histiocytoma amplified sequence I 2.7 0.018 0.05 0.84 2.09 0.057 0.11 0.62 -0.8 0.438 0.67 -0.22
1451 247_at Mfsdl 66868 major facilitator superfamily domain containing 2.48 0.027 0.05 0.66 1.89 0.08 0.15 0.48 -0.76 0.458 0.68 -0.18
I426350_at Mgat2 217664 mannoside acetylglucosaminyltransferase 2
-4.16 0.001 0.07 -1.58 -3.49 0.004 0.29 -1.27 0.93 0.368 0.44 0.31
1428643_at Mgat5 107895 mannoside acetylglucosaminyltransferase 5 4.54 0.001 0.05 1.53 2.86 0.013 0.07 0.92 -2.06 0.06 0.44 -0.61
I428644_at Mgat5 107895 mannoside acetylglucosaminyltransferase 5 4.56 0 0.05 1.8 3.22 0.006 0.07 1.21 -1.68 0.115 0.53 -0.58
141 6765_s_at MGI: 1913699 66449 granulocyte-macrophage CSF signal transduct.
-4.15 0.001 0.08 -0.86 -1.33 0.205 0.38 -0.26 3.28 0.006 0.20 0.6
I423986_a_at MGI:1915044 66940 scotin gene 2.82 0.014 0.05 1.38 1.47 0.164 0.09 0.69 -1.61 0.132 0.55 -0.69
I437503_a_at MGI:1915044 66940 scotin gene 2.61 0.021 0.05 1.0 I 1.55 0.145 0.10 0.57 -1.28 0.221 0.64 -0.43
I448505_at MGI:I927354 57316 nuclear DNA binding protein
-3.75 0.002 0.11 -0.82 -1.7 0.111 0.34 -0.36 2.41 0.031 0.22 0.47
1451 255_at MGI:I927471 54135 liver-specific bHLH-Zip transcription factor 2.64 0.02 0.05 1.0 I 1.03 0.322 0.22 0.37 -1.89 0.08 0.44 -0.63
I437250_at MGI:2151839 381269 whn-dependent transcript 2
-2.81 0.014 0.11 -1.09 -1.54 0.146 0.34 -0.58 1.52 0.152 0.32 0.52
I435385_at MGI:2153084 228911 serologically defined colon cancer antigen like 4.64 0 0.05 1.37 1.78 0.097 0.15 0.5 -3.34 0.005 0.10 -0.87
I426743_at MGI:2384914 216190 Dip3 beta I 0.337 0.22 0.24 2.9 0.012 0.10 0.67 2.02 0.064 0.27 0.43
1424614_at MGI:2385286 233575 FGF receptor activating protein I 1.97 0.07 0.09 0.51 -1.93 0.075 0.33 -0.48 -4.34 0.001 0.05 -I
I437904_at MGI:2387367 241490 developmentally regulated RNA binding protein 1.93 0.074 0.08 0.96 2.79 0.015 0.09 1.32 0.83 0.419 0.38 0.36
1441 963_at MGI:2656976 241638 ProSAPiPI protein 3.48 0.004 0.05 0.94 2.66 0.019 0.10 0.68 -1.07 0.304 0.66 -0.25
I427480_at MGI:2672795 259301 liver-expressed antimicrobial peptide 2 -2.29 0.039 0.26 -0.82 -0.25 0.803 0.39 -0.09 2.33 0.036 0.20 0.73
1456510_x_at MGI:3026615 393082 UbiE-YGHLI fusion protein -2.51 0.026 0.22 -0.65 -1.77 0.1 0.34 -0.44 0.93 0.369 0.48 0.21
I450391_a_at MglI 23945 monoglyceride lipase -0.64 0.533 0.40 -0.18 2.05 0.06 0.13 0.55 2.96 0.011 0.20 0.72
I453836_a_at MglI 23945 monoglyceride lipase -0.21 0.835 0040 -0.07 1.81 0.093 0.15 0.58 2.21 0.045 0.22 0.65
I448300_at Mgst3 66447 microsomal glutathione S-transferase 3 0.33 0.745 0.26 0.13 2.72 0.017 0.10 1.04 2.58 0.022 0.20 0.91
I424862_s_at Mib2 76580 mindbomb homolog 2 (Drosophila) 1.0 I 0.33 0.22 0.27 2.29 0.038 0.09 0.58 1.35 0.201 0.38 0.31
I434853y_at Mkrnl 54484 makorin, ring finger protein, I 2.9 0.012 0.05 0.79 3048 0.004 0.07 0.91 0049 0.634 0.58 0.12
1448897 at Mkrn2 67027 makorin, ring finger protein, 2
-1.18 0.257 0.31 -0.37 1.67 0.118 0.17 0.5 3.16 0.007 0.20 0.86
1420870_at MlitlO 17354 myeloidllymphoid or mixed lineage-leukemia 0.64 0.536 0.26 0.2 204 0.031 0.10 0.74 1.89 0.08 0.27 0.53
translocation to 10 homolog
I423488_at Mmd 67468 monocyte to macrophage differentiation-assoc -2044 0.029 0.23 -0.83 -0.34 0.741 0.39 -0.11 2041 0.031 0.22 0.72
I435645_at Mmd 67468 monocyte to macrophage differentiation-assoc -3.03 0.009 0.15 -1.14 -0.68 0.505 0.39 -0.25 2.71 0.017 0.20 0.89
I438654_x_at Mmd2 75104 monocyte to macrophage differentiation-assoc 4.39 0.001 0.05 1.88 3.28 0.006 0.07 1.34 -1042 0.179 0.62 -0.53
145596I_at Mme 17380 membrane metallo endopeptidase -1.37 0.194 0.28 -0047 1.19 0.255 0.22 0.39 2.85 0.013 0.20 0.86
I454867_at Mnl 433938 meningioma I 4.36 0.001 0.05 1.04 4.4 0.001 0.07 I -0.17 0.867 0.68 -0.04
I42009 I_s_at Morc3 338467 microrchidia 3 0.33 0.747 0.26 0.09 2.47 0.028 0.09 0.68 2.31 0.037 0.27 0.58
14241 24_at Mospd2 76763 motile sperm domain containing 2 -2.05 0.061 0.25 -0.54 0.78 00447 0.30 0.2 3.18 0.007 0.20 0.73
I427076_at Mpegl 17476 macrophage expressed gene I 3.14 0.008 0.05 1.7 1.95 0.072 0.09 1.0 I -1044 0.172 0.60 -0.69
449348_at Mpp6 56524 membrane protein, palmitoylated 6 -0.73 00478 0040 -0.22 1.25 0.232 0.24 0.35 2.19 0.046 0.20 0.57
432216_s_at Mpp7 75739 membrane protein, palmitoylated 7 2.6 0.022 0.05 0.83 0.94 0.362 0.25 0.29 -1.93 0.075 0.41 -0.54
4541 58_at Mpp7 75739 membrane protein, palmitoylated 7 6.79 0 0.05 1.72 3.88 0.002 0.07 0.94 -3.51 0.004 0.05 -0.78
457632_s_at Mrgl 17536 myeloid ecotropic viral integration site-related 1.22 0.244 0.17 0.46 2.32 0.036 0.10 0.84 1.14 0.274 0.30 0.38
42665 I_at Mrpl44 69163 mitochondrial ribosomal protein L44 -3.21 0.007 0.08 -1.44 -0.9 0.382 0.39 -0.39 2.67 0.019 0.20 1.06
451 266_at Mrpl50 28028 mitochondrial ribosomal protein L50 -3.05 0.009 0.15 -0.74 -1.6 0.134 0.35 -0.37 1.73 0.106 0.32 0.37
451 I78_at Mrpl53 68499 mitochondrial ribosomal protein L53 -2.71 0.017 0.17 -0.65 -1041 0.18 0.39 -0.33 1.55 0.145 0.32 0.33
41 8267_at Mstl 15235 macrophage stimulating I (hepatocyte growth factor-like) 3.54 0.003 0.05 0.88 1.71 0.11 0.17 0041 -2.16 0.049 0.36 -0047
422557_s_at Mtl 17748 metallothionein I 3.38 0.005 0.05 3.75 2.22 0.044 0.07 2.35 -1.43 0.175 0.50 -1.39
428942_at Mt2 17750 metallothionein 2 2.85 0.013 0.05 3.38 1.53 0.15 0.07 1.73 -1.58 0.137 0046 -1.65
416091_at Mtap4 17758 microtubule-associated protein 4 0.76 0046 0.25 0.21 2.34 0.035 0.10 0.63 1.68 0.116 0.30 0042
434883_at Mtdh 67154 Metadherin 0.36 0.725 0.26 0.09 2.7 0.018 0.10 0.62 2.53 0.025 0.22 0.53
451 536_at Mtfrl 67472 mitochondrial fission regulator I -4.5 0.001 0.07 -1.21 -1.69 0.114 0.34 -0043 3.29 0.006 0.20 0.77
415685 at Mtif2 76784 mitochondrial translational initiation factor 2 -2.16 0.049 0.26 -0.59 -0.71 00489 0.39 -0.19 1.69 0.115 0.30 004
v.>!j
Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene 10 t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I425485_at Mtmr6 219135 myotubularin related protein 6
-2.75 0.016 0.15 -0.85 -1.45 0.169 0.35 -0.43 1.55 0.145 0.36 0.42
1437457_a_at Mtpn 14489 myotrophin 1.91 0.077 0.10 0.49 2.52 0.025 0.10 0.62 0.56 0.582 0.55 0.13
141 69 I4_s_at Mtvr2 17826 mammary tumor virus receptor 2
-0.96 0.352 0.38 -0.23 -2.68 0.018 0.32 -0.6 -1.82 0.091 0.46 -0.37
141 8521_a_at Mtxl 17827 metaxin I 1.98 0.069 0.08 0.52 2.36 0.034 0.11 0.59 0.32 0.757 0.62 0.07
I426014_a_at Mucdhl 72040 mucin and cadherin like 3.57 0.003 0.05 1.08 0.38 0.707 0.30 0.11 -3.65 0.003 0.09 -0.97
I430893_at Mupl 17840 major urinary protein I
-2.74 0.016 0.14 -1.52 -3.03 0.009 0.07 -1.6 -0.17 0.869 0.68 -0.08
1418052_at Mvk 17855 mevalonate kinase 1.61 0.13 0.09 0.62 -0.42 0.683 0.39 -0.15 -2.29 0.039 0.22 -0.77
1448618_at Mvp 78388 major vault protein 3.58 0.003 0.05 1.23 3.59 0.003 0.07 1.18 -0.16 0.873 0.68 -0.05
I456586y_at Mvp 78388 major vault protein 2.97 0.01 0.05 0.97 3.14 0.008 0.07 0.98 0.03 0.977 0.63 0.01
I434378_a_at Mxd4 17122 Max dimerization protein 4 2.11 0.054 0.07 0.62 2.58 0.023 0.10 0.72 0.4 0.696 0.60 0.1
1417472_at Myh9 17886 myosin heavy chain IX 4.34 0.001 0.05 1.3 3.17 0.007 0.07 0.91 -1.49 0.16 0.63 -0.39
1420171_s_at Myh9 17886 myosin heavy chain IX 3.95 0.002 0.05 1.05 3.34 0.005 0.09 0.85 -0.87 0.4 0.67 -0.2
1420172 at Myh9 17886 myosin heavy chain IX 3.54 0.003 0.05 1.16 2.88 0.013 0.09 0.9 -0.89 0.387 0.66 -0.26
I450650_at MyolO 17909 myosin X 3.29 0.006 0.05 0.72 4.22 0.001 0.07 0.88 0.85 0.411 0.48 0.16
1419649_s_at Myolc 17913 myosin IC 3.08 0.008 0.05 0.71 3.41 0.004 0.07 0.75 0.2 0.845 0.63 0.04
1418031_at Myo9b 17925 myosin IXb 2.2 0.046 0.07 0.64 1.96 0.071 0.13 0.54 -0.38 0.711 0.68 -0.1
I42763 I_x_at na 17842 similar to Mup3 protein -2.66 0.019 0.15 -1.12 -1.77 0.1 0.31 -0.71 1.11 0.288 0.41 0.41
1439816_at na 69312 hypothetical gene supported by AK0879 I5 3.09 0.008 0.05 1.95 3.99 0.001 0.07 2.41 0.83 0.423 0.46 0.46
1449043_at Naga 17939 N-acetyl galactosaminidase, alpha 2.57 0.023 0.05 0.77 3.01 0.01 0.09 0.86 0.35 0.734 0.60 0.09
141 7706_at Naglu 27419 alpha-N-acetylglucosaminidase 2.26 0.041 0.07 0.55 1.71 0.111 0.17 0.4 -0.71 0.488 0.68 -0.15
1420477_at Nap"l 53605 nucleosome assembly protein I-like I -2.19 0.047 0.26 -0.56 0.3 0.767 0.30 0.07 2.82 0.014 0.20 0.64
I424069_at Napg 108123 N-ethylmaleimide sensitive fusion protein attachment 1.23 0.239 0.18 0.31 2.36 0.034 0.10 0.58 1.17 0.262 0.44 0.26
protein gamma
1418022_at Nargl 74838 NMDA receptor-regulated gene I -1.7 0.112 0.26 -0.5 0.81 0.435 0.30 0.23 2.81 0.014 0.20 0.72
I423046_s_at Ncbp2 68092 nuclear cap binding protein subunit 2 -2.56 0.023 0.23 -0.77 -1.48 0.163 0.36 -0.42 1.31 0.212 0.36 0.35
1415773_at NcI 17975 nucleolin 0.6 0.556 0.26 0.26 -2.33 0.036 0.32 -0.94 -3.23 0.006 0.05 -1.2
I424203_at Ncln 103425 nicalin homolog (zebrafish) 2.3 0.038 0.05 0.83 0.66 0.518 0.30 0.23 -1.89 0.08 0.41 -0.6
I41 8594_a_at Ncoal 17977 nuclear receptor coactivator 1 3.04 0.009 0.05 0.78 2.79 0.015 0.10 0.69 -0.42 0.681 0.68 -0.1
I423202_a_at Ncorl 20185 nuclear receptor co-repressor I 2.07 0.059 0.05 0.69 2.26 0.041 0.11 0.72 0.11 0.915 0.63 0.03
I422554_at Ndnl2 66647 necdin-like 2 0.57 0.575 0.26 0.15 3.12 0.008 0.07 0.8 2.75 0.016 0.20 0.65
I428367_at Ndstl 15531 N-deacetylaseiN-sulfotransferase (heparan glucosaminyl) 1.5 0.157 0.14 0.39 2.87 0.013 0.09 0.72 1.42 0.179 0.38 0.33
I
1433513y_at Ndufal2 66414 NADH dehydrogenase (ubiquinone) I alpha 12 -2.65 0.02 0.24 -0.72 -0.86 0.407 0.39 -0.22 2.08 0.057 0.22 0.49
1455749_x_at Ndufa7 66416 NADH dehydrogenase (ubiquinone) I alpha 7 -1.91 0.078 0.27 -0.49 0.14 0.892 0.30 0.03 2.32 0.036 0.22 0.52
I428075_at Ndufb4 68194 NADH dehydrogenase (ubiquinone) I beta 4 -3.13 0.008 0.17 -0.6 -1.26 0.23 0.39 -0.23 2.2 0.046 0.22 0.37
1417102_a_at Ndufb5 66046 NADH dehydrogenase (ubiquinone) I beta 5 -3.18 0.007 0.15 -0.69 -1.52 0.152 0.35 -0.32 1.96 0.071 0.27 0.38
I448589_at Ndufb5 66046 NADH dehydrogenase (ubiquinone) I beta 5 -2.55 0.024 0.26 -0.53 -0.26 0.802 0.39 -0.05 2.62 0.021 0.20 0.48
144833 I_at Ndufb7 66916 NADH dehydrogenase (ubiquinone) I beta 7 -1.36 0.198 0.28 -0.32 1.39 0.188 0.22 0.32 3.05 0.009 0.20 0.64
1416494_at Ndufs5 595136 NADH dehydrogenase (ubiquinone) Fe-S 5 -2.03 0.062 0.27 -0.42 0.78 0.45 0.30 0.15 3.16 0.007 0.20 0.57
1416495_s_at Ndufs5 595136 NADH dehydrogenase (ubiquinone) Fe-S 5 -2.99 0.01 0.15 -0.59 0.29 0.779 0.30 0.05 3.72 0.002 0.20 0.65
1421 955_a_at Nedd4 17999 neural precursor cell expressed 1.35 0.2 0.05 0.71 -3.85 0.002 0.22 -1.95 -5.73 0 0.00 -2.66
1416331_a_at Nfe211 18023 nuclear factor, erythroid derived 2,-like I 0.95 0.358 0.18 0.35 3.12 0.008 0.07 1.11 2.31 0.037 0.22 0.76
I438236_at Nfia 18027 nuclear factor 1/A 2.61 0.021 0.05 0.96 0.84 0.415 0.29 0.3 -2.05 0.06 0.44 -0.66
1456087_at Nfia 18027 nuclear factor 1/A 2.35 0.035 0.07 0.48 1.63 0.126 0.17 0.32 -0.9 0.383 0.67 -0.16
I450661_x_at Nfic 18029 nuclear factor I/C 1.49 0.159 0.05 0.85 -0.74 0.472 0.39 -0.4 -2.51 0.026 0.16 -1.26
I448306_at Nfkbia 18035 nuclear factor of kappa light chain gene enhancer in B- 2.18 0.048 0.05 0.66 3.1 0.008 0.09 0.9 0.9 0.383 0.48 0.24
cells inhibitor, alpha
1448963 at Nfyc 18046 nuclear transcriotion factor-Y l1"amma 1.69 0.113 0.12 0.39 2.23 0.043 0.11 0.49 0.5 0.624 0.58 0.1
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1449376_at Nicnl 66257 nicolin I
-0.63 0.539 0.40 -0.17 1.52 0.151 0.17 0.39 2.37 0.033 0.22 0.55
1421968_a_at Nipa2 93790 non imprinted in Prader-Willi/Angelman syndrome 2 -2.9 0.012 0.15 -0.75 -1.67 0.117 0.34 -0.41 1.48 0.162 0.36 0.34
homolog (human)
14521 56_a_at Nisch 64652 nischarin 2.55 0.024 0.07 0.55 1.53 0.15 0.20 0.32 -1.24 0.237 0.65 -0.24
I424323_at Noell 57741 nucleolar complex associated 2 homolog 1.63 0.127 0.14 0.4 2.36 0.034 0.10 0.56 0.71 0.487 0.53 0.15
1448103_s_at Nono 53610 non-POU-domain-containing, octamer binding 2.75 0.016 0.05 0.64 2.09 0.056 0.11 0.47 -0.85 0.409 0.67 -0.18
I455556_at Notch2 18129 Notch gene homolog 2 (Drosophila) 3.81 0.002 0.05 1.09 3.22 0.006 0.09 0.88 -0.83 0.421 0.67 -0.21
I423086_at Npcl 18145 Niemann Pick type C I 1.09 0.294 0.17 0.32 2.53 0.024 0.10 0.72 1.52 0.153 0.36 0.4
1416353_at Nrlh2 22260 nuclear receptor subfamily I, group H 2 2.01 0.065 0.07 0.58 0.1 0.925 0.30 0.03 -2.18 0.047 0.41 -0.56
1460647_a_at Nr2f6 13864 nuclear receptor subfamily 2, group F 6 2.91 0.012 0.05 0.88 2.67 0.019 0.10 0.78 -0.4 0.693 0.68 -0.11
I420410_at Nr5a2 26424 nuclear receptor subfamily 5, group A 2 1.36 0.197 0.12 0.38 -1.31 0.211 0.39 -0.35 -2.98 0.01 0.15 -0.74
I434384_at Nripl 268903 nuclear receptor interacting protein I 1.68 0.115 0.11 0.56 3.19 0.007 0.07 1.01 1.56 0.142 0.30 0.45
14571 98_at Nrpl 18186 neuropilin I -2.43 0.03 0.11 -1.33 -1.88 0.081 0.33 -0.99 0.71 0.49 0.48 0.34
I435349_at Nrp2 18187 neuropilin 2 0.81 0.429 0.23 0.31 2.38 0.033 0.10 0.86 1.66 0.119 0.27 0.55
1417201_at NtSc2 76952 5'-nucleotidase, cytosolic II 1.13 0.277 0.20 0.29 2.23 0.043 0.11 0.54 1.14 0.273 0.41 0.25
I428547_at NtSe 23959 5' nucleotidase, ecto 1.9 0.079 0.05 1.68 2.53 0.024 0.07 2.14 0.59 0.563 0.53 0.46
1453 I39_at Nudtl2 67993 nudix -type motif 12 -2.95 0.011 0.15 -0.86 -1.4 0.184 0.34 -0.39 1.84 0.088 0.30 0.47
I435902_at Nudtl8 213484 nudix -type motif 18 1.64 0.124 0.09 0.66 2.16 0.049 0.10 0.83 0.48 0.636 0.58 0.17
I430896_s_at Nudt7 67528 nudix -type motif 7 -1.67 0.118 0.28 -0.41 -2.34 0.035 0.32 -0.55 -0.65 0.527 0.68 -0.14
1431302_a_at Nudt7 67528 nudix-type motif 7 -1.24 0.237 0.32 -0.27 -2.37 0.033 0.32 -0.5 -1.17 0.263 0.66 -0.23
1417585_at Nup210 54563 nucleoporin 210 3.35 0.005 0.05 0.84 1.38 0.19 0.20 0.33 -2.31 0.037 0.41 -0.51
1422719_s_at Nup50 18141 nucleoporin 50 3.08 0.008 0.05 0.9 0.47 0.649 0.30 0.13 -3 0.01 0.14 -0.77
I437843_s_at Nupll 71844 Nucleoporin like I (Nupll), mRNA 1.42 0.179 0.15 0.36 2.72 0.017 0.10 0.66 1.35 0.199 0.41 0.3
4377II_x_at Odcl 18263 ornithine decarboxylase, structural I -3.1 0.008 0.11 -1.37 -1.74 0.105 0.32 -0.73 1.64 0.125 0.30 0.64
4291 78_at Odz3 23965 odd Ozlten-m homolog 3 (Drosophila) 0.87 0.4 0.20 0.32 3.08 0.009 0.07 1.08 2.36 0.034 0.22 0.76
4493 I5_at Odz3 23965 odd Ozlten-m homolog 3 (Drosophila) 1.15 0.271 0.14 0.46 3.15 0.007 0.07 1.21 2.12 0.053 0.27 0.75
424413_at Ogfrll 70155 opioid growth factor receptor-like I 2.22 0.044 0.08 0.58 1.62 0.129 0.20 0.4 -0.77 0.455 0.67 -0.18
425898_x_at Olfm3 229759 olfactomedin 3 0.02 0.984 0.26 0.01 2.14 0.051 0.11 0.75 2.31 0.037 0.20 0.74
452090_a_at Olfm3 229759 olfactomedin 3 -0.56 0.588 0.40 -0.19 1.68 0.115 0.17 0.56 2.46 0.Q28 0.20 0.76
456974_at Onecutl 15379 one cut domain, family member I -3.31 0.005 0.07 -1.55 -3.64 0.003 0.20 -1.63 -0.2 0.845 0.68 -0.08
460373_a_at ORF21 224440 open reading frame 21 1.75 0.103 0.08 0.51 2.64 0.02 0.10 0.73 0.88 0.393 0.48 0.22
451054_at Orml 18405 orosomucoid I 2.2 0.046 0.08 0.68 -0.21 0.84 0.39 -0.06 -2.72 0.017 0.17 -0.75
420438_at Orm2 18406 orosomucoid 2 3.55 0.003 0.05 4.39 0.78 0.452 0.11 0.92 -3.19 0.007 0.06 -3.47
436615_a_at Otc 18416 ornithine transcarbamylase -2.99 0.01 0.15 -0.9 -1.12 0.281 0.37 -0.32 2.18 0.048 0.27 0.58
426933_at Oxsrl 108737 oxidative-stress responsive I -0.14 0.89 0.40 -0.04 2.09 0.057 0.13 0.54 2.43 0.03 0.22 0.58
425525_a_at P2rx4 18438 purinergic receptor PlX, ion channel 4 3.39 0.005 0.05 0.96 2.08 0.057 0.10 0.56 -1.59 0.136 0.62 -0.39
I422848_a_at Pabpnl 54196 poly(A) binding protein, nuclear I 2.06 0.059 0.10 0.48 2.36 0.034 0.09 0.53 0.22 0.827 0.63 0.05
1422849_a_at Pabpnl 54196 poly(A) binding protein, nuclear I 0.71 0.491 0.26 0.2 2.49 0.027 0.10 0.67 1.9 0.078 0.27 0.47
I41 6874_a_at Pafl 54624 RNA polymerase II associated factor, homolog 1.23 0.241 0.15 0.34 2.31 0.037 0.11 0.61 1.12 0.284 0.44 0.27
I436298y_at Paics 67054 phosphoribosylaminoimidazole carboxylase -3.22 0.006 0.08 -1.16 -2.24 0.042 0.32 -0.77 1.22 0.242 0.41 0.39
1451 740_at Palpl 218693 polyadenylate binding protein-interacting prot. -0.97 0.35 0.38 -0.23 1.59 0.135 0.17 0.36 2.83 0.014 0.20 0.59
I430875_a_at Paklipl 68083 PAK 1 interacting protein I 0.85 0.409 0.18 0.28 -1.56 0.143 0.36 -0.49 -2.67 0.019 0.20 -0.76
1424216_a_at Papola 18789 poly (A) polymerase alpha -1.31 0.213 0.32 -0.35 -2.23 0.044 0.32 -0.56 -0.93 0.367 0.66 -0.22
1421987_at Papss2 23972 3'-phosphoadenosine -phosphosulfate synthase 2.74 0.016 0.05 0.81 2.62 0.021 0.10 0.74 -0.27 0.793 0.68 -0.07
1451 564_at Parpl4 432411 poly (ADP-ribose) polymerase family 14 2.52 0.025 0.05 0.92 1.8 0.095 0.10 0.63 -0.91 0.38 0.66 -0.29
I4269 IO_at Pawr 114774 PRKC, apoptosis, WTI, regulator 1.16 0.265 0.18 0.33 3.26 0.006 0.07 0.88 2.22 0.044 0.27 0.55
1418894 s at Pbx2 18515 ore B-ceilleukemia transcriotion factor 2 2.19 0.047 0.07 0.51 1.83 0.09 0.17 0.41 -0.5 0.625 0.68 -0.1
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1451 I32_at Pbxipl 229534 pre-B-cell leukemia transcription factor interacting 4.73 0 0.05 1.35 4.72 0 0.07 1.29 -0.25 0.809 0.68 -0.06
protein I
I435881_at Pcbp2 18521 poly(rC) binding protein 2 3.76 0.002 0.05 0.86 4.59 0 0.07 I 0.72 0.483 0.53 0.14
I448733_at Pcgf4 12151 polycomb group ring finger 4
-2.41 0.031 0.23 -0.84 -0.53 0.608 0.39 -0.17 2.17 0.048 0.22 0.66
I427075_s_at Pcmtd2 245867 protein-L-isoaspartate (D-aspartate) O-methyltransferase -2.23 0.043 0.27 -0.58 -0.91 0.378 0.39 -0.23 1.55 0.144 0.32 0.36
domain containing 2
I448435_at Pcqap 94112 positive cofactor 2, multiprotein complex, glutamine/Q- 3.87 0.002 0.05 1.0 I 4.98 0 0.07 1.24 1.01 0.33 0.46 0.23
rich-associated protein
I425824_a_at Pcsk4 18551 proprotein convertase subtilisin/kexin type 4
-0.41 0.687 0.40 -0.13 2.28 0.04 0.10 0.7 2.95 0.011 0.20 0.83
I434082_at Pctk2 237459 PCTAIRE-motif protein kinase 2 0.09 0.927 0.26 0.02 2.21 0.045 0.13 0.46 2.3 0.038 0.22 0.44
I420493_a_at Pcyt2 68671 phosphate cytidylyltransferase 2, ethanolamine 2.79 0.015 0.05 0.68 2.73 0.017 0.10 0.64 -0.21 0.841 0.68 -0.04
I448527_at PdcdlO 56426 programmed cell death 10
-1.88 0.081 0.26 -0.52 -2.18 0.048 0.33 -0.58 -0.22 0.826 0.68 -0.05
1425149_a_at Pdcl 67466 phosducin-like -3.27 0.006 0.10 -1.07 -2.68 0.018 0.32 -0.84 0.8 0.437 0.46 0.23
I422473_at Pde4b 18578 phosphodiesterase 4B, cAMP specific 3.27 0.006 0.05 1.47 1.45 0.169 0.15 0.63 -2.14 0.051 0.30 -0.85
I422474_at Pde4b 18578 phosphodiesterase 4B, cAMP specific 4.78 0 0.05 1.36 1.75 0.103 0.17 0.48 -3.54 0.003 0.09 -0.88
1418406_at Pde8a 18584 phosphodiesterase 8A 0.97 0.348 0.23 0.21 2.5 0.026 0.10 0.53 1.62 0.129 0.32 0.31
41 8560_at Pdhal 18597 pyruvate dehydrogenase EI alpha I -1.48 0.163 0.28 -0.37 1.42 0.178 0.22 0.34 3.23 0.006 0.20 0.71
4491 37_at Pdhal 18597 pyruvate dehydrogenase EI alpha I -0.34 0.737 0.40 -0.09 1.68 0.117 0.17 0.42 2.22 0.044 0.22 0.51
448214_at Pdhb 68263 pyruvate dehydrogenase (Iipoamide) beta -2.81 0.014 0.11 -0.92 0.17 0.867 0.30 0.05 3.39 0.005 0.20 0.97
423747_a_at Pdkl 228026 pyruvate dehydrogenase kinase, isoenzyme I -2.83 0.014 0.18 -0.84 0.05 0.957 0.30 0.D2 3.28 0.006 0.20 0.85
435836_at Pdkl 228026 pyruvate dehydrogenase kinase, isoenzyme I -2.04 0.061 0.27 -0.57 0.5 0.625 0.30 0.13 2.87 0.013 0.20 0.7
416501_at Pdpkl 18607 3-phosphoinositide dependent protein kinase-I 0.33 0.746 0.26 0.07 2.24 0.043 0.13 0.46 2.06 0.06 0.22 0.39
427929_a_at Pdxk 216134 pyridoxal (pyridoxine, vitamin B6) kinase 2.19 0.046 0.08 0.53 0.79 0.441 0.30 0.18 -1.63 0.126 0.58 -0.34
41 7689_a_at Pdzkl ipl 67182 PDZK I interacting protein I 1.26 0.227 0.14 0.69 2.35 0.035 0.09 1.22 1.11 0.285 0.41 0.53
455477_s_at Pdzkl ipl 67182 PDZK I interacting protein I 2.23 0.043 0.05 1.15 2.73 0.017 0.07 1.35 0.44 0.667 0.58 0.2
435440_at Pdzk8 107368 PDZ domain containing 8 0.46 0.656 0.26 0.12 2.4 0.032 0.11 0.58 2.09 0.056 0.27 0.47
41 9365_at Pexlla 18631 peroxisomal biogenesis factor II a -2.25 0.042 0.23 -0.84 1.29 0.218 0.20 0.46 3.96 0.002 0.07 1.31
449442_at Pexlla 18631 peroxisomal biogenesis factor II a -1.63 0.127 0.27 -0.41 2.47 0.028 0.11 0.59 4.54 0.001 0.07 I
419053_at Pexl4 56273 peroxisomal biogenesis factor 14 2.47 0.028 0.05 0.63 2 0.066 0.15 0.49 -0.64 0.534 0.68 -0.14
425021_a_at Pexl6 18633 peroxisome biogenesis factor I6 2.77 0.016 0.05 0.67 3.21 0.007 0.09 0.75 0.35 0.733 0.62 0.07
426770_at Pex5 19305 peroxisome biogenesis factor 5 0.81 0.434 0.22 0.23 2.21 0.045 0.11 0.6 1.49 0.16 0.36 0.37
452279_at Pfc 18636 properdin factor, complement 2.11 0.054 0.05 1.29 -0.06 0.951 0.39 -0.04 -2.47 0.027 0.17 -1.33
421 950_at Pfdn2 18637 prefoldin 2 0.38 0.711 0.26 0.09 2.94 0.011 0.10 0.7 2.77 0.016 0.20 0.6
41 6780_at Pfkm 18642 phosphofructokinase, muscle 0.87 0.397 0.24 0.22 2.71 0.018 0.10 0.66 1.95 0.072 0.27 0.44
449018_at Pfnl 18643 profilin I 2.03 0.062 0.09 0.51 3.03 0.009 0.09 0.73 0.98 0.345 0.46 0.22
423706_a_at Pgd 110208 phosphogluconate dehydrogenase 1.83 0.09 0.08 0.72 2.74 0.016 0.09 1.03 0.9 0.382 0.46 0.31
43677I_x_at Pgd 110208 phosphogluconate dehydrogenase 2.52 0.025 0.05 0.74 3.59 0.003 0.07 1.01 1.04 0.315 0.44 0.27
437380_x_at Pgd 110208 phosphogluconate dehydrogenase 2.39 0.032 0.07 0.69 3.62 0.003 0.07 I 1.21 0.247 0.41 0.31
438627_x_at Pgd 110208 phosphogluconate dehydrogenase 2.4 0.031 0.07 0.68 3.67 0.003 0.07 0.99 1.26 0.229 0.38 0.31
4205 I5_a_at Pglyrp2 57757 peptidoglycan recognition protein 2 2.36 0.034 0.07 0.79 1.37 0.194 0.17 0.44 -1.2 0.251 0.64 -0.35
I428714_at Pgrmc2 70804 progesterone receptor membrane 2 2.62 0.021 0.05 0.89 3.04 0.009 0.09 0.99 0.33 0.748 0.60 0.1
I452882_at Pgrmc2 70804 progesterone receptor membrane 2 2.34 0.035 0.07 0.7 4 0.001 0.Q7 1.14 1.68 0.1 IS 0.30 0.44
I434258_s_at Phactr4 100169 phosphatase and actin regulator 4 3.12 0.008 0.05 0.75 2.74 0.016 0.10 0.63 -0.57 0.579 0.68 -0.12
I448563_at Phb 18673 prohibitin -2.16 0.05 0.24 -0.68 -0.15 0.886 0.39 -0.04 2.3 0.038 0.22 0.64
1437239_x_at Phc2 54383 polyhomeotic-like 2 (Drosophila) 2.32 0.037 0.05 0.74 2.33 0.036 0.10 0.71 -0.1 0.924 0.68 -0.03
I426753_at Phfl7 269424 PHD finger protein 17 3.55 0.003 0.05 1.1 I -0.36 0.725 0.39 -0.11 -4.43 0.001 0.05 -1.22
I429000_at PhfJ 213109 PHD finger protein 3 -1.44 0.171 0.28 -0.51 1.31 0.211 0.22 0.44 3.07 0.009 0.20 0.95
1428488 at Pi['k 329777 DhosDhatidvlinositol ['Ivcan class K 2.52 0.D25 0.07 0.64 2.17 0.048 0.11 0.53 -0.51 0.618 0.68 -0.11
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH V5. CONTROL IGT/6·NASH V5. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-vaJue q-value Fold Ch t-stat p-value q-value Fold Ch.
14381 55_x_at Pigo 56703 phosphatidylinositol glycan, class 0 3.02 0.01 0.05 0.86 2.88 0.013 0.10 0.78 -0.31 0.763 0.68 -0.08
141 5946_at Pigq 14755 phosphatidylinositol glycan, class Q
-1.32 0.209 0.31 -0.38 0.98 0.342 0.24 0.27 2.57 0.023 0.22 0.65
14251 34_a_at Pigx 72084 phosphatidylinositol glycan, class X
-2.85 0.013 0.12 -0.98 -1.78 0.098 0.33 -0.58 1.31 0.211 0.38 0.39
I42983 I_at Pik3apl 83490 phosphoinositide-3-kinase adaptor protein I 3.02 0.01 0.05 1.84 3.22 0.006 0.07 1.88 0.07 0.947 0.63 0.04
1425514_at Pik3rl 18708 phosphatidylinositol 3-kinase
-1.39 0.186 0.27 -0.58 1.54 0.147 0.15 0.61 3.26 0.006 0.20 1.2
I438682_at Pik3rl 18708 phosphatidylinositol 3-kinase 2.69 0.018 0.05 0.62 0.58 0.572 0.30 0.13 -2.43 0.03 0.36 -0.49
1441937_s_at Pink I 68943 PTEN induced putative kinase I
-2.66 0.019 0.18 -0.87 0.28 0.782 0.30 0.09 3.34 0.005 0.07 0.95
141 6387_at Pip5k2c 117150 phosphatidylinositol-4-phosphate 5-kinase 2.44 0.029 0.07 0.66 3.09 0.008 0.09 0.8 0.58 0.57 0.55 0.14
I460585y_at Pisd 320951 phosphatidylserine decarboxylase 2.61 0.021 0.05 0.82 2.83 0.014 0.09 0.85 0.11 0.916 0.63 0.03
1421013_at Pitpnb 56305 phosphatidylinositol transfer protein, beta I 0.333 0.17 0.3 -4.63 0 0.15 -1.33 -6.18 0 0.00 -1.63
I435066_at Pitpncl 71795 phosphatidylinositol transfer protein 2.31 0.037 0.07 0.76 1.51 0.154 0.17 0.47 -0.99 0.34 0.66 -0.28
I455204_at Pitpncl 71795 phosphatidylinositol transfer protein 2.65 0.02 0.05 0.85 2.09 0.056 0.11 0.65 -0.74 0.473 0.68 -0.21
I452083_a_at Pjal 18744 praja I, RING-H2 motif containing
-3.08 0.008 0.15 -0.9 -0.85 0.408 0.39 -0.24 2.58 0.022 0.22 0.66
I434383_at Pja2 224938 praja 2, RING-H2 motif containing
-2.25 0.042 0.23 -0.75 -0.69 0.502 0.39 -0.22 1.81 0.092 0.27 0.53
143871 I_at Pklr 18770 pyruvate kinase liver and red blood cell 1.85 0.087 0.09 0.75 2.53 0.025 0.10 0.98 0.65 0.527 0.50 0.23
1437295_at Pkn2 109333 protein kinase N2 2.78 0.015 0.05 0.93 2.65 0.02 0.09 0.85 -0.28 0.784 0.68 -0.08
1429 I83_at Pkp2 67451 plakophilin 2 2.09 0.056 0.07 0.7 0.11 0.913 0.30 0.04 -2.26 0.041 0.32 -0.66
1422147_a_at Pla2g6 53357 phospholipase A2, group VI 1.11 0.287 0.20 0.32 2.46 0.Q28 0.10 0.68 1.42 0.179 0.36 0.36
I426450_at Plcl2 224860 phospholipase C-like 2 -1.62 0.129 0.27 -0.5 1.23 0.241 0.24 0.36 3.18 0.007 0.20 0.86
1416013_at Pld3 18807 phospholipase D3 3.29 0.006 0.05 0.92 2.16 0.049 0.11 0.58 -1.4 0.185 0.63 -0.34
1419835_s_at Plecl 18810 plectin I 4.07 0.001 0.05 1.01 2.22 0.044 0.13 0.52 -2.22 0.044 0.38 -0.48
I437554_at Plecl 18810 plectin I 2.92 0.012 0.05 1.03 -0.06 0.953 0.39 -0.02 -3.39 0.005 0.10 -1.05
14521 78_at Plecl 18810 plectin I 3.94 0.002 0.05 0.87 3.22 0.006 0.09 0.68 -0.99 0.34 0.66 -0.19
I42467 I_at Plekhfl 72287 pleckstrin homology domain containing, family F member -0.56 0.584 0.40 -0.16 2.08 0.057 0.13 0.57 2.91 0.012 0.20 0.73
I
I456253_s_at Plekhnl 231002 pleckstrin homology domain containing 3.19 0.007 0.05 0.82 3.65 0.003 0.07 0.9 0.34 0.74 0.62 0.08
1448961_at Plscr2 18828 phospholipid scramblase 2 -2.33 0.036 0.23 -0.75 -1.98 0.069 0.33 -0.61 0.5 0.627 0.58 0.14
141 7963_at Pltp 18830 phospholipid transfer protein 2.18 0.048 0.05 1.39 2.05 0.061 0.10 1.25 -0.25 0.805 0.68 -0.14
1418090_at Plvap 84094 plasmalemma vesicle associated protein 2.19 0.046 0.07 0.66 -0.23 0.821 0.39 -0.07 -2.75 0.016 0.20 -0.72
I453286_at Plxna2 18845 plexin A2 0.92 0.373 0.20 0.44 2.95 0.011 0.07 1.36 2.16 0.049 0.22 0.92
1435254 at Plxnbl 235611 plexin BI 2.41 0.031 0.05 1.11 0.87 0.399 0.25 0.38 -1.8 0.095 0.38 -0.73
1416683_at Plxnb2 140570 plexin B2 2.6 0.022 0.05 0.57 1.78 0.097 0.17 0.38 -1.02 0.328 0.66 -0.2
I448757_at Pml 18854 promyelocytic leukemia 3.12 0.008 0.05 0.9 0.82 0.426 0.24 0.23 -2.66 0.019 0.27 -0.67
I426838_at Pold3 67967 polymerase (DNA-directed), delta 3 1.99 0.067 0.10 0.48 2.19 0.047 0.11 0.5 0.11 0.911 0.63 0.02
1423371_at Pole4 66979 polymerase (DNA-directed), epsilon 4 -2.38 0.033 0.26 -0.72 -1.01 0.328 0.39 -0.29 1.6 0.133 0.32 0.43
I423372_at Pole4 66979 polymerase (DNA-directed), epsilon 4 -2.12 0.053 0.27 -0.46 0.03 0.978 0.30 0.01 2.44 0.029 0.22 0.47
I426242_at Polr2a 20020 polymerase (RNA) II (DNA directed) 2.48 0.027 0.05 0.8 2.38 0.032 0.11 0.73 -0.23 0.819 0.68 -0.07
I437525_a_at Polr3a 218832 polymerase (RNA) III (DNA directed) -0.72 0.482 0.40 -0.28 1.58 0.138 0.10 0.57 2.54 0.024 0.22 0.85
I438004_at Pols 210106 polymerase (DNA directed) sigma 2.42 0.03 0.08 0.52 2.96 0.011 0.07 0.61 0.47 0.649 0.58 0.09
141 6933_at Por 18984 P450 (cytochrome) oxidoreductase 2.92 0.011 0.05 1.71 1.67 0.118 0.15 0.93 -1.51 0.153 0.46 -0.78
1451210_at Ppap2c 50784 phosphatidic acid phosphatase type 2c 3.7 0.003 0.05 1.46 2.16 0.049 0.09 0.82 -1.86 0.085 0.48 -0.65
141 7473_a_at Ppcs 106564 phosphopantothenoylcysteine synthetase -3.67 0.003 0.07 -1.55 -2.31 0.037 0.32 -0.93 1.66 0.119 0.27 0.62
14481 28_at Ppgb 19025 protective protein for beta-galactosidase 3.49 0.004 0.05 0.97 2.64 0.02 0.09 0.7 -1.1 0.291 0.66 -0.27
I425537_at Ppmla 19042 protein phosphatase IA -2.8 0.015 0.14 -0.87 -0.28 0.781 0.39 -0.08 2.88 0.013 0.20 0.78
I435787_at Ppmll 242083 protein phosphatase I (formerly 2C)-like 2.09 0.056 0.07 0.79 2.83 0.014 0.09 1.02 0.7 0.493 0.50 0.23
1428351_at Ppmlm 67905 protein phosphatase IM 0.95 0.361 0.20 0.27 2.39 0.032 0.11 0.65 1.53 0.15 0.32 0.38
I426205_at Ppplcb 19046 protein phosphatase I, catalytic subunit -3.7 0.003 0.08 -1.22 -1.9 0.08 0.32 -0.6 2.15 0.05 0.27 0.62
1433540 x at PDDlcb 19046 orotein ohosohatase I catalytic subunit -3.65 0.003 0.08 -0.92 -1.39 0.186 0.39 -0.34 2.64 0.02 0.22 0.59
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I456462_x_at Ppplcb 19046 protein phosphatase I, catalytic subunit
-2.38 0.032 0.22 -0.64 -1.3 0.216 0.39 -0.33 1.3 0.214 0.41 0.31
I429487_at Pppl rl2a 17931 protein phosphatase I, regulatory (inhibitor) 3.83 0.002 0.05 I 3.18 0.007 0.09 0.8 -0.89 0.387 0.66 -0.21
1459751_s_at Ppplrl6a 73062 protein phosphatase I, regulatory (inhibitor) 5.5 0 0.05 1.53 4.03 0.001 0.07 1.07 -1.87 0.083 0.50 -0.46
I438383_x_at Ppp2rla 51792 protein phosphatase 2 regulatory subunit A 2.15 0.05 0.08 0.52 2.45 0.028 0.10 0.56 0.22 0.829 0.63 0.05
I438991_x_at Ppp2rla 51792 protein phosphatase 2 regulatory subunit A 1.94 0.073 0.09 0.46 2.79 0.015 0.10 0.63 0.82 0.426 0.50 0.17
1455929_x_at Ppp2rla 51792 protein phosphatase 2 regulatory subunit A 2.1 0.055 0.08 0.51 2.67 0.019 0.10 0.62 0.52 0.612 0.58 0.11
I427003_at Ppp2r5c 26931 protein phosphatase 2, regulatory subunit B 0.85 0.408 0.24 0.2 2.6 0.021 0.10 0.58 1.86 0.085 0.30 0.38
I42640 I_at Ppp3ca 19055 protein phosphatase 3, catalytic subunit, alpha 1.71 0.109 0.14 0.43 3.46 0.004 0.07 0.82 1.81 0.092 0.27 0.4
I425632_a_at Pqlc2 212555 PQ loop repeat containing 2 2.52 0.025 0.07 0.75 1.86 0.085 0.15 0.53 -0.85 0.412 0.65 -0.22
I453068_at PrIGT/6-DM2 110593 PR domain containing 2. with ZNF domain 2.23 0.043 0.07 0.57 0.76 0.459 0.30 0.19 -1.71 0.11 0.55 -0.38
141 61 66_a_at Prdx4 53381 peroxiredoxin 4
-2.89 0.012 0.10 -1.11 -1.91 0.078 0.33 -0.7 1.21 0.246 0.38 0.41
1456037_x_at Preb 50907 prolactin regulatory element binding 0.32 0.752 0.26 0.1 2.81 0.014 0.09 0.86 2.69 0.018 0.20 0.76
1423 I67_at Prei3 19070 preimplantation protein 3
-3.29 0.006 0.09 -0.83 -1.31 0.213 0.39 -0.32 2.32 0.037 0.27 0.51
I449824_at Prg4 96875 proteoglycan 4 3.01 0.01 0.05 1.12 2.15 0.05 0.09 0.76 -1.09 0.294 0.65 -0.36
1429463_at Prkaa2 108079 protein kinase, AMP-activated
-2.36 0.034 0.26 -0.55 3.71 0.002 0.07 0.83 6.73 0 0.00 1.39
1424119_at Prkabl 19079 protein kinase, AMP-activated 2.62 0.021 0.05 1.01 1.99 0.067 0.11 0.73 -0.81 0.432 0.66 -0.27
I435874_at Prkab2 108097 protein kinase, AMP-activated 2.48 0.027 0.07 0.67 1.82 0.091 0.13 0.47 -0.84 0.414 0.68 -0.2
I428783_at Prkar2a 19087 protein kinase, cAMP dependent type II alpha 2.45 0.029 0.07 0.56 1.19 0.255 0.24 0.26 -1.49 0.159 0.63 -0.3
I44469 I_at Prkcn 75292 protein kinase C, nu
-3.29 0.006 0.07 -1.82 -2.42 0.03 0.30 -1.28 1.11 0.286 0.38 0.54
1422005_at Prkr 19106 protein kinase. interieron-inducible double stranded RNA 3.83 0.002 0.05 1.19 1.47 0.166 0.17 0.43 -2.77 0.016 0.17 -0.75
dependent
I426482_at Prkrir 72981 protein-kinase
-1.64 0.124 0.28 -0.37 -2.48 0.027 0.32 -0.54 -0.83 0.42 0.67 -0.17
1421 382_at Prlr 19116 prolactin receptor 4.46 0.001 0.05 1.27 4.58 0 0.07 1.25 -0.1 0.925 0.68 -0.02
I450226_at Prlr 19116 prolactin receptor 2.82 0.014 0.05 1.03 3.41 0.004 0.07 1.2 0.5 0.623 0.55 0.16
I426246_at Pros I 19128 protein S (alpha) 2.81 0.014 0.05 0.85 0.89 0.387 0.25 0.26 -2.23 0.044 0.36 -0.59
I437894_at Proxl 19130 prospero-related homeobox I 1.66 0.121 0.07 0.76 -1.88 0.081 0.33 -0.83 -3.93 0.002 0.05 -1.59
I457432_at Proxl 19130 prospero-related homeobox I 1.9 0.079 0.05 0.78 -3.57 0.003 0.27 -1.4 -6.04 0 0.00 -2.17
I425498_at Prpf4b 19134 PRP4 pre-mRNA processing factor 4 homo. -3.41 0.004 0.12 -1.03 -1.06 0.307 0.36 -0.31 2.73 0.017 0.22 0.72
I454843_at Prps2 110639 phosphoribosyl pyrophosphate synthetase 2 2.24 0.043 0.09 0.57 3.35 0.005 0.07 0.82 1.1 0.291 0.38 0.25
I428365_a_at Prss 15 74142 protease. serine. I5 0.93 0.37 0.23 0.21 2.54 0.024 0.10 0.56 1.71 0.111 0.30 0.35
1418320_at Prss8 76560 protease, serine, 8 (prostasin) 3.21 0.007 0.05 1.26 3.41 0.004 0.07 1.28 0.06 0.956 0.63 0.02
I433522_at Pskhl 244631 protein serine kinase HI 2.87 0.013 0.05 0.71 1.82 0.091 0.17 0.43 -1.28 0.222 0.63 -0.28
I448632_at PsmblO 19171 proteasome (prosome. macropain) subunit 2.5 0.026 0.05 0.98 1.81 0.092 0.11 0.68 -0.87 0.398 0.66 -0.3
1417052_at Psmb3 26446 proteasome (prosome, macropain) subuni -0.94 0.366 0.39 -0.22 1.44 0.172 0.20 0.32 2.64 0.02 0.22 0.53
I422962_a_at Psmb8 16913 proteosome (prosome, macropain) subunit 2.36 0.034 0.05 1.25 1.5 0.156 0.10 0.76 -1.05 0.312 0.65 -0.49
1417769_at Psmc6 67089 proteasome (prosome. macropain) 26S subunit -5.55 0 0.04 -1.58 -4.79 0 0.15 -1.3 1.11 0.284 0.41 0.28
I423696_a_at Psmd6 66413 proteasome (prosome. macropain) 26S subunit -2.03 0.063 0.24 -1.02 0.29 0.775 0.30 0.14 2.63 0.02 0.20 1.16
I426824_at Psme4 103554 proteasome (prosome. macropain) activator 0.82 0.429 0.20 0.41 -2.75 0.016 0.30 -1.33 -3.92 0.002 0.04 -1.74
1451 337_at Psmfl 228769 proteasome (prosome, macropain) inhibitor 2.43 0.03 0.05 0.59 1.63 0.126 0.17 0.38 -0.99 0.34 0.66 -0.21
I458284_at Ptbpl 19205 polypyrimidine tract binding protein I -1.4 0.184 0.28 -0.4 -2.32 0.036 0.32 -0.63 -0.93 0.366 0.66 -0.23
I426728_x_at Ptdss2 27388 phosphatidylserine synthase 2 1.91 0.077 0.08 0.58 2.51 0.026 0.10 0.72 0.55 0.59 0.55 0.15
1417068_a_at Ptpnl 19246 protein tyrosine phosphatase type I 3.7 0.003 0.05 1.12 2.01 0.065 0.10 0.58 -2.03 0.063 0.44 -0.54
I438670_at Ptpnl 19246 protein tyrosine phosphatase type I 2.47 0.028 0.05 0.75 -0.41 0.687 0.39 -0.12 -3.25 0.006 0.11 -0.87
1419054_a_at Ptpn21 24000 protein tyrosine phosphatase type 21 3.63 0.003 0.05 0.89 2.7 0.018 0.10 0.63 -1.2 0.252 0.65 -0.26
1422124_a_at Ptprc 19264 protein tyrosine phosphatase, receptor type, C 2.2 0.046 0.07 1.18 1.31 0.211 0.11 0.67 -1.08 0.301 0.65 -0.51
I420842_at Ptpri 19268 protein tyrosine phosphatase, receptor type, F 3.88 0.002 0.05 0.89 3.09 0.008 0.09 0.68 -1.05 0.311 0.66 -0.21
I423278_at Ptprk 19272 protein tyrosine phosphatase, receptor type. K 2.07 0.058 0.09 0.6 3.23 0.006 0.07 0.9 1.16 0.268 0.41 0.3
1418015 at Pum2 80913 oumilio 2 (Drosoohila) 2.25 0.042 0.05 0.87 1.18 0.259 0.24 0.44 -1.28 0.223 0.63 -0.43
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Probe Symbol Entrez Description IGTI6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene 10 t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1418016_at Pum2 80913 pumilio 2 (Drosophila) 1.14 0.273 0.18 0.28 2.59 0.022 0.10 0.62 1.52 0.152 0.36 0.33
1423331_a_at Pvrl3 58998 poliovirus receptor-related 3
-2.27 0.04 0.26 -0.65 -2.02 0.063 0.33 -0.56 0.38 0.711 0.60 0.1
14561 35_s_at Pxn 19303 paxillin 1.76 0.101 0.09 0.44 2.34 0.036 0.11 0.55 0.54 0.599 0.58 0.12
1429318_a_at Qk 19317 quaking 2.46 0.028 0.08 0.52 2.76 0.016 0.09 0.56 0.2 0.847 0.63 0.04
1456542_s_at Qrsll 76563 glutaminyl-tRNA synthase-like I
-2.73 0.017 0.17 -0.79 -0.98 0.343 0.39 -0.27 2.03 0.062 0.27 0.52
I438097_at Rab20 19332 RAB20, member RAS oncogene family 2.68 0.018 0.05 1.36 2.33 0.036 0.10 1.13 -0.52 0.615 0.68 -0.23
1421 872_at Rab24 19336 RAB24, member RAS oncogene family
-2.25 0.042 0.26 -0.62 -1.09 0.296 0.39 -0.29 1.38 0.192 0.36 0.33
1451 643_a_at Rab4b 19342 RAB4B, member RAS oncogene family 2.56 0.023 0.05 0.69 0.69 0.503 0.30 0.18 -2.16 0.049 0.41 -0.51
141 6426_at Rab5a 271457 RAB5A, member RAS oncogene family
-3.45 0.004 0.11 -0.87 -0.74 0.474 0.39 -0.18 3.12 0.008 0.20 0.69
I447776_x_at Rab6 19346 RAB6, member RAS oncogene family
-3.28 0.006 0.15 -0.82 -1.48 0.163 0.37 -0.35 2.12 0.053 0.22 0.46
I44839 I_at Rab9 56382 RAB9, member RAS oncogene family -1.77 0.099 0.27 -0.34 0.78 0.448 0.30 0.14 2.86 0.013 0.20 0.49
14241 88_at Rabgapl 227800 RAB GTPase activating protein 1 1.42 0.179 0.15 0.34 2.38 0.033 0.11 0.55 0.98 0.347 0.48 0.21
1416161_at Rad21 19357 RAD21 homolog (S. pombe) -2.13 0.052 0.25 -0.59 -0.06 0.954 0.39 -0.02 2.36 0.034 0.22 0.58
I455938_x_at Rad21 19357 RAD21 homolog (S. pombe)
-2.85 0.013 0.12 -I -0.52 0.613 0.39 -0.17 2.68 0.018 0.20 0.82
I428789_at Ralgps2 78255 Ral GEF with PH domain and SH3 binding motif 0.62 0.546 0.26 0.2 2.4 0.032 0.10 0.74 1.91 0.078 0.27 0.54
1418573_a_at Raly 19383 hnRNP-associated with lethal yellow 3.09 0.008 0.05 0.97 4.22 0.001 0.07 1.27 1.08 0.299 0.44 0.3
I434578_x_at Ran 19384 RAN, member RAS oncogene family -3.04 0.009 0.12 -0.77 -1.92 0.076 0.33 -0.46 1.37 0.194 0.38 0.3
1438977_x_at Ran 19384 RAN, member RAS oncogene family -2.81 0.014 0.17 -0.67 -2.08 0.058 0.33 -0.47 0.95 0.361 0.46 0.2
I439270_x_at Ran 19384 RAN, member RAS oncogene family -2.53 0.024 0.23 -0.57 -1.97 0.07 0.33 -0.42 0.74 0.473 0.53 0.15
I424585_at RanbplO 74334 RAN binding protein 10 2.37 0.033 0.08 0.55 2.01 0.065 0.11 0.45 -0.51 0.62 0.68 -0.1
I435614_s_at Rasgrfl 19417 RAS protein-specific guanine nucleotide-releasing factor I 2.78 0.015 0.05 1.21 3.1 0.008 0.07 1.29 0.22 0.832 0.63 0.08
1418924_at Rassfl 66985 Ras association (RaIGDS/AF-6) domain family 7 2.45 0.028 0.05 0.65 1.9 0.079 0.15 0.48 -0.73 0.479 0.68 -0.17
I452283_at Rassf8 71323 Ras association (RaIGDS/AF-6) domain family 8 -2.28 0.039 0.27 -0.57 0.2 0.844 0.30 0.05 2.81 0.014 0.20 0.62
I436695_x_at Rbedl 232089 RNA binding motif and ELMO domain I 1.66 0.121 0.10 0.58 2.16 0.049 0.10 0.72 0.46 0.649 0.58 0.14
1436979_x_at Rbml4 56275 RNA binding motif protein 14 1.81 0.092 0.09 0.46 2.18 0.047 0.11 0.53 0.31 0.762 0.62 0.07
I45269 I_at Rbml7 76938 RNA binding motif protein 17 1.37 0.192 0.15 0.34 2.71 0.017 0.10 0.65 1.39 0.188 0.38 0.31
1451237_s_at Rbm7 67010 RNA binding motif protein 7 -3.7 0.003 0.11 -0.76 -2.59 0.022 0.32 -0.51 1.4 0.183 0.36 0.25
141 8703_at Rbmsl 56878 RNA binding motif, single stranded interacting 2.53 0.D25 0.05 0.86 1.84 0.088 0.11 0.6 -0.87 0.398 0.66 -0.26
I434005_at Rbmsl 56878 RNA binding motif 2.65 0.02 0.07 0.64 3.24 0.006 0.09 0.75 0.52 0.615 0.55 0.11
I433979_at Rbms2 56516 RNA binding motif, single stranded interacting 2.28 0.039 0.07 0.56 1.51 0.154 0.20 0.35 -0.96 0.355 0.66 -0.2
I42054 I_at Rdh6 19683 retinol dehydrogenase 6 0.98 0.343 0.15 0.46 3.08 0.009 0.07 1.39 2.23 0.043 0.22 0.93
141 61 79_a_at Rdx 19684 radixin -2.35 0.035 0.20 -0.77 -1.2 0.252 0.39 -0.38 1.37 0.194 0.38 0.39
141 8342_at Reccl 19687 replication factor C I 2.18 0.047 0.05 0.64 2.3 0.038 0.11 0.65 0.01 0.99 0.63 0
1416216_at Repsl 19707 RalBP I associated Eps domain protein 2.69 0.018 0.05 0.69 3.72 0.002 0.07 0.91 0.98 0.345 0.46 0.22
I454670_at Rere 68703 arginine glutamic acid dipeptide (RE) repeats 3.11 0.008 0.05 0.89 3.49 0.004 0.07 0.95 0.26 0.797 0.62 0.07
1423103_at Rfx5 53970 regulatory factor X, 5 1.26 0.23 0.15 0.5 3.21 0.007 0.07 1.22 2.07 0.059 0.22 0.72
1426037_a_at Rgsl6 19734 regulator of G-protein signaling 16 0.28 0.78 0.26 0.4 2.42 0.031 0.07 3.26 2.31 0.038 0.20 2.86
I455265_a_at Rgsl6 19734 regulator of G-protein signaling 16 -0.33 0.746 0.40 -0.45 2.01 0.065 0.07 2.61 2.56 0.023 0.20 3.06
I449027_at Rhou 69581 ras homolog gene family, member U 1.82 0.091 0.12 0.49 2.79 0.015 0.09 0.71 0.96 0.352 0.46 0.23
I449028_at Rhou 69581 ras homolog gene family, member U 3.34 0.005 0.05 0.76 2.84 0.014 0.10 0.62 -0.71 0.489 0.68 -0.14
1431805_a_at Rhpn2 52428 rhophilin, Rho GTPase binding protein 2 -0.41 0.686 0.40 -0.15 1.7 0.111 0.15 0.61 2.33 0.036 0.20 0.76
I434628_a_at Rhpn2 52428 rhophilin, Rho GTPase binding protein 2 -1.63 0.127 0.27 -0.54 1.18 0.26 0.24 0.37 3.13 0.008 0.20 0.91
I434684_at Rin3 217835 Ras and Rab interactor 3 2.59 0.022 0.05 0.69 1.84 0.088 0.15 0.47 -0.95 0.357 0.66 -0.22
I436684_a_at Riok2 67045 RIO kinase 2 (yeast) -3.36 0.005 0.08 -1.02 -1.67 0.117 0.35 -0.49 2 0.066 0.27 0.54
1423 I02_a_at RnflO 50849 ring finger protein 10 2.92 0.012 0.05 0.74 0.86 0.403 0.29 0.21 -2.38 0.032 0.17 -0.53
143461 I_at Rnfl23 84585 ring finger protein I23 2.85 0.013 0.05 0.7 2.2 0.046 0.10 0.52 -0.84 0.415 0.68 -0.18
1424514_at Rnfl26 70294 ring finger protein 126 3.04 0.009 0.05 0.72 2.43 0.03 0.11 0.55 -0.82 0.425 0.68 -0.17
1437207 at Rnfl70 77733 rinl" finl"er orotein 170 -3.89 0.002 0.07 -0.9 -4.42 0.001 0.22 -0.97 -0.38 0.707 0.68 -0.08
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1429108_at Rnfl84 77853 ring finger protein 184
-1.4 0.183 0.30 -0.4 1.27 0.224 0.22 0.35 2.98 0.01 0.20 0.75
I453030_at Rnfl84 77853 ring finger protein 184 0.25 0.809 0.26 0.06 -1.83 0.089 0.32 -0.44 -2.28 0.04 0.38 -0.51
I424794_at Rnfl86 66825 ring finger protein 186
-1.7 0.112 0.26 -1.02 0.47 0.648 0.30 0.27 2.44 0.029 0.20 1.29
I454753_at Rnpepll 108657 arginyl aminopeptidase (aminopeptidase B)-like 2.99 0.01 0.05 0.65 2.42 0.03 0.11 0.51 -0.77 0.455 0.68 -0.15
1439399_a_at Rnu22 83673 RNA, U22 small nucleolar
-3.41 0.004 0.08 -1.06 -0.45 0.661 0.39 -0.13 3.4 0.005 0.20 0.93
I450778_a_at Rnuxa 56698 RNA U, small nuclear RNA export adaptor 1.89 0.081 0.10 0.54 -0.75 0.466 0.39 -0.21 -2.97 0.011 0.16 -0.75
I460729_at Rockl 19877 Rho-associated coiled-coil forming kinase I
-1.83 0.09 0.26 -0.9 -2.75 0.016 0.27 -1.3 -0.91 0.378 0.66 -0.4
I436326_at Rora 19883 RAR-related orphan receptor alpha 0.07 0.942 0.26 0.02 2.07 0.058 0.13 0.59 2.17 0.049 0.22 0.57
14581 29_at Rora 19883 RAR-related orphan receptor alpha 2.87 0.013 0.05 0.88 -3.51 0.004 0.27 -1.03 -7.09 0 0.00 -1.91
I41 8337_at Rpia 19895 ribose 5-phosphate isomerase A 1.37 0.192 0.14 0.52 3.17 0.007 0.07 1.14 1.88 0.081 0.27 0.62
I433928_a_at Rpl13a 22121 ribosomal protein L13a
-2.69 0.018 0.22 -0.55 -2 0.067 0.33 -0.39 0.89 0.389 0.48 0.16
I450372_a_at Rpl18 19899 ribosomal protein L18
-2.18 0.047 0.26 -0.65 0.17 0.864 0.30 0.05 2.67 0.019 0.20 0.7
14171 26_a_at Rpl2211 68028 ribosomal protein L22 like I
-4.7 0 0.07 -1.06 -3.89 0.002 0.27 -0.84 1.12 0.283 0.44 0.22
1451077_at Rpl5 19983 ribosomal protein L5
-3.68 0.003 0.11 -1.02 -2.69 0.018 0.31 -0.72 1.26 0.229 0.38 0.31
1451120_at Rpol-3 20018 RNA polymerase 1-3
-2.16 0.049 0.26 -0.58 0.57 0.581 0.30 0.15 3.08 0.009 0.20 0.73
1416089_at Rpsl5 20054 ribosomal protein SIS -2.98 0.01 0.15 -0.82 -0.44 0.67 0.39 -0.11 2.92 0.011 0.20 0.71
I438776]_at Rpsl7 20068 ribosomal protein S17
-3.34 0.005 0.15 -0.69 -0.68 0.506 0.39 -0.13 3.06 0.009 0.20 0.55
I455662_x_at Rpsl7 20068 ribosomal protein S17
-2.38 0.033 0.27 -0.49 0.18 0.86 0.30 0.04 2.9 0.012 0.20 0.53
1433549_x_at Rps21 66481 ribosomal protein S21
-2.95 0.011 0.15 -0.69 -2.53 0.025 0.32 -0.57 0.6 0.555 0.55 0.13
I434358_x_at Rps21 66481 ribosomal protein S21
-2.28 0.04 0.23 -0.49 -1.92 0.077 0.34 -0.4 0.51 0.62 0.58 0.1
1439415_x_at Rps21 66481 ribosomal protein S21
-3.06 0.009 0.08 -1.36 -1.93 0.075 0.32 -0.82 1.38 0.19 0.36 0.54
I456628_x_at Rps24 20088 ribosomal protein S24
-3.92 0.002 0.10 -0.84 -2.12 0.053 0.33 -0.43 2.15 0.05 0.22 0.4
41 5716_a_at Rps27 57294 ribosomal protein S27
-2.64 0.02 0.15 -0.77 -1.15 0.269 0.39 -0.32 1.75 0.103 0.30 0.45
45598 I_at Rps6 20104 ribosomal protein S6
-3.42 0.004 0.11 -0.77 -1.97 0.07 0.33 -0.42 1.75 0.104 0.30 0.35
41 6896_at Rps6kal 20111 ribosomal protein S6 kinase polypeptide I 3.57 0.003 0.05 1.3 4.5 0.001 0.07 1.57 0.83 0.423 0.46 0.26
460705_at Rps6kbl 72508 ribosomal protein S6 kinase, polypeptide I 0.76 0.458 0.15 0.28 -1.22 0.244 0.39 -0.43 -2.2 0.046 0.38 -0.72
41 8448_at Rras 20130 Harvey rat sarcoma oncogene, subgroup R 3 0.01 0.05 1.08 2.53 0.Q25 0.10 0.87 -0.66 0.52 0.68 -0.21
426452_a_at Rsb30 75985 RAB30, member RAS oncogene family -1.16 0.266 0.27 -0.61 0.96 0.355 0.25 0.48 2.36 0.034 0.22 1.09
459981_s_at Rsbnl 229675 rosbin, round spermatid basic protein I 1.25 0.232 0.15 0.47 2.45 0.029 0.10 0.89 1.24 0.237 0.38 0.41
455607_at Rspo3 72780 R-spondin 3 homolog (Xenopus laevis) -2.97 0.011 0.11 -0.82 -1.96 0.Q71 0.33 -0.52 1.25 0.234 0.41 0.3
418101_a_at Rtn3 20168 reticulon 3 2.36 0.034 0.07 0.63 1.9 0.079 0.15 0.48 -0.61 0.551 0.68 -0.14
424243_at Rwdd4a 192174 RWD domain containing 4A -2.75 0.016 0.20 -0.9 -0.52 0.611 0.39 -0.16 2.56 0.023 0.22 0.73
41 6762_at SIOOalO 20194 SIOO calcium binding protein AIO (calpactin) -2.6 0.022 0.15 -0.83 -0.57 0.581 0.39 -0.17 2.34 0.035 0.22 0.65
419075_s_at Saal 20208 serum amyloid A I 3.37 0.005 0.05 3.21 1.4 0.184 0.07 1.27 -2.32 0.037 0.17 -1.94
I450788_at Saal 20208 serum amyloid A I 3.32 0.005 0.05 2.62 1.09 0.295 0.11 0.82 -2.59 0.022 0.14 -1.79
I449326_x_at Saa2 20209 serum amyloid A 2 3.37 0.005 0.05 4.31 0.82 0.428 0.10 I -2.95 0.011 0.07 -3.31
1419318_at Saa4 20211 serum amyloid A 4 3.77 0.002 0.05 0.97 1.73 0.106 0.13 0.43 -2.4 0.031 0.38 -0.54
1419319_at Saa4 20211 serum amyloid A 4 3.84 0.002 0.05 2.51 1.2 0.251 0.20 0.75 -3.07 0.009 0.09 -1.76
I454928_at Safb 224903 scaffold attachment factor B 2.53 0.025 0.05 0.88 3.64 0.003 0.07 1.22 1.09 0.295 0.38 0.33
I427988_s_at Safb2 224902 scaffold attachment factor B2 2.8 0.015 0.05 0.7 1.43 0.175 0.22 0.34 -1.63 0.126 0.62 -0.36
I434402_at Samd8 67630 sterile alpha motif domain containing 8 1.5 0.157 0.15 0.34 2.32 0.036 0.11 0.5 0.82 0.424 0.50 0.16
I455800_x_at Samm50 68653 sorting and assembly machinery component 50 1.49 0.159 0.15 0.41 2.42 0.03 0.10 0.64 0.94 0.363 0.46 0.23
I443762_s_at Sbf2 319934 SET binding factor 2 1.33 0.205 0.15 0.44 2.51 0.Q25 0.09 0.79 1.22 0.245 0.41 0.35
1451190_a_at Sbk 104175 SH3-binding kinase -0.9 0.383 0.36 -0.33 1.21 0.247 0.20 0.42 2.34 0.035 0.22 0.75
1434612_s_at Sbnol 243272 sno, strawberry notch homolog 1 (Drosophila) 1.18 0.26 0.18 0.25 3.33 0.005 0.09 0.68 2.29 0.039 0.22 0.43
I456466_x_at ScalO 54138 spinocerebellar ataxia 10 homolog (human) -3.3 0.005 0.15 -0.89 -2.29 0.038 0.31 -0.59 1.26 0.228 0.41 0.3
I460653_at Sca2 20239 spinocerebellar ataxia 2 homolog (human) 3.13 0.008 0.05 0.88 1.28 0.222 0.24 0.34 -2.17 0.048 0.38 -0.53
1426775 s at ScamDI 107767 secretorv carrier membrane Drotein I 3.01 0.01 0.05 0.87 2.38 0.033 0.10 0.66 -0.83 0.421 0.67 -0.21
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene 10 t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
141661 I_at Scamp2 24044 secretory carrier membrane protein 2 2.38 0.033 0.Q7 0.59 2 0.066 0.13 0.47 -0.54 0.601 0.68 -0.12
1416294 at Scamp3 24045 secretory carrier membrane protein 3 2.26 0.041 0.Q7 0.59 1.38 0.189 0.20 0.35 -1.06 0.306 0.66 -0.24
I448868_at Scandl 19018 SCAN domain-containing I 2.19 0.046 0.07 0.97 2.32 0.037 0.10 0.98 0.03 0.98 0.63 0.01
1451204_at Scara5 71145 scavenger receptor class A, member 5 2.82 0.014 0.05 2.05 -0.46 0.65 0.39 -0.32 -3.72 0.002 0.05 -2.38
1416050_a_at Scarb I 20778 scavenger receptor class B, member I 2.97 0.011 0.05 0.76 1.18 0.258 0.22 0.29 -2.1 0.056 0.44 -0.47
I455820_x_at Scarb I 20778 scavenger receptor class B, member I 2.66 0.019 0.05 0.76 1.94 0.074 0.13 0.53 -0.92 0.375 0.67 -0.23
I41 9974_at Scp2 20280 sterol carrier protein 2, liver
-3.15 0.007 0.08 -1.04 -1.66 0.119 0.34 -0.52 1.77 0.099 0.30 0.51
1426555 at Scpepl 74617 serine carboxypeptidase I 2.37 0.033 0.05 0.9 -0.06 0.95 0.39 -0.02 -2.77 0.015 0.16 -0.92
1451822_a_at Scrn2 217140 secernin 2 2.3 0.038 0.05 0.72 2.5 0.026 0.11 0.74 0.1 0.922 0.63 0.03
1426917_s_at Scrn3 74616 secernin 3
-3.08 0.008 0.15 -0.75 -0.18 0.862 0.39 -0.04 3.32 0.005 0.20 0.71
141 5943_at Sdcl 20969 syndecan I 2.96 0.011 0.05 0.76 2.88 0.013 0.09 0.71 -0.24 0.815 0.68 -0.05
41 5944_at Sdcl 20969 syndecan I 4.12 0.001 0.05 1.1 I 2.43 0.03 0.11 0.62 -2.04 0.061 0.44 -0.48
450027_at Sdc3 20970 syndecan 3 2.67 0.019 0.05 1.37 0.75 0.467 0.22 0.37 -2.23 0.043 0.32 -1.01
41 7654_at Sdc4 20971 syndecan 4 1.91 0.078 0.05 0.75 2.49 0.027 0.10 0.93 0.54 0.6 0.55 0.18
427233_at Sdccag33 110796 serologically defined colon cancer antigen 33 -0.79 0.444 0.40 -0.22 1.4 0.184 0.20 0.37 2.42 0.03 0.22 0.59
437489_x_at Sdhd 66925 succinate dehydrogenase complex -3.2 0.007 0.10 -0.96 -1.57 0.139 0.35 -0.45 1.93 0.075 0.27 0.51
424744_at Sds 231691 serine dehydratase 2.17 0.048 0.07 0.84 1.25 0.231 0.22 0.46 -1.11 0.288 0.65 -0.38
41 8490_at Sdsl 257635 serine dehydratase-like 2.47 0.027 0.05 0.75 2.25 0.042 0.11 0.65 -0.37 0.721 0.68 -0.1
460698_a_at Sec 1113 66286 Sec II-like 3 (S. cerevisiae) -2.43 0.03 0.26 -0.56 -2.71 0.017 0.31 -0.6 -0.19 0.855 0.68 -0.04
422684_a_at Sec811 20336 SEC8-like 1 (S. cerevisiae) 2.55 0.024 0.05 0.89 2.42 0.03 0.10 0.81 -0.26 0.798 0.68 -0.08
422685_at Sec811 20336 SEC8-like I (S. cerevisiae) 2.28 0.039 0.08 0.64 3.68 0.003 0.Q7 0.98 1.4 0.183 0.38 0.35
424200_s_at Sehll 72124 SEH I-like (S. cerevisiae -0.32 0.756 0.40 -0.06 2.58 0.022 0.10 0.5 3.17 0.007 0.20 0.57
448110_at Sema4a 20351 sema domain 2.89 0.012 0.05 0.93 2.35 0.035 0.10 0.72 -0.73 0.477 0.68 -0.21
449202_at Sema4g 26456 sema domain 2.33 0.036 0.05 0.59 1.05 OJ II 0.25 0.25 -1.51 0.155 0.63 -0.33
437995_x_at Sept7 235072 septin 7 -3.55 0.003 0.08 -1.04 -1.94 0.074 0.33 -0.54 1.92 0.076 0.27 0.5
417038_at Sept9 53860 septin 9 2.07 0.058 0.09 0.57 2.93 0.011 0.09 0.78 0.84 0.416 0.48 0.2
41 8888_a_at Sepxl 27361 selenoprotein X I 0.75 0.466 0.20 0.26 -1.7 0.113 0.34 -0.56 -2.7 0.018 0.17 -0.82
434291_a_at Serf I 20365 small EDRK-rich factor I -2.04 0.061 0.27 -0.45 -0.16 0.877 0.39 -0.03 2.15 0.05 0.22 0.41
435887_at Serpinall 380780 serine (or cysteine) proteinase inhibitor 2.42 0.03 0.05 0.76 0.77 0.456 0.30 0.23 -1.92 0.076 0.44 -0.53
449321]_at Serpina 1a-4 20700 serine (or cysteine) peptidase inhibitor -1.21 0.246 0.35 -0.32 -3.31 0.005 0.27 -0.83 -2.22 0.044 0.38 -0.51
419100_at Serpina3n 20716 serine (or cysteine) proteinase inhibitor 3.4 0.005 0.05 1.17 1.41 0.182 0.13 0.46 -2.34 0.036 0.36 -0.71
444296_a_at Serpina4-ps I 321018 serine (or cysteine) proteinase inhibitor -2.65 0.019 0.04 -2.7 -2.89 0.012 0.27 -2.81 -0.13 0.9 0.68 -0.11
444297_at Serpina4-ps I 321018 serine (or cysteine) proteinase inhibitor -3.52 0.004 0.04 -3.32 -3.1 0.008 0.20 -2.79 0.63 0.536 0.50 0.52
448092_x_at Serpina4-ps I 321018 serine (or cysteine) proteinase inhibitor -2.59 0.022 0.07 -2.75 -2.67 0.019 0.27 -2.71 0.04 0.969 0.63 0.04
448506_at Serpina6 12401 serine (or cysteine) proteinase inhibitor 2.92 0.011 0.05 0.96 3.15 0.007 0.09 0.99 0.1 0.923 0.63 0.03
416666_at Serpine2 20720 serine (or cysteine) proteinase inhibitor -3.54 0.003 0.07 -2.49 -3.77 0.002 0.00 -2.53 -0.07 0.942 0.68 -0.05
438931_s_at Sesnl 140742 sestrin I -3.25 0.006 0.12 -0.94 -1.54 0.147 0.35 -0.42 2.03 0.063 0.27 0.51
429362_a_at SBb2 319322 splicing factor 3b, subunit 2 2.53 0.025 0.07 0.57 -1.12 0.283 0.39 -0.24 -4.1 0.001 0.05 -0.82
456040_at SBb2 319322 splicing factor 3b, subunit 2 4.26 0.001 0.05 1.1 -0.92 0.372 0.39 -0.23 -5.86 0 0.00 -1.32
422894_at Sfmbtl 54650 Scm-like with four mbt domains I 0.81 0.435 0.17 0.27 -1.36 0.197 0.39 -0.43 -2.39 0.032 0.36 -0.7
427269_at Sfrsll 69207 splicing factor, arginine/serine-rich I I -2.53 0.025 0.26 -0.52 -0.34 0.738 0.39 -0.07 2.51 0.026 0.22 0.45
427333_s_at Sfrs 15 224432 splicing factor, arginine/serine-rich 15 2.95 0.011 0.05 0.73 1.32 0.21 0.24 0.31 -1.93 0.075 0.41 -0.42
424033_at Sfrs7 225027 splicing factor, arginine/serine-rich 7 -3.38 0.005 0.11 -0.87 -2.43 0.03 0.32 -0.6 1.21 0.248 0.41 0.27
436618_at Sfxn5 94282 sideroflexin 5 2.18 0.048 0.05 0.79 0.84 0.413 0.29 0.29 -1.56 0.142 0.62 -0.5
420919_at Sgk3 170755 serum/glucocorticoid regulated kinase 3 2.26 0.041 0.05 0.77 1.79 0.096 0.15 0.58 -0.62 0.543 0.68 -0.19
42082 I_at Sgppl 81535 sphingosine-I-phosphate phosphatase I -2.49 0.027 0.18 -0.9 -1.28 0.221 0.35 -0.44 1.43 0.174 0.36 0.46
428107_at Sh3bgrl 56726 SH3-binding domain glutamic acid-rich protein -2.54 0.024 0.17 -0.68 -2.13 0.052 0.33 -0.54 0.57 0.579 0.55 0.13
436997 x at Sh3bl1r1 56726 SH3-bindinl1 domain l1lutamic acid-rich protein -3.12 0.008 0.12 -0.75 -1.45 0.171 0.38 -0.33 1.98 0.069 0.27 0.42
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t·stat p-value q-value Fold Ch t·stat p-value q-value Fold Ch.
1425177_at Shmtl 20425 serine hydroxymethyl transferase I (soluble) 2.4 0.032 0.05 0.89 1.99 0.067 0.11 0.71 -0.56 0.584 0.68 -0.18
1449733_s_at Siahla 20437 seven in absentia IA 1.12 0.281 0.15 0.36 2.25 0.042 0.11 0.7 1.16 0.264 0.41 0.33
1449343_s_at Sin3a 20466 transcriptional regulator, SIN3A (yeast)
-0,3 0.769 0.40 -0.1 1.66 0.119 0.15 0.51 2.15 0.05 0.27 0.6
I426373_at Ski 20481 Sloan-Kettering viral oncogene homolog 2.1 0.055 0.09 0.62 2.2 0.046 0.11 0.62 0.01 0.995 0.63 0
14291 92_at Ski 20481 Sloan-Kettering viral oncogene homolog 4.85 0 0.05 1.5 3.97 0.001 0.07 1.18 -1.19 0.254 0.65 -0.32
I429002_at Skiip 66354 SKI interacting protein 3,39 0.005 0.05 0.73 1.15 0.269 0.24 0.24 -2.6 0.021 0.20 -0.49
I448502_at Sic 16a7 20503 solute carrier family I6 1.85 0.086 0.08 0.53 4.01 0.001 0.07 1.1 2.26 0.041 0.27 0.57
I456003_a_at Sic Ia4 55963 solute carrier family I 4 2.59 0.022 0.05 1.41 1.86 0.085 0.09 0.97 -0.92 0.373 0.66 -0.44
I434235_at Slc20a2 20516 solute carrier family 20, member 2 2.7 0.018 0.05 0.77 3.1 0.008 0.09 0.85 0.3 0.769 0.62 0.08
1421912_at Slc23a I 20522 solute carrier family 23 2.99 0.01 0.05 1.2 0.53 0.608 0.30 0.2 -2.83 0.014 0.11 -0.99
I434996_at Slc25a 16 73132 solute carrier family 25
-2.23 0.043 0.26 -0.64 -0.6 0.558 0.39 -0.16 1.89 0.08 0.27 0.48
1437459_x_at Slc25a 19 67283 solute carrier family 25
-3.81 0.002 0.07 -1.78 -4.24 0.001 0.09 -1.89 -0.28 0.784 0.68 -0.11
1423108_at Slc25a20 57279 solute carrier family 25
-1.42 0.179 0.31 -0.34 0.73 0.476 0.30 0.17 2.41 0.031 0.22 0.51
1423109_s_at Slc25a20 57279 solute carrier family 25
-1.27 0.225 0.31 -0,38 0.67 0.516 0.30 0.19 2.17 0.048 0.22 0.57
1419045_at Slc25a23 66972 solute carrier family 25 2.64 0.02 0.05 0.95 -0.39 0.702 0.39 -0.13 -3.43 0.004 0.09 -1.09
1428929_s_at SIc25a26 67582 solute carrier family 25 2.22 0.044 0.08 0.59 2.29 0.039 0.10 0.58 -0.03 0.973 0.68 -0.01
I450018_s_at SIc25a30 67554 solute carrier family 25, member 30
-1.69 0.114 0.27 -0.66 0.63 0.541 0.29 0.24 2.61 0.021 0.20 0.9
1417750_a_at Slc25a37 67712 solute carrier family 25, member 37
-0.26 0.802 0.40 -0.08 2.32 0.036 0.07 0.69 2.82 0.014 0.20 0.77
I438360_x_at Slc25a5 11740 solute carrier family 25
-2.67 0.019 0.23 -0.59 -1.23 0.24 0.39 -0.26 1.71 0.111 0.32 0.33
I438545_at Slc25a5 11740 solute carrier family 25
-3.21 0.007 0.11 -0.74 -1.86 0.085 0.34 -0.41 1.62 0.128 0.32 0,33
I438922_x_at Slc25a5 11740 solute carrier family 25 -2,37 0.034 0.26 -0.52 -1.13 0.278 0.39 -0.24 1.46 0.166 0,38 0.28
I426568_at Slc2a9 117591 solute carrier family 2 4.07 0.001 0.05 1.09 5.05 0 0.07 1.3 0.86 0.403 0.50 0.2
14361 64_at Slc30a I 22782 solute carrier family 30 2.75 0.016 0.05 0.78 1.68 0.116 0.17 0.46 -1.31 0.213 0.64 -0.33
I423621_a_at SIc33al 11416 solute carrier family 33
-2.51 0.025 0.23 -0.77 -1.27 0.226 0.38 -0,37 1.48 0.163 0,32 0.4
I41 997 I_s_at SIc35a5 74102 solute carrier family 35, member A5
-2.39 0.032 0.14 -1.34 -1.08 0.299 0.39 -0.58 1.54 0.147 0.27 0.76
I41 8706_at Slc38a3 76257 solute carrier family 38, member 3 4.04 0.001 0.05 1.03 2.15 0.05 0.13 0.53 -2.26 0.041 0.41 -0.51
1446013_at Slc38a3 76257 solute carrier family 38, member 3 3.02 0.01 0.05 1.24 2.39 0.032 0.10 0.94 -0.83 0.42 0.67 -0.3
I424424_at Slc39a I 30791 solute carrier family 39 2.24 0.042 0.08 0.58 1.52 0.151 0.17 0.38 -0.89 0.387 0.67 -0.2
I43375 I_at SIc39al0 227059 solute carrier family 39
-1.11 0.285 0.28 -0.65 1.35 0.2 0.20 0.75 2.74 0.017 0.20 1.4
I427035_at Slc39a 14 213053 solute carrier family 39 2.19 0.047 0.08 0.66 1.7 0.112 0.11 0.49 -0.64 0.533 0.68 -0.17
I438490_at SIc39al4 213053 solute carrier family 39 3.51 0.004 0.05 1.34 -0.08 0.934 0.39 -0.03 -4.09 0.001 0.05 -1.37
1451 I39_at Slc39a4 72027 solute carrier family 39 0.86 0.407 0.14 0.5 -1.16 0.266 0.38 -0.64 -2.24 0.043 0.30 -1.14
I44874 I_at Slc3a I 20532 solute carrier family 3, member I 2.75 0.016 0.05 1.32 1.32 0.21 0.17 0.6 -1.7 0.111 0.41 -0.71
I448566_at Slc40a I 53945 solute carrier family 40 2.21 0.045 0.08 0.79 1.53 0.15 0.13 0.52 -0.86 0.407 0.67 -0.27
1452445_at Slc41 a2 338365 solute carrier family 41, member 2 2.68 0.018 0.05 1.6 1.28 0.221 0.13 0.73 -1.65 0.121 0.44 -0.87
1438559_x_at Slc44a2 68682 solute carrier family 44, member 2 2.4 0.032 0.05 1.17 3.66 0.003 0.07 1.71 1.25 0.233 0.38 0.54
1425109_at Slc44a3 213603 solute carrier family 44, member 3 2.9 0.012 0.05 1.27 1.4 0.183 0.17 0.59 -1.77 0.099 0.48 -0.68
1416637_at SIc4a2 20535 solute carrier family 4 4.1 0.001 0.05 1.04 2.95 0.011 0.10 0.71 -1.46 0.166 0.62 -0.33
1421 346_a_at Slc6a6 21366 solute carrier family 6 5.06 0 0.05 1.6 5.01 0 0.07 1.52 -0.3 0.768 0.68 -0.08
1437149_at Slc6a6 21366 solute carrier family 6 5,36 0 0.05 1.08 3.45 0.004 0.07 0.66 -2.35 0.035 0.36 -0.41
I450703_at Slc7a2 11988 solute carrier family 7 1.27 0.227 0.11 0.88 -1.71 0.109 0.32 -1.13 -3.31 0.005 0.05 -2.01
1438115_a_at SIc9a3r I 26941 solute carrier family 9 3.42 0.004 0.05 0.88 0.94 0.363 0.29 0.23 -2.87 0.013 0.15 -0.65
1438116_x_at Slc9a3rl 26941 solute carrier family 9 2.46 0.028 0.05 0.66 0.59 0.567 0.30 0.15 -2.16 0.05 0.38 -0.51
I450982_at Slc9a3r I 26941 solute carrier family 9 2.42 0.031 0.05 0.82 -0.02 0.986 0.39 -0.01 -2.77 0.015 0.14 -0.82
I435008_at Slc9a6 236794 solute carrier family 9 -0.93 0.366 0.38 -0.22 1.12 0.281 0.25 0.26 2.29 0.039 0.22 0.48
1420405_at Sicola4 28250 solute carrier organic anion transporter family, 1.75 0.102 0.08 0.67 3.13 0.008 0.09 1.14 1.41 0.18 0.32 0.47
1420913_at Slco2a I 24059 solute carrier organic anion transporter family 2.68 0.019 0.05 0.69 1.35 0.198 0.22 0,33
-1.57 0.139 0.55 -0.36
1448208 at Smadl 17125 MAD homolop I (Drosoohila) 1.68 0.115 0.11 0.42 2.51 0.025 0.11 0.6 0.82 0.427 0.50 0.18
v.>
v.>
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene 10 t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I459843_s_at Smadl 17125 MAD homolog I (Drosophila) 1.35 0.201 0.15 0.32 3.38 0.005 0.07 0.77 2.15 0.05 0.27 0.45
I442062_at Smad2 17126 MAD homolog 2 (Drosophila) 1.21 0.248 0.14 0.33 2.29 0.039 0.11 0.59 1.12 0.284 0.44 0.27
I422485_at Smad4 17128 MAD homolog 4 (Drosophila)
-0.06 0.954 0.40 -0.02 -3.29 0.006 0.27 -1.29 -3.52 0.004 0.09 -1.26
I452333_at Smarca2 67155 SWI/SNF related regulator of chromatin, 1.77 0.099 0.10 0.64 -1.27 0.227 0.38 -0.44 -3.4 0.005 0.05 -1.08
I424207_at Smarca5 93762 SWI/SNF related regulator of chromatin 0.88 0.395 0.22 0.25 -2.12 0.053 0.33 -0.57 -3.3 0.005 0.10 -0.82
1416620_at Smarcall 54380 Swi/SNF related regulator of chromatin 2.73 0.017 0.05 0.76 1.19 0.254 0.24 OJ2 -1.82 0.091 0.41 -0.44
I422675_at Smarcel 57376 SWI/SNF related regulator of chromatin -1.61 0.13 0.27 -0.42 1.96 0.071 0.15 0.48 3.97 0.002 0.07 0.9
1417831_at Smelll 24061 SMC -like I (S. cerevisiae) 3.1 0.008 0.05 0.76 1.15 0.268 0.24 0.27 -2.27 0.04 0.27 -0.49
1422910_s_at Smc611 67241 SMC6 -like I (yeast) 2.82 0.014 0.05 0.77 1.32 0.208 0.20 0.35 -1.78 0.098 0.53 -0.43
I44832 I_at Smocl 64075 SPARC related modular calcium binding I 1.2 0.25 0.18 0.39 2.2 0.046 0.11 0.67 1.02 0.325 OAI 0.29
I447643_x_at Snai2 20583 snail homolog 2 (Drosophila) 2.77 0.016 0.05 0.69 4.55 0.001 0.07 1.08 1.8 0.095 0.27 0.39
I420897_at Snap23 20619 synaptosomal-associated protein 23 -1.52 0.151 0.27 -0.45 -2.87 0.013 OJI -0.8 -1.39 0.186 0.64 -0.36
1436703_x_at Snapc2 102209 small nuclear RNA activating complex, 2.26 0.041 0.08 0.55 2.06 0.059 0.11 0.48 -0.32 0.751 0.68 -0.07
I448864_at Snrk 20623 SNF related kinase 2.45 0.029 0.05 0.59 3.51 0.004 0.09 0.81 1.03 0.323 0.46 0.22
1454807_a_at Snxl2 55988 sorting nexin 12 2.4 0.032 0.07 0.7 3.51 0.004 0.07 0.98 1.09 0.296 0.41 0.28
I438803_s_at Snxl6 74718 sorting nexin I6 1.39 0.187 0.15 0.39 2.52 0.025 0.09 0.68 1.17 0.263 0.44 0.29
I447234_s_at Snx6 72183 sorting nexin 6 -2.73 0.017 0.20 -0.61 -0.31 0.765 0.39 -0.07 2.78 0.015 0.20 0.55
1436737_a_at Sorbs I 20411 sorbin and SH3 domain containing I -1.92 0.076 0.27 -0.55 0.54 0.597 0.30 0.15 2.78 0.015 0.20 0.7
1421504_at Sp4 20688 trans-acting transcription factor 4 1.89 0.081 0.09 0.51 -0.57 0.575 0.39 -0.15 -2.77 0.015 0.15 -0.65
448392_at Sparc 20692 secreted acidic cysteine rich glycoprotein 2.25 0.042 0.07 0.88 1.42 0.179 0.17 0.53 -1.02 0.325 0.65 -0.35
437865_at Spata 13 219140 spermatogenesis associated 13 1.93 0.075 0.10 0.55 3.12 0.008 0.07 0.85 1.21 0.248 0.41 0.3
454656_at Spata 13 219140 spermatogenesis associated 13 1.8 0.094 0.11 0.48 2.49 0.027 0.09 0.63 0.66 0.522 0.53 0.15
460677_at Spats2 72572 spermatogenesis associated, serine-rich 2 1.98 0.069 0.10 0.59 3.23 0.006 0.07 0.92 1.26 0.228 0.36 0.33
41 9256_at Spnb2 20742 spectrin beta 2 2.92 0.012 0.05 0.86 1.3 0.215 0.22 0.37 -1.91 0.078 0.41 -0.49
41 6525_at Spop 20747 speckle-type paz protein 0.18 0.859 0.26 0.08 -2.57 0.023 0.31 -1.09 -3 0.01 0.11 -1.17
451073_at Sppl3 74585 signal peptide peptidase 3 1.69 0.114 0.09 0.48 2.37 0.033 0.11 0.64 0.66 0.519 0.53 0.16
436726_s_at Sptlc I 268656 serine palmitoyltransferase, long chain base -2.23 0.044 0.23 -0.72 -1.72 0.109 0.34 -0.53 0.67 0.516 0.53 0.19
420641_a_at Sqrdl 59010 sulfide quinone reductase-like (yeast) 1.33 0.206 0.15 0.37 2.44 0.029 0.11 0.64 1.14 0.273 0.41 0.28
426690_a_at Srebfl 20787 sterol regulatory element binding factor 1 4.19 0.001 0.05 1.23 3.29 0.006 0.09 0.93 -1.18 0.259 0.64 -0.3
41 6422_a_at Ssb 20823 Sjogren syndrome antigen B -1.58 0.138 0.28 -0.49 0.52 0.612 OJO 0.16 2.36 0.034 0.22 0.65
427917_s_at Ssbp3 72475 single-stranded DNA binding protein 3 3.32 0.005 0.05 0.86 4.56 0 0.07 1.13 1.18 0.258 0.41 0.27
455854_a_at Sshl 231637 slingshot homolog I (Drosophila) 3.93 0.002 0.05 0.89 4.42 0.001 0.07 0.96 0.34 0.736 0.62 0.07
141 7764_at Ssrl 107513 signal sequence receptor, alpha 3.62 0.003 0.05 1.66 2.76 0.016 0.09 1.21 -1.11 0.285 0.44 -0.45
I426790_at Ssrpl 20833 structure specific recognition protein I 2.99 0.01 0.05 0.9 1.42 0.179 0.20 0.41 -1.86 0.085 0.32 -0.49
I420928_at St6gall 20440 beta galactoside alpha 2,6 sialyltransferase I 2J2 0.037 0.07 0.8 2.57 0.023 0.07 0.84 0.16 0.876 0.63 0.05
1427916_at St71 229681 suppression of tumorigenicity 7-like -2.55 0.024 0.20 -0.71 -2.91 0.012 0.30 -0.78 -0.26 0.796 0.68 -0.06
43 I921_a_at Stag I 20842 stromal antigen I -1.28 0.222 OJ2 -0.32 0.75 0.463 0.30 0.18 2.28 0.04 0.22 0.51
429239_a_at Stard4 170459 StAR-related lipid transfer (START) domain -3.18 0.007 0.14 -0.75 -2.43 0.03 0.32 -0.55 0.98 0.345 0.48 0.2
42191 I_at Stat2 20847 signal transducer and activator of transcription 2.71 0.017 0.05 0.8 0.45 0.662 0.30 0.13 -2.6 0.022 OJO -0.67
426587_a_at Stat3 20848 signal transducer and activator of transcription 3.36 0.005 0.05 1.21 3.05 0.009 0.07 1.05 -0.51 0.619 0.68 -0.16
460700_at Stat3 20848 Signal transducer and activator of transcription 4.43 0.001 0.05 1.31 3.11 0.008 0.07 0.88 -1.66 0.119 0.58 -0.43
438179_s_at Statip 1 58523 signal transducer and activator of transcription 3.19 0.007 0.05 0.69 3.05 0.009 0.09 0.63 -0.31 0.761 0.68 -0.06
460197_a_at Steap4 117167 STEAP family member 4 3.66 0.003 0.05 1.32 1.8 0.095 0.09 0.62 -2.21 0.045 0.38 -0.7
448320_at Stiml 20866 stromal interaction molecule I 1.2 0.251 0.18 0.3 2.31 0.037 0.10 0.56 1.15 0.27 0.44 0.26
426248_at Stk24 223255 serinelthreonine kinase 24 3.03 0.009 0.05 0.85 3.6 0.003 0.07 0.97 0.47 0.649 0.58 0.12
423535_at Strn3 94186 striatin, calmodulin binding protein 3 -2.62 0.021 0.22 -0.69 -0.68 0.51 0.39 -0.17 2.24 0.043 0.27 0.52
428917_at Stxl7 67727 syntaxin 17 0.51 0.621 0.26 0.12 2.71 0.017 0.10 0.63 2.37 0.033 0.20 0.51
435058 x at StxbD3 20912 syntaxin bindinl' Drotein 3 -2.73 0.017 0.12 -1.07 -IAI 0.18 0.35 -0.53 1.57 0.138 0.30 0.54
V.>
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1418940_at Sultlbl 56362 sulfotransferase family IB, member I
-2.24 0.042 0.27 -0.65 -2 0.067 0.31 -0.55 0.38 0.711 0.60 0.1
I449409_at Sultl c2 69083 sulfotransferase family, cytosolic, IC 0.9 0.386 0.18 0.36 2.45 0.029 0.10 0.94 1.65 0.123 0.27 0.58
I448973_at Sultldl 53315 sulfotransferase family ID, member I
-3.36 0.005 0.10 -0.99 -2.78 0.015 0.30 -0.78 0.8 0.436 0.50 0.21
1449816_at Sult5al 57429 sulfotransferase family SA, member I
-3.16 0.007 0.08 -1.87 -4.71 0 0.00 -2.67 -1.53 0.148 0.55 -0.8
I42422 I_at Susd4 96935 sushi domain containing 4
-0.77 0.454 0.34 -0.38 -3.03 0.009 0.30 -1.43 -2.42 0.03 0.20 -1.05
1460593 at Susd4 96935 sushi domain containing 4
-0.42 0.684 0.40 -0.18 -3.01 0.01 0.30 -1.25 -2.8 0.015 0.15 -1.07
1441906y_at Syapl 67043 synapse associated protein I
-3.35 0.005 0.09 -1.15 -1.49 0.159 0.34 -0.49 2.2 0.046 0.27 0.66
I426269_at Sybil 20955 synaptobrevin like I
-2.87 0.013 0.15 -0.84 -1.07 0.302 0.39 -0.3 2.09 0.056 0.22 0.54
1452007 at Sybil 20955 synaptobrevin like I
-5.21 0 0.04 -1.87 -3.46 0.004 0.24 -1.19 2.16 0.049 0.27 0.68
I422769_at Syncrip 56403 synaptotagmin binding 3.17 0.007 0.05 0.92 -2.13 0.052 0.32 -0.59 -5.92 0 0.00 -1.52
I428546_at Syncrip 56403 synaptotagmin binding, cytoplasmic RNA 0.11 0.912 0.26 0.03 2.21 0.045 0.11 0.49 2.28 0.039 0.27 0.46
I455493_at Synel 64009 synaptic nuclear envelope I 2.26 0.041 0.05 0.87 1.78 0.097 0.11 0.65 -0.63 0.538 0.68 -0.21
I435082_at Sypl 19027 synaptophysin-Iike protein 1.52 0.151 0.15 0.37 3.7 0.003 0.07 0.86 2.29 0.039 0.20 0.49
I428070_at Syvnl 74126 synovial apoptosis inhibitor I, synoviolin
-2.51 0.026 0.15 -1.09 -1.89 0.081 0.33 -0.78 0.8 0.436 0.46 0.31
I443609_s_at Syvnl 74126 synovial apoptosis inhibitor I, synoviolin
-2.34 0.035 0.15 -1.04 -1.98 0.069 0.33 -0.84 0.51 0.619 0.53 0.2
1452310_at Tada21 217031 transcriptional adaptor 2 1.76 0.102 0.11 0.53 2.47 0.028 0.10 0.72 0.69 0.503 0.50 0.18
I438250_s_at Taf9 108143 TAF9 RNA polymerase II, TATA box binding -2.98 0.01 0.17 -0.74 -1.17 0.264 0.39 -0.28 2.12 0.053 0.27 0.46
I424657_at Taokl 216965 TAO kinase I 2.86 0.013 0.05 0.75 1.98 0.068 0.13 0.5 -1.1 0.29 0.66 -0.25
1453913_a_at Tap2 21355 transporter 2, ATP-binding cassette 2.55 0.024 0.05 1.24 1.73 0.107 0.09 0.8 -1.02 0.326 0.66 -0.44
1421812_at Tapbp 21356 TAP binding protein 3.63 0.003 0.05 0.99 3.54 0.003 0.07 0.92 -0.28 0.785 0.68 -0.07
1451544_at Tapbpl 213233 TAP binding protein-like 2.88 0.013 0.05 0.84 1.86 0.085 0.13 0.52 -1.25 0.232 0.65 -0.32
455871_s_at Taxlbp3 270106 Taxi (human T-cell leukemia virus type I) 0.8 0.44 0.25 0.21 2.2 0.046 0.10 0.55 1.49 0.16 0.36 0.34
416062_at Tbcldl5 66687 TBC I domain family, member 15 1.7 0.111 0.05 0.67 -2.14 0.051 0.32 -0.81 -4.27 0.001 0.05 -1.48
423659_a_at Tbcldl7 233204 TBC I domain family, member 17 2.25 0.042 0.07 0.59 2.41 0.031 0.11 0.61 0.06 0.951 0.63 0.01
456205_x_at Tbca 21371 tubulin cofactor a -3.18 0.007 0.15 -0.63 -1.04 0.317 0.39 -0.2 2.48 0.027 0.22 0.43
455801_x_at Tbcd 108903 tubulin-specific chaperone d 2.65 0.019 0.05 0.63 1.42 0.179 0.22 0.32 -1.48 0.163 0.63 -0.31
434643_at Tbllx 21372 transducin (beta)-Iike I X-linked 2.55 0.024 0.05 0.72 0.75 0.464 0.30 0.2 -2.08 0.057 0.44 -0.5\
455042_at Tbllx 21372 transducin (beta)-like I X-linked 2.17 0.048 0.09 0.52 3.76 0.002 0.07 0.86 1.62 0.129 0.30 0.34
418171_at Tceal8 66684 transcription elongation factor A (SII)-like 8 1.81 0.093 0.05 1.54 2.46 0.Q28 0.07 2 0.62 0.543 0.50 0.47
421910_at Tcf20 21411 transcription factor 20 0.08 0.936 0.26 0.02 3.98 0.001 0.07 0.84 4.24 0.001 0.20 0.82
41 6724_x_at Tcf4 21413 transcription factor 4 4.01 0.001 0.05 I 3.96 0.002 0.07 0.94 -0.25 0.804 0.68 -0.06
424089_a_at Tcf4 21413 transcription factor 4 2.92 0.012 0.05 0.76 3.26 0.006 0.07 0.81 0.23 0.824 0.63 0.05
434 I48_at Tcf4 21413 transcription factor 4 1.32 0.209 0.17 0.42 3.71 0.002 0.07 1.12 2.54 0.024 0.20 0.71
434 149_at Tcf4 21413 transcription factor 4 2.52 0.Q25 0.07 0.66 3.39 0.005 0.07 0.86 0.82 0.424 0.48 0.19
429427_s_at Tcf712 21416 transcription factor 7-like 2, T-cell specific -0.41 0.69 0.40 -0.18 1.62 0.128 0.15 0.68 2.23 0.044 0.22 0.86
420635_a_at Tcirgl 27060 T-cell, immune regulator I 3.8 0.002 0.05 1.28 2.65 0.019 0.09 0.86 -1.44 0.173 0.62 -0.43
447800_x_at Tcn2 21452 transcobalamin 2 2.59 0.022 0.05 0.73 3.34 0.005 0.07 0.89 0.68 0.51 0.53 0.17
447842_x_at Tcn2 21452 transcobalamin 2 2.32 0.037 0.07 0.67 2.27 0.04 0.10 0.63 -0.17 0.866 0.68 -0.04
448200_at Tcn2 21452 transcobalamin 2 3.48 0.004 0.05 0.96 2.27 0.04 0.11 0.6 -1.48 0.162 0.63 -0.36
457825_x_at Tcn2 21452 transcobalamin 2 2.82 0.014 0.05 0.83 2.19 0.047 0.11 0.62 -0.83 0.419 0.67 -0.22
459854_s_at Tcte II 67117 t-complex-associated-testis-expressed I-like -4.29 0.001 0.07 -1.09 -1.86 0.085 0.33 -0.45 2.87 0.013 0.20 0.64
41 5838_at Tde2 56442 tumor differentially expressed 2 1.5 0.158 0.11 0.55 -0.8 0.437 0.39 -0.28 -2.57 0.023 0.14 -0.84
434382_at Tde21 230779 tumor differentially expressed 2-like 2.87 0.013 0.05 1.11 3.41 0.004 0.07 1.27 0.45 0.662 0.58 0.15
455770_at Tdo2 56720 tryptophan 2,3-dioxygenase -2.37 0.033 0.26 -0.73 -1.76 0.1 0.32 -0.52 0.78 0.449 0.50 021
455054_a_at Tes3-ps 114893 testis derived transcript 3, pseudogene -3.19 0.007 0.11 -0.84 -3.01 0.01 0.31 -0.76 0.35 0.731 0.60 0.08
41 9954_s_at Tex27 21769 testis expressed gene 27 0.11 0.912 0.26 0.03 2.59 0.022 0.10 0.57 2.69 0.018 0.22 0.54
426998_at Tex27 21769 testis expressed gene 27 -0.12 0.906 0.40 -0.02 2.32 0.036 0.11 0.46 2.66 0.019 0.22 0.48
421943 at Tlria 21802 transforminl1 I1rowth factor alDha -0.81 0.433 0.36 -0.31 1.2 0.251 0.22 0.44 2.23 0.044 0.22 0.76
'-"
'-"
'-"
Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6·NASH vs. IGT/6-DM
Gene 10 t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I433795_at Tgfbr3 21814 transforming growth factor, beta receptor III 1.22 0.242 0.17 0.36 2.15 0.05 0.10 0.61 0.95 0.36 0.46 0.25
I428426_s_at Tgfbrapl 73122 TGFb receptor associated protein 1 2.53 0.024 0.05 0.66 1.8 0.095 0.17 0.45 -0.93 0037 0.67 -0.21
1417500_a_at Tgm2 21817 transglutaminase 2, C polypeptide 2.27 0.04 0.07 0.79 2.21 0.045 0.10 0.74 -0.17 0.865 0.68 -0.05
I433428_x_at Tgm2 21817 transglutaminase 2, C polypeptide 3.53 0.004 0.05 I 2.72 0.017 0.07 0.74 -1.05 00312 0.66 -0.26
1437277_x_at Tgm2 21817 transglutaminase 2, C polypeptide 3.45 0.004 0.05 I 3.09 0.008 0.07 0.86 -0.56 0.584 0.68 -0.14
I455900_x_at Tgm2 21817 transglutaminase 2, C polypeptide 3.47 0.004 0.05 0.98 2.67 0.019 0.07 0.72 -1.05 0.311 0.66 -0.26
1455003_at Thapl 73754 THAP domain containing, apoptosis associated
-3.08 0.009 0.15 -0.69 -1.56 0.142 0.36 -0.34 1.8 0.093 0.27 0.36
I424641_a_at Thocl 225160 THO complex I
-3.09 0.008 0.08 -1.35 -2.32 0.037 0.32 -0.97 0.99 0.338 0.44 0.38
I423970_at Thoc3 73666 THO complex 3 1.42 0.178 0.12 0.4 2.23 0.043 0.11 0.6 0.81 0.431 0.50 0.2
1423971_at Thoc3 73666 THO complex 3 2.23 0.044 0.08 0.58 1.23 0.24 0.22 0.3 -1.2 0.252 0.65 -0.27
I434603_at Thrap2 76199 thyroid hormone receptor associated protein 2 1.21 0.248 0.15 0.28 3.63 0.003 0.07 0.79 2.57 0.023 0.22 0.52
14441 66_at Thrsp 21835 thyroid hormone responsive SPOT 14 homolog 0 0.998 0.40 0 -2.51 0.026 0.24 -1.73 -2.73 0.017 0.10 -1.73
I449886_a_at TimmlO 30056 translocase of inner mitochondrial membrane -3.53 0.004 0.08 -1.34 -2.21 0.045 0.32 -0.8 1.61 0.131 0.27 0.54
1417670_at Timm44 21856 translocator of inner mitochondrial membrane 1.6 0.132 0.08 0.5 3.2 0.007 0.09 0.96 1.66 0.12 0032 0.46
I433662_s_at Timp2 21858 tissue inhibitor of metalloproteinase 2 1.92 0.077 0.08 0.73 2.41 0.031 0.10 0.88 0.44 0.666 0.58 0.15
I454677_at Timp2 21858 tissue inhibitor of metalloproteinase 2 2.06 0.059 0.07 0.73 3.04 0.009 0.09 1.04 0.97 0.35 0.44 0.3
145 I587_a_at Tlprl 226591 TIP4I, TOR signalling pathway regulator-like -1.75 0.103 0.27 -0.41 0.36 0.725 0030 0.08 2.38 0.033 0.22 0.5
41 9655_at Tle3 21887 transducin-like enhancer of split 3, homolog 1.49 0.159 0.15 0.47 2.38 0.033 0.09 0.71 0.89 0.388 0.48 0.24
456663_x_at Tm2d2 69742 TM2 domain containing 2 -4.44 0.001 0.07 -1.27 -2.97 0.01 0.27 -0.81 1.82 0.091 0.30 0.46
423924_s_at Tm4sfl4 52588 transmembrane 4 superfamily member 14 2.17 0.049 0.05 0.85 3.5 0.004 0.07 1.32 1.35 0.199 0.38 0.47
424962_at Tm4sf4 229302 transmembrane 4 superfamily member 4 1.75 0.103 0.09 0.47 2.66 0.019 0.10 0.69 0.91 0.38 0.48 0.22
42S079_at Tm6sf2 107770 transmembrane 6 superfamily member 2 3.69 0.003 0.05 1.42 3.11 0.008 0.07 1.14 -0.82 0.428 0.66 -0.28
428098_a_at Tm7sf3 67623 transmembrane 7 superfamily member 3 -2.25 0.042 0.11 -0.74 -1.2 0.252 0.39 -0.38 1.26 0.229 0.41 0.36
438504_x_at Tm7sf3 67623 transmembrane 7 superfamily member 3 -3.52 0.004 0.04 -1.14 -2.21 0.045 0.33 -0.68 1.6 0.132 0.32 0.45
423295_at Tm9sf2 68059 transmembrane 9 superfamily member 2 -2.32 0.036 0.24 -0.73 -0.9 0.386 0.39 -0.27 1.67 0.118 0.30 0.46
423205_at Tm9sf4 99237 transmembrane 9 superfamily protein member 2.37 0.033 0.07 0.62 1.26 0.228 0.24 0.32 -1.32 0.207 0.64 -0.31
452934_at Tmc5 74424 transmembrane channel-like gene family 5 2.63 0.02 0.05 1.65 1.78 0.097 0.09 1.07 -1.06 0.309 0.65 -0.58
440384_at Tmccl 330401 transmembrane and coiled coil domains I 4.14 0.001 0.05 0.93 3.74 0.002 0.07 0.8 -0.64 0.533 0.68 -0.13
424708_at TmedlO 68581 transmembrane emp24-like trafficking protein 2.19 0.047 0.08 0.63 0.58 0.569 0.30 0.16 -1.85 0.086 0.44 -0.47
420868_s_at Tmed2 56334 transmembrane emp24 domain trafficking -2.28 0.04 0.25 -0.72 -1.09 0.296 0.39 -0.33 1.41 0.181 0.36 0.39
416108_a_at Tmed3 66111 transmembrane emp24 domain containing 3 -2.28 0.04 0.18 -0.97 -1.85 0.087 0.33 -0.75 0.58 0.572 0.53 0.22
424574_at Tmed5 73130 transmembrane emp24 protein transport -1.23 0.239 0.31 -0.34 1.38 0.189 0.20 0.37 2.91 0.012 0.20 0.71
419918_at Tmed7 66676 transmembrane emp24 protein transport -1.52 0.151 0.27 -0.46 0.77 0.455 0.30 0.22 2.57 0.023 0.20 0.68
428095_a_at Tmem24 71764 transmembrane protein 24 1.9 0.079 0.07 0.52 2.54 0.024 0.10 0.67 0.61 0.553 0.55 0.15
425568_a_at Tmem33 67878 transmembrane protein 33 -2.28 0.04 0.25 -0.68 -0.99 0.338 0.39 -0.28 1.51 0.154 0.36 0.4
452053_a_at Tmem33 67878 transmembrane protein 33 -2.51 0.026 0.26 -0.68 -0.05 0.965 0.39 -0.01 2.81 0.014 0.20 0.67
424191_a_at Tmem4la 66664 transmembrane protein 41 a 1.87 0.083 0.11 0.54 2.25 0.042 0.10 0.62 0.31 0.76 0.62 0.08
428586_at Tmem4lb 233724 transmembrane protein 41 B -3.11 0.008 0.15 -0.95 -2.81 0.014 0.31 -0.82 0.49 0.635 0.55 0.13
421 I27_at Tmem42 66079 transmembrane protein 42 -1.66 0.12 0.27 -0.41 -2.81 0.014 0.31 -0.66 -1.17 0.264 0.65 -0.25
424357_at Tmem45b 235135 transmembrane protein 45b 1.61 0.13 0.05 1.22 2.36 0.034 0.09 1.7 0.73 0.479 0.48 0.48
454797_at Tmem55b 219024 transmembrane protein 55b 1.84 0.088 0.07 0.46 2.19 0.047 0.13 0.52 0.29 0.774 0.62 0.06
434553_at Tmem56 99887 transmembrane protein 56 -2.79 0.015 0.15 -0.8 -0.53 0.602 0.39 -0.15 2.59 0.022 0.22 0.66
428883_at Tmem57 66146 transmembrane protein 57 0.55 0.594 0.26 0.13 2.47 0.027 0.09 0.55 2.07 0.058 0.27 0.42
423871_at Tmem63a 208795 transmembrane protein 63a 2.58 0.022 0.05 0.89 2.99 0.01 0.09 0.99 0.32 0.757 0.62 0.1
433735_a_at Tmem64 100201 transmembrane protein 64 -2.27 0.04 0.15 -0.92 -0.6 0.559 0.39 -0.23 1.93 0.Q75 0.27 0.69
420725_at Tmlhe 192289 trimethyllysine hydroxylase, epsilon -3.06 0.009 0.11 -0.91 -1.22 0.244 0.39 -0.35 2.15 0.05 0.27 0.56
420726_x_at Tmlhe 192289 trimethyllysine hydroxylase, epsilon -4.55 0 0.07 -1.19 -1.6 0.133 0.35 -0.4 3.44 0.004 0.20 0.79
449369 at Tmorss2 50528 transmembrane orotease serine 2 3.16 0.007 0.05 1.6 2.33 0.036 0.09 1.13 -1.06 0.306 0.64 -0.47
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1458347_s_at Tmprss2 50528 transmembrane protease, serine 2 3.2 0.007 0.05 1.53 2.54 0.024 0.09 1.16 -0.88 0.395 0.66 -0.37
14491 25_at Tnfaip811 66443 tumor necrosis factor, alpha-induced protein 8-
-2.76 0.016 0.22 -0.67 -0.14 0.894 0.39 -0.03 2.99 0.01 0.20 0.64
1417291_at Tnfrsfl a 21937 tumor necrosis factor receptor superfamily, 3.52 0.004 0.05 1.11 2.17 0.049 0.09 0.66 -1.65 0.122 0.60 -0.46
1418099_at Tnfrsfl b 21938 tumor necrosis factor receptor superfamily, 1.99 0.067 0.09 0.57 2.28 0.039 0.11 0.63 0.22 0.828 0.63 0.06
I439680_at TnfsflO 22035 tumor necrosis factor (ligand) superfamily, 1.25 0.232 0.17 0.5 2.33 0.036 0.11 0.9 1.11 0.286 0.30 0.39
1427689_a_at Tnipl 57783 TNFAIP3 interacting protein I 2.88 0.013 0.05 0.88 1.6 0.133 0.15 0.47 -1.54 0.148 0.60 -0.41
I428388_at Tnks2 74493 tankyrase, TRF I-interacting ankyrin-related 1.47 0.165 0.15 0.39 2.64 0.02 0.10 0.67 1.2 0.251 0.41 0.28
I447522_s_at Tnks2 74493 tankyrase, TRF I-interacting ankyrin-related
-1.92 0.076 0.27 -0.53 0.54 0.598 0.30 0.14 2.77 0.015 0.20 0.67
I433585_at Tnpol 238799 transportin I
-1.45 0.17 0.29 -0.35 1.61 0.132 0.20 0.37 3.4 0.005 0.20 0.71
1417310_at Tob2 57259 transducer of ERBB2, 2 1.46 0.168 0.07 0.77 -1.12 0.283 0.39 -0.56 -2.88 0.013 0.11 -1.33
I423047_at Tollip 54473 toll interacting protein 1.91 0.077 0.10 0.4 2.4 0.031 0.11 0.47 0.43 0.671 0.60 0.08
1431 I88_a_at Toml 21968 target of myb I homolog (chicken) 1.31 0.212 0.15 0.53 2.26 0.041 0.10 0.87 0.97 0.349 0.38 0.34
I435055_a_at Toml 21968 target of myb I homolog (chicken) 2.59 0.022 0.05 0.62 2.68 0.019 0.10 0.61 -0.03 0.976 0.68 -0.01
1423079_a_at Tomm20 546321 translocase of outer mitochondrial membrane
-3.91 0.002 0.08 -I -2.27 0.04 0.32 -0.55 1.99 0.067 0.27 0.44
I435534_a_at Tomm20 67952 translocase of outer mitochondrial membrane -3.82 0.002 0.08 -1.18 -2.07 0.058 0.32 -0.61 2.09 0.056 0.27 0.57
1455357_x_at Tomm20 67952 translocase of outer mitochondrial membrane -4.41 0.001 0.08 -1.15 -2.44 0.029 0.32 -0.61 2.36 0.034 0.22 0.54
I434420_x_at Tomm22 223696 translocase of outer mitochondrial membrane -3.14 0.008 0.12 -0.77 -1.44 0.172 0.37 -0.34 2 0.066 0.27 0.43
I434732_x_at Tomm7 66169 Translocase of outer mitochondrial membrane -3.94 0.002 0.08 -0.89 -2.4 0.032 0.32 -0.52 1.87 0.083 0.27 0.37
141 7820_at Torlb 30934 torsin family I, member B 4 0.001 0.05 0.95 4.19 0.001 0.07 0.95 0.01 0.992 0.63 0
I448848_at Torlb 30934 torsin family I, member B 2.19 0.047 0.D7 0.6 2.81 0.014 0.10 0.73 0.57 0.58 0.55 0.14
I434768_at Tppl 12751 tripeptidyl peptidase I 3.56 0.003 0.05 0.89 2.51 0.026 0.10 0.6 -1.33 0.207 0.64 -0.29
I438264_a_at Tpp2 22019 tripeptidyl peptidase II -0.39 0.703 0.40 -0.13 -4.58 0 0.15 -1.49 -4.55 0.001 0.00 -1.36
1416086_at Tpst2 22022 protein-tyrosine sulfotransferase 2 2.48 0.027 0.05 I 1.36 0.196 0.17 0.52 -1.35 0.2 0.50 -0.48
1418233_a_at Trappc5 66682 trafficking protein particle complex 5 2.43 0.03 0.05 0.69 2.98 0.01 0.09 0.81 0.48 0.641 0.58 0.12
1417034_at Trappc6a 67091 trafficking protein particle complex 6A -0.19 0.855 0.40 -0.06 1.84 0.088 0.15 0.52 2.22 0.044 0.22 0.58
I442049_at Trf 22041 transferrin 2.49 0.026 0.05 1.57 1.26 0.229 0.11 0.76 -1.46 0.166 0.58 -0.81
1425381_a_at Trfr2 50765 transferrin receptor 2 3.92 0.002 0.05 0.91 2.25 0.042 0.11 0.5 -2.02 0.063 0.48 -0.41
I427258_at Trim24 21848 tripartite motif protein 24 2.73 0.017 0.05 0.92 1.64 0.124 0.15 0.53 -1.33 0.206 0.64 -0.39
I456308_x_at Trim28 21849 tripartite motif protein 28 2.19 0.047 0.08 0.5 1.18 0.257 0.24 0.26 -1.2 0.251 0.65 -0.24
I449041_a_at Trip6 22051 thyroid hormone receptor interactor 6 2.84 0.014 0.05 0.7 3.15 0.007 0.07 0.75 0.2 0.846 0.63 0.04
I426956_a_at Trp53bpl 27223 transformation related protein 53 binding 2.23 0.043 0.08 0.6 2.72 0.017 0.10 0.7 0.42 0.681 0.60 0.1
1416799_at Trpm7 58800 transient receptor potential cation channel, -1.52 0.151 0.28 -0.45 0.5 0.624 0.30 0.14 2.28 0.039 0.22 0.6
I41 6532_at Trrap 100683 transformation/transcription domain-associated 4.42 0.001 0.05 1.4 3.52 0.004 0.07 1.07 -1.2 0.252 0.65 -0.33
I425742_a_at Tsc22d 1 21807 TSC22 domain family, member I -3.53 0.004 0.08 -1.1 -2.54 0.024 0.32 -0.75 1.26 0.23 0.38 0.34
1433899_x_at Tsc22dl 21807 TSC22 domain family, member I -3.46 0.004 0.11 -0.96 -2.18 0.048 0.32 -0.58 1.56 0.141 0.32 0.38
I454758_a_at Tsc22dl 21807 TSC22 domain family, member I -3.58 0.003 0.08 -1.43 -1.87 0.083 0.32 -0.71 2.04 0.061 0.22 0.71
I454971]_at Tsc22dl 21807 TSC22 domain family, member I -3.09 0.008 0.15 -0.81 -1.38 0.189 0.37 -0.35 2.01 0.065 0.27 0.46
I425206_a_at Tsc22d4 78829 TSC22 domain family 4 3.07 0.009 0.05 1.48 -4.97 0 0.00 -2.29 -8.91 0 0.00 -3.77
1430029_a_at Tspan31 67125 tetraspanin 3I 2.08 0.057 0.08 0.53 2.37 0.033 0.11 0.58 0.21 0.834 0.63 0.05
1428197_at Tspan9 109246 tetraspanin 9 2.32 0.037 0.07 0.63 1.89 0.08 0.15 0.49 -0.58 0.574 0.68 -0.14
1415908_at Tspyll 22110 testis-specific protein, Y-encoded-like I -3.01 0.01 0.11 -1.1 -2.18 0.048 0.32 -0.76 1.06 0.307 0.44 0.34
I448609_at Tst 22117 thiosulfate sulfurtransferase, mitochondrial 2.62 0.021 0.05 1.16 0.29 0.773 0.30 0.12 -2.66 0.019 0.16 -1.04
1443819_x_at Ttcll 66437 tetratricopeptide repeat domain I I 0.17 0.868 0.26 0.05 2.69 0.018 0.10 0.7 2.74 0.016 0.22 0.65
143863 I_x_at Ttel3 234875 tetratricopeptide repeat domain I3 1.06 0.308 0.20 0.24 3.01 0.01 0.09 0.64 2.07 0.058 0.27 0.4
I448361_at ltc3 22129 tetratricopeptide repeat domain 3 2.57 0.023 0.05 0.9 4.02 0.001 0.07 1.35 1.45 0.17 0.36 0.45
I435334_at Ttc7 225049 tetratricopeptide repeat domain 7 2.36 0.034 0.05 0.67 2.03 0.063 0.13 0.55 -0.48 0.642 0.68 -0.12
I434500_at Ttyh2 117160 tweety homolog 2 (Drosophila) 4.97 0 0.05 1.23 4.02 0.001 0.07 0.95 -1.28 0.221 0.63 -0.28
1426796 at Txln 109658 taxilin -0.17 0.87 0.40 -0.04 2.11 0.054 0.13 0.45 2.49 0.027 0.22 0.49
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I455640_a_at Txn2 56551 thioredoxin 2 1.54 0.147 0.15 0.37 3.27 0.006 0.09 0.74 1.8 0.094 0.30 0.38
1415738 at Txndcl2 66073 thioredoxin domain containing I2
-0.18 0.861 0,40 -0.05 2,41 0.031 0.11 0.59 2.83 0.014 0.20 0.63
I423299_at Txnll 53382 thioredoxin-like I
-2.19 0.047 0.27 -0.71 -0.37 0.714 0.39 -0.12 2.08 0.057 0.20 0.59
1436947_a_at Txnll 53382 thioredoxin-like I
-2.55 0.024 0.26 -0.64 -0.03 0.974 0.39 -0.01 2.86 0.013 0.20 0.63
I456244_x_at Txnl2 30926 thioredoxin-like 2
-3.16 0.007 0.15 -0.77 -1.95 0.072 0.33 -0,46 1.47 0.163 0.38 0.32
I423034_at Txnl5 52700 thioredoxin-like 5
-2.66 0.019 0.22 -0.58 -1.66 0.12 0.35 -0.34 1.23 0.241 0,41 0.23
14391 84_s_at Txnl5 52700 thioredoxin-like 5 -3,4 0.005 0.12 -0.83 -1.36 0.196 0.37 -0.32 2.39 0.032 0.22 0.51
I424486_a_at Txnrdl 50493 thioredoxin reductase I -0.82 0,429 0.34 -0,42 -3.3 0.006 0.29 -1.63 -2.66 0.019 0.11 -1.21
I42997 I_at Txnrd2 26462 thioredoxin reductase 2 -0.97 0.35 0.37 -0.23 1.08 0.3 0.27 0.25 2.28 0.04 0.22 0,48
I429972_s_at Txnrd2 26462 thioredoxin reductase 2 -1,43 0.177 0.28 -0.34 0.53 0.601 0.30 0.12 2.21 0.045 0.27 0,47
I449097_at Txnrd2 26462 thioredoxin reductase 2 0.99 0.341 0.22 0.25 2.39 0.032 0.11 0.58 1,48 0.163 0.36 0.33
I449623_at Txnrd3 232223 thioredoxin reductase 3 0.6 0.557 0.26 0.18 2.3 0.038 0.11 0.67 1.82 0.091 0.30 0,49
1435164_s_at Ubelc 22200 ubiquitin-activating enzyme EIC -2.86 0.013 0.08 -1.13 -1.84 0.088 0.33 -0.7 1.25 0.231 0.38 0,44
141 7609_at Ube2a 22209 ubiquitin-conjugating enzyme E2A, RAD6 -1.55 0.145 0.29 -0.37 1.21 0.248 0.24 0.27 3.08 0.009 0.20 0.64
I423 I06_at Ube2b 22210 ubiquitin-conjugating enzyme E2B, RAD6 -2.15 0.05 0.25 -0.5 -1.28 0.222 0.39 -0.28 1.06 0.31 0,46 0.21
1423107 at Ube2b 22210 ubiquitin-conjugating enzyme E2B, RAD6 -3.28 0.006 0.10 -0.89 -1.96 0.071 0.33 -0.51 1.6 0.133 0.32 0.38
141 6943_at Ube2el 22194 ubiquitin-conjugating enzyme E2E I, UBC4/5 -3.07 0.009 0.12 -0.84 -2.73 0.017 0.31 -0.72 0.52 0.611 0.58 0.13
I455094_s_at Ube2g1 67128 ubiquitin-conjugating enzyme E2G I (UBC7 1.13 0.278 0.20 0.31 2.33 0.036 0.10 0.61 1.26 0.231 0.38 0.3
I438971_x_at Ube2h 22214 ubiquitin-conjugating enzyme E2H 0.52 0.608 0.26 0.12 2.6 0.022 0.10 0.57 2.23 0.043 0.27 0,45
141 5755_a_at Ube2vl 66589 ubiquitin-conjugating enzyme E2 variant I 3.12 0.008 0.05 0.96 0.82 0,425 0.29 0.24 -2.66 0.019 0.17 -0.71
I444523_s_at Ube2vl 66589 ubiquitin-conjugating enzyme E2 variant I 3.25 0.006 0.05 0.95 1.14 0.275 0.24 0.32 -2,46 0.028 0.32 -0.64
1448410_at Ube4b 63958 ubiquitination factor E4B, UFD2 homolog 0.75 0,466 0.26 0.16 3.14 0.008 0.09 0.64 2.56 0.023 0.22 0,48
I430021_a_at Ublela 56459 ubiquitin-Iike I (sentrin) activating enzyme EIA 1.96 0.071 0.05 1.16 2.67 0.019 0.09 1.51 0.68 0.511 0,48 0.35
I437278_a_at Ublelb 50995 ubiquitin-Iike I (sentrin) activating enzyme EIB -2.3 0.038 0.25 -0.65 -1.09 0.294 0.39 -0.3 1,43 0.176 0.36 0.36
I424399_at Uckl 22245 uridine-cytidine kinase I -2.56 0.023 0.11 -0.85 -0.7 0,497 0.39 -0.22 2.16 0.049 0.27 0.63
I455839_at Ugcgll 320011 UDP-glucose ceramide glucosyltransferase-like 2,42 0.03 0.08 0.57 0.2 0.848 0.30 0.04 -2.55 0.024 0.16 -0.53
I426460_a_at Ugp2 216558 UDP-glucose pyrophosphorylase 2 -1.95 0.073 0.26 -0.55 0.63 0.542 0.30 0.17 2.9 0.012 0.20 0.71
I434485_a_at Ugp2 216558 UDP-glucose pyrophosphorylase 2 -3,45 0.004 0.14 -0.79 -1.24 0.237 0.38 -0.27 2.58 0.022 0.22 0.52
I41 9622_at Ugt2b5 22238 UDP-glucuronosyltransferase 2 family, member -2.22 0.044 0.27 -0.58 -1.75 0.102 0.32 -0,44 0.61 0.549 0.55 0.14
1423397_at Ugt2b5 100559 UDP-glucuronosyltransferase 2 family, member -2.83 0.014 0.08 -3,4 -3.6 0.003 0.00 -4.13 -0.69 0.501 0.66 -0.73
I448370_at Ulkl 22241 Unc-51 like kinase I (c. elegans) 2.2 0.046 0.05 0.85 1.59 0.134 0.15 0.59 -0.77 0,454 0.68 -0.26
1451 565_s_at Urocl 243537 urocanase domain containing I 2.27 0.041 0.07 0.6 2.26 0.041 0.11 0.57 -0.12 0.902 0.68 -0.03
1443849-,,_at Urod 22275 uroporphyrinogen decarboxylase 1.76 0.101 0.12 0,48 3,44 0.004 0.07 0.9 1.74 0.104 0.30 0,42
434483_at Uspl2 22217 ubiquitin specific protease I2 2.59 0.022 0.05 0.57 0.58 0.569 0.30 0.12 -2.31 0.037 0,41 -0,45
426709_a_at Usp33 170822 ubiquitin specific protease 33 -2.9 0.012 0.15 -0.95 -1,47 0.165 0.35 -0,46 1.71 0.11 0.30 0,49
44831 I_at UspS 22225 ubiquitin specific protease 5 (isopeptidase T) -1.01 0.331 0.38 -0.25 2.34 0.035 0.10 0.56 3.7 0.003 0.20 0.81
440883_at Usp6nl 98910 MKIAAOO 19 protein 2.36 0.034 0.05 0.77 2.37 0.033 0.10 0.74 -0.1 0.92 0.68 -0.03
426892_at Utrn 22288 utrophin 1.83 0.089 0.07 1.02 -1.59 0.134 0.33 -0.85 -3.82 0.002 0.04 -1.87
452011_a_at Uxsl 67883 UDP-glucuronate decarboxylase I -0.81 0,43 0.39 -0.25 1.2 0.251 0.24 0.35 2.23 0.043 0.22 0.59
416231_at Vacl4 234729 Vac 14 homolog (S. cerevisiae) 2.84 0.014 0.05 0.66 2,41 0.031 0.11 0.53 -0.61 0.554 0.68 -0.12
41 8486_at Vnnl 22361 vanin I -1.31 0.212 0.26 -1.98 0.64 0.532 0.29 0.93 2.19 0.047 0.20 2.91
447845_s_at Vnnl 22361 vanin I -1.25 0.231 0.26 -1.77 1.09 0.293 0.20 1,48 2.62 0.021 0.20 3.25
428109_at Vpsll 71732 vacuolar protein sorting I I (yeast) 1.82 0.091 0.09 0.63 2.25 0.042 0.11 0.74 0.37 0.716 0.60 0.11
421 05 I_s_at Vps25 28084 vacuolar protein sorting 25 (yeast) -2.37 0.034 0.26 -0.66 0.02 0.981 0.30 0.01 2.72 0.017 0.20 0.67
45 I494_at Wac 225131 WW domain containing adaptor coiled-coil -1.37 0.193 0.28 -0,43 0.6 0.558 0.30 0.18 2.21 0.045 0.22 0.6
45 I495_at Wac 225131 WW domain containing adaptor -0.26 0.795 0,40 -0.06 2 0.066 0.13 0,42 2,48 0.027 0.22 0,48
I427456_at Wdfy3 72145 WD repeat and FYVE domain containing 3 2.29 0.038 0.07 0.56 -0.24 0.817 0.39 -0.06 -2.87 0.013 0.16 -0.62
1423054 at Wdrl 22388 WD reDeat domain I 1.83 0.09 0.09 0.51 2.82 0.014 0.10 0.75 0.99 0.341 0,46 0.24
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145085 I_at Wdrl 22388 WD repeat domain I 2.21 0.045 0.05 0.66 2.67 0.019 0.10 0.76 0.39 0.701 0.60 0.1
I438727_at Wdr32 242418 WD repeat domain 32
-2.36 0.034 0.26 -0.6 -1.52 0.153 0.34 -0.37 1.04 0.318 0.46 0.23
I434076_at Wdr37 207615 WD repeat domain 37 3.15 0.007 0.05 0.61 0.14 0.893 0.30 0.03 -3.43 0.004 0.09 -0.59
1452713_a_at Wdr57 66585 WD repeat domain 57 (US snRNP specific) -3.26 0.006 0.11 -1.07 -1.73 0.107 0.34 -0.54 1.82 0.09 0.22 0.53
I455940_x_at Wdr6 83669 WD repeat domain 6 2.87 0.013 0.05 0.87 2.67 0.019 0.10 0.77 -0.36 0.724 0.68 -0.1
14291SI_at Wdr68 71833 WD repeat domain 68 2.76 0.016 0.05 0.67 3.05 0.009 0.07 0.71 0.19 0.856 0.63 0.04
141919S_at WfdclS 192201 WAP four-disulfide core domain 15 2.71 0.017 0.05 1.7 1.64 0.124 0.11 0.99 -1.29 0.217 0.55 -0.72
I448 I45_at Wwp2 66894 E3 ubiquitin protein ligase 2 2.28 0.039 0.07 0.66 2.22 0.044 0.13 0.61 -0.18 0.861 0.68 -0.05
1456319_at X83313 13957 EST X83313 3.52 0.004 0.05 2.4 -0.15 0.882 0.39 -0.1 -4.17 0.001 0.04 -2.5
14481 34_at X99384 27355 cDNA sequence X99384 2.48 0.027 0.05 0.67 1.85 0.086 0.15 0.48 -0.8 0.435 0.68 -0.19
1422759_a_at Xpo6 74204 exportin 6 2.24 0.042 0.07 0.59 2.14 0.051 0.11 0.54 -0.22 0.826 0.68 -0.05
I422842_at Xrn2 24128 5'-3' exoribonuclease 2 1.98 0.068 0.05 0.69 -2.38 0.033 0.32 -0.79 -4.84 0 0.05 -1.48
1426706_s_at Xylb 102448 xylulokinase homolog (H. influenzae) 4.07 0.001 0.05 0.98 3.04 0.009 0.09 0.7 -1.32 0.208 0.65 -0.28
I423399_a_at Yaf2 67057 YY I associated factor 2 -3.41 0.004 0.11 -0.99 -1.53 0.15 0.34 -0.42 2.22 0.044 0.22 0.56
I439442_x_at Yars2 70120 tyrosyl-tRNA synthetase 2 (mitochondrial) -3.2 0.007 0.15 -0.82 -1.5 0.156 0.34 -0.37 2.01 0.064 0.27 0.45
I426624_a_at Ypel3 66090 yippee-like 3 (Drosophila) 1.39 0.189 0.15 0.32 2.22 0.044 0.13 0.5 0.84 0.416 0.48 0.17
141 5767_at Ythdfl 228994 YTH domain family I 0.29 0.778 0.26 0.06 -2.12 0.053 0.32 -0.45 -2.63 0.02 0.27 -0.51
I426840_at Ythdf3 229096 YTH domain family 3 -2.34 0.035 0.25 -0.72 -1.23 0.24 0.37 -0.36 1.33 0.207 0.38 0.36
I435702_s_at Ywhae 22627 tyrosine 3-monooxygenaseltryptophan 5-monooxygenase -3.08 0.009 0.14 -1.1 -1.37 0.194 0.33 -0.47 2.01 0.065 0.27 0.63
1450012_x_at Ywhag 22628 3-monooxgenaseltryptophan 5-monooxgenase activation -2.11 0.054 0.26 -0.6 0.52 0.611 0.30 0.14 2.97 0.01 0.20 0.74
protein, gamma
14291 39_at Za20dl 229603 zinc finger, A20 domain containing I 2.32 0.037 0.05 0.69 2.72 0.017 0.09 0.78 0.32 0.752 0.62 0.08
I42203 I_a_at Za20d3 65098 zinc finger, A20 domain containing 3 0.27 0.794 0.26 0.06 -1.94 0.074 0.33 -0.43 -2.41 0.031 0.30 -0.49
I422032_a_at Za20d3 65098 zinc finger, A20 domain containing 3 -2.79 0.015 0.17 -0.62 0.28 0.787 0.30 0.06 3.48 0.004 0.20 0.68
I450093_s_at Zbtb7 16969 zinc finger and BTB domain containing 7 1.7 0.112 0.07 0.64 -1.3 0.216 0.38 -0.47 -3.35 0.005 0.10 -1.11
1415764_at Zc3hlla 70579 zinc finger CCCH type containing II A 2.4 0.031 0.07 0.53 3.34 0.005 0.09 0.7 0.9 0.384 0.48 0.17
1426360_at Zc3hlla 70579 zinc finger CCCH type containing II A 3.5 0.004 0.05 0.86 0.48 0.636 0.30 0.11 -3.46 0.004 0.06 -0.75
1418168_at Zcchcl4 142682 zinc finger, CCHC domain containing 14 2.34 0.036 0.08 0.62 2.44 0.029 0.10 0.62 0 0.999 0.68 0
I423755_at Zcchc8 70650 zinc finger, CCHC domain containing 8 2.12 0.053 0.09 0.47 3.13 0.008 0.09 0.67 0.98 0.342 0.48 0.19
1438619_x_at Zdhhcl4 224454 zinc finger, DHHC domain containing 14 2.42 0.03 0.07 0.78 1.94 0.073 0.13 0.59 -0.64 0.532 0.68 -0.18
I433748_at Zdhhcl8 503610 zinc finger, DHHC domain containing 18 1.88 0.081 0.11 0.47 2.37 0.033 0.10 0.57 0.44 0.669 0.60 0.1
I425332_at Zfpl06 20402 zinc finger protein 106 -0.05 0.96 0.40 -0.01 2.16 0.05 0.13 0.55 2.41 0.031 0.20 0.57
1422810_at Zfpl91 59057 zinc finger protein 191 3.3 0.006 0.05 0.92 1.47 0.163 0.20 0.4 -2.15 0.051 0.41 -0.53
448705_at Zfp297 81630 zinc finger protein 297 2.39 0.032 0.05 0.58 2.65 0.02 0.10 0.62 0.17 0.868 0.63 0.04
419181_at Zfp326 54367 zinc finger protein 326 -3.19 0.007 0.15 -0.88 -1.44 0.173 0.35 -0.38 2.07 0.059 0.27 0.5
436081_a_at Zfp414 328801 zinc finger protein 414 2.5 0.026 0.07 0.57 -0.27 0.788 0.39 -0.06 -3.15 0.007 0.11 -0.63
427254_at Zfp445 235682 zinc finger protein 445 3.52 0.004 0.05 1.14 1.14 0.273 0.24 0.35 -2.76 0.016 0.16 -0.78
435002_at zfp507 243924 zinc finger protein 507 -1.25 0.231 0.34 -0.3 1.1 0.29 0.25 0.26 2.63 0.02 0.20 0.56
425495_at Zfp62 22720 zinc finger protein 62 -2.33 0.036 0.26 -0.71 -1.34 0.201 0.37 -0.39 1.19 0.254 0.38 0.32
426625_at Zfp623 78834 zinc finger protein 623 2.79 0.015 0.05 0.71 3.29 0.006 0.07 0.81 0.41 0.691 0.60 0.09
424752_x_at Zfp71-rs 1 235907 zinc finger protein 71, related sequence I -4.11 0.001 0.08 -1.33 -1.56 0.142 0.33 -0.48 2.99 0.01 0.20 0.85
426326_at Zfp91 109910 zinc finger protein 91 2.98 0.01 0.05 0.72 -0.23 0.818 0.39 -0.05 -3.65 0.003 0.09 -0.78
451046_at Zfpml 22761 zinc finger protein, multitype I 2.57 0.023 0.05 0.9 0.48 0.64 0.30 0.16 -2.4 0.031 0.17 -0.74
452306_at Zfyve26 211978 zinc finger, FYVE domain containing 26 2.33 0.036 0.05 0.66 2.4 0.031 0.11 0.65 -0.04 0.967 0.68 -0.01
427923_at Zmpste24 230709 zinc metalloproteinase, STE24 homolog 3.88 0.002 0.05 0.87 1.74 0.105 0.15 0.37 -2.52 0.025 0.27 -0.5
426532_at Zmyndll 66505 zinc finger, MYND domain containing I I 1.73 0.107 0.11 0.46 -2.04 0.061 0.33 -0.53 -4.19 0.001 0.05 -0.99
455291_s_at Znrf2 387524 zinc and ring finger 2 -1.88 0.082 0.27 -0.45 0.2 0.848 0.30 0.04 2.35 0.034 0.22 0.5
415712 at Zranbl 360216 zinc finl!er RAN-bindinl! domain contalninl! I -0.25 0.804 0.40 -0.07 2.48 0.027 0.09 0.67 2.99 0.01 0.20 0.74
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1427539_a_at Zwint 52696 ZW I0 interaetor 0.35 0.729 0.26 0.1 2.2 0.045 0.11 0.58 2 0.066 0.27 0.49
1438487_s_at Zzz3 108946 zinc finger, ZZ domain containing 3 -3.24 0.006 0.08 -1.74 -1.65 0.122 0.32 -0.85 1.89 0.081 0.27 0.89
I423909_at 0610011104Rik 66058 RIKEN eDNA 0610011104 gene 3.21 0.007 0.05 1.11 2.43 0.03 0.09 0.8 -1.02 0.327 0.65 -0.31
I425603_at 06100 I 1I04Rik 66058 RIKEN eDNA 0610011104 gene 4.31 0.001 0.05 1.59 3.29 0.006 0.07 1.16 -1.32 0.209 0.63 -0.43
1441811_x_at 06100 I 1I04Rik 66058 RIKEN eDNA 0610011104 gene 3.52 0.004 0.05 1.12 2.83 0.014 0.07 0.86 -0.93 0.37 0.66 -0.26
I449096_at 06100 I 1N22Rik 67433 RIKEN eDNA 0610011 N22 gene -2.72 0.017 0.22 -0.75 -1.32 0.209 0.39 -0.35 1.66 0.12 0.27 0.4
1417002_at 0610012G03Rik 106264 RIKEN eDNA 061 0012G03 gene -0.4 0.694 0.40 -0.09 1.9 0.08 0.15 0.42 2.52 0.025 0.22 0.51
I448540_a_at 0610012G03Rik 106264 RIKEN eDNA 0610012G03 gene -1.99 0.067 0.27 -0.46 0.63 0.539 0.30 0.14 2.95 0.011 0.20 0.6
I428078_at 0610013E23Rik 76892 RIKEN eDNA 06100 13E23 gene -3.3 0.005 0.09 -1.04 -2.32 0.037 0.32 -0.7 1.23 0.238 0.38 0.34
I456377_x_at 0610025L06Rik 67803 RIKEN eDNA 0610025L06 gene 2.29 0.039 0.05 0.83 1.11 0.287 0.24 0.39 -1.4 0.185 0.60 -0.45
141 6830_at 0610031 j06Rik 56700 RIKEN eDNA 061 0031j06 gene 2.35 0.034 0.07 0.76 1.98 0.068 0.13 0.61 -0.52 0.61 0.68 -0.15
1428798_s_at 06 10039j04Rik 66083 RIKEN eDNA 061 0039j04 gene 1.83 0.089 0.12 0.46 2.54 0.024 0.09 0.61 0.68 0.506 0.53 0.15
I434214_at 0910001 L09Rik 66096 RIKEN eDNA 091000 IL09 gene -1.37 0.194 0.29 -0.37 0.66 0.521 0.30 0.17 2.27 0.04 0.22 0.54
1416767_a_at 1II0003EOIRik 68552 RIKEN eDNA I0003EO I gene -2.66 0.019 0.23 -0.58 -1.29 0.217 0.38 -0.27 1.61 0.13 0.36 0.31
I429735_at 10003F05Rik 66145 RIKEN eDNA I0003F05 gene 2.86 0.013 0.05 0.84 0.76 0.458 0.29 0.22 -2.42 0.03 0.36 -0.63
I428926_at 10003008Rik 76291 RIKEN eDNA 10003008 gene 1.79 0.096 0.09 0.52 2.44 0.029 0.10 0.68 0.62 0.546 0.55 0.16
I429058_at I0004B 13Rik 66910 RIKEN eDNA I0004B 13 gene -2.81 0.014 0.12 -1.27 -3.08 0.008 0.15 -1.34 -0.16 0.877 0.68 -0.06
1424315_at 10004E09Rik 68001 RIKEN eDNA I0004E09 gene -0.93 0.369 0.35 -0.26 1.25 0.234 0.24 0.33 2.41 0.031 0.22 0.59
1451448_a_at 10005A03Rik 74319 RIKEN eDNA 10005A03 gene -5.43 0 0.07 -1.11 -3.72 0.002 0.24 -0.73 2.13 0.052 0.27 0.38
I453485_s_at 10005A03Rik 74319 RIKEN eDNA I0005A03 gene -3.94 0.002 0.04 -1.56 -2.86 0.013 0.30 -1.08 1.36 0.195 0.36 0.47
I439438_a_at 10005A23Rik 66118 RIKEN eDNA I0005A23 gene -2.47 0.027 0.24 -0.59 -1.63 0.127 0.35 -0.37 1.04 0.315 0.46 0.22
I435333_at 10007M04Rik 68493 RIKEN eDNA I0007M04 gene -2.29 0.039 0.26 -0.59 -0.86 0.404 0.39 -0.21 1.67 0.119 0.30 0.38
I448480_at 10017CI5Rik 66164 RIKEN eDNA 10017CI5 gene -2.26 0.041 0.26 -0.58 -0.97 0.348 0.39 -0.24 1.51 0.154 0.36 0.34
I429468_at 10018FI6Rik 68594 RIKEN eDNA I00 I8F I6 gene 1.3 0.215 0.17 0.38 2.27 0.04 0.10 0.63 0.99 0.34 0.44 0.25
143444 I_at I0018J 18Rik 66129 RIKEN eDNA 10018JI8 gene -2.8 0.014 0.15 -0.98 -1.51 0.155 0.33 -0.5 1.55 0.143 0.32 0.48
I437285_at 10020G09Rik 68646 RIKEN eDNA I0020G09 gene -2.61 0.021 0.12 -0.95 -1.46 0.168 0.36 -0.51 1.38 0.19 0.36 0.44
I437286_x_at 10020G09Rik 68646 RIKEN eDNA I0020G09 gene -3.01 0.01 0.14 -1.07 -1.63 0.125 0.34 -0.56 1.65 0.122 0.27 0.51
1437287_at 10020G09Rik 68646 RIKEN eDNA I0020G09 gene -1.38 0.19 0.30 -0.34 -2.63 0.02 0.32 -0.61 -1.3 0.217 0.65 -0.28
I429652_at 90002C06Rik 73137 RIKEN eDNA 190002C06 gene -2.18 0.048 0.27 -0.57 0.57 0.576 0.30 0.14 3.1 0.008 0.20 0.72
1433581_at 190002N I5Rik 68861 RIKEN eDNA I90002NI 5 gene -0.43 0.672 0.40 -0.13 1.54 0.147 0.20 0.45 2.17 0.049 0.22 0.58
I427932_s_at 200003110Rik 319202 RIKEN eDNA 200003110 gene 1.42 0.18 0.15 0.37 -1.91 0.077 0.34 -0.48 -3.69 0.003 0.06 -0.86
14281 96_a_at 200015F23Rik 67809 RIKEN eDNA 200015F23 gene 3.18 0.007 0.05 1.13 2.87 0.013 0.09 0.97 -0.49 0.629 0.68 -0.15
I428654_at 12000 16B IORik 66875 RIKEN eDNA 2000 16B I0 gene -2.79 0.015 0.23 -0.66 -0.32 0.755 0.39 -0.07 2.83 0.014 0.20 0.59
1435137_s_at 1200016E24Rik 319202 RIKEN eDNA 200016E24 gene 0.98 0.344 0.20 0.23 -1.46 0.167 0.38 -0.33 -2.71 0.017 0.17 -0.56
I429690_at 300003B 13Rik 74149 RIKEN eDNA 300003B 13 gene -1.6 0.134 0.27 -0.42 -2.36 0.034 0.32 -0.59 -0.75 0.464 0.68 -0.17
455376_at 300010F03Rik 219189 RIKEN eDNA 3000 IOF03 gene 0.31 0.76 0.26 0.08 2.36 0.034 0.11 0.59 2.21 0.045 0.27 0.5
431251_at 3000 II L04Rik 71763 RIKEN eDNA 300011 L04 gene 2.42 0.031 0.07 0.68 1.59 0.136 0.20 0.43 -1.02 0.324 0.65 -0.25
423425_at 300012G 16Rik 71772 RIKEN eDNA 300012G 16 gene 3.32 0.005 0.05 1.07 2.82 0.014 0.09 0.87 -0.71 0.491 0.68 -0.2
42885 I_at 300014106Rik 66895 RIKEN eDNA 300014106 gene -2.29 0.039 0.14 -1.12 -0.38 0.707 0.39 -0.18 2.19 0.047 0.22 0.94
430130_at 300015B04Rik 71768 RIKEN eDNA 300015B04 gene 1.62 0.128 0.15 0.38 2.43 0.03 0.10 0.55 0.8 0.439 0.50 0.16
447380_at 300019j08Rik 71761 RIKEN eDNA 300019j08 gene 0.35 0.731 0.26 0.09 2.35 0.035 0.10 0.55 2.16 0.049 0.27 0.46
451 640_a_at 50001lj06Rik 208606 RIKEN eDNA 50001lj06 gene 2.47 0.028 0.05 0.8 -1.49 0.158 0.36 -0.46 -4.44 0.001 0.05 -1.27
41 7427_at 500026D 16Rik 68209 RIKEN eDNA 500026D 16 gene -1.25 0.231 0.31 -0.34 0.72 0.485 0.30 0.18 2.21 0.045 0.27 0.52
439453_x_at 500026D 16Rik 68209 RIKEN eDNA 1500026D 16 gene -0.58 0.571 0.40 -0.15 1.43 0.177 0.22 0.36 2.21 0.045 0.27 0.51
435527_at 500041016Rik 69000 RIKEN eDNA 1500041016 gene 2.68 0.018 0.05 0.75 2.21 0.045 0.11 0.59 -0.64 0.531 0.68 -0.16
424444_a_at 6000 14C IORik 72244 RIKEN eDNA 1600014CI0 gene 2.08 0.057 0.08 0.43 2.36 0.034 0.11 0.47 0.2 0.847 0.63 0.04
452972_at 7000 I3G20Rik 75516 RIKEN eDNA 1700013G20 gene -3.57 0.003 0.08 -0.87 -2.28 0.039 0.32 -0.53 1.58 0.136 0.36 0.34
451166 a at 7000230 II Rik 75565 RIKEN eDNA 1700023011 I'ene 2.07 0.059 0.08 0.49 2.86 0.013 0.10 0.65 0.76 0.461 0.53 0.16
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
1425190_a_at 1700048E23Rik 73373 RIKEN eDNA I700048E23 gene
-1.28 0.223 0.31 -0.39 -2.16 0.049 0.32 -0.64 -0.9 0.386 0.66 -0.24
1417886_at 181 0009A 15Rik 66276 RIKEN eDNA 1810009AI5 gene
-3.64 0.003 0.09 -1.15 -1.25 0.232 0.37 -0.38 2.78 0.015 0.20 0.78
I454668_at 181 0009A 16Rik 69116 RIKEN eDNA 1810009AI6 gene 1.65 0.123 0.14 0.37 2.97 0.01 0.09 0.64 1.36 0.196 0038 0.27
1418004_a_at 181 0009MO IRik 65963 RIKEN eDNA 1810009MOI gene 3034 0.005 0.05 I 2.39 0.032 0.10 0.68 -1.21 0.248 0.65 -0.32
1451381_at 181 0020D 17Rik 66273 RI KEN eD NA 181 0020D 17 gene
-1.78 0.097 0.27 -0.54 -2.27 0.041 0.32 -0.65 -0.44 0.67 0.68 -0.12
1425120J_at 1810023F06Rik 217845 RIKEN eDNA 1810023F06 gene 2.85 0.013 0.05 2.59 2.38 0.033 0.07 2.07 -0.65 0.525 0.68 -0.52
1447923_at 1810026B05Rik 69170 RIKEN eDNA 181 0026B05 gene
-3.75 0.002 0.08 -1.09 -1.5 0.158 0.35 -0.41 2.64 0.02 0.22 0.67
I430985_at 18100270 10Rik 69186 RIKEN eDNA 18100270 I0 gene
-2.54 0.024 0.20 -0.53 -1.55 0.145 0.37 -0.31 1.21 0.248 0.41 0.22
14421 29_at 18 I0058124Rik 67705 RIKEN eDNA 1810058124 gene 1.53 0.149 0.10 0.62 2.4 0.032 0.10 0.93 0.87 0.401 0.44 0.31
I428508_at 1810061 M12Rik 67016 RIKEN eDNA 1810061MI2gene 3.15 0.007 0.05 0.71 1.43 0.176 0.22 0.31 -2.03 0.063 0.44 -0.4
I427294_a_at 1810073N04Rik 72055 RIKEN eDNA 181 0073N04 gene 2.48 0.027 0.05 0.72 1.97 0.07 0.15 0.54 -0.68 0.506 0.68 -0.17
I424626_at 20 I0003K II Rik 69861 RIKEN eDNA 2010003KII gene 0.67 0.514 0.23 0.38 2.69 0.018 0.07 1.45 2.17 0.049 0.22 1.07
1456587_x_at 20 I0005j08Rik 72046 RIKEN eDNA 20 I0005j08 gene 2.54 0.024 0.05 0.64 2.72 0.017 0.09 0.66 0.08 0.94 0.63 0.02
I450459_at 20 I0 I06GO 1Ril< 66552 RIKEN eDNA 2010106GOI gene 2.28 0.04 0.05 1.1 0.64 0.532 0.30 0.3 -1.89 0.08 0.22 -0.8
1415758_at 20 I0313D22Rik 72313 RIKEN eDNA 20 I03 I3D22 gene 2.05 0.06 0.11 0.43 3.18 0.007 0.07 0.64 1.13 0.278 0.44 0.21
1460456_at 20 I03 I6F05Rik 67939 RIKEN eDNA 201 03 I6F05 gene
-2.66 0.019 0.25 -0.57 -0.19 0.855 0.39 -0.04 2.83 0.014 0.20 0.53
I438074_at 2210010CI7Rik 70080 RIKEN eDNA 2210010C17 gene 1.09 0.296 0.17 0.29 2.99 0.01 0.09 0.77 2.01 0.064 0.27 0.48
1431 284_a_at 2210013K02Rik 73658 RIKEN eDNA 221 0013K02 gene 1.41 0.182 0.15 0.34 2.43 0.03 0.10 0.56 1.04 0.317 0.44 0.22
1433645_at 2210409B22Rik 70174 RIKEN eDNA 221 0409B22 gene 2.15 0.05 0.08 0.74 2.02 0.064 0.11 0.66 -0.25 0.803 0.68 -0.08
I428327_at 2310001 H 13Rik 67095 RIKEN eDNA 2310001 H 13 gene 1.06 0.31 0.17 0.29 2.51 0.025 0.10 0.67 1.53 0.148 0.36 0.38
I456393_at 2310002j21Rik 66360 RIKEN eDNA 231 0002j21 gene 2.23 0.044 0.05 0.68 0.07 0.948 0.30 0.02 -2.46 0.028 0.27 -0.66
451 322_at 23 100 I6A09Rik 69574 RIKEN eDNA 2310016A09 gene -2.31 0.038 0.26 -0.58 -0.83 0.421 0.39 -0.2 1.72 0.108 0.30 0.38
4245 I8_at 23 100 I6F22Rik 223672 RIKEN eDNA 231 0016F22 gene 2.59 0.022 0.05 0.99 1.14 0.275 0.22 0.42 -1.7 0.111 0.50 -0.57
455006_at 23 1001 6M24Rik 66379 RIKEN eDNA 231 0016M24 gene -0.9 0.385 0038 -0.21 1.05 0031 0.25 0.23 2.17 0.048 0.27 0.44
452290_at 2310036D22Rik 71900 RIKEN eDNA 231 0036D22 gene 1.06 0.308 0.17 0.33 2.21 0.045 0.11 0.66 1.2 0.251 0.41 0.33
416171_at 2310037124Ril< 69612 RIKEN eDNA 2310037124 gene 1.72 0.109 0.11 0.41 3 0.01 0.10 0.68 1.31 0.212 0.41 0.27
424038_a_at 23 I0044H IORik 69683 RIKEN eDNA 231 0044H I0 gene 2.83 0.014 0.05 0.73 1.14 0.273 0.25 0.28 -1.97 0.069 0.48 -0.44
42843 I_at 2310047AO IRik 71918 RIKEN eDNA 23 I0047AOI gene 1.99 0.067 0.08 0.53 2.15 0.05 0.11 0.55 0.07 0.944 0.63 0.02
455389_s_at 2310051 F07Rik 108745 RIKEN eDNA 2310051 F07 gene OJ 0.771 0.26 0.08 2.93 0.011 0.10 0.78 2.85 0.013 0.20 0.7
428647_at 2310056B04Rik 70402 RIKEN eDNA 231 0056B04 gene 1.17 0.262 0.20 0.33 2.86 0.013 0.09 0.76 1.78 0.098 0.27 0.44
437327_x_at 231 0057D 15Rik 67870 RIKEN eDNA 2310057DI5 gene 0.34 0.739 0.26 0.1 2.91 0.012 0.09 0.84 2.78 0.015 0.22 0.73
441915_s_at 2310076L09Rik 66968 RIKEN eDNA 231 0076L09 gene -1.58 0.138 0.28 -0.45 1.5 0.158 0.17 0.41 3.43 0.004 0.20 0.86
427897_s_at 2400003N08Rik 71954 RIKEN eDNA 2400003N08 gene -3.06 0.009 0.12 -0.79 -0.59 0.566 0.39 -0.15 2.85 0.013 0.20 0.65
433997_at 2410127EI8Rik 76788 RIKEN eDNA 2410127EI8 gene 0.76 0.46 0.25 0.17 2.49 0.026 0.10 0.55 1.85 0.087 0.30 0.37
455052_a_at 241 0129H 14Ril< 76789 RIKEN eDNA 2410129HI4 gene -4.65 0 0.07 -0.99 -2.6 0.022 0.32 -0.53 2.47 0.027 0.22 0.46
419074_at 25 I0006C20Rik 68044 RIKEN eDNA 251 0006C20 gene -2.71 0.017 0.20 -0.75 -1.42 0.178 0.38 -0.38 1.54 0.146 0.30 0.38
438646J_at 2510039018Rik 77034 RIKEN eDNA 2510039018 gene 1.06 0.306 0.17 0.29 2.36 0.034 0.11 0.62 1.36 0.196 0.38 0.33
423672_at 25 I0042P03Rik 72421 RIKEN eDNA 251 0042P03 gene -2.98 0.01 0.15 -0.7 0.35 0.733 0.30 0.08 3.77 0.002 0.20 0.78
4563 IO_a_at 26 I0002j02Rik 67513 RIKEN eDNA 2610002j02 gene 2.06 0.059 0.07 0.78 2.65 0.02 0.09 0.96 0.54 0.601 0.55 0.18
424743_at 26 10003j06Rik 72106 RIKEN eDNA 2610003j06 gene 3.03 0.009 0.05 0.82 2.21 0.045 0.11 0.57 -1.04 0.316 0.66 -0.25
452997_at 26 I0005L07Rik 381598 RIKEN eDNA 2610005L07 gene 2.22 0.045 0.07 0.51 3.08 0.008 0.09 0.68 0.83 0.421 0.50 0.17
428708J_at 261 0009E 16Rik 69202 RIKEN eDNA 2610009EI6 gene 2.16 0.049 0.07 0.67 0.5 0.623 0.30 0.15 -1.92 0.077 0.44 -0.52
427937_at 2610030H06Rik 434793 RIKEN eDNA 2610030H06 gene -0.8 0.435 0.36 -0.32 -2.78 0.015 0.30 -1.06 -2.11 0.054 0.38 -0.74
452607_at 2610030H06Rik 434793 RIKEN eDNA 261 0030H06 gene -1032 0.208 0.33 -OJ 1.37 0.192 0.22 0.3 3 0.01 0.20 0.6
450057_at 2610042014Rik 66460 RIKEN eDNA 2610042014 gene 3.09 0.008 0.05 0.77 1.83 0.09 0.15 0.44 -1.53 0.15 0.58 -0.33
434942_at 261010lj03Rik 66580 RIKEN eDNA 261010lJ03 gene 1.01 0.329 0.20 0.25 2.47 0.028 0.10 0.58 1.53 0.149 0.36 0.33
434300_at 2610101 N IORik 67958 RIKEN eDNA 2610101 NIO gene 0.89 0.391 0.22 0.23 -1.05 0.312 0.39 -0.26 -2.15 0.05 0.41 -0.49
436216 s at 2610204M08Rik 70435 RIKEN eDNA 261 0204M08 ~ene 2.43 0.03 0.05 1.05 1.93 0.075 0.13 0.79 -0.67 0.515 0.66 -0.25
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Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I429336_at 2610301 K12Rik 72477 RIKEN eDNA 261030 IK12 gene 2.58 0.023 0.05 0.77 -1.11 0.285 0.39 -0.32 -4.14 0.001 0.06 -1.09
I433740_at 2610301 K12Rik 72477 RIKEN eDNA 2610301 KI2 gene 1.55 0.145 0.15 0.44 2.32 0.036 0.09 0.63 0.77 0.457 0.50 0.19
1427887_at 2610304G08Rik 70470 RIKEN eDNA 2610304G08 gene 3.2 0.007 0.05 0.84 3.13 0.008 0.07 0.79 -0.24 0.814 0.68 -0.06
I426820_at 261 0507B I IRik 72503 RIKEN eDNA 2610507BII gene 0.75 0.463 0.26 0.15 3.12 0.008 0.09 0.6 2.54 0.024 0.22 0.45
I453208_at 2700089E24Rik 381820 RIKEN eDNA 2700089E24 gene -0.87 0.402 0.35 -0.29 -2.48 0.027 0.32 -0.8 -1.71 0.109 0.50 -0.51
I42898 I_at 28 I0007J24Rik 76971 RIKEN eDNA 2810007J24 gene -3.82 0.002 0.10 -1.04 -3.36 0.005 0.15 -0.88 0.7 0.498 0.53 0.17
142831 I_at 281 0012H 18Rik 76551 RIKEN eDNA 2810012HI8 gene 2.25 0.042 0.08 0.68 1.46 0.168 0.17 0.42 -0.98 0.346 0.66 -0.26
I428529_at 281 0026P 18Rik 72655 RIKEN eDNA 2810026PI8 gene -1.01 0.331 0.32 -0.33 1.35 0.2 0.22 0.42 2.62 0.021 0.22 0.75
I423266_at 2810405K02Rik 66469 RIKEN eDNA 28 I0405K02 gene 2.78 0.015 0.05 1.19 1.65 0.121 0.15 0.68 -1.37 0.194 0.38 -0.52
I430053_a_at 28 I0409H07Rik 67059 RIKEN eDNA 281 0409H07 gene -1.83 0.089 0.27 -0.37 -4.22 0.001 0.22 -0.81 -2.5 0.026 0.16 -0.44
I41 8542_s_at 2810429005Rik 52504 RIKEN eDNA 2810429005 gene 0.35 0.734 0.26 0.1 2.27 0.04 0.11 0.61 2.07 0.058 0.27 0.51
I446769_at 2810439F02Rik 72747 RIKEN eDNA 2810439F02 gene 1.41 0.181 0.15 0.33 -0.97 0.348 0.39 -0.22 -2.67 0.019 0.22 -0.54
I427334_s_at 2810474019Rik 67246 RIKEN eDNA 2810474019 gene 2.46 0.028 0.05 1.05 -1.31 0.212 0.37 -0.53 -4.22 0.001 0.04 -1.58
1429089_s_at 2900026A02Rik 243219 RIKEN eDNA 2900026A02 gene 3.58 0.003 0.05 0.96 3.51 0.004 0.07 0.9 -0.26 0.8 0.68 -0.06
1443916_at 2900026A02Rik 243219 RIKEN eDNA 2900026A02 gene 2.03 0.063 0.07 0.65 3.81 0.002 0.07 1.17 1.84 0.088 0.30 0.52
I455340_at 30 I0003L21 Rik 109163 RIKEN eDNA 3010003L21 gene -0.81 0.431 0.40 -0.29 1.41 0.182 0.11 0.48 2.46 0.Q28 0.22 0.77
I426558_x_at 3 100002L24Rik 66376 RIKEN eDNA 31 00002L24 gene -2.57 0.023 0.15 -0.8 -2.39 0.032 0.32 -0.71 0.33 0.75 0.60 0.09
I450642_at 31 1000 1120Rik 70354 RIKEN eDNA 3110001120 gene -1.25 0.232 0.30 -0.31 1.26 0.228 0.24 0.3 2.8 0.015 0.20 0.61
I453004_at 3 I 10004L20Rik 73102 RIKEN eDNA 311 0004L20 gene 1.32 0.208 0.15 0.34 2.59 0.022 0.10 0.64 1.32 0.21 0.38 0.3
I430568_at 311 0050K21 Rik 67302 RI KEN eDNA 3 I I0050K2 I gene 2.8 0.015 0.05 0.83 1.65 0.123 0.15 0.46 -1.4 0.185 0.63 -0.36
1455430_at 3200001 K10Rik 381626 RIKEN eDNA 3200001K10 gene 1.58 0.137 0.10 0.45 2.26 0.041 0.11 0.61 0.66 0.523 0.53 0.16
1434150_a_at 3300001 H21 Rik 393082 RIKEN eDNA 330000 IH21 gene -2.9 0.012 0.15 -0.86 -2.03 0.063 0.32 -0.57 1.09 0.293 0.44 0.28
I452769_at 373241311 IRik 74315 RIKEN eDNA 3732413111 gene 1.72 0.109 0.12 0.49 3.02 0.01 0.Q7 0.83 1.33 0.206 0.38 0.34
I453345_at 3830408G IORik 70701 RIKEN eDNA 3830408G I0 gene 2.46 0.028 0.05 1.49 2.17 0.049 0.10 1.26 -0.44 0.669 0.68 -0.23
I452252_at 3830408P06Rik 70683 RIKEN eDNA 3830408P06 gene 1.73 0.106 0.11 0.59 2.98 0.01 0.Q7 0.97 1.27 0.224 0.38 0.38
I453259_at 3830422K02Rik 233752 RIKEN eDNA 3830422K02 gene 2.21 0.045 0.07 0.82 0.66 0.519 0.30 0.24 -1.8 0.095 0.32 -0.59
1451994_s_at 393040 IK13Rik 74022 RIKEN eDNA 393040 IK13 gene 2.11 0.054 0.09 0.6 2.46 0.028 0.09 0.67 0.28 0.785 0.62 0.07
I426975_at 4632413K 17Rik 216440 RIKEN eDNA 4632413K 17 gene 0.91 0.379 0.18 0.34 -1.62 0.128 0.35 -0.59 -2.8 0.015 0.11 -0.93
I427008_at 4732452J 19Rik 207742 RIKEN eDNA 4732452J19 gene 1.92 0.077 0.12 0.45 2.27 0.041 0.10 0.51 0.28 0.782 0.62 0.06
I427059_at 4732495E 13Rik 223693 RIKEN eDNA 4732495E 13 gene 3.16 0.007 0.05 0.76 4.2 0.001 0.07 0.97 0.97 0.347 0.46 0.21
1418185_at 473340 IH 18Rik 66706 RIKEN eDNA 4733401 HI8 gene 0.92 0.372 0.17 0.35 2.26 0.041 0.11 0.82 1.4 0.183 0.36 0.47
I437089_at 4833409A17Rik 74580 RIKEN eDNA 4833409AI7 gene 2.44 0.029 0.05 I 2.8 0.014 0.09 1.1 0.27 0.788 0.62 0.1
1427202_at 4833442J 19Ril< 320204 RIKEN eDNA 4833442J 19 gene 1.17 0.264 0.18 0.38 -1.22 0.244 0.35 -0.38 -2.65 0.019 0.22 -0.76
1457915_at 4833442J 19Rik 320204 RIKEN eDNA 4833442J 19 gene 0.04 0.968 0.26 0.01 -2.03 0.063 0.32 -0.68 -2.25 0.042 0.32 -0.7
I435698_at 4921 505C I7Ril< 78757 RIKEN eDNA 4921505C 17 gene -0.09 0.929 0.40 -0.02 3.02 0.01 0.10 0.68 3.39 0.005 0.20 0.7
14281 26_a_at 4921506J03Rik 382423 RIKEN eDNA 4921506J03 gene 2.43 0.03 0.05 0.72 2.1 0.055 0.11 0.6 -0.48 0.638 0.68 -0.13
455381_at 4921513D23Rik 320675 RIKEN eDNA 4921513023 gene 2.71 0.018 0.05 0.94 2.63 0.02 0.10 0.88 -0.22 0.831 0.68 -0.07
428762_<lt 4921 526G09Rik 66724 RIKEN eDNA 4921 526G09 gene -0.07 0.945 0.40 -0.02 2.03 0.062 0.13 0.47 2.29 0.039 0.22 0.49
428113_at 4930403J22Rik 70551 RIKEN eDNA 4930403J22 gene 2.07 0.059 0.07 0.45 2.53 0.025 0.11 0.52 0.4 0.693 0.60 0.08
423918_at 4930418P06Rik 76867 RIKEN eDNA 4930418P06 gene 1.15 0.268 0.18 0.31 2.15 0.05 0.11 0.56 1.03 0.321 0.46 0.25
41 8996_<l_at 4930469P 12Rik 67636 RIKEN eDNA 4930469PI2 gene -3.17 0.007 0.12 -0.76 -1.56 0.141 0.36 -0.36 1.91 0.Q78 0.30 0.4
431 228_s_<lt 4930526115Rik 75135 RIKEN eDNA 4930526115 gene 1.87 0.083 0.08 0.56 2.85 0.013 0.09 0.82 0.98 0.345 0.46 0.26
433276_at 4930556A 12Rik 75333 RIKEN eDNA 4930556A 12 gene -2.64 0.02 0.20 -0.75 -2.72 0.017 0.31 -0.74 0.05 0.96 0.63 0.01
425042_s_at 4930563C04Rik 75273 RIKEN eDNA 4930563C04 gene 2.42 0.03 0.05 0.85 1.04 0.315 0.25 0.35 -1.62 0.129 0.53 -0.5
4504 1O_<l_at 4930570C03Rik 67739 RIKEN eDNA 4930570C03 gene 2.46 0.028 0.05 0.62 0.35 0.732 0.30 0.08 -2.42 0.03 0.32 -0.53
431806_at 493 I408D 14Rik 77059 RIKEN eDNA 4931408D 14 gene 1.4 0.183 0.08 0.58 2.82 0.014 0.09 1.1 I 1.47 0.164 0.36 0.53
454730_at 4932414KI8Rik 231225 RIKEN eDNA 4932414K18 gene 1.82 0.091 0.11 0.45 2.86 0.013 0.09 0.67 1.04 0.315 0.46 0.23
454799 at 4933408F15 231510 hypothetical orotein 4933408F 15 2.19 0.047 0.05 1.2 3.15 0.007 0.07 1.65 0.94 0.365 0.41 0.45
(,;>
~
Probe Symbol Entrez Description IGT/6-DM vs. CONTROL IGT/6-NASH vs. CONTROL IGT/6-NASH vs. IGT/6-DM
Gene ID t-stat p-value q-value Fold Ch. t-stat p-value q-value Fold Ch t-stat p-value q-value Fold Ch.
I454606_<lt 4933426M II Rik 217684 RIKEN eDNA 4933426M II gene 2.93 0.011 0.05 0.86 2.01 0.065 0.13 0.56 -1.15 0.272 0.65 -0.29
I439675_<lt 4933429D07Rik 399624 RIKEN eDNA 4933429D07 gene 0.59 0.566 0.26 0.16 3.31 0.005 0.09 0.84 2.94 0.011 0.20 0.68
1453 I45_<lt 4933439C20Rik 236604 RIKEN eDNA 4933439C20 gene
-3.09 0.008 0.11 -1.19 -2.25 0.042 0.32 -0.83 1.07 0.305 0.38 0.36
I436894_<lt 5330438103Rik 381325 RIKEN eDNA 5330438103 gene 2.5 0.026 0.05 0.91 0.06 0.951 0.30 0.02 -2.78 0.015 0.16 -0.89
1431109_<lt 5430406M 13Rik 71373 RIKEN eDNA 5430406M 13 gene
-2.76 0.016 0.18 -0.86 -1.23 0.238 0.38 -0.37 1.79 0.095 0.27 0.49
1415730_<lt 57304531 I6Rik 269061 RIKEN eDNA 5730453116 gene 2.16 0.05 0.08 0.69 0.41 0.691 0.30 0.12 -2.01 0.065 0.27 -0.56
I454621_s_<lt 5730472N09Rik 108958 RIKEN eDNA 5730472N09 gene 1.36 0.197 0.09 0.6 2.74 0.016 0.09 1.15 1.44 0.173 0.32 0.55
I436752_<lt 5730478M09Rik 70573 RIKEN eDNA 5730478M09 gene -2.92 0.012 0.17 -0.98 -2.83 0.014 0.30 -0.91 0.24 0.815 0.62 0.07
141 6633_<l_<lt 5730536A07Rik 68250 RIKEN eDNA 5730536A07 gene
-3.43 0.004 0.11 -0.83 -2.34 0.035 0.32 -0.54 1.35 0.198 0.38 0.29
I436344_<lt 5830404H04Rik 207781 RIKEN eDNA 5830404H04 gene 2.56 0.023 0.05 0.76 3.71 0.002 0.07 1.05 1.13 0.279 0.41 0.29
I443901_<lt 5830404H04Rik 207781 RIKEN eDNA 5830404H04 gene 0.39 0.706 0.26 0.14 -2.6 0.021 0.31 -0.93 -3.27 0.006 0.11 -1.07
1418006_<lt 583041 6A07Rik 76014 RIKEN eDNA 5830416A07 gene 3.66 0.003 0.05 0.83 1.39 0.186 0.22 0.3 -2.65 0.019 0.17 -0.53
I433624_<lt 5830434P21 Rik 227723 RIKEN eDNA 5830434P21 gene 3.48 0.004 0.05 0.8 2.96 0.011 0.09 0.65 -0.73 0.478 0.68 -0.15
I438233_<lt 6030443007Rik 226151 RIKEN eDNA 6030443007 gene 1.62 0.128 0.12 0.41 2.39 0.032 0.11 0.57 0.75 0.466 0.53 0.16
1440831_<lt 6230421 P05Rik 109033 RIKEN eDNA 6230421 P05 gene 1.64 0.125 0.14 0.4 3.01 0.01 0.09 0.7 1.41 0.18 0.38 0.3
1416911_<l_<lt 6330407G I IRik 68050 RIKEN eDNA 6330407G II gene -2.17 0.049 0.24 -0.67 -1.06 0.309 0.39 -0.31 1.31 0.211 0.38 0.36
I429723_<lt 6330409N04Rik 66674 RIKEN eDNA 6330409N04 gene -3.11 0.008 0.12 -0.98 -1.81 0.092 0.33 -0.55 1.57 0.139 0.32 0.43
1426315_<l_<lt 6330416G 13Rik 230279 RIKEN eDNA 6330416G 13 gene 3.81 0.002 0.05 2.32 2.71 0.017 0.07 1.58 -1.38 0.189 0.50 -0.74
I438736_<lt 6330441 0 12Rik 331401 RIKEN eDNA 6330441012 gene 1.86 0.085 0.11 0.41 -0.43 0.672 0.39 -0.09 -2.59 0.022 0.27 -0.5
I434009_<lt 6430596G II Rik 232906 RIKEN eDNA 6430596G II gene 2.52 0.Q25 0.07 0.62 2.89 0.012 0.09 0.68 0.28 0.785 0.62 0.06
I429 I46_<lt 6620401 M08Rik 75744 RIKEN eDNA 6620401 M08 gene -2.74 0.016 0.15 -0.67 -1.46 0.167 0.37 -0.34 1.53 0.149 0.36 0.33
I4 I8258_s_<lt 6720463 E02Rik 68097 RIKEN eDNA 6720463E02 gene -1.37 0.192 0.31 -0.31 0.61 0.551 0.30 0.13 2.23 0.043 0.27 0.45
I437066_<lt 7330412A 13Rik 78143 RIKEN eDNA 7330412A 13 gene 2.51 0.026 0.07 0.7 0.61 0.549 0.30 0.16 -2.19 0.047 0.41 -0.54
I433837_<lt 8430408G22Rik 213393 RIKEN eDNA 8430408G22 gene 0.27 0.794 0.26 0.21 2.36 0.034 0.09 1.78 2.26 0.041 0.20 1.57
I455337_<lt 9030023J02Rik 320417 RIKEN eDNA 9030023J02 gene -2.31 0.038 0.26 -0.68 0.01 0.992 0.30 0 2.64 0.02 0.22 0.68
1418979_<lt 9030611 N 15Rik 105387 RIKEN eDNA 9030611 N 15 gene -3.38 0.005 0.08 -1.16 -2.88 0.012 0.30 -0.95 0.72 0.486 0.53 0.22
I424226_<lt 9030617003Rik 217830 RIKEN eDNA 9030617003 gene 1.43 0.177 0.14 0.38 2.53 0.025 0.10 0.65 1.13 0.278 0.44 0.27
I453397_<lt 91 3001 6M20Rik 71620 RIKEN eDNA 91 3001 6M20 gene -2.7 0.018 0.08 -1.24 -0.98 0.346 0.39 -0.43 2.01 0.065 0.27 0.81
I455958_s_<lt 9130017AI5Rik 320717 RIKEN eDNA 9130017AI5 gene 2.31 0.037 0.07 0.64 2.18 0.047 0.13 0.58 -0.25 0.803 0.68 -0.06
I429749_<lt 9330 180L21 Rik 77268 RIKEN eDNA 9330180L21 gene 2.51 0.025 0.05 0.69 3.67 0.003 0.07 0.96 1.14 0.274 0.41 0.27
1433597_<It 94300 I0003Rik 234023 RIKEN eDNA 9430010003 gene 1.49 0.16 0.15 0.35 -0.6 0.557 0.39 -0.14 -2.35 0.035 0.38 -0.49
I433761_<lt 9430063L05Rik 229622 RIKEN eDNA 9430063L05 gene -3.02 0.01 0.15 -1.13 -2.13 0.052 0.32 -0.77 1.12 0.284 0.36 0.37
14251 56_<lt 9830 I47J24Rik 229900 RIKEN eDNA 9830147J24 gene 3.09 0.008 0.05 1.53 1.78 0.097 0.09 0.84 -1.58 0.138 0.55 -0.69
I435635_<lt A0300 12M09Rik 319263 RIKEN eDNA A030012M09 gene 3.44 0.004 0.05 1.24 -0.57 0.579 0.39 -0.2 -4.53 0.001 0.05 -1.44
I435640_x_<lt A I30040M 12Rik 319269 RIKEN eDNA A 130040M 12 gene -2.25 0.042 0.26 -0.57 -2.29 0.039 0.32 -0.55 0.07 0.948 0.63 0.01
I455305_x_<lt A130091K22Rik
---
RIKEN eDNA A 130091 K22 gene 0.76 0.46 0.23 0.21 3.19 0.007 0.09 0.82 2.6 0.021 0.22 0.62
1435193_<lt A230050P20Rik 319278 RIKEN eDNA A230050P20 gene 3.09 0.008 0.05 1.15 2.4 0.031 0.09 0.86 -0.9 0.385 0.66 -0.29
I455733_<lt A430 I05105Rik 414088 RIKEN c1one:F730031 B04 product 2.25 0.042 0.05 0.76 1.83 0.089 0.15 0.59 -0.57 0.579 0.68 -0.17
1436576_<lt A630077B 13Rik 215900 RIKEN eDNA A630077B 13 gene 3.56 0.003 0.05 1.75 0.89 0.39 0.22 0.42 -3.08 0.008 0.11 -1.33
1424829 <It A830007P 12Rik 227612 RIKEN eDNA A830007PI2 gene 0.5 0.623 0.26 0.17 2.81 0.014 0.09 0.92 2.48 0.027 0.22 0.75
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